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“Why is programming fun? What delights may its practitioner expect as his reward? 
 
First is the sheer joy of making things. As the child delights in his mud pie, so the adult 
enjoys building things, especially things of his own design. I think this delight must be an 
image of God's delight in making things, a delight shown in the distinctness and newness 
of each leaf and each snowflake. 
 
Second is the pleasure of making things that are useful to other people. Deep within, we 
want others to use our work and find it helpful. In this respect, the programming system 
is not essentially different from the child's first clay pencil holder "for Daddy's office." 
 
Third is the fascination of fashioning complex puzzle-like objects of interlocking moving 
parts and watching them work in subtle cycles, playing out the consequences of the 
principles built in from the beginning. The programmed computer has all the fascination 
of the pinball machine or the jukebox mechanism carried to the ultimate. 
 
Fourth is the joy of always learning, which springs from the nonrepeating nature of the 
task. In one way or another, the problem is always new, and its solver learns something: 
sometimes practical, sometimes theoretical, and sometimes both. 
 
Finally there is the delight of working in such a tractable medium. The programmer, like 
the poet, works only slightly removed from pure thought-stuff. He builds his castles in the 
air, from air, creating by exertion of the imagination. Few media of creation are so 
flexible, so easy to polish and rework, so readily capable of realizing grand conceptual 
structures. 
 
Yet the program construct, unlike the poet's words, is real in the sense that it moves and 
works, producing visible outputs seperate from the construct itself. It prints results, 
draws pictures, produces sounds, moves arms. The magic of myth and legend has come 
true in our time. One types the correct incantation on the keyboard, and a display screen 
comes to life, showing things that never were nor could be. 
 
Programming then is fun because it gratifies creative longings built deep within us and 
delights sensibilities we have in common with all men." 
 
 - Frederick P. Brooks, The Mythical Man-Month 
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Foreword 
 
The field of proteomics is quickly maturing into what might very well be its golden age. 
Indeed, over the past several years, the foundations of this promising branch of the life 
sciences have been firmly established. The first tier was laid down by three technological 
improvements: the invention of the two-dimensional polyacrylamide gel electrophoresis 
(2D-PAGE) method for separating proteins from a complex mixture, the development of 
automated search algorithms that could identify a protein from a sequence database by 
the (fragment) masses of its peptide ions, and the improvement of mass spectrometry 
instrumentation for the analysis of large biomolecules.  
The second tier built primarily upon the completion of the human genome sequencing 
projects. The resulting wealth of genomic sequence information was combined with 
expressed sequence tag (EST) data that had been gathered in parallel to help prediction 
algorithms in their search for open reading frames (ORF’s). These massive efforts in turn 
fed their data to protein sequence databases, greatly increasing the amount of primary 
protein structure information available to the abovementioned identification algorithms. 
At this point in time however, proteomics remained a métier rather than a protocol step, 
with the outcome of an experiment more dependent on the hands and minds that executed 
it than on the instrumentation and methodology applied. Correspondingly, the output of 
the average proteomics lab was typically limited to several identified proteins per week. 
As the instrumentation became ever more sophisticated however, the community started 
to develop novel ways to tackle old problems and over a relatively short period of time 
several groups independently published exciting new techniques that went squarely 
beyond the protein and focused on the constituent peptides instead. This third tier of 
novel peptide-centric techniques carried enormous potential, being readily automatable, 
highly sensitive and often very adaptable to suit specific research needs. Indeed, the new 
techniques combined with the dramatically improved instrumentation in a truly 
synergistic way and together they metamorphosed the field almost overnight. Where data 
production had previously resembled a rather sluggish trickling of identifications, data 
now streamed from the instruments in veritable torrents. 
In order to maximize the information contained in this data flood, novel bioinformatics 
applications were desperately needed as both existing data management software as well 
as available data processing software were lagging behind these new developments. 
On a global level, dissemination and validation of the identifications obtained posed 
another problem: whereas the identifications obtained could previously be published in 
neat, well-annotated tables inserted in the main text of a paper, the several hundreds of 
protein identifications routinely obtained using the new techniques were necessarily 
exiled to the supplementary information, losing much of their informative aspect in the 
process. 
 
In this work some contributions to alleviate these software requirements will be 
discussed. These applications cover solutions to a wide range of bottlenecks, from the 
processing of sequence databases (section 2.1), the management and analysis of the 
information flow (section 2.2), spectrum quality filtering (section 2.3) and global 
proteomics data dissemination (section 2.4). Finally, a summary of all of the above tools 
is given through an applied example to catalogue the most complete human platelet 
proteome to date in section 2.5. 
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3 
1. Introduction 
1.1. From genomics to proteomics 
1.1.1. The genomic era 
The independent completion of the sequencing of the human genome by both Celera 
Corporation [Venter 2001] and the Human Genome Organisation (HUGO) [Lander 2001] 
has been one of the milestone achievements of biology. The corresponding availability of 
automated, high-throughput sequencers allowed the completion of several genomes of 
model organisms since then [Aparicio 2002, Waterston 2002, Gibbs 2004, Hillier 2004, 
Mikkelsen 2005]. 
In turn, the availability of whole-genome sequences started off large-scale searches for 
open reading frames (ORF’s). Both in silico efforts and mRNA sequencing contributed 
greatly to this end and today we have a very good estimate of the total number of 
expected genes in the human genome [International Human Genome Sequencing 
Consortium 2004]. 
One thing that becomes clear when one looks at the relative scarcity of coding sequences 
in the genome is that a study of the genome by itself cannot account for an explanation of 
cellular functioning [Claverie 2001, Harrison 2002]. Thus, although a genome provides 
the all-important basis for a better understanding of a living organism, it cannot by itself 
provide an explanation for the actual diversity and adaptability evident in all life. Rather, 
one has to look into the RNA and protein content of cells in order to get an idea of how 
the cell works at any given time. 
 
1.1.2. Discovering the proteome 
The term ‘proteome’ is generally attributed to Mark Wilkins, who coined the term at the 
Siena Conference in 1994 [Wasinger 1995]. Through borrowing the semantics from the 
‘genome’ term, it becomes clear that the scope of research is very similar in both cases, 
yet the topics differ. Indeed, in order to understand a living cell at the molecular level it is 
imperative to analyze its protein content. Analyzing the proteome presents a more 
daunting challenge than analyzing the genome: apart from spanning an extremely large 
concentration range (at least 10 orders of magnitude in plasma [States 2006]) it is both 
highly dynamic in concentration as well as in modification state. Indeed, even though 
cells share the same genome, their proteomes can differ markedly [Collins 2001]. 
Additionally, protein sequences are not easily duplicated to large copy-numbers as is the 
case for nucleic acid sequences through the application of the polymerase chain reaction 
(PCR). 
The most popular technique today for studying the proteome is by mass spectrometry, 
which relies on separating charged ions by their mass-to-charge ratio (m/z).  
 
1.1.3. Mass spectrometry 
In general, a mass spectrometer can be broken down into three parts: an ion source, an 
m/z analyzer and a detector. The latter is usually a specific type of electron multiplier. 
4 
Due to the high amplification that is typically required most modern instruments use a 
type of microchannel plate detector. 
Additional refinements for peptide/protein sequence analysis include so-called tandem-
MS or MS/MS instruments which are capable of more than one round of mass 
spectrometry. In this technique one mass spectrometer isolates a peptide of a particular 
m/z while a second mass spectrometer is used to catalog fragment ions resulting after 
induced or spontaneous fragmentation. 
Different sources, m/z analyzers and fragmentation mechanisms are outlined below. 
 
1.1.3.1. Ion sources 
When applied to biomolecular compounds, the ion source of the mass spectrometer can 
typically take two forms: a Matrix-Assisted Laser Desorption and Ionisation (MALDI) 
source [Karas 1988, Tanaka 1988] or an ElectroSpray Ionisation (ESI) source [Fenn 
1989]. 
In a MALDI source, energy from laser light is converted into kinetic energy of the 
irradiated molecules/ions. This light is directed towards a metallic target plate on which 
the analyte has been crystallized in the presence of so-called matrix molecules. The laser 
light itself is typically derived from a N2 laser generating UV light with a wavelength of 
337 nm. Some often-used matrix compounds are α-cyano-4-hydroxycinnamic acid for 
peptide analytes [Beavis 1990] and sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic 
acid) for proteins [Beavis, 1989]. Crystallization is usually performed in highly organic 
solvents and in the presence of 0.1% tri-fluoroacetate (TFA). 
The actual mechanisms leading to desorption and ionisation are subject of debate [Karas 
1996, Zhao 1997,Jørgensen 1998, Wong 1998, Zenobi 1998], yet it is thought to rely on 
efficient absorption of the laser energy by the matrix molecules, which ultimately convert 
it into kinetic energy. This theory explains why a high molar excess of matrix molecules 
is required to obtain efficient desorption of the analyte. Ionisation might, according to 
one hypothesis, occur in the gas phase by proton transfer between the acidic matrix ions 
and the basic residues of the analyte (lysine, arginine or histidine).  
The principle of a MALDI source is depicted according to this theory in figure 1. 
 
5 
laser irradiation
target
surface
desorption proton transfer +
analyte
matrix
molecule
H+
 
 
  Figure 1: General principle of MALDI. 
 
Electrospray ionisation follows a completely different approach to generating gas-phase 
ions from an analyte. First and foremost, an ESI source starts from the analyte in solution, 
requiring a continuous flow to be provided at the inlet. Second, the phase transition here 
is evaporation under atmospheric pressure rather than the sublimation in a vacuum used 
for a MALDI source. 
The solution in which the analyte is dissolved is composed of compounds that are more 
volatile than the analyte itself and is typically acidified for peptide analysis, causing the 
peptides to become protonated. By passing this fluid through a slightly warm (50-60 °C) 
conductive needle over which a voltage of 3 to 5 kV is applied, the positive charges of 
the peptides will be pushed out of the needle tip, forming a Taylor cone [Taylor 1964] in 
the process. The resulting aerosol of tiny, charged droplets (the actual electrospray) 
continues to evaporate (sometimes assisted by blowing a neutral carrier gas along the 
conductive needle and through the source) and migrates towards the counter electrode. 
As the droplets evaporate, the ever increasing charge density destabilizes the droplets 
which fall apart in ever smaller droplets (i.e. the Coulomb explosion phenomenon), 
ultimately creating multiply charged, individual gas-phase analyte ions. The counter 
electrode and mass analyzer inlet are often positioned at right angles to the tip of the 
needle to filter out any uncharged ions (which, blind to the electrical field, continue in a 
straight path). 
The principle of an ESI source is depicted in figure 2.  
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  Figure 2: General principle of an ESI source. 
 
It is important to highlight that, under proper conditions, MALDI samples can be 
archived for later re-use whereas ESI samples are spent over the analysis period. 
Additionally, both sources ultimately perform an incomplete sampling of the analyte 
molecules present as MALDI ionization is a competitive process in which the available 
protons are preferentially captured by some analytes. This ionisation-quenching 
phenomenon can completely obscure an instrument fed by a MALDI-source to certain 
peptides present in the original matrix crystals. For ESI sources, the limited amount of 
time during which any particular ion elutes presents the greatest hurdle towards full 
analyte coverage. Most peptide sequences will be ionized in the source, but the mass 
spectrometer can only provide a detailed (fragmentation) analysis of one of multiple ions 
that are presented at the inlet simultaneously1.  
 
1.1.3.2. Mass/charge analyzers 
Analyzers measure the mass-to-charge (m/z) ratios of the ions presented to them. There 
are two kinds of mass analyzers: those that employ electrical fields and those that rely on 
magnetic fields. The former group is composed of time-of-flight (TOF), quadrupole and 
ion trap analyzers while the latter group comprises magnetic sector and ion cyclotron 
analyzers. 
Today, the four analyzers in common use on mass spectrometers are the time-of-flight, 
quadrupole, ion trap and Fourier transform ion cyclotron resonance analyzers2. 
The analyzers used in the work discussed here will be outlined next. 
A TOF analyzer is essentially a long tube with the inlet from the ion source at one end 
and a detector at the other. The ions generated in the source are briefly (appr. 1 cm) 
                                                 
1
 Certain modern machines allow the selection and fragmentation of multiple precursors simultaneously 
thus partially overcoming this problem. 
2
 Very recently, a fifth type of analyzer was introduced by Thermo Finnigan: the orbitrap. 
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exposed to an electrical field (typically 15-30 kV), which transfers kinetic energy to the 
ions according to the following formula: 
 
2
2
mvVqEk =⋅=  
 
With q the charge of the ion, V the voltage applied, m the mass of the ion and v the speed 
of the ion. The ions are then allowed to fly through a field-free tube of known length. 
Applying the equation from Newton’s dynamics, we can resolve m and q for time (t) and 
distance (x): 
 
tvx ⋅=  
 
2
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x
tV
q
m ⋅⋅
=  
 
Since the length of the TOF tube and the voltage applied are known and the actual flight 
time itself can be determined, it is possible to resolve mass over charge (m/q, or m/z as it 
is more commonly written). 
Ions of the same mass often show a distribution of kinetic energies in a linear TOF 
analyser after being accelerated, however. This is attributed to three possible causes 
[Amft 1997] and can be countered through the use of a so-called reflectron field and a 
delayed (discontinuous) extraction of ions from the ion source. 
The principle of a reflectron TOF mass spectrometer builds on the basic layout of a linear 
instrument, but adds a reflecting electrical field (reflectron) at the end of the flight tube. 
This reflectron operates at a higher voltage than the extractor field [Mamyrin 1973] and 
thus reflects ion trajectories back in such a way that ions with equal m/z but different 
energies are re-aligned and reach the detector simultaneously [Cotter 1997]. 
A reflectron TOF analyzer is depicted in figure 3. 
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  Figure 3: Correction on the kinetic energy distributions by a reflectron field. 
 
A second type of mass analyzer is the quadrupole [Paul 1953]. It analyzes ions by 
applying an oscillating electrical field on four parallel conductors (the actual quadrupole), 
which have been connected two-by-two. The electrical field itself is generated by the 
application of a direct-current (U) and a radiofrequency alternating current (V.cos(ω.t)). 
Ions brought into this field will oscillate in the two dimensions orthogonal to the direction 
of movement. The oscillation itself is dependent on the mass and charge of the ion and 
will only yield a finite amplitude for certain m/z values given V, U and ω. All other ions 
will be subjected to ever increasing horizontal or vertical amplitudes and will finally be 
ejected from the quadrupole. The quadrupole can be configured to either select for a very 
narrow m/z range or to allow a broad range of m/z values to pass. 
The structure of a quadrupole is depicted in figure 4. 
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  Figure 4: Schematic representation of a quadrupole mass analyzer. 
 
The final mass analyzer discussed here is the ion trap mass spectrometer [March 1996, 
Jonscher 1997]. An ion trap consists of three electrodes: two capping electrodes at each 
end of the ion trap (one end is connected to the inlet from the ion source, the other leads 
to the detector) and a ring electrode that surrounds the trap chamber. The ions enter the 
trap and are subjected to an oscillating radiofrequency electrical field very similar to that 
employed in a quadrupole. This field causes the ions to move first back- and forward 
axially and inward radially, and then outward radially and inward axially, generating an 
ion cloud that is continually compressing and expanding along the axes. An inert cooling 
gas (typically helium) is added to the chamber to absorb excess energy from the ions 
through collisions. Since the voltage on the ring electrode determines the m/z ratio cut-off 
below which the ions are ejected out of the trap, stepping up the voltage on the ring 
electrode allows the ion trap analyzer to progressively scan across a mass range. 
A schematic cross-section view on an ion trap is presented in figure 5. 
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  Figure 5: cross-sectional schematic view of an ion trap. 
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1.1.3.3. Fragmentation mechanisms 
There are two important fragmentation mechanisms available in current-day mass 
spectrometers. The first of these is specific to MALDI sources and is called post-source 
decay (PSD). The second is called collision-induced dissociation (CID) and can be 
applied regardless of the source that produced the ions. 
Ions derived from a MALDI source are typically highly energetic and thus metastable. A 
significant percentage of these ions spontaneously decays into fragments during the trip 
in the field-free vacuum tube. This process is thus unimolecular and the resulting 
fragment ions are indiscernible in a linear TOF as their velocities are identical to that of 
their parent ion. By employing a reflectron field, the changes in kinetic energy due to the 
smaller mass of these fragment ions can be used to separate them. This application of the 
reflectron field has been illustrated in figure 6. 
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Figure 6: schematic representation of the separation of precursor and fragment ions 
after post-source decay using a reflectron field. 
 
CID on the other hand is a bimolecular process in which accelerated ions are sent through 
a relatively dense collision gas (typically noble gasses, although nitrogen or even air are 
sometimes used as well). The random collisions between an analyte ion and collision gas 
molecules can then lead to the fragmentation of the ion. Important parameters that 
influence the fragmentation process are the pressure of the collision gas as well as the 
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collision voltage. The latter is therefore often ramped over time to explore as broad a 
range of energies as possible. 
Fragmentation ions fall into three broad categories: those derived from the N-terminal 
end of the original peptide ion, those from the C-terminal end and internal fragments. 
Each of these fragments can be broken in several places along the peptide bond. The 
resulting fragments and their one-letter designation [Roepstorff 1984, Biemann 1988] are 
represented in figure 7. 
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  Figure 7: structure and nomenclature for the most common peptide fragment ions. 
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1.1.4. 2D-PAGE proteomics and where they fail 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) [O’Farrell and Klose 
1975] has been the workhorse of proteomics for over three decades. Its ability to separate 
complex protein mixtures in two orthogonal dimensions according to different physico-
chemical properties was fortuitously supplemented by the advent of protein identification 
by mass spectrometry. The separation by 2D-PAGE relies on protein iso-electric point 
(pI) in the first dimension (isoelectric focusing, IEF) and apparent molecular weight 
(SDS-PAGE) in the second dimension. 
In a typical analysis pipeline, a protein mixture is first separated on a 2D-PAGE system 
and the resulting proteome pattern is subsequently visualized using a staining protocol. 
Popular examples of these are Coomassie brilliant blue [Meyer 1965] and silver staining 
[Switzer 1979]. 
Visualized protein spots can then be excised followed by proteolytic digestion either after 
dissolving the proteins from the gel or, more generally, directly inside the gel itself (in-
gel digestion). The proteolytic enzyme of choice is usually trypsin, whose propensity to 
cleave on the carboxy-terminal (C-terminal) side of arginine or lysine [Olsen 2004] 
generates peptides with at least one of these basic amino acids. This property is 
advantageous when making the step to mass spectrometry as mass spectrometers can only 
analyze charged ions. 
Identification of the isolated protein(s) then proceeds through a matching of the peptide 
masses recorded by the mass spectrometers to the masses of the in silico generated 
cleavage products from the entries in a protein sequence database. This comparison is 
usually too cumbersome to perform manually and specialized software has been written 
to allow the automated matching and scoring of peptide masses to protein databases 
[Pappin 1993, Mann 1993, Yates 1993, Clauser 1999, Colinge J 2003, Geer 2004]3. Such 
algorithms usually take a coverage factor into account when scoring a protein hit. This 
behaviour builds on the assumption that the protein digest generates full sequence 
coverage through the resulting peptides for the parent protein. Furthermore, it also 
expects the mass spectrometer to recover as many peptides as possible from the sample 
presented to it. Additionally, these algorithms can also adjust the score by employing the 
principle of completeness: all non-matching masses in a spectrum can be considered to 
provide evidence contrary to the hit that is being scored. This builds on the assumption 
that proteins are isolated in pure form after the 2D separation. 
2D gel-based approaches have certainly proved their usefulness over the years, yet some 
fundamental problems with this approach also became evident over time. 
One of the first problems noticed concerned basic proteins. The first dimension separates 
proteins based on pI by applying a voltage across a pH gradient in which the proteins are 
free to migrate. Proteins thus travel in the electric field towards the pole that has opposite 
charge compared to their own. During this migration the protein will encounter various 
pH buffering conditions and its net charge will be adjusted accordingly. Whenever a 
protein reaches the location where its pI equals the local pH, its net charge will be zero, 
immediately blinding the protein in question to the voltage gradient. At this moment, 
migration will cease and the protein will stay in this location. The problem with highly 
basic proteins is that the pH gradient cannot accommodate the extreme pI of these 
                                                 
3
 These algorithms are further discussed in section 1.2.1. 
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proteins. As such, these proteins will simply continue to migrate until they finally elute 
from the strip. Possible solutions for this problem have been proposed, but these tend to 
be very work-intensive and can only be applied to specific cases [O’Farrell 1977, Görg 
1988, Görg 1997, Görg 1999]. 
A second consideration centers on low-abundance proteins. As the 2D-PAGE approach 
relies on protein staining to visualize proteins prior to excising them and submitting them 
to further analysis, the recovery of low-abundance proteins hinges on the resolving 
power of the staining procedure. It turns out that the even the best staining protocols can 
only resolve the most abundant protein spots [Gygi 2000]. A complementary problem is 
that in the IEF phase there is a limit to the amount of material that can be applied. As 
such, 2D-PAGE analyses lack the dynamic range required to gain a complete view on 
the proteome. Additionally, low-abundance proteins are quite often highly important and 
influential in the living cell and therefore highly interesting study subjects [Marko-Varga 
2003]. 
Another class of proteins that presents specific challenges to 2D-gel based analyses are 
hydrophobic proteins. These proteins are difficult to fully and reproducibly extract from 
their natural milieu (i.e. hydrophobic biological membranes) and furthermore have the 
tendency to precipitate easily during the isoelectric focusing step, preventing them from 
penetrating into the second dimension and are thus lost. This problem has even proved 
frustrating enough to prompt lyrical review titles: ‘Membrane proteins and proteomics: 
un amour impossible?’ [Santoni 2000]. Typical examples of hydrophobic proteins are 
membrane proteins and, since these are crucial for a cell to explore and communicate 
with other cells and the outside world, not being able to detect them is a major 
impediment to achieving understanding of a living cell through proteomics. 
 
1.1.5. Skipping the protein phase 
Researchers started to tackle the problems inherent in 2D-PAGE proteomics by relying 
less on the protein as a unit for separation and identification, and more on the peptides 
that result after proteolytic digestion. 
The term peptide-centric4 proteomics is typically used to designate these technologies. 
This shift from proteins to peptides presents several benefits: 
- distributions of properties are less broad: peptides tend to suffer less from extremes 
in their physico-chemical properties; 
- peptides open up ways to employ a power-by-numbers strategy: a single protein can 
typically yield tens of tryptic peptides (the average protein size in SWISS-PROT 
release 48.7 is approximately 340 amino acids, with arginine residues comprising 
5.35% of all amino acids in the database and lysine accounting for 5.93%). Where 
protein-based separation represented a binary situation (either the protein is 
recovered, or it is missed), the peptide-based separation can now be related to a more 
fuzzy situation (x out of y peptides are recovered for a given protein, versus (y-x) 
that are missed). 
                                                 
4
 Initially these technologies were catalogued as gel-free proteomics. Since this is a negative definition and 
therefore not very informative about the actual concept, it can be said that this was not the best of choices. 
Peptide-centric proteomics, as a positive definition, is much more descriptive and has therefore taken 
preference over the last years. 
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- peptides are in general easier to handle: e.g., they do not precipitate that readily and 
contemporary mass spectrometers have an inter-spectrum dynamic range of several 
orders of magnitude making it possible to simultaneously analyze abundant and 
scarce peptides. 
It is obvious from the above that the proteolytic digestion of proteins into peptides before 
proteomic analysis introduces significant redundancy in the sample. This can be deemed 
both advantageous and problematic. An example of an advantageous effect is that large, 
hydrophobic proteins will yield quite a few hydrophobic peptides that remain difficult to 
separate and identify however, chances are very good that among the many peptides 
obtained after cleavage, at least some are more readily amenable to standard analysis 
techniques and that these are finally identified. The redundancy introduced by shifting to 
the peptide level thus enables more straightforward identification of the parent protein. 
Alternatively, having many distinct peptides instead of a single protein also increases 
sample complexity dramatically. This increase in complexity needs to be subsequently 
accommodated for in the separation phases. 
 
1.1.6. Separation revisited 
With the focus on the peptide instead of the protein, the separation methods employed 
necessarily needed to change as well. The first published protocols [Link 1999, 
Washburn 2001, Wolters 2001, Washburn 2002] were two-dimensional peptide-
separation techniques in which the familiar dimensions of 2D-PAGE protein separation 
were each replaced by peptide equivalents. The iso-electric focusing for proteins was 
replaced by ion-exchange chromatography and the MW separation was replaced by 
reverse-phase HPLC. This technique is called Multidimensional Proteome Identification 
Technique (MudPIT) and is illustrated in figure 8. 
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  Figure 8: Principle of the MudPIT technology. 
 
1.1.7. Selection as an alternative to separation 
As calculated above, the digestion of proteins by trypsin (by far the most commonly used 
proteolytic enzyme in proteomics) yields on average thirty, ten amino acid long peptides 
per protein. Assuming these peptide sequences are all unique, this directly leads to a 
dramatic increase in sample complexity. The separation methods employed in peptide-
centric proteomics however, cannot accommodate such a saturated mixture even after 
separating peptides in two dimensions. Consequently, the mass spectrometers analysing 
the resulting badly separated sample will be unable to select every passing peptide for 
fragmentation [Liu 2004]. 
For this reason, techniques have been developed that isolate representative subsets from 
the peptide mixture in order to reduce its complexity rather than relying solely on 
separation to spread the sample constituents over time [Gygi 1999, Spahr 2000, Wang & 
Regnier 2001, Oda 2001]. These methods are briefly discussed below: 
 
- Isotope coded affinity tag (ICAT) [Gygi 1999].  
The original ICAT molecule selects for cysteine-containing peptides by exploiting 
the highly reactive properties of the sulfhydryl side-chain of the cysteine. Typically, 
an affinity label (biotin) is attached to this side-chain via a thiol-reactive group such 
as iodoacetamide. A linker segment between these two groups is also present, which 
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can carry up to eight 2H (D) residues for differential labeling. Subsequently, 
cysteinyl peptides are affinity-isolated (streptavidin) and analyzed by MS techniques. 
The ICAT molecule is shown in figure 9. 
 
O
NH NH
S
N
H
O
O
OX
X
O N
H
X
X
X
X
X
X
I
O
biotin thiol-specific
reactive group
 
 
Figure 9: The ICAT molecule. Note the location of ‘X’ residues. These locations can 
contain either 1H or 2H (D), allowing the labeling strategy to be used for 
relative quantification of proteins. 
 
The principle of tagging peptide subsets in order to enable their subsequent isolation 
has been extended to include capture of diverse sequence elements and peptide 
modification states [Oda 2001, Wang 2002, Zhang 2003, Peng 2003, Khidekel 2004, 
Kho 2004, Denison 2005]. 
 
- Combined fractional diagonal chromatography (COFRADIC) [Gevaert 2002, 
Gevaert 2003, Gevaert 2004, Gevaert 2005]. 
COFRADIC is a technique based on diagonal chromatography of peptides in a 
HPLC system. The technique employs two identical reverse-phase (RP) HPLC runs 
on the same system, introducing a modification step in between the two runs that 
selectively targets certain peptides in the mixture by altering their chromatographic 
properties. Peptides can now be isolated because they show changed 
chromatographic behaviour (‘forward’ COFRADIC), or because they retain their 
original behaviour while all other peptides shift (‘reverse’ COFRADIC). A general 
depiction of the COFRADIC sorting procedure is given in figure 10. COFRADIC is 
discussed in detail in the next section. 
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Figure 10: General COFRADIC sorting principle. The changed chromatographic 
properties of targeted peptides following the modification reaction moves 
them outside of the original elution fraction (lower chromatogram).  
 
These techniques all have to maximize the reduction of sample complexity whilst 
simultaneously minimizing the amount of proteins that are lost due to the absence of 
identifiable peptides in their sequences. It is clear that the selection procedure is often 
based on sequence features of the peptides and that the most popular targets are therefore 
modifiable rare amino acids and functional groups. The relative scarceness of these 
amino acids allows them to act as prime complexity reducers. As an illustration, the 
theoretical reduction in complexity as well as the loss of sample coverage against the 
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SWISS-PROT database (dd. 24th of January 2006) are given for the most popular rare 
amino acids and proteolytic enzymes in table 1 below. 
 
Enzyme Selection Complexity reduction Proteins missed 
All 0% 0.16% 
Met 74% 1.73% 
Mu 77% 4.34% 
Cys 75% 4.22% 
His 70% 3.78% 
Trypsin 
Trp 84% 9.29% 
     
    
All 0% 0.95% 
Met 71% 4.97% 
Mu 75% 9.95% 
Cys 73% 9.61% 
His 66% 8.43% 
Arg-C 
Trp 82% 17.75% 
 
Table 1: Theoretical complexity reduction and unrecoverable protein fraction using 
several common subset isolation strategies for both trypsin and ArgC digests of 
the human subset of SWISS-PROT (24 January 2006). ‘Mu’ denotes methionine 
residues minus initiator methionines. 
 
1.1.8. COFRADIC 
1.1.8.1. Methionine COFRADIC 
Isolation of methionyl peptides hinges on the modification reaction of methionine to 
its sulfoxide by peroxide [Gevaert 2002]. This reaction is shown in figure 11. 
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Figure 11: Conversion of methionine to its sulfoxide by peroxide between the primary 
and secondary COFRADIC runs. 
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Because of the dipole moment introduced, this methionine-sulfoxide is more hydrophilic 
than the original methionine, inducing a hydrophilic shift for all methionyl peptides. In 
order to optimize the throughput of this technique, several primary fractions can be 
pooled5 prior to the secondary run reducing the number of required secondary HPLC 
separations. The pooling of four fractions is illustrated in figure 12. 
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Figure 12: Pooling of four different methionine COFRADIC fractions. Traces of shifted 
peptides are set against a grey background in the second RP-HPLC step. 
 
                                                 
5
 Or ‘combined’, yielding the ‘CO’ in the acronym COFRADIC. 
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1.1.8.2. Cysteine COFRADIC 
Isolation of cysteinyl peptides follows a slightly different scenario [Gevaert 2004]. 
The chromatographic shift is accomplished here by the removal of a thionitrobenzoyl 
(TNB) moiety from the cysteine side-chain between the first and second 
chromatographic step. The modification of cysteine residues with Ellman’s reagent 
(5,5-dithiobis(2-nitrobenzoic acid) or DTNB) to obtain the mixed disulfide (TNB-
cysteine) therefore takes place before the primary HPLC run. The TNB-cysteine is 
more hydrophobic than free cysteine and removal of the TNB moiety by tris(2-
carboxyethyl)phosphine (TCEP) reduction prior to the secondary COFRADIC run 
results in a hydrophilic shift for cysteine-containing peptides. The entire process is 
represented in figure 13. 
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Figure 13: Cysteine modification with Ellman’s reagent prior to the primary COFRADIC 
run yields TNB-cysteine which is more hydrophobic than regular cysteine. 
After the primary run, a simple reduction step decouples the thionitrobenzoyl 
moiety and the resulting free cysteines display a hydrophilic shift in the 
secondary run. 
 
1.1.8.3. Amino terminal (N-terminal) COFRADIC 
N-terminal COFRADIC is an odd duck in the pond when one considers peptide-
isolation strategies [Gevaert 2003]. Unlike most other strategies, this technique 
isolates peptides based on a positional parameter instead of their amino acid 
composition. Another peculiarity of N-terminal COFRADIC is that it is considered 
‘reverse’ COFRADIC since the chemistry employed between the primary and 
secondary separation step will shift all non-N-terminal peptides. The collected 
peptides will therefore be the non-shifting ones that have retained their original 
chromatographic properties. 
In practice, the sample is first prepared by the addition of iodoacetamide to alkylate 
free cysteines and subsequently treated with sulfo-N-hydroxysuccinimide acetate to 
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acetylate all free amines (both α- and ε-amines). Note that up to this point, all 
reactions are applied to a protein mixture. The next step is tryptic digestion. Because 
the ε-amines of the lysine residues have been acetylated, trypsin will only cleave C-
terminally of arginine residues, thus effectively behaving like endoprotease Arg-C. 
There are now two kinds of peptides in the mixture: those that formed the original 
protein N-termini and those resulting from the proteolytic cleavage with trypsin. The 
former carry acetylated α-amines while the latter present a free α-amine. The next 
step then is to perform the primary COFRADIC run. After this first run, the collected 
fractions are subjected to 2,4,6-trinitrobenzenesulfonic acid (TNBS). This reagent 
reacts with free amines to form trinitrophenyl-peptides. Since only the internal 
peptides possess free amines, these are the only ones modified. The trinitrophenyl-
peptides are much more hydrophobic than their original counterparts and will 
therefore shift outside the original collection interval. Since the targeted peptides are 
the unaltered N-terminal peptides the non-shifting peptides will be collected here. 
The TNBS reaction step is displayed in figure 14 for both N-terminal peptides and 
internal peptides.  
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Figure 14: TNBS modification reaction. Note that cysteines have been alkylated and 
protein N-termini and lysines have been acetylated. 
 
Example chromatograms (UV absorbance measured at 214 nm) for the primary and 
secondary run are shown in figure 15, illustrating the concept of ‘reverse’ 
COFRADIC. 
 
22 
6
min40 45 50 55 60 65 70 75 80 85
mAU
0
200
400
600
800
1000
1200
1 2 3 4 5 6 7 8 9 10 11 12
primary run
min40 45 50 55 60 65 70 75 80 85
0
25
50
75
100
125
150
175
200
225
mAU
internal TNP-peptides
amino
terminal
peptides
secondary run
TNBS modification
 
 
Figure 15: N-terminal or ‘reversed’ COFRADIC. Note that the shifting peptides are the 
unwanted fraction here. 
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1.2. Identification of proteins by mass spectrometry 
The process by which mass spectrometry data is converted into protein lists is governed 
by two important assets: software algorithms that take care of identifying mass spectra 
and, for most of these, the protein sequence databases they use as search space. 
The various types of identification algorithms as well as the importance and 
characteristics of protein sequence databases will be discussed in the next subsections. 
 
1.2.1. Identification algorithms 
1.2.1.1. Classification and description of common approaches 
Identification algorithms can be roughly divided in two separate groups: those that utilize 
solely the information contained in a spectrum (de novo algorithms) and those that 
require a sequence database to search against (search algorithms). 
The former approach is often used when unknown post-translational modifications need 
to be picked up or when there is insufficient proteomic or genomic information available 
for the organism under study to apply search algorithms. De novo algorithms usually 
require very clean fragmentation spectra and high ion series coverage in order to operate 
reliably. When applied to high-throughput spectra this usually leads to incomplete 
sequencing or reporting of many indiscernible possibilities. Because of the problems 
associated with coupling de novo sequence analysis to high-throughput proteomics and 
the growing availability of good proteomic or genomic sequences databases for nearly all 
model organisms, these identification algorithms tend to be reserved for semi-automatic 
or manual application in special cases. Several algorithms exist, including Lutefisk, 
Sherenga, PEAKS and PepNovo [Dancik 1999, Taylor 2000, Fernandez-de-Cossio 2000, 
Ma 2003, Zhang 2004, Frank 2005, Grossmann 2005]. 
The search algorithms all attempt to match a spectrum (or spectrum-derived information) 
to sequence databases at some point during their processing. There  are two main 
approaches to matching a spectrum to a database, the first of which represents a hybrid 
between de novo and search algorithms. A spectrum is first examined for the presence of 
short sequence tags, small groups of a few consecutive amino acids that can be extracted 
even from spectra with incomplete ion series coverage. These sequence tags are 
subsequently matched against the database. Several tag-based engines have been 
developed over time, with PeptideSearch [Mann 1994] being one of the first and 
GutenTag [Tabb 2003] one of the most recent algorithms. A completely different 
algorithmic approach with a similar mixture of de novo sequencing and database 
searching is taken by Popitam [Hernandez 2003]. This software uses an Ant Colony 
Optimization algorithm to attempt the fitting of sequences to a spectrum in a massively 
parallel way. The result is a set of ‘walks’ through the spectrum, each of which is inspired 
and limited by a sequence from a database. When a walk is highly successful, it will 
become more pronounced, attracting more ‘ants’ to further explore it. The end result is an 
optimal explanation of the spectrum by a sequence in the database. 
The other type of database search algorithm is fully database-centric. In this category the 
two most popular search engines in the field today can be found: Mascot [Perkins 1999] 
and SEQUEST [Eng 1994]. Apart from these two commercial algorithms, some open 
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source search engines are also available, most notably OMSSA [Geer 2004] and 
X!Tandem [Fenyo 2003]. All of the algorithms in these categories first generate in silico 
peptide sequences from the available protein sequences and then construct theoretical 
fragmentation spectra from these peptide sequences. These in silico spectra are then 
compared with the experimental fragmentation spectrum and a score is assigned to the 
match. The difference between these algorithms can be found in the scoring function 
applied and whether or not thresholds are reported. 
SEQUEST applies a cross-correlation function to derive its main score (a preliminary, 
filtering score called ‘p-score’ is first calculated based on the number of matching 
fragment peaks, possible sequence continuity in them and their intensities) where Mascot 
uses the MOWSE score function [Pappin 1993]. Another main difference between 
SEQUEST and Mascot lies in the fact that Mascot also provides a statistically relevant 
threshold score for each spectrum. Whenever a peptide match scores below this 
threshold, the identification should be disregarded. This threshold is set at a 95% 
confidence interval by default, but can be readily adapted in stringency if desired. Even 
though SEQUEST does not have a built-in thresholding scheme, the Expectation-
Maximization and Bayesian statistics applied post-identification by the PeptideProphet 
algorithm [Keller 2002] can provide a highly useful distinction between true positives 
and false positives for SEQUEST. It is of note that the combination 
SEQUEST/PeptideProphet achieved very similar results to Mascot in a large-scale test 
performed by Kapp et al. and that these two algorithms clearly outperformed the other 
algorithms tested [Kapp 2005]. Other approaches to achieve a better discrimination 
between true and false positives for SEQUEST include RScore [Li 2004] and machine-
learning strategies [Anderson 2003, Baczek 2004]. 
The approach taken by the OLAV [Colinge 2003] algorithm refines the generation of a 
theoretical fragmentation spectrum from a sequence in a database by a stochastic 
prediction of the chances for each fragment ion to appear, thus attempting to predict the 
actual measured spectrum as well as possible before scoring the match. 
 
1.2.1.2. Mascot threshold calculation 
Since the work described in this dissertation has been performed using the Mascot search 
engine, the threshold calculation performed by this particular algorithm is examined in a 
little more detail here. It is important to know that the actual MS/MS-based identification 
engine of Mascot has not been published, and that all information about its workings has 
therefore to be inferred from its observed behaviour. Within the scope of this text 
however, these indirect clues are more than sufficient. 
A probabilistic algorithm such as Mascot attempts to estimate an a priori chance of 
random matching against a sequence database. This estimate necessarily relies on the 
number of unique peptide sequences in the search base, which we will here call the 
information content of the database for a specific proteolytic enzyme. In order to provide 
a practical estimate of this information content for a certain proteolytic enzyme, Mascot 
takes the size of the database (expressed as the total number of amino acids in that 
database) and the prevalence of the recognized residues for cleavage into account when 
calculating the identity threshold score. Indeed, the average identity threshold score for a 
certain enzyme in a certain sequence database is the reciprocal of the logarithm to base 
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10 of the total number of amino acids in that database. This relationship is illustrated for 
trypsin across a few often-used databases in figure 16. 
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Figure 16: Relationship between the number of amino acids in a search space and its 
average identity threshold score for a trypsin digest in Mascot. 
 
1.2.2. Protein sequence databases 
As has been outlined in section 1.2.1.1, high-throughput protein identification is usually 
based on database search algorithms. Interestingly, even though the sequence database 
employed represents the most basic source of information in these identifications, its 
importance is often disregarded. In the next three subsections the most commonly used 
sequence databases for protein identification will be briefly discussed and in the fourth 
subsection a note is given on the instability in time of sequence databases. 
 
1.2.2.1. UniProt KnowledgeBase (SWISS-PROT/TrEMBL) 
The central UniProt [Wu 2006] database builds on two well-established pillars in the 
sequence database world: the SWISS-PROT and TrEMBL databases. The key difference 
between SWISS-PROT and TrEMBL6 lies in the manual curation effort that underlies the 
former. Indeed, all entries in SWISS-PROT have passed through a rigorous manual 
control by human curators. During this curation process diverse information sources are 
consulted and cross-verified in order to establish which annotations are clearly supported 
by trustworthy evidence. The result of these efforts is an extremely high-quality and 
stable7 protein sequence database with heavily cross-linked annotations. Obviously, the 
                                                 
6
 This statement can actually be extended to ‘the key difference between SWISS-PROT and any other 
popular protein sequence database’. 
7
 The number of sequences curated into SWISS-PROT continues to grow, so ‘stable’ here simply means 
that it is unlikely that an entry will be deleted from SWISS-PROT. 
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curation process is labour-intensive and this limits the reach of the SWISS-PROT 
database. The TrEMBL database complements this nicely, however. It contains 
automatically annotated proteins, including predicted protein sequences for which 
corroborating evidence exists. 
UniProt is more than simply a list of sequences and their annotations, however. Apart 
from the UniProt KnowledgeBase, the system encompasses a complete sequence archive 
called UniParc and UniRef, a set of reference clusters at different sequence identity 
levels. 
 
1.2.2.2. The NCBI non-redundant database 
The National Center for Bioinformatics Information (NCBI, http://www.ncbi.nih.gov) 
provides a non-redundant sequence database that is usually referred to as the ‘NCBI nr’ 
database. This database groups sequence information from a variety of sources, including 
SWISS-PROT, TrEMBL and RefSeq. The latter consists of two distinct types of entries, 
NP and XP, which are readily identifiable by their accession numbers. The NP sequence 
have corroborating evidence such as cDNA to back up their validity while the XP 
sequences are based purely on predictions. It is clear that the level of annotation and 
available cross-links varies considerably between entries and is largely dependent on the 
source of the sequence.  
The database is non-redundant at the absolute protein sequence level, meaning that no 
two sequences are completely identical in the database. History management is also 
provided via the Entrez web interface (http://www.ncbi.nlm.nih.gov/entrez/). 
 
1.2.2.3. The International Protein Index (IPI) 
This database finds its origins in the human genome project [Lander 2001] and was 
originally conceived as a non-redundant view on all known human proteins. Over the 
years the reach and scope of the IPI database has grown [Kersey 2004], yet the basic 
premise of providing an intelligently designed non-redundant protein sequence database 
has remained. IPI is now available for a variety of model organisms, including human, 
mouse, rat and Arabidopsis. IPI now presents an automatically curated view on the total 
contents of a large collection of sequence databases (including UniProt, RefSeq and 
EnsEMBL) by a rather complex algorithm to remove sequence redundancy in a thorough 
way. Simply put, the algorithm can be described as follows: instead of simply requiring 
each protein sequence to be unique, sequences are also collapsed into clusters when they 
show more than 95% overlap over the full match length. When a cluster consists of 
sequences of different lengths (which often happens due to the presence of protein 
fragments as separate entries in several source sequence databases), the longest sequence 
is chosen as the master sequence. Notable exceptions to the clustering rule are the 
annotated UniProt splice-variants, which are retained as separate entries. Each cluster is 
finally assigned an IPI accession number and all source references aggregated in the 
cluster are expressly reported in the IPI entry. 
IPI also provides complete history files, which trace the history of every entry that has 
ever carried an IPI identifier. 
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1.2.2.4. Time-instability of sequence databases 
In the above sections it has been mentioned that each of the sequence databases maintains 
sequence history in a specific way. The ability to trace a sequence (or its (versioned) 
accession number) through time is once again a much-overlooked yet highly important 
characteristic of a sequence database. 
Indeed, sequences in any database are subject, to a greater or lesser degree, to changes 
over time. The primary event of any sequence is of course its first inclusion in a database. 
This can be traced for each entry in the abovementioned sequence databases. Once a 
sequence has been recorded in a database, it can undergo alterations as well. Depending 
on the database, these alteration events can trigger a change in the accession 
versionnumber or even cause the assignment of a new accession number. In the latter 
case, tracing is usually provided in such a way that the original accession number will 
still link up to the sequence. 
Certain sequences can be subjected to removal from the database, invalidating the 
accession number without providing a replacement. This effect is most pronounced for 
purely theoretical predictions (such as the abovementioned RefSeq XP entries). Indeed, a 
change in the prediction algorithm usually renders a number of previous predictions 
obsolete. From figure 17 it can be clearly seen that this deletion of spurious predictions 
has been most clearly noticeable over the period between December 2001 and December 
2003, inclusive, for RefSeq XP. Also note that a database such as IPI, which combines 
information from different sources (including RefSeq XP), suffers the same fluctuations 
as its source databases. 
An often-heard complaint from proteomics researchers concerns this deletion of 
sequences that have been identified by proteomics approaches. For example, using the IPI 
version of April 2002 one can clearly and uniquely identify several proteins that are 
derived solely from RefSeq XP. After a few months (for example in September 2002) re-
examination of the data set may reveal that all RefSeq XP sequences have been deleted 
from the database. This issue is all the more unfortunate since the main difference 
between RefSeq XP and NP numbers lies in the availability of external evidence for the 
correctness of the prediction, which has in fact been furnished by the mass spectrometric 
identification of the sequence. 
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Figure 17: Changes in the IPI database and its subsidiary databases over the October 
2001 – October 2004 period. Figure was obtained from the IPI website 
(http://www.ebi.ac.uk/ipi). 
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1.3. Mass spectrometry for the (relative) quantification of proteins 
Proteomics studies often require differential labeling of two distinct samples to find 
proteins (or their modified forms) that differ in concentration. Some reviews are given 
here for differential labeling [Monteoliva 2004, Julka 2005] as well as for absolute 
quantification [Bronstrup 2004, Kirkpatrick 2005], although the latter falls outside the 
scope of this dissertation. In some cases, differential labeling of differently treated 
aliquots of the same sample may be required [Gevaert 2005]. The result of either 
approach can be seen as two distinct containers, each containing either a ‘light’ label or a 
‘heavy’ label. This nomenclature is derived from stable isotopes such as 1H and D, 16O 
and 18O, 14N and 15N or 12C and 13C. These isotopes differ only in their mass and thus 
yield otherwise identical compounds upon incorporation into molecules8. As mass is the 
only difference between the molecules subjected to differential isotopic labeling, it makes 
them ideal subjects for mass spectrometry where they can be readily separated into light 
and heavy peptides9. Subsequent analysis of the intensities of the corresponding m/z 
signals can yield insight into the ratio of these peptides in the mixture, thus allowing the 
experimentalist to obtain differential data and back-couple this to the state of the 
proteome. 
The detectors utilized by mass spectrometers have their limitations in terms of dynamic 
range, however. This dynamic range was studied in detail for the detector of the Bruker 
Ultraflex instrument. A complete N-terminal COFRADIC sample was divided to two 
aliquots which were labelled with 16O and 18O respectively. The labelled peptides were 
subsequently mixed in different ratios, yielding eighteen aliquots ranging from a 1/9 to a 
10/1 light over heavy ratio. Each of these mixtures was analyzed by the mass 
spectrometer and the resulting observed ratios were plotted against the known ratios in 
figure 18. 
 
                                                 
8
 In practice, elution characteristics on HPLC columns sometimes differ slightly for different isotopes of 
the same element, an effect that can become noticeable when incorporation of multiple isotopes (especially 
H/D) is used. 
9
 Heavy isotopes occur naturally and will be incorporated into any biomolecules in ratios corresponding to 
their prevalence. As such, each biomolecule (such as a peptide) will display an isotopic pattern when 
analyzed by mass spectrometry. Certain incorporations such as single incorporations of 18O or up to two 
incorporations of 2H can lead to clearly overlapping isotopic patterns, presenting a more complex challenge 
in extracting the original abundances of light and heavy labeled peptides. 
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  Figure 18: Dynamic range of the detector of the Bruker Ultraflex instrument. 
 
The measured ratio is seen to level off at the extremes with the more extreme ratios also 
suffering from a larger standard deviation. There are two complementary explanations for 
this behaviour. The first one is that the detector response levels off at a certain amount of 
ions detected. This is due to saturation effects on the electron multiplier that amplifies 
detected signals. This saturation effect will be influenced by the actual amount of ions 
detected by the detector, which will depend on the amount of peptides spotted, the 
ionization properties of the peptides and those of other peptides in the same spot on the 
target10. 
The second effect is associated with the software processing of the mass spectra as 
recorded by the instrument. In order to calculate ratios, the instrument software must first 
determine peak intensities for both light and heavy isotopes. This in turn hinges on being 
able to detect a set of m/z peaks as the isotope envelope of a peptide, and this for both 
labeled peptides. When the ratios of mixed peptides approach a tenfold overabundance of 
either light or heavy labeled peptides, the signals generated by the minor component will 
be more readily lost in the noise, making detection difficult. This decreases the number of 
available measurements, negatively influencing the standard deviation. 
                                                 
10
 All peptides on the same spot compete with each other for the available charges. If a particular peptide is 
for instance much more prone to capturing a charge than all others, the resulting peptide ions will be 
prominently observed by the detector, even if this particular peptide is not dominantly present in the 
mixture contained within the spot. 
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1.4. Making every peptide count 
1.4.1. Defining coverage 
The term ‘coverage’ suffers from ambiguity in the context of this text and it therefore 
stands to reason that we clearly define it here. The number of proteins correctly identified 
from a mixture will be called ‘sample coverage’. The coverage of a protein sequence by 
the individual sequences of the identified peptides will be referred to as ‘protein sequence 
coverage’11. 
 
1.4.2. Concerning coverage and complexity 
As has been explained in section 1.1.4, protein sequence coverage plays a significant role 
in the processing of identifications after mass spectrometric analysis of the spots on 2D 
gels. For the gel-free approaches however, this situation changes. Whereas MudPIT 
approaches (at least in theory) retain the ability to generate full protein sequence 
coverage, most of the peptide-centric techniques apply a peptide-isolation step to reduce 
complexity. Obviously, selecting for only a subset of peptides removes the possibility of 
having 100% protein sequence coverage. The extreme case of this is found in amino 
terminal COFRADIC, which (theoretically) yields only a single amino terminal peptide 
and obvious exceptions (e.g. peptides with TNBS inaccessible N-termini such as proline 
and pyroglutamic acid). 
Since mass spectrometers often have difficulties fully analysing very complex samples 
[Liu 2004], gel-free techniques that retain a high level of protein sequence coverage (and 
therefore a highly complex peptide mixture) suffer from a corresponding loss of sample 
coverage. Approaches exist that can partially alleviate this problem under certain 
circumstances. These are detailed below: 
- Increase separation [Wang 2005] 
By performing additional (preferably independent) separation steps the peptides are 
spread over a much broader range and the time between the presentation of 
individual peptides to the mass spectrometer increases. There are two major 
difficulties with this approach. The first of these concerns the additional 
manipulation of the sample. Due to surface adsorption, incomplete chemistry or 
precipitation effects losses occur, making it likely that low abundance proteins or 
their peptides have altogether disappeared from the sample by the time it reaches the 
mass spectrometer. Secondly, the increased separation steps can be laborious work, 
requiring skilled operators. Additionally, if a step n yields Fn fractions after 
separation, the number of times the (n+1)th step needs to be applied is given by the 
following multiplicative series: 
 
                                                 
11
 Note that protein sequence coverage can be exactly calculated when the peptide sequence and enzymatic 
cleavage applied are known, whereas the sample coverage is usually unknowable. Indeed, if we would a 
priori know the total number of proteins in a mixture, we would have already detected all of them, 
obviating the need for re-analysis. 
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This is also illustrated in figure 19. 
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Figure 19: multiplicative increase in the number of separation steps required 
 
In all, the combined workload together with the poor automation of these steps and 
the finite time required to perform each separation make this system largely unsuited 
to high-throughput analysis. 
- Use of dynamic (in time) and static exclusion lists [Spahr 2000] 
One can instruct most modern mass spectrometers with an ESI source to disregard 
certain peptide m/z values when selecting precursors to fragment during analysis. 
This can be done using both dynamic and static techniques. The dynamic exclusion 
approach is applied on the fly during the analysis: after having selected a particular 
precursor for fragmentation, the mass spectrometer will ignore that precursor mass 
for a preset time interval, enabling it to fragment a less intense precursor next. Two 
problems are immediately evident: mass spectrometers usually select the most 
intense precursor for fragmentation first. During the fragmentation cycle, the 
machine is blind to all other ions that elute and chances are real that a less intense 
peak has completely eluted from the column by the time fragmentation of the first 
precursor completes. Secondly, very abundant peptides can elute over a broad time 
interval, which can be several times larger than the period of blindness that was set 
on the mass spectrometer. As such, multiple fragmentation spectra will still be 
recorded for this peptide while ignoring less intense, co-eluting ions. With static 
exclusion a run is fully completed (often using dynamic exclusion within that run) 
and subsequently the full list of m/z values for identified peptides is presented to the 
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mass spectrometer. The run will then be repeated and the machine will ignore all 
precursors in the exclusion list. Again, two problems can be found. First of all, when 
the mass spectrometer cannot deduce charge state correctly, the exclusion list needs 
to contain at least 2 or 3 different m/z values for each precursor. This leads to an 
increase in the number of possible matching peptides, including peptides that have 
not been identified. These novel peptides will thus be erroneously ignored and cannot 
be detected. Second, the analysis time is doubled using this approach while the 
sample needs to be halved. 
Finally, the exclusion list approach cannot alleviate the problems of quenching that 
occur for MALDI sources [Gevaert submitted]. 
- Selection of a subset of peptides from the digest prior to separation [Gygi 1999, 
Spahr 2000, Wang & Regnier 2001, Oda 2001] 
By selecting a subset of the total number of peptides from the initial proteolytic 
mixture, the complexity can be greatly reduced. This reduction can also be tailored 
through the use of an appropriate selection criterion (see table 1). The efficiency of 
the separation step(s) is enhanced by performing them on a less complex mixture, 
requiring less steps and thus minimizing sample-handling losses. Since there are less 
peptides presented to the mass spectrometer over a given time interval or within a 
certain spot on a MALDI target, higher recovery rates can be expected (a higher 
percentage of peptides presented are analysable in detail by the mass spectrometer). 
This increased sensitivity will subsequently allow better sample coverage, especially 
for low abundant proteins or hydrophobic proteins. An important problem with 
selecting peptide subsets is that the increased sample coverage advantage can be lost 
when peptide fragmentation spectra cannot be assigned to database entries. Indeed, 
selecting peptides from the mixture implicitly reduces the information redundancy at 
the peptide level. This is illustrated in figure 20 for various peptide selection 
techniques. It is therefore vital for these techniques to make every analyzed peptide 
count. 
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Figure 20: Boxplots of the number of in silico predicted retrievable peptides per 
protein using different sequence-based peptide selection strategies in 
SWISS-PROT (dd. 24 January 2006) for (a) trypsin and (b) Arg-C digests. 
The median for each boxplot is indicated. ‘Mu’ denotes methionines without 
taking initiator methionine into account.  
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1.4.3. The issue of undersampling 
From the previous section it is clear that peptide selection has the benefit of dramatically 
reducing complexity while maintaining high theoretical sample coverage. It has also been 
established that this sample coverage is less robust because of lower redundancy at the 
peptide level (lower protein sequence coverage) requiring higher identification efficiency 
in order to obtain sufficient sample coverage. There is another issue with regards to 
sample coverage and peptide selection that remains to be discussed, however.  
Whenever a sample is analysed by any proteomics technique, it will not be completely 
covered in one single analysis. This problem can be described as undersampling: the 
analysis method samples only a fraction of the complete sample for detailed analysis and 
thus identification. One of the problems of 2D-PAGE based methods as highlighted in 
section 1.1.4 above for instance, is that these approaches consistently fail to pick up 
certain classes of proteins. Sample coverage thus reaches a nearly unbreachable 
threshold, regardless of the number of times the analysis is applied. 
Peptide-centric approaches (peptide-subset isolating as well as non-isolating techniques) 
provide a different case, however. It has been reported that with each new iteration, 
repeated applications of an analysis technique reveal novel proteins, together with 
redundant identifications of proteins identified in one of the previous iterations [Liu 
2004]. 
In order to show how non-selective and selective peptide-centric strategies fare over 
multiple iterations with regards to coverage, a simplistic but revealing thought 
experiment is conceived: consider a complete digest of a sample consisting of 100.000 
peptides. Now suppose that the LC-coupled ESI mass spectrometer used for producing 
fragmentation spectra has an upper limit of producing 8.000 peak lists over the gradient 
applied on the LC column. Also suppose that these peak lists are spread randomly across 
all peptides present in the mixture. This implies that in optimal conditions we only cover 
8% of the peptides in the sample in a single iteration. Now consider a second analysis 
attempt, employing the exact same set-up. We now have 8.000 ‘known’ peptides and 
92.000 ‘unknown’ peptides in the mixture. Since our mass spectrometer samples in an 
unbiased way, it can be expected that, of the 8.000 fragmentation spectra recorded, 7.360 
(94%) will be derived from the 92.000 unknown peptides, and 640 (6%) from the 8.000 
known peptides. This leads to a total number of 15.360 ‘known’ peptides, reducing the 
number of unknown peptides to 84.640 and reaching sample coverage of a little over 
15%. Applying successive iterations will yield an ever dwindling number of novel 
identifications as the ‘unknown’ fraction becomes smaller and the unbiased mass 
spectrometer is less prone to sample from among them. 
Of course, the limited capacity of our mass spectrometer is something we cannot change, 
but we can reduce the original sample complexity by selecting for a subset of peptides. If, 
for instance, we select for cysteine or methionine-containing peptides, we reduce 
complexity by roughly 75% (see table 1 and the boxplots in figure 20 above). This yields 
an initial sample complexity of 25.000 peptides. The 8.000 peak lists recorded by the 
mass spectrometer now not only provide a larger sample coverage in the first iteration, 
but also keep the coverage increase from dropping too quickly in subsequent iterations. 
The N-terminal COFRADIC approach goes one step further and theoretically reduces 
each protein to a single N-terminal peptide, which would decrease sample complexity 
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even further to 3% of the original (SWISS-PROT has an average of 34 tryptic peptides 
per protein; see section 1.1.5). In practice, pyro-glutamate and proline-starting peptides 
are also picked up, so we will (somewhat pessimistically) state that we have 10.000 
peptides in the mixture. It is clear that the sampling efficiency of our mass spectrometry 
(with its limited capacity) is now 80%! 
The theoretical results of this thought experiment are visualized in figure 21. 
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Figure 21: Sample coverage over successive iterations for peptide selecting and non-
selecting techniques. 
 
Of course, the above thought experiment lacks certain key features of real-life 
experiments. Peptide copy number is not taken into account nor the difficulty in eluting 
certain peptides on an RP-column or sequence-specific variability in the ability to 
generate good fragmentation spectra, to name but a few. Although these additional 
parameters would lower the absolute performances, it is also clear that they would affect 
the three strategies discussed above equally and therefore would probably not 
significantly alter their relative performance. The thought experiment thus provides a 
useful way to clearly show that, because of the effect of undersampling, a significant 
reduction of sample complexity is a very desirable characteristic of any peptide-centric 
technique that aims to achieve decent sample coverage over a minimum number of 
iterations. 
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1.5. Informatics challenges for a high-throughput proteomics 
laboratory 
Data generation in a high-throughput proteomics lab very quickly reaches a volume that 
can no longer be supported by manual management of spectra and identifications. This is 
illustrated in figure 22, where the total number of fragmentation spectra in the ms_lims 
database of the proteomics laboratory in Ghent is shown for each month over a two-and-
a-half year interval. Note that this growth curve corresponds to an average increase of 
approximately 38.000 spectra per month. Due to this high volume of data generated, a 
high-throughput proteomics lab today is confronted with at least three distinct software 
issues (and corresponding user roles): data integration, data processing and data analysis. 
Ideally, the results of the research will be published, raising a fourth software issue: data 
dissemination. We will discuss each of these separately in the following four subsections. 
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Figure 22: Number of spectra in the ms_lims database of the proteomics group in Ghent 
over time. 
 
1.5.1. Data integration 
It is clear that the flood of proteomics data necessitates the transition from manual 
management of the data produced to the use of specialized software for automated 
handling and structured storage. The software in question must first and foremost allow 
transparent and straightforward integration of the data presented by different producers, 
ideally converting this data to a common format in a shared infrastructure. 
The different primary data producers in the proteomics laboratory in Ghent are outlined 
in figure 23. This set-up can be considered typical for many proteomics labs, as it is often 
the case that various instruments of various manufacturers are combined on the basis of 
the complementarity of their respective strong points. 
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Figure 23: Schematic representation of the data producers in the proteomics lab in Ghent 
(situation dd.30 January 2006). 
 
It is clear from even this rough schema that the different producers nearly all produce 
different output formats (this is even the case for machines from the same vendor!). 
Additionally, each machine has a different instrument management software and a 
different operator yielding different file management strategies for each machine as well. 
Software that successfully integrates the data produced by these machines therefore has 
to be tuned to each specific instrument while providing all operators with a consistent 
interface. The output of this software should be provided in a common format and stored 
in a common structure so that downstream applications need not concern themselves with 
the disparities in original formatting and structure. Finally, the integration software must 
also be easily extensible; whenever a new instrument is added to the pool of data 
producers, the amount of time and effort to include this new data source should be 
minimal. 
 
1.5.2. Data processing 
Data processing can encompass a whole range of possible manipulations of the data. The 
most essential of these is the step from spectrum to identified peptide and further to 
identified protein. This task is usually delegated to commercially or publicly available 
software such as SEQUEST [Eng 1994], Mascot [Perkins 1999] or X!Tandem [Fenyo 
2003]. The challenge for the data management software here lies in integrating the 
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submission of spectra and retrieval of identifications from the third-party software. 
Additionally, some post-processing is usually required to filter out identifications that are 
deemed incorrect and to assign protein identifiers to reported peptides in a more apt way. 
These latter tasks can be incorporated into the data management software, or can be 
derived from third-party applications such as PeptideProphet [Keller 2002], DTASelect 
[Tabb 2002], CHOMPER [Eddes 2002] or ProteinProphet [Nesvizhskii 2003]. 
 
1.5.3. Data analysis 
When the source data has been converted and stored, subsequently submitted to a third-
party identification algorithm and the results have been retrieved, parsed and stored, the 
now complete dataset needs to be presented to the operator or the scientist in order for 
them to extract value from the data. As there are many possible ways to analyse the data, 
there can be no single data analysis application that can take care of handling all possible 
questions a data consumer might have. For this reason, the data analysis software is 
usually composed of a suite of several (independent) modules, each of which retrieves 
and analyses those sections of the total data storage it deems relevant. These modules are 
the most variable part of the entire software package. Apart from a few basic data 
retrieval and visualisation applications, most of the modules will have been tailored to 
answer a specific question at a specific time. When the relevance of this question has 
diminished, the specific application may fall into disuse. Of course, at any specific time 
in the future, the question might gain in importance again, prompting a data consumer to 
revert to using the application once more. The relevance of this is that an analysis 
application once programmed and released in production, will usually require 
maintenance even if it seems to have fallen into disuse. 
 
1.5.4. Data dissemination 
Data dissemination is the Achilles heel of proteomics research [Prince 2004, Rohlff 
2004]. This tendency to hold back or obfuscate data used in published results is 
particularly sad as any scientific undertaking since the Enlightenment hinges on the free 
communication of results. Indeed, it can be stated that data is the blood of the scientific 
community and that papers are the pumps that should drive its circulation. 
There are numerous reasons why so little data has been made available and so little of the 
available data is readily accessible. These reasons fall into two broad categories: 
logistical and sociological (for lack of a better term) reasons. The logistical reasons are 
outlined and discussed next. It is of course beyond the scope of this dissertation to 
thoroughly analyse the sociological phenomena that occur in the proteomics scientific 
community and these will not be discussed here. 
In order to publish a large amount of data (e.g. tens of thousands of peak lists, yielding 
thousands of peptide identifications which in turn support several hundred protein 
identifications) in a queryable, human and machine readable way poses three distinct 
challenges. 
The first problem centers on local data management. If data is managed manually from 
start to end, it is usually impossible to back-trace from protein to supporting peptides to 
original peak lists. Even if data has been collected automatically using third-party 
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software, it is often impossible to export the required data in a meaningful format for 
general dissemination because the software does not contain this feature by default and 
its data is insufficiently accessible to provide a solution in-house. 
The second problem concerns standardization. Standardization works on two separate 
levels. The first part of any standard describes the minimal amount of information that 
needs to be reported. This is in fact the most difficult issue in the entire data 
dissemination discussion. A young and quickly changing field such as high-throughput 
proteomics makes it extremely dangerous to attempt to set certain rules in stone. The use 
of specialized protocols and very different data processing pipelines only adds to this 
problem. In fact, having every single protocol and data processing step documented does 
not necessarily result in allowing reproduction of the analyses performed in order to 
validate the results, as specific steps may not be available to other researchers12. 
The second part of any standard concerns data formats. Once the specific data that should 
be communicated has been decided upon, a format needs to be found that can 
accommodate this information in a universally readable way.  
The Human Proteome Organisation (HUPO) [Hanash 2002] has created the Proteomics 
Standards Initiative (PSI) [Orchard 2005] to tackle both standardization problems. 
Minimal reporting guidelines are being drafted in the Minimal Information About a 
Proteomics Experiment (MIAPE) documentation and standardized formats for mass 
spectrometry data (mzData) and data analysis (analysisXML) are under active 
development. Other published mass spectrometry data standards are also available 
[McDonald 2004, Pedrioli 2004]. Additionally, certain journals have also published 
guidelines aimed at setting standards [Carr 2003, Bradshaw 2005, Wilkins 2006] that 
submitted manuscripts should minimally adhere to. Of course, this heterogeneity of 
standards bodies (HUPO PSI, several journals) will need to be resolved in full before real 
progress can be made in this matter. 
The third problem is the availability of a centralized, publicly available repository for the 
published data. Solutions relying on private websites of researchers or laboratories suffer 
from three problems: (1) they are notoriously unstable over time and are quite often 
discouraged by journals for this reason13, (2) they can never provide a uniform interface 
or data model to potential users and (3) they delegate the cost of site construction, site 
maintenance and bandwidth to the authors, discriminating against the less affluent and 
exacerbating the already short website half-life discussed in (1). 
The only real solution is to provide steadily funded, centralized data repositories at 
specialized institutes that can collect, publish and maintain data submitted by authors and 
present users with a uniform interface. This approach has of course been in place for 
years for nucleic acid and protein sequence databases and has repeatedly proven to 
greatly aid researchers worldwide. 
                                                 
12
 Examples of these are prohibitively expensive reagents, the use of a custom-built apparatus at one or 
more steps and the use of proprietary data processing algorithms to achieve certain results. 
13
 An example of a similar distrust in private website stability can be found in the ‘Instructions to Authors’ 
of the BioMedCentral journal BMC Bioinformatics, where authors are encouraged to submit the software 
applications they describe in their manuscripts as supplementary information to the journal rather than 
distributing the software through their own homepages. 
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1.6. The choice of a programming language 
"It's not difficult to look at computer languages and see which ones are trying to be 
modern by driving something into the ground. Think about Lisp, and parentheses. 
Think about Forth, and stack code. Think about Prolog, and backtracking. Think 
about Smalltalk, and objects. (Or if you don't want to think about Smalltalk, think 
about Java, and objects.)" 
- Larry Wall 
 
Whenever any software development is to take place, one of the first questions raised 
concerns the programming language to use. This choice is often disregarded as trivial 
(one simply picks the language one is most proficient at using) yet carries far-reaching 
consequences. When considering the large software systems which are designed to tackle 
the points raised throughout section 1.4, it becomes clear that the initial choice of the 
programming language will need to be carried through for many years, possibly suffering 
changes in programmer staff over that time period. The selection of a suitable 
programming language then becomes considerably less trivial. 
Any software that is put into production needs to be fixed, maintained and updated. Each 
of these aspects requires the modification or addition of source code. It is therefore of the 
utmost importance that key software systems (such as a data management and analysis 
system) are written in clear, understandable and documented code. 
Java was the language of choice for the software developed in the course of the work 
outlined in this dissertation. Java has the benefit of being a very robust object-oriented 
language with the highly interesting property of providing cross-platform binaries. This 
means that the compiled code itself can be distributed and run on widely diverse 
platforms and architectures without any problems and with only minor (if any) 
differences in the presented graphical user interface. It is clear that in any academic 
setting this is an advantage, especially when one aims at sharing the software in question 
across the community. Additionally, Java contains powerful tools that allow in-code 
documentation to be compiled into external HTML-based documentation using a 
standardized format. Java also has an excellent track record concerning the completely 
transparent integration with enterprise-level tools such as databases. In practice this 
means that a system built to run on one relational database platform can be run without 
any code-modification on a completely different relational database engine. Finally, the 
popularity of Java and the elegance of its object-oriented design have made it a favourite 
in undergraduate programming courses. As such, there are many Java-knowledgeable 
programmers available, lessening the sting of the infamous ‘hit-by-a-bus-factor’14. 
                                                 
14
 This factor is a somewhat whimsical way in which software developers refer to ‘how many people can 
get hit by a bus before the project gets in trouble’. Dark humor aside, the statement often rings true: the 
situation where a single developer leaving a team (for whatever reason) wrecks havoc on the whole system 
is not an uncommon one. 
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1.7. Relational databases 
1.7.1. Introduction 
Relational databases have been the mainstay of structured data storage for decades. They 
offer a very fast, reliable mechanism for inserting, updating and retrieving data. The 
ability to query these databases through an official standard language (Structured Query 
Language, or SQL) only adds to their usefulness. Enterprise-level relational database 
engines are available from many vendors (notably Oracle, IBM (DB2), Microsoft (SQL-
server) and Sybase), but many free and/or open source solutions are available as well 
(notably MySQL and PostgreSQL). These latter solutions have become feature-rich and 
highly competitive systems in their own right, bringing the complete power of a relational 
database system into the reach of everyone. 
Relational databases have a drawback however: object-oriented models are not readily 
compatible with a relational schema. Key object-orientation concepts such as inheritance 
and typing are not straightforward to implement in a relational schema. As an alternative, 
object-oriented databases have been created, but these tend to be slower and far less 
manageable than relational stores. They also lack a uniform query language and suffer 
from far less support in popular programming languages. 
For the majority of data-centric applications however, relational data storage is 
sufficiently expressive to allow complete modeling of the data structure without having to 
resort to arcane manipulations. 
Relational databases are constructed from tables. These define a number of columns, each 
of which carries a certain type of data. Whenever data is added to such a table, rows are 
inserted. There are two special columns which are instrumental to creating relations 
between otherwise unconnected columns. These are the ‘primary key’ column(s) and 
‘foreign key’ column(s). Whenever more than one column is used to create such a key it 
is called a ‘compound key’. For the sake of simplicity compound keys will not be 
discussed further here. A foreign key is a column that references a column in another 
table, typically the primary key for that table. It is this referencing that creates the 
connection between the tables. Whenever a reference between keys is followed, it is 
called a ‘join’ of the corresponding tables. 
In modeling a relational database schema one can make use of three basic relations, all 
defined by primary key-foreign key referencing. These atomic elements of relational 
database design are discussed in the following subsections. 
 
1.7.2. One-to-one mapping (1:1) 
A one-to-one mapping (often abbreviated to ‘1:1’) consists of two tables that are 
interrelated in such a way that a single row in one table is matched by a single row in the 
other table. This relationship is reciprocal. It is rarely ever used as one-to-one 
relationships can be readily collapsed into a single table. They sometimes come in handy 
to overcome potential limitations of the underlying database engine15. An example for 
two simple one-to-one tables is depicted in figure 24. Note that they share their primary 
                                                 
15
 A common example of this is the limit on the number of columns that a table can accommodate. 
43 
key and that this will be the join column. This relation therefore does not require foreign 
keys. 
 
Schema
Data
common_id name
1
2
3
pi
e
planck
common_id value
1
2
3
3.14159 
2.71828 
4.13566
Query What is the value in Value for name ‘planck’ in Constant?
SQL select v.value from Value as v, Constant as c 
where c.common_id=v.common_id
and c.name = ‘planck’
Result 4.13566
 
 
  Figure 24: Example for a 1:1 relationship between tables. 
 
1.7.3. One-to-many mapping (1:n) 
A one-to-many mapping is often abbreviated to ‘1:n’. This relation can safely be called 
the workhorse of most relational database schemas. Indeed, it will be argued in the next 
section that many-to-many mappings are actually a peculiar combination of two one-to-
many mappings. 
One-to-many mappings rely on foreign keys to work their magic. The primary key of a 
single row in table ‘A’ can be referenced by the foreign keys of many rows in table ‘B’, 
allowing a data consumer to retrieve all matching records (‘many’) in table ‘B’ for a 
specific row in table ‘A’ (‘one’). When applied in the inverse direction, a single row in 
table ‘B’ will only link a single row in table ‘A’. This relationship is thus clearly 
unidirectional. An example for two simple tables is given in figure 25. 
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Schema
Data
Query Which Paper(s) have been published in the Journal with 
name ‘Nature’?
SQL select p.title from Journal as j, Paper as p 
where j.journalid = p.l_journalid
and j.name = ‘Nature’
Result
journalid name
1
2
3
Nature
Science
SciAm
paperid title
1
2
3
Paper 1
Paper 2
Paper 3
l_journalid
1
1
2
4 Paper 43
Paper 1 
Paper 2
 
 
  Figure 25: Example for a 1:n relationship between tables. 
 
1.7.4. Many-to-many mapping (n:m) 
Many-to-many mappings, or ‘n:m’ in short are the third basic element of relational data 
storage. In this construct a single row from table ‘A’ can be joined to many rows in table 
‘B’, but it is also possible to link many rows in table ‘A’ from a single row in ‘B’. The 
actual relations retrieved need not be reciprocal however. The key to this element is an 
extra table often referred to as the ‘indirection table’. This table consists of only two 
foreign key columns in its most simplistic form. For two tables ‘A’ and ‘B’ to have a 
many-to-many relationship, a third table ‘C’ is thus required. Table ‘C’ will have at least 
two columns, one of which will contain a foreign key referencing table ‘A’ (let us call it 
‘c1’), whereas the other will be a foreign key referencing table ‘B’ (‘c2’). It now becomes 
possible to start with the primary key of a single row in table ‘A’, find all rows in table 
‘C’ that have a foreign key in ‘c1’ referencing this primary key and then use the foreign 
keys in ‘c2’ for these rows in table ‘C’ to locate the corresponding rows in ‘B’. Note that 
this boils down to applying a one-to-many relationship and an inverted one-to-many 
relationship in sequence. Also note that the inverse operation (going from a single row in 
table ‘B’ to all matching rows in table ‘A’ via the foreign keys of table ‘C’) will also 
work. An example for two tables and a single, minimalist indirection table is given in 
figure 26. 
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Schema
Data
Query Which Paper(s) have been (co-)authored by Author ‘Author 1’?
SQL select p.title from Paper as p, Paper_has_author as i, Author as a
where p.paperid = i.l_paperid 
and i.l_authorid = a.authorid
and a.name = ‘Author 1’
Result Paper 1 
Paper 3
paperid title
1
2
3
Paper 1
Paper 2
Paper 3
l_paperid l_authorid
1 1
authorid name
1
2
3
Author 1
Author 2
Author 3
1 2
2 3
3 1
3 3
 
 
  Figure 26: Example for an n:m relationship between tables. 
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2. Results 
2.1. DBToolkit: creating the right database for the job 
“The solutions all are simple... after you have arrived at them. But they're simple only 
when you know already what they are.” 
 - Robert M. Pirsig, Zen and the Art of Motorcycle Maintenance 
 
Peptide identification from fragmentation spectra relies on three main elements: the 
quality of the MS/MS spectrum, the quality of the search engine and the quality of the 
search base against which the spectrum is matched. 
One of the most crucial elements is the search base used for peptide identification. 
Indeed, if the sequence of the peptide that led to the recorded fragmentation spectrum is 
not contained in the search base, it will be impossible to find. This problem becomes 
particularly pressing for those peptide-centric approaches that specifically pick up 
processed peptides such as N-terminal COFRADIC as the site of processing will only 
sporadically conform to a standard enzymatic site. An illustration of this problem for 
(partial) cleavage of a caspase substrate can be found in figure 27. It is immediately clear 
from this representation that, when the blue peptide is missed, the entire cleavage event is 
missed. This nicely illustrates the principle put forward in section 2.1: we must make 
every peptide count. 
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Figure 27: Partial cleavage of a caspase substrate, resulting in a novel N-terminal 
peptide that is not present in regular Arg-C digested databases. 
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In this section we will introduce the DBToolkit software application, which was designed 
to aid in making every peptide count. We first discuss the processing of a protein 
sequence database in terms of information content and information ratio. We will then 
proceed to illustrate the usefulness of corrupting the information content of a database 
and we will highlight the part of the design of DBToolkit that gives it the essential ability 
to be easily adapted to changing needs by third-party developers. The section is 
completed by inclusion of the published DBToolkit paper and illustrations of its 
usefulness in published applications of peptide-centric databases. 
 
2.1.1. Transforming protein sequence databases into peptide databases 
In shifting the focus from gel-based to gel-free methods, the unit of analysis shifted from 
the protein to the peptide (hence the term ‘peptide-centric’ proteomics). The sequence 
databases used as search bases for the identification algorithms however, necessarily 
remain protein-centric. DBToolkit was designed to solve this discrepancy by allowing 
the processing of protein sequence databases into peptide sequence databases. 
Additionally, DBToolkit can enhance both the information content as well the 
information ratio of the peptide sequence database16. Strategies for the former will be 
discussed in section 2.2.1.1, the mechanism for the latter is detailed in section 2.2.1.2.  
 
2.1.1.1. Enhancing the information content of a peptide database 
We have illustrated above that the most interesting N-terminal peptides are often 
obtained after some form of in vivo processing, typically through a proteolytic event. We 
have also pointed out that a standard in silico protein database digest using trypsin or 
endopeptidase Arg-C will generally not generate these peptides and that a search 
algorithm such as Mascot will therefore not be directly able to consider these as potential 
matches. The end result is that the biologically most interesting peptides will be 
completely missed. There are some strategies available that attempt to correct this 
problem. First of these is the semi-specific setting for the in-silico proteolytic enzyme 
which requires only one terminus (either the C- or N-terminus) to correspond to a correct 
enzymatic cleavage. Thus, the following sequence: 
 
    >Protein 1 
    NARTMA 
 
will yield the following list of peptides by applying semi-specific tryptic cleavage (note 
the subscript ‘c’, indicating a correct tryptic terminus): 
 
    cNARc 
    cTMAc 
    ARc 
    Rc 
    cNA 
                                                 
16
 Interestingly, one of the other highly useful features of DBToolkit is that it can also corrupt the 
information content of a sequence database, which is explained in section 2.2.2. 
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    cN 
    MAc 
    Ac 
    cTM 
    cT 
 
A more brute-force approach is the Mascot ‘No Enzyme’ setting. This setting effectively 
considers all possible peptide sequences for a given polypeptide. For our example 
protein above, we would get the following non-redundant peptide list: 
 
    NARTM 
    NART 
    NAR 
    NA 
    N 
    ARTMA 
    RTMA 
    TMA 
    MA 
    A 
    ARTM 
    RTM 
    TM 
    M 
    ART 
    RT 
    T 
    AR 
    A 
    R 
     
It is cle ar that the semi-specific approach will most probably cover every possible form 
of processing and that the No Enzyme setting will cover every possible sequence that can 
be derived from the parent protein. The information content of the database (which we 
will consider to be the number of unique sequences in that database) is thus increased by 
these settings. 
This increase in information comes with a price, however. Mascot is a probabilistic 
algorithm and relies on the number of amino acids in a sequence database to estimate its 
information content (see section 1.2.1.2). When applying semi-specific or No Enzyme 
cleavage, the corresponding increase in information content must be taken into account 
when estimating the chance of random matching. We can easily plot the effect on a 
simple chart for the human subsets of SWISS-PROT, IPI and the NCBI non-redundant 
database (figure 28). 
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Figure 28: Increase in identity threshold when applying semi-specific enzyme or No 
Enzyme setting in Mascot 
 
It is obvious from this figure that the resulting penalties are steep. It is therefore to be 
expected that, even though the information content of the databases can be raised to an 
adequate level using these settings, the chances of correctly linking a peptide sequence to 
its fragmentation spectrum are somewhat reduced due to the high identity threshold 
score. It is also interesting to note that the search space employed is not necessarily 
optimized with regards to what can be reasonably expected from the protocols used. 
Let us first consider the example of regular N-terminal COFRADIC. As this technique 
allows the efficient selection and retrieval of the N-terminal peptide of a protein, it is a 
very useful tool to study in vivo protein processing. The peptides resulting from this 
protocol will conform to Arg-C cleavage on their C-terminus (thus ending in arginine) as 
described in section 1.1.8.3. The N-terminus of part of the peptides will conform to Arg-
C cleavage as well, but another part (those that correspond to the N-terminus of a protein 
that was processed during maturation) of the peptides in the mixture will carry an N-
terminus that results from a completely different proteolysis event. We can therefore 
make the a priori prediction that the N-termini can not be clearly specified, but the C-
termini of the peptides should end in arginine. Now let us reconsider the peptide list 
created by an in silico semi-specific Arg-C cleavage as given above, only now the 
peptides which we would accept as reasonable are given in bold face: 
 
cNARc 
    cTMAc 
    ARc 
    Rc 
    cNA 
    cN 
    MAc 
    Ac 
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    cTM 
    cT 
 
It is clear that, of the ten possible peptide sequences, only six can be considered plausible. 
Another way to say this is that the truly useful information content of this database is 
only 60% of the total information content. Since we have established that the identity 
threshold of a database relies on its total information content, it is clear that the identity 
threshold will be overly pessimistic for our purposes. 
It is actually straightforward to provide a solution for this problem. When we apply our a 
priori knowledge to the in silico protocol, we can create a peptide sequence database that 
contains all regular Arg-C peptides next to possible N-terminally truncated versions of 
these. To continue our above example, we would create the following peptide list: 
 
cNARc 
    ARc 
    Rc 
    cTMAc 
    MAc 
    Ac 
 
Note that this list is simply a rearranged version of the bold entries in the list above. 
Applying this algorithm, optionally complemented with mass limits, will then produce a 
more informative peptide-centric database, which can be used as an optimized search 
base for regular N-terminal COFRADIC (figure 29). 
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Figure 29: threshold scores and sizes compared for regular enzymatic databases, semi-
specific and No Enzyme databases and non-redundant ragged databases 
output by DBToolkit 
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A schematic representation of the actual algorithm can be found in figure 30. 
 
Remove N-terminal AA
Calculate mass
Mass in 
range?
no
Add to peptide collection
yes
Below lower
treshold?
no
yes
Continue
Main
process
Regular Arg-C peptide
Add to peptide collection
 
 
Figure 30: N-terminal ‘ragging’ of Arg-C peptides. The ‘Main process’ cycles all protein 
entries in the database and generates regular Arg-C peptides that are fed to 
this ragging process. 
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2.1.1.2. Enhancing the information ratio of a peptide database 
“Pessimists, we're told, look at a glass containing 50% air and 50% water 
and see it as half empty. Optimists, in contrast, see it as half full. Engineers, of 
course, understand the glass is twice as big as it needs to be.” 
- Robert Lewis 
 
One of the problems encountered when transforming protein sequence databases into 
peptide-based sequence databases has to do with redundancy. Usually protein sequence 
databases are deemed non-redundant when each protein sequence in the database is 
unique. Proteins from large families with extensive sequence homology such as members 
of the globin family tend to produce many identical peptides after proteolytic digest. The 
redundancy at the peptide level is thus generally much higher than for the original protein 
sequence database. This redundancy becomes problematic when one looks at the 
workings of probabilistic protein identification algorithms such as Mascot. Indeed, a 
large amount of sequence redundancy at the peptide level implies that the total number of 
amino acids in the database becomes a progressively more optimistic estimate of the 
information content of that database as the redundancy increases. Consider for example 
the following two-protein database: 
 
>Protein 1 
LENNARTMARTENS 
>Protein 2 
LENNARTMARTENT 
 
and the six-peptide database generated by an in silico digest using Arg-C: 
 
>Protein 1 (1-6) 
LENNAR 
>Protein 1 (7-10) 
TMAR 
>Protein 1 (11-14) 
TENS 
>Protein 2 (1-6) 
LENNAR 
>Protein 2 (7-10) 
TMAR 
>Protein 2 (11-14) 
TENT 
 
Even though the sequence redundancy at the protein level is 0%, the redundancy at the 
peptide level is 33% (two out of six peptides are redundant). Correspondingly, the 
information content of the Arg-C peptide database is equal to four unique peptides. If we 
now define the information ratio of a database as its information content divided by the 
total number of sequences in that database, we find an information ratio of 67% in the 
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above example. The relationship of this measurement with the number of amino acids in 
a sequence database is readily established: 
 
aa
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==  
 
Where Ir equals the information ratio, Ic the information content, Ss the total number of 
sequences, Saa the total number of amino acids and Lp the average peptide length in a 
database. 
It is clear that an ideal database would have an information ratio of 100%; i.e. every 
sequence in that database is unique and therefore informative, allowing the most efficient 
estimate for random matching from the total number of amino acids in the database. 
To raise the information ratio of a database it is therefore only necessary to remove 
sequence redundancy. In the above example of the six-peptide database, we get the 
following list of unique peptides: 
 
    LENNAR 
    TMAR 
    TENS 
    TENT 
 
The redundancy in these peptide sequences is obviously 0%, and the information content 
remains at four unique peptides. With an information ratio of 100% we now have an ideal 
search base to present Mascot with. 
A good illustration of the real-life impact of removing peptide-level redundancy is the 
information ratio of the NCBI nr database (dd. 28th of January 2006) after Arg-C 
cleavage (allowing 1 missed cleavage), which amounts to a meager 33%! With only one 
in every three peptide sequences actually contributing to the information content of the 
database, clearing the redundancy becomes vital to allowing a probabilistic search engine 
like Mascot to correctly estimate the chances for random matching. This effect is also 
depicted in figure 31 for the ragged human subsets of the NCBI nr (dd. 28 January 2006), 
SWISS-PROT (24 January 2006) and IPI (24 January 2006) databases, digested by Arg-
C. 
Note that the NCBI nr database contains nearly double the amount of ragged human 
peptide sequences after digestion with ArgC, yet adds only a marginal fraction of novel 
sequences when compared to the human subset of the IPI database. This is not 
particularly surprising when one considers the composition of these databases (see 
section 1.2.2) and clearly highlights the importance of the choice of sequence database in 
protein identification. 
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Figure 31: information ratio for ragged SWISS-PROT, IPI and NCBI nr human subsets. 
The line plots are matched to the left vertical axis, the bars to the right axis. 
 
There is one important caveat regarding the removal of redundancy, however. The four 
sequences presented in the non-redundant list of the example above contain two 
degenerate peptides [Nesvizhskii 2005]. These peptides can not be clearly and 
unambiguously linked to a single protein sequence unless there is additional, conclusive 
evidence to perform an informed selection at the protein level17. This information is 
typically absent from peptide-centric approaches.We must therefore make sure we 
maintain all possible protein matches for these peptides in the non-redundant peptide 
database as none of these can be disregarded in favour of another. The final non-
redundant peptide database will therefore be written by DBToolkit in the following 
way18: 
 
>Protein 1 (1-6)^AProtein 2 (1-6) 
LENNAR 
>Protein 1 (7-10)^AProtein 2 (7-10) 
TMAR 
>Protein 1 (11-14) 
TENS 
>Protein 2 (11-14) 
TENT 
 
                                                 
17
 Usually obtained from separation steps at the protein level. Examples are apparent protein MW and pI. 
18
 Note that the ‘^A’ notation is the standard notation to indicate multiple progenitor accession numbers in 
cases of sequence redundancy as employed by the NCBI. 
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The result is a peptide database that employs maximum parsimony at the sequence level 
while retaining full information on sequence origins in the header. Indeed, it can be said 
that we have performed a lossless compression of the original peptide database. 
 
2.1.2. Corrupting the information content of a sequence database 
“The importance of nonsense can hardly be overstated. The more clearly we 
experience something as ‘nonsense’, the more clearly we are experiencing the 
boundaries of our own self-imposed cognitive structures.” 
- Gary Zukav, The Dancing Wu-Li Masters: An Overview of the New 
Physics 
 
The use of randomized, shuffled or reversed databases in establishing rates of false-
positive identification for database search algorithms has been firmly established [Elias 
2005, Stephan 2005]. We will discuss these three types of decoy databases and their 
properties next. 
A reversed database is a sequence database in which each sequence has simply been 
replaced by the reverse of its sequence, e.g.: 
 
>Protein 1 
LENNARTMARTENS 
>Protein 2 
LENNARTMARTENT 
 
becomes: 
 
>Protein 1 (rev) 
SNETRAMTRANNEL 
>Protein 2 (rev) 
TNETRAMTRANNEL 
 
Note that this approach maintains both the amino acid composition of the original 
database19 as well as the lengths of the peptides generated20. 
A second approach is the shuffled database, which transforms a database by randomly 
shuffling the amino acids per sequence. For our two-protein example database this could 
yield: 
 
>Protein 1 (shuf) 
TNTALEERNMSNRA 
>Protein 2 (shuf) 
NMERLANATERTTN 
 
                                                 
19
 The amino acid composition is also preserved at the level of the individual sequence 
20
 Note that this statement is not entirely true. For instance, for trypsin, un-cleavable KP and RP reversed, 
gives cleavable PK and RP, thus changing the lengths of some peptides. For the grand majority of peptides 
however, the lengths are maintained. 
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Obviously, if the shuffling algorithm is well-designed, the actual resulting sequences will 
probably differ each time it is applied to a given sequence database. Note that, although 
this approach maintains amino acid composition, it does not maintain peptide lengths at 
the sequence level. 
The third approach employs randomized databases. In this case, the amino acids 
constituting a sequence are replaced by randomly chosen amino acids. Usually, the 
algorithm can be instructed to maintain a certain amino acid composition or can 
substitute amino acids purely at random if desired21. It is clear that, although amino acid 
composition can potentially be maintained for the complete database, this is usually no 
longer the case for each sequence. Obviously, peptide lengths will not be maintained at 
the sequence level. 
This third approach for generating randomized databases is not often employed. Usually 
shuffled and reversed databases yield a better decoy database as they maintain more 
characteristics of the original database. DBToolkit therefore only supports the generation 
of both shuffled and reversed databases. 
From a purely conceptual point of view, the shuffled database maximizes the sequence 
variability of the decoy database when compared to the more conservative reversed 
database. The first benefit of shuffling is that peptide families (large collections of 
peptides with very homologous sequences) are nearly completely dispersed among all 
possible shuffled variants in shuffled databases (see figure 32). Secondly, palindromic 
peptide sequences are simply repeated in reversed databases, contributing to a higher 
degree of overlap between the source database and the reversed database. 
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Figure 32: Mass distribution of all tryptic peptides (1 missed cleavage allowed) in the 
human subset of the NCBI nr database (dd. 27th of July 2003). Note the 
elimination of the various ‘spikes’ in the shuffled database. 
 
                                                 
21
 Purely random usually implies giving each amino acid a one-in-twenty chance of being picked to 
substitute at a given location. 
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The above points are also summarized in table 2. 
 
 Composition maintained Peptide lengths maintained 
Decoy mechanism sequence database sequence database 
Potential 
overlap 
Reversing yes yes yes° yes low 
Shuffling yes yes no yes very low 
Randomizing† no yes no yes very low 
Randomizing∗ no no no no very low 
 
Table 2: Comparisons of algorithms for the creation of decoy databases.° see footnote 19 
above;  † randomizing using a compositional bias; * randomizing using a one-
in-twenty chance for each amino acid to be used as substitute. 
 
Mascot was tested using shuffled versions of the human proteins in SWISS-PROT and 
NCBI nr for two distinct datasets: the methionyl and cysteinyl COFRADIC peptides from 
human platelets (see section 2.5). The results are given in table 3. 
 
Identifications 
Database Spectra Regular Shuffled False (+) 
3565 1270 29 2.28% SWISS-PROT 
2665 586 29 4.95% 
3565 1137 28 2.46% NCBI nr 
2665 481 21 4.37% 
 
Table 3: Estimation of false positives for Mascot at the 95% confidence interval using 
shuffled decoy versions of the human entries in the SWISS-PROT (dd. 25 July 
2003) and NCBI nr (dd. 27 July 2003) databases for two distinct datasets. 
 
It is clear that Mascot does not exceed its self-imposed maximum of 5% allowed false 
positives. Additionally, it seems that the quality of the dataset (as can be estimated by the 
identification ratio22) has more bearing on the false-positive rate than the actual database 
used. 
 
2.1.3. Frameworked database loaders and filters 
DBToolkit needs to be able to load a variety of sequence database formats in order to be 
widely applicable. However, as one can not foresee nor support all possible database 
formats out-of-the-box, it is reasonable to develop DBToolkit in such a way that 
interpreters for additional database formats can be added easily at a later time by third-
party programmers. From the perspective of the user it is of course also important that 
DBToolkit can quickly and automatically recognize known database formats, and this for 
both built-in as well as added interpreters. 
                                                 
22
 The identification ratio is the number of identified spectra divided by the total number of presented 
spectra. 
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Additionally, one of the typical tasks in processing sequence databases is the filtering of a 
database to obtain a certain subset of entries. Examples of these are the human-derived 
proteins in SWISS-PROT or the mouse proteins in the NCBI non-redundant database. Of 
course, the available filtering options depend heavily on the actual (meta-)information 
present in the database and are thus format-specific. Finally, it should also be easy to 
define and integrate new filtering capabilities by third-party developers, again for both 
built-in database formats as well as for added ones. 
In order to achieve the above set of goals, the core design of DBToolkit relies on two 
interconnected frameworks for database loading and filtering. 
The filtering framework performs an ostensibly straightforward task. It should enable a 
picky data consumer to ask whether a given database entry passes or fails the filter. In 
DBToolkit the main interface of this framework is the Filter class. It defines two methods 
to which any filter implementation must adhere. Each method accepts a database entry in 
a certain format and returns a boolean to indicate whether the entry passes this filter. To 
enable easy addition of custom-built filters, the filter-loading mechanism is completely 
dynamic. This means that filter classes are only loaded when they are explicitly 
requested. As such, it becomes possible to define known filters descriptively (in a text 
file) instead of declaratively (inside compiled code). Adding a new filter to DBToolkit is 
therefore reduced to writing a suitable implementation for the Filter interface, and 
describing the resulting class in the correct text file. No recompilation of the DBToolkit 
sources is required23. 
The framework for database loading centers round the DBLoader interface. There are two 
abstract subclasses available for this interface, DefaultDBLoader and ZippedDBLoader. 
The former focuses on loading data straight from the database text files, while the second 
will load the same data from zipped or GZIPped text files (since sequence databases can 
be very large, this latter functionality is often useful to limit the strain on disk space). 
More interestingly however, both abstract super classes implement the following methods 
that were defined on the DBLoader interface: nextFilteredProtein(Filter aFilter) and 
nextFilteredRawEntry(Filter aFilter). It is of note that the effective implementation of 
these methods can be provided at this abstract level due to the successful abstraction of 
the filtering functionality. These two methods thus define the complete intersection 
between the two frameworks. 
The frameworks and their connection are represented as Unified Modelling Language 
(UML) diagrams24 in figure 33. 
 
                                                 
23
 It is not even required to have the DBToolkit sources at all. 
24
 This UML diagram is not a conceptual model; it is automatically generated on the basis of the actual 
DBToolkit code itself. 
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Figure 33: DBLoader and Filter frameworks and their connection. 
  
The DBLoader framework also relies on a text file that lists the available database loaders 
and is thus fully descriptive in nature as well. Addition of a database loader therefore 
requires only an implementation of DBLoader (usually through extension of one of the 
abstract ancestors) and an additional line in the correct text file detailing the fully 
qualified class name for the loader. Again, no recompilation of DBToolkit is necessary at 
any point. 
Finally, the DBLoader interface also defines the canReadFile(File aFile) method, 
which is the keystone for automatically detecting the correct DBLoader implementation 
for a given database file. The corresponding factory (DBLoaderLoader) can therefore 
sequentially present a database file to all registered DBLoader implementations, 
requesting whether the implementation recognizes the file formatting. It is of note that 
this mechanism represents an implementation of a simplified version of a command 
pattern and allows the automatic recognition of known database formats irrespective of 
whether a DBLoader implementation was packaged with DBToolkit or separately 
developed and added by a third party. 
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2.1.4. License and availability 
The DBToolkit software has been released as open source software under the GNU25 
General Public License (GPL) (http://www.gnu.org/licenses/licenses.html#GPL) and is 
freely available in both source and binary versions from 
http://genesis.UGent.be/dbtoolkit. 
 
2.1.5. Publication 
                                                 
25
 Interestingly, GNU is a recursive acronym for ‘Gnu is Not Unix’. 
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ABSTRACT
Summary: DBToolkit is a user-friendly, easily extensible tool that
allows the processing of protein sequence databases to peptide-
centric sequence databases. This processing is primarily aimed at
enhancing the useful information content of these databases for use as
optimized search spaces for efficient identification of peptide fragment-
ation spectra obtained by mass spectrometry. In addition, DBToolkit
can be used to reliably solve a range of other typical tasks in processing
sequence databases.
Availability: DBToolkit is open source under the GNU GPL license.
The source code, full user and developer documentation and cross-
platform binaries are freely downloadable from the project website at
http://genesis.UGent.be/dbtoolkit/
Contact: lennart.martens@UGent.be
INTRODUCTION
As the tool of choice in present-day high-throughput proteomics,
mass spectrometry has evolved substantially over the last years.
The classical approach of two-dimensional polyacrylamide gel elec-
trophoresis (2D-PAGE) (O’Farrell, 1975) requires merely a mass
measurement of the peptides generated from an enzymatic digest of
an isolated protein (Cottrell, 1994). A refinement of this approach
uses fragmentation spectra of a few peptides as additional inform-
ation for the identification of the original protein. In most recent
so-called gel-free techniques (e.g. as reviewed by Zhang et al., 2004
and Gevaert et al., 2005) however, mass spectrometers must be able
to generate high-quality fragmentation spectra from extremely com-
plex peptide mixtures, obtained following proteolytic digestion of
an unfractionated proteome of a cell or tissue. These peptide-centric
methods were primarily developed to deal with the inherent short-
comings of classical 2D-PAGE techniques and allow for a greater
coverage of the proteome while simultaneously increasing the sensit-
ivity of the analysis (Aebersold and Mann, 2003). The peptide-centric
technologies have driven the exchange of the protein for the peptide
as the basic unit in proteomics research (Aebersold and Mann, 2003;
Kearney and Thibault, 2003).
Sequence databases like SWISS-PROT, IPI and the NCBI
non-redundant database remain protein-based however. Since this
∗To whom correspondence should be addressed.
discrepancy between the respective fundamental units can lead to a
loss of highly interesting identifications, we developed the DBToolkit
suite of software tools to allow the conversion of protein sequence
databases into peptide sequence databases.
APPLICATION FUNCTIONALITIES
The software can recognize FASTA and EMBL formatted databases
out of the box, with UniProt and IPI the most prominent examples of
the latter. It is also extremely easy for developers to include automatic
recognition of different database formats as detailed below.
DBToolkit can perform various types of processing on sequence
databases. Of course, simple in silico enzymatic digests using a
variety of predefined enzymes or user-added enzymes are possible
as well as database concatenation and FASTA output of differently
formatted databases. The enzymatic digest even allows for ‘dual spe-
cificity’ enzymes that generate peptides for which the aminoterminus
(N-terminus) is the result of a different cleavage pattern than the
carboxyterminus (C-terminus). In addition, it is also possible to fil-
ter databases (the exact filtering options depend on the database
format loaded) and to limit output to sequences in a certain mass
range. Additional filters by other developers are also readily included
in the software (see below). The three most powerful functions of
DBToolkit however, are sequence-based filtering through a simple
query language, N-terminal or C-terminal ragging (optionally trun-
cating sequences in the process) and sequence-based redundancy
clearing. The ragging process creates a series of subsequences for
each ‘mothersequence’ where in eachn-th subsequence, the firstn−1
residues have been removed from the N-terminal or C-terminal side,
respectively.
These functions are readily applied serially to achieve compound
results such as a non-redundant, N-terminally ragged subset of a
trypsin digest of the Homo sapiens entries in the UniProt database,
all of which have a mass between 600 and 4000 Da.
Several applications for these processed databases are outlined
below.
APPLICATION DESIGN
DBToolkit is completely written in the Java programming language
and its only requirement is a Java runtime environment 1.3 or above.
© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University
Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its
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Creating peptic-centric databases
The suite consists of both an intuitive graphical user interface present-
ing the user with interactive controls to all processing steps, and an
equivalent set of command-line tools for straightforward automation
of the processing steps through simple scripting. This latter function-
ality has allowed us to tie different processing steps in with the auto-
matic database updating of Mascot (http://www.matrixscience.com)
for the most popular sequence databases, creating multiple derived
databases overnight.
DBToolkit was designed from the start to be easily extensible. The
use of robust frameworking allows the addition of novel database
loaders or filters without requiring recompilation.
Full user and developer documentation for the suite is available
from the project website, along with the cross-platform binaries and
CVS repository coordinates.
DISCUSSION
We have applied DBToolkit in the lab for numerous purposes, most
notably the generation of specialized databases for use as search-
bases for protein identification in Mascot. One approach used ragged,
non-redundant peptide databases to increase the number of identi-
fied spectra in an N-terminal COFRADIC experiment with ∼40%
(Gevaert et al., 2003). Interestingly, most of the peptides identified
only in the ragged databases corresponded to the novel N-termini of
their progenitor proteins after in vivo processing (e.g. the N-termini
of nuclear-encoded proteins that are imported into mitochondria
and lost their transit peptide). Since these processing sites typic-
ally did not conform to standard tryptic sites, they were absent
from searches solely performed in the original sequence databases.
Another application has been found in picking up peptides from
apoptose substrates, yielding the exact cleavage location in those
proteins. For this we created non-redundant, enzymatically digested
peptide databases using a bifunctional enzyme that created peptides
with an N-terminus derived from caspase activity (i.e. consensus
cleavage C-terminal to aspartic acid) and a C-terminus derived from
trypsin activity. In this way, a large number of caspase cleavage sites
have been confirmed and many tentative new sites have been found
that would otherwise have eluded identification (unpublished data).
A third application centers on the a priori calculation of the potential
success a certain COFRADIC procedure could have by rapidly cre-
ating non-redundant, comprehensive lists of all detectable peptides
containing a specified amino acid. Note that this functionality can be
applied to any peptide-centric proteomics approach that can select
for sequences by their aminoacid content (see Zhang et al., 2004 and
Gevaert et al., 2005 for an overview of these techniques).
DBToolkit has proven to be a highly versatile yet very simple tool
for routine tasks in sequence database processing. Furthermore, as
the applicability and popularity of peptide-centric proteomics exper-
iments expands further, DBToolkit can perform the essential task of
complementing proven, probabilistic protein identification software
like Mascot with peptide-centric search databases, optimized for the
specific conditions and requirements of the research.
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2.1.6. Published applications 
2.1.6.1. N-terminal proteome of unstimulated human blood platelets 
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Exploring proteomes 
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Current non-gel techniques for analyzing proteomes rely heavily
on mass spectrometric analysis of enzymatically digested protein
mixtures. Prior to analysis, a highly complex peptide mixture is
either separated on a multidimensional chromatographic system1,2
or it is first reduced in complexity by isolating sets of representative
peptides3–8. Recently, we developed a peptide isolation procedure
based on diagonal electrophoresis9 and diagonal chromatogra-
phy10. We call it combined fractional diagonal chromatography
(COFRADIC). In previous experiments, we used COFRADIC to
identify more than 800 Escherichia coli proteins by tandem mass
spectrometric (MS/MS) analysis of isolated methionine-containing
peptides11. Here, we describe a diagonal method to isolate N-ter-
minal peptides.This reduces the complexity of the peptide sample,
because each protein has one N terminus and is thus represented
by only one peptide. In this new procedure, free amino groups in
proteins are first blocked by acetylation12 and then digested with
trypsin. After reverse-phase (RP) chromatographic fractionation
of the generated peptide mixture, internal peptides are blocked
using 2,4,6-trinitrobenzenesulfonic acid (TNBS)13,14; they display a
strong hydrophobic shift and therefore segregate from the unal-
tered N-terminal peptides during a second identical separation
step. N-terminal peptides can thereby be specifically collected for
further liquid chromatography (LC)-MS/MS analysis. Omitting the
acetylation step results in the isolation of non-lysine-containing
N-terminal peptides from in vivo blocked proteins.
We used this technique to identify 264 proteins and 78 in vivo–
acetylated proteins in a cytosolic and membrane skeleton fraction of
human thrombocytes. In addition to showing that this method can be
used for gel-free proteomics, we demonstrate that it allows one to
examine N-terminal protein processing such as removal of signal
sequences and modifications. A general scheme depicting the proce-
dure for sorting N-terminal peptides is shown in Figure 1. At the pro-
tein level, cysteines are alkylated with iodoacetamide, and free primary
amines are blocked by acetylation. Upon trypsin digestion, two types
of peptides are generated: internal peptides with a free α-amino
group and blocked N-terminal peptides. These peptides are fraction-
ated by RP–high-performance (HP) LC, typically in 
12 fractions (primary run, Fig. 2A). The dried fractionated peptides
are redissolved in an appropriate buffer for reaction with TNBS. Only
internal peptides react with TNBS to form very hydrophobic trinitro-
phenyl-peptides (TNP-peptides), whereas blocked N-terminal pep-
tides are not affected. On average, this TNBS modification reaction
proceeds to more than 98% completion. Each TNBS-treated primary
fraction is separately rerun on the same column and under conditions
identical to those for the primary run. The TNP-labeled internal pep-
tides now shift to later elution times and separate from the unaltered
N-terminal peptides, which do not shift and can be easily collected for
further analysis (Fig. 2B). The secondary run and analysis step is
repeated for each TNBS-modified fraction.
With this procedure we analyzed the proteome of a cytosolic and
membrane skeleton fraction of human thrombocytes15. Sorted 
N-terminal peptides in all fractions were analyzed using 96 LC-MS/MS
runs, during which 5,640 collision-induced dissociation (CID)
Department of Medical Protein Research, Flanders Interuniversity Institute 
for Biotechnology, Department of Biochemistry, Ghent University,
A. Baertsoenkaai 3, B-9000 Ghent, Belgium.
*Corresponding author (kris.gevaert@rug.ac.be).
Figure 1. Scheme summarizing the chemistry and chromatographic steps
during N-terminal peptide sorting. (1) All protein-cysteine residues are
first alkylated using iodoacetamide (open circles). (2) Then, all free
amines (α- and ε-amines) are acetylated (indicated by filled diamonds)
and the proteins are digested with trypsin (3), which will now only cleave
C-terminal to arginine residues. As shown, this creates two types of
peptides: N-terminal peptides with a blocked N terminus and internal
peptides with a free N terminus. Following the primary RP-HPLC
fractionation of the generated peptide mixture, all peptides present in one
HPLC fraction are treated with TNBS (4). Only the internal peptides are
altered to trinitrophenyl-peptides (indicated by TNP in open boxes), which
have become more hydrophobic and will thus shift out of their original
position during the secondary chromatographic run (5), which is identical
to the first RP-HPLC separation. These internal peptides are discarded for
further analysis. However, N-terminal peptides are unaltered by the TNBS
reaction, thus elute at exactly the same time interval as during the first run
and can be specifically collected and analyzed further by LC-MS/MS (6).
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spectra were generated. Because proteins are variably processed at
their N termini, their exact in vivo N-terminal boundaries are often
not known. This poses a problem for peptide identification when
conventional protease-based MS/MS-based peptide identification
routes are followed. Therefore, we created databases containing
sequentially N-terminally trimmed Arg-C-type peptides. Using these
peptide-centric databases in combination with established database
searching tools, the number of peptides identified increased by 50%.
In total, 1,247 CID spectra were unambiguously assigned to peptides
using MASCOT16, implying that 22.83% of all MS/MS spectra
obtained could be positively identified. This is somewhat less than the
proportion (34.48%) identified in the previously published E. coli
study11; however, in that study, all the open reading frames were pub-
licly available and could thus be searched using MS/MS data. Of the
spectra we identified, 920 (73.77%) correspond to 305 different
acetylated peptides, from which 264 unique human proteins were
identified (see Supplementary Table 1 online). Thus, on average, each
protein was identified by one peptide, clearly indicating the reduction
in the complexity of the analyte mixture. The proteins were ranked
according to the frequency at which their N-terminal peptides were
identified (see Supplementary Table 2 online). This ranking can be
considered as a semiquantitative measure of their abundance in the
sample (the 50 most abundant proteins are shown).
Proline and pyroglutamate residues seem to react slowly or not at all
with TNBS. Peptides with such N-terminal residues do not show a shift
in our system and are isolated together with the blocked 
N-terminal peptides (see Supplementary Table 1 online). Some pro-
line-peptides clearly constitute the extreme N terminus of proteins,
whereas others may have been derived from internal cleavage, either in
situ or during protein preparation. An example is transgelin (P37802),
for which both the intact acetyl-ANRGPAYGLSR and truncated
PAYGLSR peptides were identified (see Supplementary Table 1 online).
Pyroglutamate-peptides represent about 10% of the selected peptides
and therefore do not hamper further LC-MS/MS analysis of sorted N-
terminal peptides, but rather may provide additional information when
N-terminal peptide analysis fails. This is illustrated by nonmuscle
myosin heavy chain (P35579), where such peptides are frequently
encountered, whereas the N terminus is not found (see Supplementary
Table 1 online). Next to these ‘expected contaminants,’ we identified 74
internal tryptic peptides, derived from 47 abundant proteins. The pres-
ence of these unsorted internal peptides is due to incomplete reaction of
some abundant peptides with TNBS. This number can be reduced with
an additional coupling step, which was omitted here in order to limit
losses. The number of internal peptides is very low compared to the
number of N termini discovered. For instance, an in silico Arg-C diges-
tion of the human proteome reveals the presence of 17.5 internal pep-
tides per N-terminal peptide.With 305 different N termini identified, we
would encounter 5,337 (17.5 × 305) internal peptides if no sorting were
done. The 74 internal peptides detected show that our N-terminal
selection procedure had an overall efficiency of more than 98%.
Excluding the amino acetylation step (Fig. 1) automatically leads to
the isolation of the N-terminal peptides of in vivo N-blocked pro-
teins. These peptides should not contain lysine, as the latter will also
react in its unprotected form with TNBS. Thus, here, we will only sort
for arginine-containing peptides with a blocked N terminus, repre-
senting approximately half of the in vivo–blocked proteins. In our
platelet fraction, this amounts to 78 acetylated proteins (see
Supplementary Table 3 online).
Using our procedure, established or predicted N-terminal protein
processing can easily be verified. For example, the signal peptides of
two identified putative mitochondrial proteins, malic enzyme and
dihydroorotate dehydrogenase, have been predicted by homology.
Here we found that the malic enzyme 2 (NAD-dependent malic
enzyme) starts at residue 19 rather than at amino acid 21
(http://us.expasy.org/cgi-bin/niceprot.pl?P23368) and dihydrooro-
tate dehydrogenase starts at residue 28 rather than at amino acid 
11 (http://us.expasy.org/cgi-bin/niceprot.pl?Q02127) (see Supple-
mentary Table 4 online). Identified putative membrane proteins (see
Supplementary Table 5 online) segregate in three groups: those with
an N-terminal signal sequence (type I), those lacking a pre-sequence,
and those that are cleaved internally. In vivo–blocked proteins fall into
four categories (see Supplementary Table 6 online): those carrying an
acetylated initiator methionine, generally followed by an acidic
residue; those with the initiator methionine removed and with the
second residue acetylated; those from which a small number of N-ter-
minal residues are removed before acetylation; and those that are
cleaved internally and re-acetylated. An interesting representative of
the latter group is the hitherto undiscovered form of a truncated form
of actin. Normally, actins are acetylated on position three; this new
variant starts at residue 29 (see Supplementary Table 6 online).
Various N-terminal modifications can also be considered while
searching the protein databases. When N-terminal formylation was
considered, a variant of the macrophage migration inhibitory factor
(MIF, NCBI GenBank accession no. 5542179) was found to be formy-
lated (MIFPAM), whereas the protein lacking this alanine residue
Figure 2. Peptide elution profiles during the primary and secondary run of
N-terminal peptide sorting. (A) Chromatographic fractionation of a tryptic
digest of a human thrombocyte protein fraction. During this primary run, a
total of 12 fractions are collected and treated with TNBS to block the free
amines.When the TNBS-treated fractions are separately rerun on the same
column and under identical conditions, the internal (trinitrophenyl) peptides
shift to later elution times (hydrophobic shift), whereas the unaltered 
N-terminal peptides elute within the same time interval and can be collected
in a number of secondary fractions (only shown for primary fraction 6 in B).
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(MIFPM) yielded an acetylated peptide (Fig. 3). Interestingly, the cor-
responding MIFPM peptide is present in the list of in vivo–blocked
proteins (see Supplementary Table 3 online). Therefore, we conclude
that the MIFPM variant was only acetylated during the first step of our
procedure (Fig. 1). Thus, in vivo, MIFPM has a free N-terminal pro-
line, whereas MIFPAM is formylated.
Because N-terminal peptide mixtures are much less complex than
an unfractionated mixture1,2 or mixtures of selected Met-containing
peptides11, our approach may lead the way to a proteomics approach
in which proteins are identified by the mass of their N-terminal pep-
tides only. Such an approach should be feasible using highly accurate
mass spectrometers measuring with errors less than 1 ppm17. This will
significantly accelerate proteomics and bring the field one step closer
to high-throughput analysis for diagnostics and drug discovery.
Experimental protocol
Sorting of N-terminal peptides. A cytosolic and membrane skeleton fraction
prepared from 109 human thrombocytes15 (obtained from the Red Cross
Blood Transfusion Centre Oost-Vlaanderen, Ghent, Belgium) was dissolved in
4 M guanidium chloride (Fluka Chemie GmbH, Buchs, Switzerland) in 0.1 M
sodium phosphate buffer (pH 7.0). Proteins were reduced for 90 min in 0.02%
tributylphosphine (Fluka) and alkylated for 30 min at 37 °C in 5 mM iodoac-
etamide (Fluka). About 10 nmol of protein material was desalted on a NAP-5
column (Amersham Pharmacia Biotech, Uppsala, Sweden) in 1 ml
of 1 M guanidinium chloride in 50 mM sodium phosphate buffer
(pH 8.0.) and reduced to half its volume by vacuum drying.
Free amines were acetylated in 10 mM sulfo-N-hydroxysuccin-
imide acetate (Perbio, Helsingborg, Sweden) for 90 min at 30 °C.
This step was omitted for the isolation of lysine-free N termini of in
vivo–acetylated proteins. Partial acetylation of serine and threonine
was reversed by adding 1 µl of hydroxylamine (Fluka) to the protein
mixture. This mixture was desalted on a NAP-5 column in 1 ml of
0.25 M guanidinium chloride in 50 mM Tris-HCl (pH 7.9) and
reduced to 0.5 ml by vacuum drying. It was then boiled for 5 min
and digested overnight at 37 °C with 10 µg of sequencing-grade
modified trypsin (Promega Corporation, Madison, WI).
The peptide mixture was separated on a RP-HPLC column (2.1
mm internal diameter × 150 mm 300SB-C18 column; Zorbax,Agilent
Technologies, Waldbronn, Germany) on an Agilent 1100 Series HPLC
system. Following a 10 min wash with solvent A (98:2 (vol/vol)
water/acetonitrile in 0.1% trifluoroacetic acid (TFA), both Baker
HPLC analyzed, Mallinckrodt Baker B.V., Deventer, The
Netherlands), a linear gradient to 100% solvent B (30 parts 0.1%
(vol/vol) TFA in water/70 parts acetonitrile) was applied over 100 min
with a flow rate of 80 µl/min. Peptides eluting between 40 and 88 min
were collected in 12 fractions of 4 min each in a 96 microwell plate.
Three consecutive programs were written for the Agilent well
plate sampler for the TNBS modification of peptides. First, the dried
peptides were redissolved in 50 µl of 50 mM sodium borate (pH
9.5). Then, 2 µmol of dried TNBS (stored in two separate vials) were
redissolved in 200 µl of 50 mM sodium borate (pH 9.5), of which 15
µl was transferred to each sample well. The peptides were incubated
with TNBS for 55 min at 37 °C. This reaction was repeated once,
after which the samples were dried. The modification procedure,
including the two reaction steps, was repeated once to assure nearly
quantitative TNBS modification.
The samples were dried a final time before the secondary HPLC
runs. Each secondary run began with an injector program in which
the sample was redissolved in 70 µl 0.5% TFA, of which 65 µl was
loaded onto the column. The same solvent gradient was used as in
the primary run. N-terminal peptides were collected in the same 4
min time interval as used during the primary run in eight subfrac-
tions of 30 s (or 40 µl). We thus collected 96 subfractions for subse-
quent LC-MS/MS analysis11. Briefly, after drying, the peptides were
redissolved in 20 µl of 0.1% formic acid in water and 10 µl of this
solution was separated by nano-RP-HPLC connected to a Q-TOF1
mass spectrometer (Micromass UK Ltd., Cheshire, UK). Mass spec-
tra obtained by automated LC-MS/MS analysis were used to identi-
fy the corresponding peptides using MASCOT16 (see Supplementary
Experimental Protocol and Supplementary Figure 1 online).
Note: Supplementary information is available on the Nature Biotechnology
website.
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Continuous high-titer HIV-1
vector production
Yasuhiro Ikeda1, Yasuhiro Takeuchi1, Francisco Martin1,
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Human immunodeficiency virus type 1 (HIV-1)–based vectors are
currently made by transient transfection, or using packaging cell lines
in which expression of HIV-1 Gag and Pol proteins is induced1–3.
Continuous vector production by cells in which HIV-1 Gag-Pol is sta-
bly expressed would allow rapid and reproducible generation of large
vector batches. However, attempts to make stable HIV-1 packaging
cells by transfection of plasmids encoding HIV-1 Gag-Pol have
resulted in cells which secrete only low levels of p24 antigen (20–80
ng/ml)4–6, possibly because of the cytotoxicity of HIV-1 protease7.
Infection of cells with HIV-1 can result in stable virus production8; cell
clones that produce up to 1,000 ng/ml secreted p24 antigen have
been described9.Here we report that expression of HIV-1 Gag-Pol by
a murine leukemia virus (MLV) vector allows constitutive, long-term,
high-level (up to 850 ng/ml p24) expression of HIV-1 Gag. Stable
packaging cells were constructed using codon-optimized HIV-1 Gag-
Pol10 and envelope proteins of gammaretroviruses; these producer
cells could make up to 107 293T infectious units (i.u.)/ml (20 293T
i.u./cell/day) for at least three months in culture.
The vectors pCNC-GPRT and pCNC-SYNGP (Fig. 1A) were either
transfected into HeLa or HT1080 cells, or first packaged into MLV
1Department of Immunology and Molecular Pathology, Windeyer Institute,
University College London, 46 Cleveland St., London W1T 4JF, UK.
2Vectorologie Retrovirale et Therapie Genique, Ecole Normale Superieure de
Lyon, Lyon, France. 3Oxford BioMedica Limited, The Oxford Science Park,
Oxford, UK. *Corresponding author (mary.collins@ucl.ac.uk).
virions using a transient MLV packaging system11 and then used to
infect HeLa, HT1080, or 293T cells. Transfected or infected HeLa
and HT1080 cells were selected in G418; infected 293T cells 
were cloned by limiting dilution, as the cells are already G418
resistant. Each clone was then analyzed for HIV-1 p24 capsid (CA)
expression by immunofluorescence microscopy. Compared to
transfection, infection with either MLV vector generated a higher
frequency of clones expressing HIV-1 p24 (Table 1A). In all cell
lines, infection with the codon-optimized CNC-SYNGP vector gen-
erated a higher frequency of positive clones than the CNC-GPRT
vector (Table 1A).
To determine which of the cell lines would make the best stable
packaging cells, we measured p24 secretion. The infected HeLa cells
secreted more p24 than the transfected cells (Fig. 1B). The amount of
p24 secreted by 293T cells infected with wild-type HIV-1 Gag-Pol
could be increased by using the MLV vector CNC-Rev to express addi-
tional Rev, which controls nuclear export of HIV-1 RNA 
(Fig. 1B). This suggests that pCNC-GPRT expresses a suboptimal level
of Rev. Clones of 293T and HT1080 cells infected with CNC-SYNGP
produced the most p24 (Fig. 1B). Greater p24 secretion by infected
cells, compared to transfected cells, resulted from higher RNA
expression. Infected HeLa cells (clone B, Fig. 1B) expressed consider-
ably more HIV-1 Gag-Pol RNA than the transfected cells (clone A)
(Fig. 1C). The predominant RNA species was the correct size for the
transcript driven by the cytomegalovirus immediate early (CMV)
promoter. This higher RNA expression in the infected cells did not
result from a higher number of CNC-GPRT copies (Fig. 1C). 293T
cells secreted more p24 than HeLa cells for a given level of RNA
expression (Fig. 1B,C). Immunoblot analysis of cell lysates and cell
supernatants showed that HeLa cells retain higher levels of HIV-1
Gag precursors within the cell (data not shown). Because of this
higher p24 secretion and the efficiency of transfection, we pursued
packaging-cell construction with HT1080 and 293T cells.
To generate stable packaging cells, we chose to express envelopes
of gammaretroviruses because they are not cytotoxic, can produce
relatively high-titer pseudotypes of HIV-1, and have been used in
clinical and preclinical gene therapy12–14. The 293T clone express-
ing GPRT and Rev (GPRT1+R1 cells) and clones of the
HT1080SYNGP1 or 293TSYNGP1 cells engineered to express the
HIV-1 transactivator of transcription Tat, and Rev (HT-STAR and
STAR) were transfected with envelopes of MLV 4070A (Ampho15),
RD114 with an HIV protease site introduced at the R-peptide
cleavage site (RDpro), or gibbon ape leukemia virus (GALV) with
an MLV cytoplasmic tail (GALV+16). In each case a clone express-
ing a high level of envelope was chosen (1 clone from 12).
Packaging of three HIV-1 genomes—the Rev-encoding pH7G10,
pHRSIN-CSGW17, or its non-self-inactivating derivative pHV
(Fig. 2A)—was compared. The STAR-Ampho cells produced the
highest titer of virus, over 107 i.u./ml from a bulk population after
infection by the HIV-1 genome (Table 1B). Both H7G and HV
produced high titers, suggesting that the amount of Rev in the
packaging cell was sufficient for vector production (Table 1B).
Transfection and selection of STAR-Ampho cells also gave a high
titer of virus, with clones producing 107 i.u./ml of self-inactivating
vectors (Table 1B). Like transient lentiviral vector preparations,
virus produced from the STAR cells could transduce target cells at
high efficiency (Fig. 2B) and could infect 293T cells arrested by
aphidicolin (data not shown). Transiently produced virus with
vesicular stomatitis virus glycoprotein (VSV-G) envelope was
more infectious per mg p24 than stably produced virus with gam-
maretroviral envelopes (Fig. 2B). This was a property of the VSV-G
envelope, rather than the stable packaging cells, as we observed the
same increased infectivity when transiently produced virus with
VSV-G envelope was compared to transiently produced virus with
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2.1.6.2. Proteolytic processing by caspases in apoptotic Jurkat T-cells 
Caspase-specific and nonspecific in vivo protein
processing during Fas-induced apoptosis
Petra Van Damme, Lennart Martens, Jozef Van Damme, Koen Hugelier, An Staes, Joe¨l Vandekerckhove &
Kris Gevaert
We generated a comprehensive picture of protease substrates in
anti-Fas–treated apoptotic human Jurkat T lymphocytes. We used
combined fractional diagonal chromatography (COFRADIC) sorting
of protein amino-terminal peptides coupled to oxygen-16 or
oxygen-18 differential labeling. We identified protease substrates
and located the exact cleavage sites within processed proteins.
Our analysis yielded 1,834 protein identifications and located 93
cleavage sites in 71 proteins. Indirect evidence of apoptosis-
specific cleavage within 21 additional proteins increased the total
number of processed proteins to 92. Most cleavages were at
caspase consensus sites; however, other cleavage specificities
suggest activation of other proteases. We validated several new
processing events by immunodetection and by an in vitro assay
using recombinant caspases and synthetic peptides containing
presumed cleavage sites. The spliceosome complex appeared
a preferred target, as 14 of its members were processed.
Differential isotopic labeling further revealed specific release
of nucleosomal components from apoptotic nuclei.
The interest in proteases and their substrates is steadily growing
because of the major roles they have in crucial molecular events
such as protein maturation, enzyme regulation, protein localiza-
tion, protein complex formation and stabilization. Their impor-
tance is illustrated by the fact that up to 1,200 human genes are
estimated to encode proteases1 and that the present version of the
MEROPS protease database (http://merops.sanger.ac.uk/) contains
505 known or putative peptidases. In agreement with their biolo-
gical relevance, altered protease expression or activation, and/or
substrate proteolysis, may trigger human diseases like rheumatoid
arthritis, cancer, neurodegenerative and cardiovascular diseases2,3.
Consequently, proteases are recognized as important drug targets4,
orienting research and technologies toward a better understanding
of degradation processes within protein networks and their result-
ing physiological effects.
A cellular process that is largely steered by proteases is apoptosis,
a genetically programmed, morphologically and physiologically
distinct form of cell death. The cysteine-dependent aspartate-
specific proteases or caspases are the main players in the initiation
and execution of apoptosis5. Caspase cleavage occurs at restricted
sites and the resulting cleavage products are often stable in cells and
potentially acquire alternative functions.
To obtain a better understanding of the cellular events associated
with the generation of these apoptosis-specific products, it is
important to have access to a comprehensive picture of the
apoptotic degradome. A compilation of different studies carried
out in various cells and organisms has so far resulted in the
identification of close to 300 different caspase substrates6. Most
of the compiled approaches identified potential apoptotic sub-
strates, but seldom the exact cleavage sites7–14.
With the idea to develop a more direct and general procedure to
measure protein degradation, we developed a differential gel-free
proteomics technique that specifically identifies the processed site(s)
within the protease substrate. As such, it is the most direct way to
study protein processing. We used the method to identify protease
substrates and to locate their cleavage sites in Fas (CD95/Apo1)-
stimulated15 human Jurkat T lymphocytes. We identified 2,462
peptides, 93 of which were due to specific proteolysis of substrate
proteins in apoptotic cells. We confirmed several results by western
blotting and by in vitro peptide cleavage. These studies provide for
the first time a comprehensive view of the apoptotic degradome in a
model system, and the method described here can be applied to
similar analyses in other biomedically relevant systems.
RESULTS
Peptide sorting and quantitative analysis
We induced apoptosis in human Jurkat cells by Fas antibody
treatment for 24 h. At this time point, fluorescence activated
cell sorting (FACS) analysis showed that 70% of the cells were
in apoptotic phases while the activities of caspases 3 and 7 reached
their highest values (data not shown). We prepared lysates from
apoptotic and living cells for differential N-terminal peptide
analysis. The latter is a modification of a previously published
peptide sorting procedure, COFRADIC16. We mixed peptides
from both digests (one 16O-labeled and one 18O-labeled)17 in a
one-to-one ratio (total peptide amount) and sorted them by
N-terminal COFRADIC.
Different cleavage scenarios lead to a repertoire of sorted
peptides (Fig. 1). As expected, the vast majority of these (over
RECEIVED 10 JUNE; ACCEPTED 11 AUGUST; PUBLISHED ONLINE 22 SEPTEMBER 2005; DOI:10.1038/NMETH792
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94%) does not appear to be the result of protein processing
(Fig. 1a) and is present in highly comparable concentrations in
the proteome digests of living and apoptotic cells (Supplementary
Fig. 1 online). Most of these peptides are located at the very N
terminus of proteins, and a fraction contains acetylated peptides
derived from processing, which was similar in both apoptotic and
living cells (for example, the removal of transit peptides upon
mitochondrial import, Supplementary Table 1 online).
Direct identification of protein cleavage sites
The simplest scenario is a specific cleavage in the apoptotic
proteome yielding stable products. One could then expect to
find the N-terminal peptides of the parent protein in equal
concentrations, next to a new internal a-N-acetylated peptide
(Fig. 1b). We illustrate this scenario for the serine- and arginine-
rich splicing factor U2AF 65 kDa subunit (Fig. 2). Next to the
N-terminal peptide doublet (Ac-SDFDEFER; residues 2–9) in a
1.04 ratio, we identified a second, but now singlet peptide
(Ac-GLAVTPTPVPVVGSQMTR; residues 129–146) owing to clea-
vage in apoptotic cells at the MetThrProAsp consensus caspase
site18. A list of 93 such directly assigned proteolytic sites located in
71 different proteins from apoptotic cells is available (Supplemen-
tary Table 2 online). Of these cleavages, 58 correspond to caspase
consensus sites (Table 1 and Supplementary Table 2). We validated
some previously unidentified apoptotic protein processing
events by probing the lysates of control and apoptotic cells (in
the presence or absence of the caspase inhibitor z-DEVD-FMK19)
with antibodies specific for three new and one known
substrate20 (PARP) and visualizing protein processing by
immunoblotting (Fig. 3).
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Figure 1 | Scenarios leading to different categories of N-blocked peptides in
apoptotic lysates. (a) No cleavage in both samples. (b) The protein is cleaved
in apoptotic cells: a 16O-labeled a-N-acetylated peptide is generated.
(c) Cleavage is very close to the N terminus: the short N-terminal peptide is
lost. (d) The N-terminal part of the protein is degraded after cleavage. (e) The
protein is cleaved at a site, fortuitously located within a Q* or P peptide:
the 18O variant is recovered; sometimes the new a-N-acetylated peptide is
observed. (f) The C-terminal part of the protein is degraded after cleavage.
Proteins are shown as long bars and cleavage sites are indicated with vertical
arrows. Tryptic peptides from apoptotic lysates (+ Fas) are 16O-labeled, and
peptides from living control cells ( Fas) are 18O-labelled. Colored bars
represent peptides that were sorted by the N-terminal COFRADIC procedure
(either a-N-acetylated (Ac) or start with PCA (Q*) or proline (P)): peptides
at the extreme N termini of proteins (blue), previously unidentified internal
a-N-acetylated peptides (green), internal TNBS nonreacting peptides starting
with either Q* or P (red), and an internal Q*/ P peptide containing an
apoptosis-specific processing site (yellow). Red crosses delineate protein
fragments that were generated by cleavage but further degraded or lost during
the sorting procedure.
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Figure 2 | Identification of cleavage sites in death substrates. This illustration
represents the majority of the cleavages and corresponds to the scenario in
Figure 1b. The amino-acid sequence of the serine- and arginine-rich splicing
factor U2AF 65 kDa subunit is at the bottom. The peptide corresponding to
the eight N-terminal residues (underlined) was recovered as an isotopic couple
separated by 4 Da (upper left). The new peptide derived from an apoptosis-
specific cleavage (bold) was recovered as the 16O-variant (upper right). The
tandem MS fragmentation spectrum of this internal peptide (middle) provides
data for its unambiguous assignment (the b-type fragment ions are italic and
the y-type are roman; the number in bold corresponds to the mass of the
intact peptide ion (singly charged)). The deduced sequence is preceded by a
potential caspase cleavage motif shown in italic in the protein sequence.
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We identified several peptides indicative for protein processing
only once (Supplementary Table 3 online). We validated the
deduced cleavage site using synthetic peptides containing these
sites as in vitro substrates of different recombinant caspases. A list of
these validated ‘single-hit wonders’ is available in Table 1 and
Supplementary Table 2.
Notably, we found 35 sites at nonaspartate residues (Supple-
mentary Table 2) suggesting caspase cleavage at noncanonical sites
(for example, as previously observed for cleavage at Glu10 in the
transcription factor Max21) and/or additional activation of one or
more proteases (see below).
Indirect characterization of protein cleavage
We observed some a-N-acetylated peptides only in the proteome
digest of living cells (Table 2 and Supplementary Table 4 online).
The scenarios depicted in Figure 1c,d explain this observation;
apoptosis-specific cleavage within the utmost N-terminal peptide
renders it unsuited for analysis. Thus, only the corresponding,
intact N-terminal peptide in the proteome digest of the living cells
can be recovered (Fig. 1c). We noticed this scenario (cleavage close
to the protein’s N terminus) for 12 proteins (Supplementary
Table 4), and it is illustrated by the observed cleavage pattern of
the lysyl-tRNA synthase. For this protein, we identified the acety-
lated N-terminal peptide spanning residues 225 in living cells but
detected the peptide indicating processing at Asp12 (amino acids
1325) only in the proteome digest of apoptotic cells (Table 1).
The complementary segment 2 to 12 was most likely lost during
sample preparation.
We obtained further support for caspase-specific cleavage in the
extreme N-terminal regions using an in vitro peptide cleavage assay
as described above. This way, we delineated the exact cleavage site,
the actual caspase(s) involved and the cleavage yield for four
extreme N termini that we only detected in lysates of living cells
(Table 2). Cleavages at Asp8 of the DNAJC7 protein, Asp12 of
GCIP-interacting protein p29 isoform 1, Asp12 of lysyl-tRNA
synthetase and at Asp8 of Ras GTPase-activating-like protein,
were hereby confirmed.
The exclusive presence of peptides in the lysate of living cells
could also be explained when the N-terminal protein half has
been extensively degraded in apoptotic cells. Such a scenario
(Fig. 1d) could account for the presence of sorted peptides
that do not contain an obvious caspase-specific cleavage site
(Supplementary Table 4).
We also detected 13 peptides in the proteome digest of
living cells that were not acetylated but started with a
Table 1 | Internally located a-N-acetylated peptides generated after aspartic acid specific cleavage
Protein description Accession number Site Identified peptide Start End Caspase (cleavage yield)
Dynamin 2a P50570 DQVDk Ac-TLELSGGAR 353 361
G-patch domain and KOW motifs 12653257 DSGDk Ac-GAGPSPEEKDFLKTVEGR 38 55
ALADk Ac-GVVSQAVKELIAESKKSLEER 99 119
DRQDk Ac-GPAAKSEKAAPR 342 353
Lysyl-tRNA synthetasea Q15046 VKVDk Ac-GSEPKLSKNELKR 13 25 Caspase 3 (65%), 6 (25%) and 8 (45%)
Splicing factor 3B subunit 2a Q13435 TEEDk Ac-TVSVSKKEKNR 292 302
Transcription intermediary factor 1-ba Q13263 LSLDk Ac-GADSTGVVAKLSPANQR 686 702
DGADk Ac-STGVVAKLSPANQR 689 702 Caspase 3 (20%) and 8 (20%)
Five representative members out of the complete list of internally located a-N-acetylated peptides (Supplementary Table 2) are shown. Their parent proteins are referred to by description and
UniProt database accession number. Information on the amino acid(s) preceding the identified peptides (site), the sequence of the identified peptide and its location within the parent protein
(start/end) is given. Ac- denotes the a-N-acetyl group. The right column shows the cleavage yields (in percent) of the corresponding synthetic peptides by recombinant caspases 3, 6, 7 and 8.
aProcessing events validated in this study by immunoblotting and/or in vitro peptide cleavage.
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1–870
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292–872
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Control Fas
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214–1013
1–136
Figure 3 | Validation of protein processing in apoptotic Jurkat cells. (a–f)
Jurkat cells were treated with a Fas antibody for various periods of time after
which an aliquot was withdrawn and the proteins separated by SDS-PAGE. As
control, cells were identically treated in the same medium but in the absence
of a Fas antibody (Control). Antibodies to TIF1b (a), dynamin 2 (c), subunit 2
of splicing factor 3B (d), the caspase-3 fragment of PARP-1 (e) and histone
H3 (f) were used in the immunoblot. TIF1-b detection in presence of a
caspase inhibitor is shown in b. Note the disappearance of generated
fragments in c and d at later time points suggesting degradation. Positions
indicating the boundaries of intact and generated fragments are given in the
right margin. They are derived from sequences in databases or from results
shown in Table 1 and Supplementary Table 2.
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2,4,6-trinitrobenzenesulfonic acid (TNBS) nonreactive N terminus
(Table 2 and Supplementary Table 4). Such peptides are likely to
contain a proteolytic site leading to the disappearance of the
corresponding peptide in apoptotic cell lysates, even though they
were recovered in intact form in lysates of living cells (Fig. 1e). An
example hereof is the processing of the G-patch domain–and KOW
motifcontaining T54 protein. For this protein, we identified three
acetylated peptides in the apoptotic proteome in accordance with
specific cleavage at Asp37, Asp98 and Asp341 (Table 1), next to a
peptide that was only present in the control proteome, starting with
an N-terminal pyrrolidone carboxylic acid (PCA), spanning amino
acids 340–353 and thus containing the Asp341 site (Table 2). Singlet
peptides with PCA or proline could also appear when, after
processing of the parent protein, the generated fragments are further
degraded under apoptotic conditions (Fig. 1f). This could explain
the presence of internal peptides that do not have an expected
cleavage site such as, for instance, peptide 310–320 of vimentin
(Supplementary Table 4), which may have lost its apoptotic
counterpart owing to cleavage at multiple sites of the parent protein.
The combined information from these two types of sorted
peptides unique to living cells now adds at least 28 more indirectly
assigned apoptosis-specific cleavage events, eventually leading to
the identification of 92 proteins that are specifically degraded
during apoptosis (Supplementary Table 5 online).
Notably, we found 23 peptides solely in the proteome digest
of apoptotic cells (Supplementary Table 6 online). As their
corresponding proteins are mainly nuclear, we believe that their
appearance might be due to their more efficient extraction upon
apoptosis-induced chromatin condensation22,23. We also confirmed
this by western blot analysis using anti–histone H3 (Fig. 3f),
revealing specific extraction of intact H3 during lysate preparation
of apoptotic cells.
DISCUSSION
We used a gel-free proteomics approach to isolate protein
N-terminal peptides. This created a less complex peptide mixture
keeping its representative status for the parent proteins. Here we
did not focus on generating an exhaustive list of proteins expressed
in human Jurkat T lymphocytes, but rather on studying apoptosis-
dependent protein processing. As protein processing leads to the
generation of new protein N termini, we strongly believe that our
approach is well-suited to study global effects of an activated
proteolytic degradome. Indeed, not only the protease substrates
are distinguished in a complex background, but also, and more
importantly, the exact cleavage sites are delineated. This combined
information is almost impossible to collect using a single genetic or
traditional, gel-based proteomics technique.
There is only one limitation to the N-terminal COFRADIC
approach, which is linked to the size of the sorted N-terminal
peptide. The distance between the N terminus and the first arginine
in the sequence determines this size of the peptide. In the study
presented here, the average length of the N-terminal peptides was
between 12 and 13 residues, ideal for obtaining good mass spectro-
metric fragmentation coverage. But when the sorted peptides are
either too short or too long, they may become undetectable; the
former because they elute in the void volume during chromato-
graphy and the latter because they are insoluble. A typical example
of the latter is the known processing of PARP-1 at Asp200, which we
observed in our samples by immunoblot analysis (Fig. 3e) but did
not detect by COFRADIC. In fact, in this case, cleavage at Asp200
generated a new N-terminal peptide containing 67 amino acids
with 15 e-N-acetylated lysines. It is likely that this peptide has
unusual solubility properties, making its separation by reverse-
phase high performance liquid chromatography (RP-HPLC) very
difficult. Taken at the level of the total human proteome, and
assuming only N-terminal peptides with size between 5 and 40
residues are detectable, the N-terminal COFRADIC approach
would theoretically cover 80% of the predicted proteins.
We directly identified 93 cleavage sites, 86 of which (92.5%)
had not been noticed previously. We confirmed some of these
cleavages by immunoblotting using specific antibodies (Fig. 3).
In addition, we obtained strong but indirect evidence for apoptosis-
specific cleavage at 28 more sites in 21 different proteins. Of these,
we confirmed seven and correctly located them using recombinant
caspasemediated cleavage of peptide mimetics (Tables 1 and 2,
and Supplementary Tables 2 and 4). Using this approach,
we were able to link specific caspases with particular substrates,
like proteasome activator complex subunit-3 as a substrate of
caspases 7 and 3.
As expected in the apoptotic Jurkat model, many of the isolated
peptides point to caspase-mediated cleavage (Table 1 and Supple-
mentary Table 2); however, 35 processing events occurred
C-terminally to nonaspartate residues, mainly involving either
basic or bulky hydrophobic amino acids (Supplementary
Table 2) suggesting apoptosis-dependent activities of at least two
other protease families. At this stage it is difficult to state if the
Table 2 | Peptides only present in lysates of living cells
Protein description
Accession
number Identified peptide Start End Site Caspase (cleavage yield)
N-acetylated peptides
DnaJ homolog subfamily C member 7a Q99615 Ac-AAAAECDVVMAATEPELLDDQEAKR 2 26 AECDk Caspase 8 (40%)
GCIP-interacting protein p29 isoform 1a 7661636 Ac-AAIAASEVLVDSAEEGSLAAAAELAAQKR 2 30 VLVDk Caspase 3 (40%), 6 (40%) and 8 (55%)
Lysyl-tRNA synthetasea Q15046 Ac-AAVQAAEVKVDGSEPKLSKNELKR 2 25 VKVDk Caspase 3 (65%), 6 (25%) and 8 (45%)
Ras GTPase-activating-like protein IQGAP1a P46940 Ac-SAADEVDGLGVAR 2 14 DEVDk Caspase 3 (100%), 6 (5%), 7 (100%) and
8 (40%)
TNBS nonreactive peptides
G-patch domain and KOW motifs 12653257 Q*DGPAAKSEKAAPR 340 353 DRQDk
Five representative members out of the complete list of peptides only present in lysates of living cells (Supplementary Table 4). Peptides shown here indirectly indicate proteolytic processing.
The sequence, location and published information is as in Table 1. The underlined residues indicate the processing sites that were validated by either in vitro peptide cleavage or by additionally
identified peptides. Proteins cleaved at specific positions (Site) are indicated. Q* refers to a PCA derivative. aProcessing events validated in this study by in vitro peptide cleavage.
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nonaspartate cleavages are the result of a direct activation process
or if these are secondary, postcaspase events, for instance, produced
by aminopeptidases. For the Acinus protein it is known that an
initial caspase-3 cleavage is necessary before a second noncaspase
hydrolysis leads to its DNA condensing activity24. In our study we
observed such ‘double heterogeneous’ cleavages in several candi-
date proteins, which could follow a similar activation process.
These are, for instance: the nascent polypeptideassociated com-
plex a polypeptide, the polypyrimidine tractbinding protein 1,
the SET protein and vimentin (Supplementary Table 2). Notably,
the set of proteins affected by nonaspartate
cleavages includes eight histone proteins,
and none of their 14 different processing
sites have been reported before. Because of
their nature, generally being quite small and
highly basic, such proteins may have
escaped conventional proteome analysis.
Histone H4 is processed such that only a
few amino acids are removed (cleavage sites
at Arg3, Gly4 and Lys5). Cleavage here is
noticed at nonaspartate residues, yet a
remarkable number of other proteins
appears to be specifically cleaved at aspar-
tate close to their N termini (for example,
RING-box protein 1 (Asp8), nucleolar pro-
tein family 1, member 2 (Asp9), polypyr-
imidine tractbinding protein 1 (Asp3 and
Asp8) and LSm3 (Asp5)). Such processing
is difficult to detect by one-dimensional gel
shotgun proteomics approaches25 because
the extent of processing is generally not
sufficient to evoke a substantial shift in
the apparent molecular weight.
The identified protease substrates are
involved in all main biological processes,
suggesting that every cellular activity is
affected during apoptosis. In particular, we
found an unusually large number of DNA-
and RNA-binding proteins. Especially note-
worthy is that we identified 14 proteins
known to be associated with the spliceo-
some26–29 and, except for two cleavage sites
in the polypyrimidine tractbinding
protein 1, the actual sites of protein proces-
sing had not been determined previously.
We used SMART30 (http://smart.embl-hei-
delberg.de/) to analyze how proteolytic
processing may interfere with the function
of these spliceosomal proteins (Fig. 4).
Some proteins are predicted to be cleaved
within one of their functional entities or
processed such that these become separated
(Fig. 4). The former may lead to loss of
function, whereas the latter could suggest
differential regulation or localization.
Given that alternative splicing has been
reported as an important aspect of apopto-
sis31, our observations hint to an (at least
partial) interference of RNA splicing by
apoptotic proteases. This may lead to the
synthesis of protein variants important in
the execution of the apoptotic process or in
signaling this event to neighboring cells, a
question that can be addressed in future
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Figure 4 | Location of the apoptotic-specific cleavage sites within the predicted domain organizations
of affected spliceosomal proteins. Spliceosomal proteins are subdivided into core and associated proteins.
Proteins are shown as blue bars. The domains or motifs are predicted by the SMART algorithm
(http://smart.embl-heidelberg.de/) and pictographically presented, and their PFAM nomenclature is
indicated (http://www.sanger.ac.uk/Software/Pfam/). Unnamed stretches of amino acids are predicted
signal peptides (purple), coiled-coil regions (green) and regions of low complexity (magenta). The
cleavage site is indicated with a vertical arrow and its position within the affected protein is given.
Cleavages assumed to separate functional entities (*) or to destroy these entities (1) are indicated.
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experiments. Similar SMART analyses of all other processed pro-
teins are available in Supplementary Figure 2 online.
As protein processing has been recognized to be a key regulator
of many processes (for example, protein translocation, complement
activation, enzyme activation, viral maturation) and perturbations
of the protease-antiprotease balance have been considered as the
major cause of major diseases (such as sepsis, chronic obstruction
pulmonary disease, Alzheimer disease, cancer metastasis and
others.) the differential N-terminal COFRADIC procedure offers
an unique tool for routine screening of substrate repertoires of
natural or pathological protein processing events.
METHODS
Sorting for N-terminal peptides. The N-terminal peptide sorting
procedure consists of three essential steps. First we alkylated
proteins present in the lysate and then blocked them by acetylation
of free amino groups followed by trypsin cleavage. We then
fractionated the peptide mixture by RP-HPLC (primary run). We
treated peptides in each fraction with TNBS, converting all peptides
with a free N terminus into hydrophobic trinitrophenyl derivatives.
Peptides with a blocked a-N-acetylated or PCA terminus and
peptides with a nonreactive N terminus (proline) will not be
modified. During a replicate secondary run, the latter elute in
the same time interval, whereas the internal, now trinitrophenyl
peptides, shift to later elution times. When this procedure is
repeated for each of the primary fractions, the complete mixture
is finally sorted into two peptide sets. The unaltered peptides that
do not shift during the two consecutive runs can be easily collected
in their previously recorded time interval and are retained for mass
spectrometric identification. These are mainly a-N-acetylated
peptides derived from the protein N termini, or internal peptides
starting with PCA or proline (Fig. 1).
The quantitative differential aspect of the procedure is based on
postcleavage, trypsin-catalyzed C-terminal 18O exchange, creating
a mass difference of 4 Da compared to the untreated peptide
mixture17. Tryptic peptides from apoptotic lysates were generally
left with the normal oxygen isotope, whereas those from living
cells were tagged with 18O. In one experiment we swapped the
oxygen labels to verify the general quantitative aspect of the 18O
exchange procedure.
Additional methods. Experimental details of the COFRADIC
procedure, cell culture, induction of apoptosis and associated
biochemical experiments are available in Supplementary
Methods online.
Accession codes. BIND identifiers (http://bind.ca): 316861,
316862, 316863, 316864, 316865, 316866, 316867, 316868,
316869, 316870, 316871, 316872, 316873, 316874, 316875,
316876, 316877, 316878, 316879, 316880, 316881, 316882,
316883, 316884, 316885, 316886, 316887 and 316888.
Note: Supplementary information is available on the Nature Methods website.
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79 
2.2. ms_lims: channeling the flood of data 
"First, the tools were primitive in the features they offered. Second, the features, when 
available, often had built-in limitations that tended to break when projects started to 
get complicated. Third, support from proprietary vendors was terrible; unless you 
were in the process of buying lots of hardware or renewing a large software site 
license, and could use the power of the purse to your advantage, you were out of luck 
when you ran into one of these built-in limitations. And finally, every vendor 
implemented their own proprietary extensions, so that when you did use the meager 
features of one platform, you became, imperceptibly at first, then more obviously 
later, inextricably tied to that platform. All in all, it was quite clear that whatever the 
merits of free market economics, they were not at work in the software marketplace. 
The extent to which the proprietary software model was a broken model made the 
study of that model extremely valuable indeed." 
- Michael Tiemann, Open Sources: Voices from the Open Source Revolution 
 
In order to fulfill the software requirements listed in section 1.4, any single lab can 
choose from two options. The first of these is to buy a Laboratory Information 
Management System (LIMS) from the marketplace and the second is to develop a system 
in-house. 
The commercial options fall into two broad categories: ‘generic’ solutions and mass 
spectrometer vendor solutions. 
The generic solutions are first and foremost prohibitively expensive. These systems are 
usually simply re-packagings of applications developed for the pharmaceutical industry 
for drug discovery and development. As such these systems have been designed around 
rigid procedures with rigorously defined user roles and access privileges combined with 
extensive auditing on every data manipulation operation. These features are of course 
essential when filing for drug approval, but can hamper purely scientific efforts because 
of their enormous hardware requirements, slow maintenance and update cycles and lack 
of transparency. Additionally, several core modules (e.g. integration of a specific data 
producing instrument) are often missing and can only be provided on a per-user basis by 
highly expensive consultants who will usually write a one-off solution that can not 
accommodate the shifting requirements that typify basic research. 
The second type of commercial system is represented by the information management 
tools developed by the instrument vendors. Their systems are typically user-friendly, 
fully integrated management systems that automate and structure common tasks well 
enough. The caveat is that integration of instruments by other vendors is typically wholly 
absent. Although efforts are sometimes made to compensate for this, many of the most 
useful features are then inaccessible for the other instruments and no single provider can 
guarantee support for future instrument purchases if these instruments are from a 
different vendor26. Additionally, since the core software development business of these 
companies is related to instrument control software27, backwards compatibility is not 
(yet) an important issue for them and can almost never be guaranteed. 
                                                 
26
 It is certainly no exaggeration that many vendors do not even want to commit themselves to guaranteeing 
support for their own future models! 
27
 Which changes version with each new model, nearly always introducing several new features. 
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Freely available solutions were simply non-existent when ms_lims was first created, 
although in the few last years, several systems have been published [Field 2002, 
Kristensen 2004, Rauch 2006], or have been made available without having been 
published as a whole (http://www.sbeams.org, http://www.thegpm.org). It is indicative of 
the poor availability of usable commercial systems that development on these published 
systems started at around the same time in different laboratories across the globe to fill 
the urgent need for automated data storage and analysis. 
In the proteomics group in Ghent, the ms_lims software was developed to tackle the data 
management problems. It builds on a centralized relational database for structured storage 
of the data and provides relevant applications for data storage, data processing and data 
analysis and presentation. The relational schema will be discussed first, as well as two 
auxiliary applications that allow for a more efficient development and deployment of the 
ms_lims data access layer. An overview of the ms_lims applications will be given next, 
broken down by the three categories explained above. Finally, published applications of 
the ms_lims system will be highlighted. 
 
2.2.1. The database schema 
"Show me your functions, and I will be confused. Show me your data, and your 
functions will be obvious." 
  - Frederick P. Brooks, The Mythical Man-Month 
 
The ms_lims relational database schema is depicted in figure 34. 
It is of note that, of the fourteen tables, only five28 are strictly related to identifications. 
This leaves nine tables, of which two29 support supplemental storage of binary files and 
one30 is an application specific, descriptive class-loading table. The remaining six31 tables 
are dedicated to source data capture, tracing and integration. 
The central table is the ‘project’ table. All other tables are connected to this table, except 
for the ‘projectanalyzertool’ table. 
An important feature of most tables32 is the presence of rudimentary auditing columns: 
‘username’, ‘creationdate’ and ‘modificationdate’. These columns allow the tracing 
through time of the user that triggered the insertion of the row, the time and date on 
which this insert was accomplished and the time and date of the last modification to the 
row. 
The occurrence of a BLOB33 or LONGBLOB column type highlights where binary files 
can be stored in the database. Each binary column in the ms_lims database contains 
zipped or GZIPped data34 to minimize storage space and table size. Conversion from 
                                                 
28
 These are ‘identification’, ‘datfile’, ‘status’, ‘phosphorylation’ and the indirection table ‘id_to_phospho’. 
29
 ‘binfile’ and ‘filedescriptor’; examples of possible supplementary binary files include: an Excel sheet, a 
Word document, a gel image (e.g. in JPEG format) and a set of files comprising the output of a third-party 
analysis tool. 
30
 ‘projectanalyzertool’ which is queried exclusively by the ProjectAnalyzer application. 
31
 ‘user’, ‘cofradic’, ‘project’, ‘instrument’, ‘lcrun’ and ‘spectrumfile’. 
32
 The only exceptions are the three phosphorylation related tables. 
33
 BLOB is an acronym for ‘Binary Large OBject’ 
34
 Zip compression is used for entities comprising multiple entries, such as folders. GZIP is used for the 
storage of single streams such as individual files. 
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compressed to uncompressed data is handled automatically by the relevant ms_lims 
applications but, thanks to the usage of common compression standards, third-party 
consumers can readily decompress the information after retrieval as well. 
 
 
 
  Figure 34: ms_lims version 5.0.x relational database schema, ‘crows-feet’ notation. 
 
2.2.2. Building on solid ground: data access code generator 
Data access is the most vital part of any data management software system. Indeed, if the 
data access layer does not retrieve (or even worse: store) the data correctly, the usability 
of the entire system becomes zero. The data access layer must therefore consist of 
proven, reliable code that at the same time performs reasonably well. Another desired 
characteristic of the data access layer is the ability to abstract its primary functions. 
Finally, it is also important to provide quick and efficient updates of the data access layer 
whenever the underlying data store changes. 
A LIMS system for a proteomics research group makes no exceptions to these basic 
requirements. The dynamic research setting even emphasizes the importance of the 
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adaptability of the data access layer, as the underlying database schema is prone to 
change frequently and often dramatically as the techniques applied or the scientific topics 
researched evolve. 
The most efficient way to create a highly adaptable yet reliable and efficient data access 
layer is not to write one at all. Instead, the task of procuring the code should be delegated 
to a software program that outputs reliable, proven code in perfectly reproducible ways 
and at speeds unrivaled by any other process. 
We have built such a general-purpose table-based code generator which outputs code that 
fits into a generic framework for data access, consisting of four interfaces each of which 
defines one of the four basic data operations: Persistable, Updateable, Retrievable and 
Deleteable. The generated data access components take care of their own data access 
operations and require only a standard Java Connection object on which their operations 
should be performed, effectively abstracting the data layer from the business logic layer. 
These data access components are also self-aware with regards to changes to their 
internal data. This functionality can be described in a UML state diagram (figure 35) and 
a single component thus represents a simplistic finite state machine. 
 
Unchanged
Changed
set new value(s) / change local data
pass initial data / change local data
persist / insert in DB
update / update in DB
retrieve / load data from DB
Instantiate 
/ create local variables
retrieve / load data from DB
persist / ignore
update / ignore
set new value(s)
/ change local data
 
 
  Figure 35: UML state diagram for a generated data accessor component. 
 
By extending the generated code to add custom extensions, it becomes possible to 
regenerate the data access component whenever the underlying database schema changes 
without suffering from downstream effects35. 
The data access generator has proven its usefulness repeatedly over the years as many 
changes have occurred to the ms_lims database schema since its inception. 
 
                                                 
35
 Typically there are some effects such as changed column names that can require a few minor 
modifications to the extending class. Major changes (e.g. the addition of one or more columns) usually also 
require updates to the user interface to display these new data fields, yet without actually making any of 
these changes, the software will still function, albeit sub-optimally as it does not yet show all data 
available. 
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2.2.3. Building on shifting ground: database migration tool 
“All successful software gets changed. Two processes are at work. First, as a 
software product is found to be useful, people try it in new cases at the edge of or 
beyond the original domain. The pressures for extended function come chiefly 
from users who like the basic function and invent new uses for it.” 
 - Frederick P. Brooks, The Mythical Man-Month 
 
Any system that has been sufficiently long in production is almost certain to undergo 
revisions to its functionalities and underlying data schema. As changes to the latter must 
be retroactively applied to the data already in the system, these updates can be 
cumbersome, time-consuming and potentially dangerous36.  
In practice the update can require complex rearrangements of existing data. It is also 
often the case that temporary changes to the database metadata37 can significantly 
increase the speed of converting an existing database into a new format. This leads to 
multi-step upgrade processes that typically require a set of Structured Query Language 
(SQL) statements as well as some more complex steps that need to call on small 
computer programs to manage intricate data transitions. All these steps need to be 
executed in a strict order, as nearly all of the steps require certain modifications to have 
been performed by one or more of the preceding steps. 
In order to allow fully automatic and monitorable updates of any kind of relational 
database, the DBTransferTool program was developed. This program reads a structured 
text file called Conversion Definition File (‘.cdf’ file) which lists all necessary steps in 
order. These steps can be of SQL type, resulting in the program executing the statement 
against the specified database, or of programmatic type, in which case the value of the 
step should be the fully qualified class name of an implementation of the 
DBConverterStep interface. This interface defines a single method, 
performConversionStep(Connection aConn) which will be executed by the 
DBTransferTool. 
Execution time as well as possible errors are tracked for each step by the transfer tool, 
allowing profiling of the steps when applied to (typically smaller) test databases. This 
feature makes it relatively easy to spot bottle-neck statements, which can then be 
analyzed and sped up by specifically tweaking them. 
Finally, the most important advantage of the tool is that the complete update procedure of 
one database version to another database version is contained and documented in a single 
text file. Knowledgeable users can thus directly read all steps38, understand the changes 
applied and potentially make modifications where appropriate if they have altered their 
local version of the database. 
 
                                                 
36
 It therefore deserves recommendation to always provide verified backups before upgrading databases to a 
new schema. 
37
 Examples of such database metadata are column types, indexes and constraints. 
38
 Note that direct reading of the programmatic code requires either the source code or reverse engineering 
of the actual Java binary that represents this step. Since ms_lims is made available under an open source 
license and the code is freely available, this is not a problem here. 
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2.2.4. Applications for data entry 
A database can only be put to use once it contains data. Data entry is often a crucial step 
as data already in the database tends to be trusted. It is also the step where different data 
sources and formats are integrated into a single common schema. Interestingly, apart 
from the clear advantages this integration effort yields, there is an important caveat: 
implicit metadata connected to the use of certain formats is lost39. It is therefore also the 
stage where this implicit metadata is converted into a structured description of the origins 
of the data. 
In developing applications for data entry it is a golden rule to automate as much of the 
processing as possible. User input should be strictly limited to the necessary, user-
specific knowledge. This way, the user can maximize her/his attention span and minimize 
the introduction of human error40. After the operation completes, the user should also be 
presented with (preferentially numerical) feedback on the proceedings, allowing a quick 
verification step to take place. It is evident that the group of users at large benefits from a 
uniform interface as the amount of training required to make the transition to a new 
instrument becomes negligible. 
In ms_lims the main data entry application is SpectrumStorageGUI41. The application 
itself is simply a graphical interface on top of a frameworked set of data loaders defined 
by the SpectrumStorageEngine interface. This framework, illustrated in the UML 
diagram42 in figure 36, is built around two basic functionalities: locating LC runs and 
storing these in the database. 
 
 
 
  Figure 36: UML diagram of the SpectrumStorageEngine framework in ms_lims. 
 
                                                 
39
 For example: the use of ‘.pkl’ files hints at a Micromass/Waters instrument while ‘.xml’ files can only be 
derived from the Bruker Ultraflex. 
40
 Human error (as opposed to machine error) tends to be non-systematic and extremely difficult to trace. 
41
 There are other data entry applications used for assigning backup medium numbers and primary LC run 
fraction numbers, but these are trivial in design and are therefore not discussed in detail. 
42
 This UML diagram is not a conceptual model; it is automatically generated on the basis of the actual 
ms_lims code itself. 
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The corresponding methods on the SpectrumStorageEngine interface are aptly named 
findAllLCRunsFromFileSystem(…) and loadAndStoreSpectrumFiles(…)43. 
It is worthwhile to walk through usage of the SpectrumStorageGUI application in full, as 
it is representative of most ms_lims applications. 
The first step in any application is managing the connection to the database. This is 
achieved in each application through the same, shared component: ConnectionDialog. A 
screenshot of this login procedure can be seen in figure 37(a). Upon database connection, 
the user is informed of this successful login (figure 37(b)) and is subsequently presented 
with a selection dialog where all available instruments are displayed (figure 37(c)). 
The contents of the instrument selection dialog screen are collected from the ms_lims 
database44. The database contains short names (shown in the dropdown box) as well as 
lengthier descriptions (shown in blue italics above the buttons). Invisible on the interface, 
but present in memory are the fully qualified class names for the relevant 
SpectrumStorageEngine implementation. This system is highly reminiscent of the 
dynamic detection of database loaders for DBToolkit described in section 2.1.3, with the 
main difference being the use of the database for descriptive data storage instead of the 
text files used by DBToolkit. 
Upon selection of the desired instrument, the SpectrumStorageGUI application attempts 
to dynamically load the corresponding SpectrumStorageEngine implementation. When 
successful, the findAllLCRunsFromFileSystem(…) method is invoked which returns a 
list of LC runs that are candidates for being moved to the database. During the search for 
LC runs on the file system, a progress bar keeps the user informed of the proceedings. 
Another silent process running in the background loads all projects currently in the 
database. 
 
   
                                                 
43
 Note that, for the sake of brevity, the method parameters are omitted. 
44
 The table that provides this information is the ‘instrument’ table. 
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a) 
 
 
 
 
  b) 
 
 
 
 
  c) 
 
 
 
Figure 37:  Screenshots of the start-up process of the SpectrumStorageGUI application. 
(a) Shared database connection dialog. Database driver and the URL are 
defined in per-installation text files so the user need not concern herself 
with them. 
(b) Example of informative user feedback: connection has been established 
and the connected database is repeated for verification purposes. 
(c) Instrument selection dialog. Note that there are more instruments in the 
list than are listed in section 1.1.4. This is due to the fact that ms_lims has 
been installed at several locations outside of Ghent, however most 
supported instruments are present for testing purposes in the development 
database. Note also the ‘Unknown instrument’, which is a placeholder for 
testing purposes. 
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Upon completion of these operations the user is presented with the main application 
screen, which is shown in figure 38 for two separate instrument selections. 
 
a) 
 
 
 
88 
 b) 
 
 
 
Figure 38: SpectrumStorageGUI main screen with some LC runs already assigned to 
projects for (a) the Micromass Q-TOF and (b) the Bruker Ultraflex 
instruments. 
 
It is clear from this figure that the only difference for the application between these two 
instruments lies in the name of the LC runs. SpectrumStorageGUI thus qualifies for the 
requirement that the interface should be consistent across multiple instruments. It also 
automates every task save the assignment of LC runs to projects, which only the machine 
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operator knows. The possibility for human error is thus reduced. Finally, detailed user 
feedback is pervasive and unobtrusive across the screen. First and foremost, the title bar 
indicates the number of LC runs found. The operator can directly compare this number 
with the expected number (i.e. the number of runs the machine was instructed to perform) 
and spot any incongruities. All known details for the currently selected project are clearly 
shown in a prominent location on screen so as to minimize erroneous project assignment. 
Projects in the dropdown can be sorted by descending project ID (equivalent to reverse 
chronological sorting) or alphabetical sorting on project title to minimize search time for 
the desired project. During the assignment process an overview is continuously updated 
at the bottom, showing all projects that carry assigned LC runs. Each LC run is annotated 
by a pair of numbers between brackets. These numbers are the total number of child LC 
runs for a specific run45 and the number of individual peak lists contained in the LC run. 
Finally, an LC run can also be affixed with ‘@’. This implies addition of a user-defined 
free-text comment to that LC run46. 
When the user is satisfied with the assignments made and wishes to store these in the 
database, she/he simply needs to click the ‘Store’ button. The application will show a 
progress bar, keeping the user informed of the proceedings while converting the 
instrument specific formatting to ms_lims standard formatting47 and storing the relevant 
data in the database48. Completion of this phase is concluded by informing the user of the 
total amount of data stored as shown in figure 39. 
 
 
 
  Figure 39: User feedback upon completion of data storage. 
 
One final aspect to discuss with respect to SpectrumStorageGUI concerns its flexibility. 
Since the data loaders are frameworked and need only implement two methods (one to 
find all LC runs on the system and the other to store the data49) in order to be fully 
compatible with the SpectrumStorageGUI application, and given the fact that these 
classes are dynamically loaded from descriptive information in the database, it becomes 
very easy to add new instruments to the pool50. 
                                                 
45
 Note that this number is always one here because of good data management practice in the settings for 
the processing software on the instruments. 
46
 Double-clicking on an LC run in the list view to the right of the screen will open a dialog that allows free 
text entry or editing for each LC run. 
47
 The current standard format for peak lists in ms_lims is the Mascot Generic Format (‘.mgf’ files) due to 
easy integration with the Mascot search engine, the high level of annotation it can carry and the relative 
ease with which both humans and machines can read it. 
48
 The ‘lcrun’ table will contain the LC runs, the ‘spectrumfile’ table the (GZIPped) peaklists and the links 
to the correct instrument in the ‘instrument’ table. 
49
 Remember that most of the data access in ms_lims happens through generated accessor objects, reducing 
the burden of data storage to simply performing the right calls at the right times. 
50
 From experience, the typical amount of work for a knowledgeable developer is half a day, including 
testing and release of the new code version. 
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2.2.5. Applications for data processing 
As was explained in section 1.4.2 the main concern for applications that automate data 
processing in a proteomics laboratory is integration with third-party software. For the 
group in Ghent, this software is Mascot. 
When processing spectra into identifications there are two distinct steps that need to be 
automated. The first is submission of a selection of the spectra in the system to the search 
engine, the second the retrieval, display and storage of the resulting identifications. 
Interestingly, the default Mascot software suite already provides a tool that takes care of 
submitting spectra to the Mascot server called ‘Mascot Daemon’. It is a small Visual 
Basic application that presents a graphical user interface for submissions and builds on an 
underlying relational database (default database engine is Microsoft Access) for storage 
and processing of the results. On top of this, query results are also automatically retrieved 
and pointers to the original result file are stored in the database. Since the functionality in 
Mascot Daemon is quite extensive, allowing for instance the re-submission of non-
identified spectra to other queries (e.g. containing different search parameters or 
searching a different database) in concatenated chains, it was decided to build ms_lims 
around this existing tool rather than trying to duplicate this functionality in an in-house 
designed application. 
In order to complement Mascot Daemon, only three things needed to be done: (1) allow 
selection of the spectra that will be queried from the ms_lims database, (2) merge these 
selected spectra in one or more “mergefiles” and (3) read and interpret the raw Mascot 
results after searching has been completed and store these in the database. 
The first and second functionality has been combined in the MergerGUI application, a 
screenshot of which is shown in figure 40(a). The top panel handles initial database 
connection, the panel in the middle contains search options and the bottom panel allows 
project selection and output options. 
The middle panel allows the selection of spectra based upon their status (whether or not 
they have been searched or identified), instrument of origin and, optionally, the spectrum 
filename. Note that the output panel allows the specification of the number of spectra to 
merge per mergefile. The creation of these mergefiles carries two important advantages: 
firstly, the resulting output will be more manageable as there is a thousand fold reduction 
in the number of files output51 and secondly, the Mascot searches will become much 
more efficient. This latter effect has to do with the way Mascot searches spectra. Each 
file it is presented with causes the execution of a search through a sequence database, 
regardless of the number of spectra in that file. This means that searching 1000 separate 
peak lists will result in 1000 independent passes through the same sequence database 
whereas one mergefile containing 1000 peak lists will result in one pass through the 
sequence database file52. Since the amount of time spent on I/O operations while reading 
a sequence database constitutes a substantial amount of the total analysis time, the speed 
gains for merging peak lists in compound mergefiles are very substantial. 
                                                 
51
 Provided of course that 1000 spectra are merged per mergefile. 
52
 It is of note that the very latest version of Mascot Daemon (2.1.03, released on the 3rd of November 
2005) now has this merging feature built-in. 
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a) 
 
 
 
b) 
 
 
 
Figure 40: (a) MergerGUI application screenshot. 
 (b) User feedback on completion of spectrum merging. 
 
The user is presented with an informative progress bar and when the selection, merging 
and output are complete, a dialog is presented with a numerical report of the actions 
performed (figure 40(b)). 
The third required functionality to complement Mascot Daemon concerns the retrieval, 
parsing, presentation and storage of the raw Mascot results. These actions are comprised 
in the IdentificationGUI application, the main screen of which is shown in figure 41(a). 
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a) 
 
 
 
b) 
 
 
 
Figure 41: (a) Screenshot of the main screen of IdentificationGUI 
 (b) Screenshot of the visualization of parsed Mascot results. 
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The tree view on the left shows the actual queries stored in the Mascot Daemon database, 
with the results as the leaves of the tree. Selecting queries (or even individual results) in 
the tree displays the details of the corresponding results on the right-hand table. These 
details are also directly derived from information stored by Mascot Daemon in its 
database. In this table, the user can then select the results she/he wants to parse. The 
identity threshold score applied for the extraction of identifications can be generated 
according to a user-defined confidence interval. The default is set at the Mascot standard 
of 95% confidence (allowing for a maximum of 5% false positive identifications). 
Pressing the ‘Preview’ button will subsequently cause the application to automatically 
retrieve all results and parse them according to the specified confidence interval. The user 
is kept updated on the proceedings by a progress bar. When all results have been parsed, 
a table is displayed (figure 41(b)) which visualizes the identified peak lists. This table can 
be manipulated by the user to suit her/his data presentation requirements53. Also note that 
the presented table is at this time not yet stored in the database. The table is meant as a 
preview, allowing the user decide whether the data should be stored in the ms_lims 
database at all, or allowing a preview of parts of the data that are already completed while 
another part is still being processed. It is also possible at this point to export this data to 
the clipboard for importing into external data analysis software. When the user decides 
that the presented data can be stored in the database, she/he needs only to click the 
‘Store’ button. The proceedings are once again shown by a progress bar and numerical 
output of the operations performed is presented to the user in the usual manner (not 
shown). 
An interesting aspect of the data processing performed by IdentificationGUI in addition 
to the identification performed by Mascot concerns the step from protein identification to 
peptide identification. IdentificationGUI processes the identified peptides in such a way 
that, whenever a degenerate peptide is encountered, the list of matching protein 
identifiers for that peptide is compared with a list of already known protein identifiers 
(both from the ms_lims database and the processing in progress). As soon as a match is 
found in this list of ‘known’ proteins, that protein accession number is selected as 
‘primary’ protein accession number and all other accession numbers are considered 
‘isoforms’54. This implicitly allows for the selection of a minimal explanatory set of 
protein identifiers as primary accession numbers while maintaining the complete list of 
matching accession numbers for future reference. 
  
2.2.6. Applications for data analysis 
The previous two sections showed initial data gathering and processing in ms_lims. Once 
the processed data is available in the database however, users will want to work with the 
                                                 
53
 This manipulation can take the form of sorting on a certain column (ascending or descending), resizing 
columns, moving columns around and clicking certain columns for retrieval of additional information from 
third-party resources on the web (e.g. clicking the protein accession number retrieves the detailed 
information from the parent database for that protein). 
54
 Note that the usage of the term ‘isoform’ here is rather specifically aimed at proteins that can all explain 
a given peptide sequence and that it has no relationship with isoforms as defined by genetic, 
posttranscriptional or posttranslational events. 
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results. This analysis stage is the most heterogeneous since many different questions will 
be asked of the data and it can therefore not be captured by a single application. For 
ms_lims it was decided to provide specialized applications for specific data querying 
tasks rather than one big application. Two applications will be discussed in detail here. 
The first of these is the ProjectAnalyzer, which is a suite of modular tools for generic 
data retrieval and analysis. The second is a DiffAnalysisGUI, a highly specialized 
application for the study of peptide-centric proteomics experiments using differentially 
labeled samples. Differential labeling for these latter experiments is typically achieved 
through the incorporation of stable isotopes, either during tryptic digestion [Staes 2004, 
Van Damme 2005] or cell culture [Ong 2002]. 
 
2.2.6.1. ProjectAnalyzer application 
This application is a control center for a suite of general-purpose analysis modules built 
around a common framework. A screenshot of the main interface is shown in figure 42. 
 
 
 
  Figure 42: Screenshot of the main ProjectAnalyzer application interface. 
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The top panel of the interface allows project selection and review or adaptation of the 
selected projects details. The middle panel allows the selection of an analysis tool from 
the suite to apply to the selected project and the bottom panel displays all currently 
opened project analysis tools in a tree view. This bottom component will organize the 
opened analysis tools by their type, with the leaves corresponding to specific instances of 
this type that are connected to specific projects. Double-clicking any one of the leaves 
will also focus the selected analyzer tool on the screen. 
These analyzer tools are all built around a framework centered on the 
ProjectAnalyzerTool interface, the UML diagram55 of which is represented in figure 43. 
 
 
 
  Figure 43: UML diagram of the ProjectAnalyzerTool framework in ms_lims. 
 
When the ProjectAnalyzer application is started, it first queries the user for database 
connection parameters. After the connection is established, it will proceed to load all 
projects from the database as well as the contents of the ‘projectanalyzertool’ table. This 
table contains a descriptive representation of all known implementations of the 
ProjectAnalyzerTool interface. This dynamic class loading via a common framework is 
again reminiscent of the system discussed in section 2.2.4 for the retrieval of instrument-
specific SpectrumStorageEngine implementations. Again, the advantage is clear: it 
allows third party additions to integrate quickly and seamlessly in a single usage and 
management interface. 
There are three default implementations provided with the latest ms_lims version 
(ms_lims 5.0): BinaryFileRetrieverTool, DescriptiveNumbersTool and ProjectSQLTool. 
The DescriptiveNumbersTool gives a numerical overview of the project and the 
ProjectSQLTool allows the user to run a set of predefined queries against the selected 
project. A screenshot of the latter tool is presented in figure 44. A linked-in component 
called SpectrumPanel is available in many ms_lims applications and will enable 
interactive exploration of a peak lists. Clicking a field in the ‘l_spectrumfileid’ column in 
the results table will pop up this component and initialize it with the corresponding 
spectrum. A screenshot is shown in figure 45. 
                                                 
55
 This UML diagram is not a conceptual model; it is automatically generated on the basis of the actual 
ms_lims code itself. 
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  Figure 44: Screenshot of the ProjectSQLTool interface. 
 
Apart form this predefined query selection tool, ms_lims also comes bundled with a 
generic SQL tool called GenericQuery. This application can connect to any Java 
DataBase Connectivity (JDBC) compatible database and allows the execution of any kind 
of query. This way, beginning or non-expert users can quickly become productive using 
the predefined queries in ProjectSQLTool and expert users can maximize their 
knowledge of the database and of the SQL language by interrogating the database 
directly. Finally, the generated data access layer delivers a well documented Application 
Programmers Interface (API) that developers can wield to their advantage when 
designing their own third-party extensions to the ms_lims system. 
The usage of the GNU GPL license (see section 2.2.7 below) guarantees that such third-
party efforts will be released back to all potential users, gently enforcing the collaborative 
aspect of software development for the proteomics community. 
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  Figure 45: Screenshot of the SpectrumPanel component. 
 
2.2.6.2. DiffAnalysisGUI application 
The analysis of differentially labeled proteome samples yields a good example of a 
complex set of processing steps which need to be performed automatically in order for 
the scientist to make sense of the mass of data acquired during the experiments. 
DiffAnalysisGUI presents such an automated processing and analysis application for 
differential proteomics studies based on isotopically labeled, identified peptides. 
The ‘identification’ table in the ms_lims database contains two columns that hold 
differential data: ‘light_isotope’ and ‘heavy_isotope’. These columns will contain the 
intensity of the signal for the peptide with the light and heavy isotopic label, respectively. 
The workflow of DiffAnalysisGUI will be discussed starting from the main interface of 
the program (figure 46). 
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  Figure 46: Main interface for the DiffAnalysisGUI application. 
 
Upon starting the program, the user is prompted to provide database connection details. 
When a connection has been established, the software will proceed to query the database 
about all known calibrated instruments and all projects that contain differential data. An 
instrument is considered calibrated when measurements of the two-base logarithms of 1/1 
ratios have been performed on this instrument to establish the standard deviation of the 
detector response and this value has been entered in the ‘differential_calibration’ column 
of the ‘instrument’ table. A project contains differential data as soon as one or more 
identified peptides for that project have non-null ‘light_isotope’ and ‘heavy_isotope’ 
columns in the ‘identification’ table. 
The top panel of the screen presents a dropdown containing all differentially calibrated 
instruments. As the standard deviation for each instrument is likely to differ, 
DiffAnalysisGUI only supports the analysis of differential identifications derived from a 
single instrument. The next panel allows the user to provide a descriptive label for the 
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sample that was labeled with the light isotope and one for the heavy isotope56. This label 
will be used throughout to facilitate interpretation of the results. The center panel is split 
in two sections, the leftmost of which contains a list of all projects containing differential 
data and the rightmost one showing those projects currently selected for differential 
analysis. Superimposed on these lists a dialog can be seen in the screenshot that pops up 
whenever the user adds a project to the currently selected list. This dialog requests a 
project alias to be entered57 as well as selection of ‘normal’ or ‘inverse’ labeling for this 
project. Note also that the table on the right of the main interface shows the information 
entered via this dialog as well as the original project information. 
The two bottom panels allow the user to choose the type of statistics that need to be 
applied and whether re-centering of the data should be performed. The type of statistics is 
set to ‘robust statistics’ by default. The influence of the choice of the statistics will be 
discussed below. The re-centering functionality is particularly important when multiple 
projects are analyzed together. Since each of the experiments is performed completely 
separate from all others, there is a very real chance that the labeled/unlabeled mixture is 
not present in an exact 1/1 ratio in each experiment. Slight deviations to this ratio will 
yield different distribution centers for each project, in turn artificially broadening the 
compound distribution. By re-centering each distribution to a specified (expected) ratio, 
this artificial broadening can be limited while each individual distribution retains its 
original scale values, thus contributing correctly to the scale of the compound 
distribution. 
The actual analysis flow consists of a few phases, some of which are optional. The user is 
kept informed of the proceedings through a progress bar. 
The first phase concerns the gathering of all data from the database. An SQL query is 
constructed to report all differential identifications for the selected project(s) and 
instrument. The second phase is optional. If the user requested a re-centering, the 
software will calculate the difference between the center of each distribution and the 
user-specified center and will correct each measured ratio with this difference. The third 
phase consists of joining all data across all experiments in one compound distribution. 
This phase also merges spectra that led to the same identified peptide in one ‘cluster’. 
The result is a list of unique (modified) sequences, with each sequence backed by one or 
more spectra with differential data from the selected instrument. The fourth stage 
concerns the actual calculation of the statistics. All subsequent calculations are based on 
the two-base logarithms of the ratios of the clusters, with the ratio for a particular cluster 
being equal to the average of the ratios of the constituent spectra. According to the user 
request, the location and scale of the distribution are either calculated by means of the 
mean and standard deviation (‘standard statistics’) or through median and Huber scale 
[Huber 1981] by iterative winsorization at k=1.558 (‘robust statistics’). The difference 
between these two approaches revolves around their sensitivity to outliers. The presence 
of these outliers tends to affect traditional statistics quite heavily yet leaves robust 
statistics largely unperturbed [Hampel, 1993]. Since differential experiments are typically 
performed because outliers are expected, robust statistics were chosen to be the default 
setting. We will designate the location estimator as µhat and the scale estimator as s[p]. 
                                                 
56
 Example descriptive labels could be ‘control’ and ‘diseased’. 
57
 Note that plain numbers are used here. More verbose aliasses are of course also possible. 
58
 Convergence was set at 10-6. 
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As the population scale is estimated with high efficiency by the Huber scale, we simply 
consider: 
 
[ ]phat s=σ 
 
Now let the base-two logarithm of each peptide ratio be r[i]. 
As standard deviation (s[i]) for each peptide ratio the calibrated standard deviation for the 
instrument as represented in the ms_lims database is taken. 
Centering is performed by subtracting µhat from each r[i] to yield a zero-centered 
measurement (delta[i]) and the resulting standard deviation (s[delta,i]) was calculated from: 
 
delta[i] = r[i] – µhat 
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We can now apply a double-sided significance test for each delta[i] at the desired 
confidence interval to: 
 
N ~ (delta[i], s[delta,i]) 
 
When the user has selected all relevant projects and verified them and the analysis 
metadata, she/he can then initiate the actual analysis by pressing the ‘Analyze differential 
data’ button. When the analysis completes, the software reports a numerical summary 
first (figure 47). In the example presented, four projects were subjected to robust 
statistical analysis and a re-centering was performed on 1.0. Note that the software 
reports the corrections applied for each separate project. This allows the user to quickly 
estimate the variability and see potential outliers. In this case, the deviations are very 
small and of roughly the same magnitude. After having evaluated this summary, clicking 
‘OK’ will bring the user to the result table, shown in figure 48. Note that the title bar of 
the frame contains the data from the numerical summary. Several entries in the table have 
been coloured red. This is indicative of outliers within the set of spectra representing this 
unique sequence. For instance, the highlighted row (identifiable by the light blue 
background and the red foreground) is composed of combined differential data of 
eighteen separate spectra all identified to be the same peptide sequence. When clicking 
this row, the user can verify the outliers on the detail table shown (figure 49). 
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Figure 47:  Numerical summary of a four-project robust statistical analysis with a re-
centering on 1.0. 
 
 
 
 
  Figure 48: Result table for the statistical analysis of four re-centered projects. 
 
This detailed view contains the individual spectra that were identified and their details. 
Colour highlighting is used here as well to show the spectra that are outliers. Yellow is 
used for outliers at the 95% confidence interval, red for those that still classify as outliers 
at the 98% interval. Tool tips also show up for these rows with this information. 
The most interesting column of this table is the ‘Significance’ column, which expresses 
the deviation of the measurement from the population center as a product of the 
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population scale. The user can now apply any desired confidence interval in order to look 
for outliers (e.g.: finding only those rows with an absolute ‘Significance’ greater than 
1.96 will deliver the outliers at the 95% confidence interval). 
 
 
 
 
  Figure 49: Detailed view on all merged spectra for one sequence. 
 
2.2.7. License and availability 
The ms_lims software has been released as open source software under the GNU General 
Public License (GPL) (http://www.gnu.org/licenses/licenses.html#GPL) and is freely 
available in both source and binary versions from http://genesis.UGent.be/ms_lims. 
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2.2.8. Published applications of ms_lims in proteomics experiments 
The ms_lims system has been instrumental in data management and analysis alike for 
nearly all of the papers presented in this dissertation. The papers included below thus 
only present a sample of the behind-the-scenes impact of the ms_lims software. 
 
2.2.8.1. Cysteine COFRADIC proteome of human blood platelets 
Reversible labeling of cysteine-containing peptides
allows their specific chromatographic isolation for
non-gel proteome studies
Kris Gevaert, Bart Ghesquière, An Staes, Lennart Martens, Jozef Van Damme,
Grégoire R. Thomas and Joël Vandekerckhove
Department of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University
and Flanders Interuniversity Institute for Biotechnology, Ghent, Belgium
We report upon a novel procedure to specifically isolate cysteine-containing peptides from a
complex peptide mixture. Cysteines are converted to hydrophobic residues by mixed disulfide
formation with Ellman’s reagent. Proteins are subsequently digested with trypsin and the gen-
erated peptide mixture is a first time fractionated by reverse-phase high-performance liquid
chromatography. Cysteinyl-peptides are isolated out of each primary fraction by a reduction
step followed by a secondary peptide separation on the same column, performed under iden-
tical conditions as for the primary separation. The reducing agent removes the covalently
attached group from the cysteine side chain, making cysteine-peptides more hydrophilic
and, thereby, such peptides can be specifically collected during the secondary separation
and are finally used to identify their precursor proteins using automated liquid chromatogra-
phy tandem mass spectrometry. We show that this procedure efficiently isolates cysteine-
peptides, making the sample mixture less complex for further analysis. This method was
applied for the analysis of the proteomes of human platelets and enriched human plasma. In
both proteomes, a significant number of low abundance proteins were identified next to ex-
tremely abundant ones. A dynamic range for protein identification spanning 4–5 orders of
magnitude is demonstrated.
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1 Introduction
Several procedures for high-throughput proteome studies
have been developed over the past few years. The major-
ity of these commence with a proteolytic digestion of an
isolated protein mixture and use peptide-related mass
spectrometric (MS) data to identify the precursor proteins
and monitor fluxes of their expression levels. The peptide
mixture is either analyzed as a whole, or specific sets of
peptides are isolated prior to analysis. Because of the
enormous complexity of the peptide mixture, the first
approach requires a rather thorough separation of this
mixture prior to (tandem) MS analysis [1–3]. The second
approach is centered around the affinity-based isolation
of representative peptides out of a proteome digest and
solely uses these to identify the corresponding proteins.
Generally, representative peptides are peptides that con-
tain rare amino acids that are well distributed over a given
proteome so that the chance that every expressed protein
is finally represented by at least one peptide is high. Affin-
ity-based techniques have been described to isolate pep-
tides containing cysteine [4–7], methionine [7, 8], histidine
[9], phosphorylated residues [10–12], and N-linked carbo-
hydrates [13] for further proteome studies. In all these
methods, a general approach for differential, non-gel pro-
teomics involves the incorporation of stable, heavy iso-
topes in one of the mixtures and MS analysis of the ratio
of ‘light’ and ‘heavy’ peptides.
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Recently, we have developed a chromatographic method
for the isolation of sets of representative peptides out of
complex mixtures called combined fractional diagonal
chromatography or COFRADIC. Central in this method
is a modification reaction which alters the retention be-
havior on reverse-phase (RP) columns of specific pep-
tides. This reaction is carried out between two identical
chromatographic separations. A peptide mixture is first
fractionated and in a number of second separations, sets
of altered peptides are isolated for further MS/MS analy-
sis. In one application, methionine peptides are isolated
following oxidation to their sulfoxide forms in an acidic
medium using hydrogen peroxide.
Since methionine-sulfoxide is more hydrophilic than
methionine, peptides carrying the oxidized side-chain
elute sooner from the column in the secondary run and
can thus be isolated from the bulk of peptides that do
not contain methionine [14]. By altering the chemical
reactions applied in between the primary and secondary
separations, we have recently shown that peptides span-
ning the amino terminal part of proteins can be specifical-
ly isolated and used for non-gel proteomics [15]. Besides
protein identification, such an analysis allows global mon-
itoring of in vivo modifications occurring on the amino
termini of proteins (e.g., blocking of the terminal amine
and processing of amino terminal amino acids). Using
the COFRADIC approach, every peptide that contains
an amino acid or a chemical group that can be specifically
modified such that its chromatographic properties are
altered, can be isolated. Here, we present a COFRADIC
approach by which cysteine-containing peptides are
isolated out of a complete proteome digest and are
used to identify their parent proteins. In this new method,
the proteins present in a mixture are first reduced and
the cysteine residues are modified using Ellman’s
reagent (5,5-dithiobis(2-nitrobenzoic acid) or DTNB) [16]
to form a mixed disulfide product (TNB-cysteine). The
hydrophobic TNB group remains covalently bound dur-
ing protein digestion and RP-HPLC separation and upon
its removal using a reducing agent, cysteine-containing
peptides become more hydrophilic and can be collected
during secondary, identical RP-HPLC runs. Finally, the
collected peptides are used to identify their precursor
proteins using automated LC-MS/MS analysis. In order
to illustrate the potential of this technique for gel-free
proteome analysis, we analyzed the proteomes of a
human blood platelet preparation and of a human
plasma sample from which serum albumin and immuno-
globulins were largely depleted. From the generated
data it is clear that a significant enrichment of cysteinyl
peptides is achieved using the developed sorting proce-
dure. The obtained reduction of the sample’s complexity
furthermore makes it possible to identify proteins of
which the concentration spans an interval of 4–5 orders
of magnitude, as is demonstrated by the proteome anal-
ysis of the plasma sample.
2 Materials end methods
2.1 Isolation of the human platelet proteome
A fresh platelet-rich suspension containing approximately
506109 cells was obtained from the Red Cross Blood
Transfusion Centre Oost-Vlaanderen, Ghent, Belgium.
This suspension was centrifuged for 10 min at 10006g
and the pellet was resuspended in 40 mL of washing buf-
fer containing 0.2 g/L KCl, 0.2 g/L MgCl2, 8 g/L NaCl, 1 g/L
D-glucose, and 70 mg/L EGTA in 25 mM sodium phos-
phate buffered at a pH of 7.5. This washing procedure
was repeated twice and the final platelets pellet was
resuspended in a total volume of 10 mL of wash buffer
and lysed by addition of 10 mL of 0.5% Triton X-100 in
25 mM of sodium phosphate buffer (pH 7.5) containing
protease inhibitors (Roche Diagnostics, Mannheim, Ger-
many). This suspension was kept for 30 min on ice fol-
lowed by centrifugation for 10 min at 100006g in order
to remove cellular debris. 500 mL of the obtained protein
mixture (corresponding to 1.256109 platelets) was de-
salted on a NAP-5 column (Sephadex G25 DNA Grade
from Amersham Biosciences, Uppsala, Sweden) in 2 M
guanidinium hydrochloride in 50 mM Tris?HCl (pH 8.7).
The desalted proteins were collected in 1 mL and stored
at 2807C until further use.
2.2 Isolation of the human plasma proteome
Human plasma was also obtained from the Red Cross
Blood Transfusion Centre Oost-Vlaanderen. It was first
centrifuged for 10 min at 10006g to remove cells that
were present in the sample. From 100 mL of cell-free
plasma serum albumin was removed using the Montage
Albumin Depletion Kit from Millipore (Billerica, MA, USA)
according to the manufacturer’s instructions. The albu-
min-depleted plasma was then further incubated with
30 mL of Protein A Sepharose 4 Fast Flow beads (Amers-
ham Biosciences) to remove immunoglobulins. The initial
plasma sample was finally collected in 600 mL. Of this,
500 mL was desalted on a NAP-5 column as described
above for the platelet proteins and collected in a 1 mL
volume.
2.3 Modification of cysteine residues
The desalted protein mixtures were lyophilized and redis-
solved in 500 mL of 50 mM tris(2-carboxyethyl)phosphine
(TCEP) (Pierce, Rockford, Il, USA). Proteins were reduced
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in this solution for 1 h at 377C and were then desalted as
described above on a NAP-5 column. This protein mix-
ture was dried and the cysteine residues were modified
by adding 500 mL of 10 mM Ellman’s reagent (Fluka, Stein-
heim, Germany) in 100 mM Tris?HCl pH 8.7 for 1 h at 377C.
The modified protein mixture was finally desalted on a
NAP-5 column in 1 mL of 10 mM Tris?HCl at pH 8.7 and
concentrated to half its volume by vacuum drying. Prior to
digestion, the protein mixture was boiled for 10 min and
cooled on ice for 15 min. Five microgram of sequencing-
grade modified trypsin dissolved in 25 mL of 1 mM of
acetic acid (Promega, Madison, WI, USA) was added
and the digestion proceeded overnight at 377C and was
stopped by acidification with 50 mL of 10% trifluoroacetic
acid (TFA). The generated peptide mixture was stored at
2207C prior to RP-HPLC separation.
2.4 COFRADIC-based isolation of cysteine-
containing peptides
For the analysis of the platelet proteome, 100 mL of the
tryptic digest was used; this corresponds to the protein
material present in about 26108 platelets. Likewise,
400 mL of the plasma proteome digest was used for pro-
teome analysis, which corresponds to about 67 mL of the
original plasma sample. Prior to RP-HPLC analysis, the
proteome digests were centrifuged to remove any insolu-
ble material and all methionine residues were converted
to their sulfoxide counterparts by adding fresh hydrogen
peroxide to a final concentration of 0.5% w/v to the pep-
tide mixtures and incubating it for 30 min at 307C [14]. This
step is necessary since during the isolation procedure,
methionine residues may become oxidized and peptides
containing such residues will show a hydrophilic shift and
will thus also be isolated. Immediately following the oxi-
dation step, the peptide mixtures were injected onto a
narrow-bore reverse-phase ZORBAX 300SB-C18 column
(2.1 mm id6150 mm; Agilent Technologies, Waldbronn,
Germany) coupled to an Agilent 1100 Series Capillary
LC-system controlled by the Agilent ChemStation soft-
ware modules. Following sample injection, a binary sol-
vent gradient was applied at a controlled constant flow
rate of 80 mL/min (microflow mode). The column was first
washed with 0.1% TFA in water (Baker HPLC analyzed;
Mallinckrodt Baker B.V., Deventer, The Netherlands)
(solvent A) for 10 min, followed by a linear gradient to
70% acetonitrile (Baker HPLC analyzed) in 0.1% TFA
(solvent B) over 100 min. This RP-HPLC separation is
referred to as the primary run. Eluting peptides were col-
lected from 40 min (30% of solvent B) onwards in a total of
48 fractions of 1 min (or 80 mL) in a microtiterplate using
the Agilent 1100 Series fraction collector (see Table 1).
Primary fractions that were separated by 16 min were
pooled (Table 1) and dried in a centrifugal vacuum con-
centrator. These dried fractions were redissolved in 70 mL
of 10 mM Tris?HCl (pH 8.7) and 30 mL freshly prepared
50 mM TCEP was added to remove the 3-carboxy-4-nitro-
phenylthiol moiety from the cysteines. This reduction re-
action proceeded for 1 h at 377C and was stopped by
acidification with TFA. The vials containing the reduced
and pooled primary fractions were then placed in the Agi-
lent 1100 Series Well-plate sampler. Per secondary run,
95 mL of each treated primary fraction was injected onto
the RP-HPLC column and the peptides were separated
using the same buffer gradient as applied during the pri-
mary run. In these conditions, cysteine-containing pep-
tides elute in a time window of 10 min to 3 min in front of
the unaltered (cysteine-free) peptides and were collected
in six subfractions per primary fraction (Table 1). Sub-
fractions with an identical subscript and derived from the
same secondary run were pooled, dried and put at2207C
until LC-MS/MS analysis was started.
Table 1. Scheme indicating the collection times for the
cysteine-containing peptides during COFRA-
DIC analysis
Primary
fractions
Elution of primary
fractions (min)
Elution of secondary
fractions (min)
A 16, 32, 48 55–56, 71–72, 87–88 45–52, 61–68, 77–84
B 15, 31, 47 54–55, 70–71, 86–87 44–51, 60–67, 76–83
C 14, 30, 46 53–54, 69–70, 85–86 43–50, 59–66, 75–82
D 13, 29, 45 52–53, 68–69, 84–85 42–49, 58–65, 74–81
E 12, 28, 44 51–52, 67–68, 83–84 41–48, 57–64, 73–80
F 11, 27, 43 50–51, 66–67, 82–83 40–47, 56–63, 72–79
G 10, 26, 42 49–50, 65–66, 81–82 39–46, 55–62, 71–78
H 9, 25, 41 48–49, 64–65, 80–81 38–45, 54–61, 70–77
I 8, 24, 40 47–48, 63–64, 79–80 37–44, 53–60, 69–76
J 7, 23, 39 46–47, 62–63, 78–79 36–43, 52–59, 68–75
K 6, 22, 38 45–46, 61–62, 77–78 35–42, 51–58, 67–74
L 5, 21, 37 44–45, 60–61, 76–77 34–41, 50–57, 66–73
M 4, 20, 36 43–44, 59–60, 75–76 33–40, 49–56, 65–72
N 3, 19, 35 42–43, 58–59, 74–75 32–39, 48–55, 64–71
O 2, 18, 34 41–42, 57–58, 73–74 31–38, 47–54, 63–70
P 1, 17, 33 40–41, 56–57, 72–73 30–37, 46–53, 62–69
During the primary run, 48 distinct fractions are obtained.
Per secondary run (A–P), 3 primary fractions (indicated in
the second column) which are separated by 16 min (elu-
tion times are given in the third column) are pooled and
reduced using TCEP. The cysteine-containing peptides
shift out of these primary collection intervals and elute in
a time frame that starts 10 min before the elution of the
primary fraction and which lasts for 7 min (see fourth col-
umn). Typically, the secondary fractions are collected in 6
subfractions and per secondary run, subfractions that are
identically indexed are pooled, dried, and applied for final
LC-MS/MS analysis.
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2.5 LC-MS/MS analysis and peptide
identification
Automated LC-MS/MS identification of cysteine-contain-
ing peptides was done essentially as described pre-
viously [14]. Pooled and dried peptides were redissolved
in 20 mL of solvent A’ consisting of 0.1% formic acid and
2% acetonitrile in water. 10 mL was loaded on a 0.3 mm
ID65 mm trapping column (PepMap, LC Packings,
Amsterdam, The Netherlands) at a flow rate of 20 mL/min
(total loading time of 5 min) using a CapLC System
(Micromass UK Limited, Cheshire, UK). By switching the
stream valve, the trapping column is back-flushed with a
binary solvent gradient, which is started simultaneously
with the injection cycle, and the sample is thereby loaded
on a nano-scale reverse-phase C18 column (0.75 mm
id6150 mm PepMap column; LC Packings). The solvent
delivery system was set at a constant flow of 5 mL/min
and using a 1/25 flow splitter, 200 nL/min of solvent was
directed through the nano-column. Peptides were eluted
from the stationary phase with a gradient from 0% to
100% solvent B’ (70% acetonitrile in 0.1% formic acid)
created over a 25 min period. The outlet of the nano-col-
umn was in-line connected to a distal metal-coated
fused-silica PicoTip needle (PicoTip FS360-20-10-D-
C7; New Objective, Woburn, MA, USA), placed in front of
the inlet of a Q-TOF1 mass spectrometer (Micromass UK
Limited). Automated data-dependent acquisition with the
Q-TOF mass spectrometer was initiated 15 min after the
stream valve was switched. The acquisition parameters
were chosen such that only doubly and triply charged
ions were selected for fragmentation and for each frag-
mented peptide spectra were obtained over a period of
8 s. The stream valve was switched back 51 min after the
start of the injection cycle.
The acquired collision-induced dissociation (CID)-spectra
were automatically converted to a MASCOT [17] ac-
ceptable format using Proteinlynx available in the Micro-
mass MassLynx software (Version 3.4). Three different se-
quence databases were used in sequence to identify the
isolated peptides. MASCOT searched first in the SWISS-
PROT database, restricting taxonomy to human proteins
(ftp://ftp.ebi.ac.uk/pub/databases/sp_tr_nrdb/fasta/sprot.
fas.gz), then in NCBI’s nonredundant protein database
(ftp://ftp.ncbi.nih.gov/blast/db/nr.tar.gz) and finally in an
in-house created database holding all possible cysteine-
containing peptide sequences derived from human pro-
teins present in the SWISS-PROT database. The only
restriction applied to these peptides was that their mass
had to fall within the range of 600 to 4000 Da. To avoid
the possibility that one MS/MS-spectrum was linked to
identical sequences stored in the three different data-
bases, the follow-up search option that is available in the
MASCOT daemon tool was used in such a way that only
the MS/MS-spectra that were not identified in one data-
base, were used to search in the larger databases. The
following MASCOTsearch parameters were set: enzyme:
trypsin, maximum number of missed cleavages: 1, vari-
able modification: deamidation (N and Q), oxidation (M),
acetyl (N-terminus of protein) and pyroglutamate forma-
tion (N-terminal Q), peptide tolerance: 0.3 Da, MS/MS
tolerance: 0.3 Da and peptide charge: 21/31. Searches
in the third, peptide-centric database were not restricted
by an enzyme setting. The DAT result files of MASCOT
were automatically queried using in-house developed
software tools and only MS/MS-spectra that were identi-
fied by a score that exceeded the identity threshold score
of MASCOT were retained. The identified peptides were
automatically stored in a MySQL relational database in
which links were made to their MS/MS-spectra and pre-
cursor proteins.
3 Results
3.1 COFRADIC-based isolation of cysteine-
containing peptides
Central in COFRADIC is the use of a chemical modifica-
tion step that alters the chromatographic behavior of a
subset of representative peptides between two identical
RP-HPLC separations such that targeted peptides can
be isolated [14, 15]. For the COFRADIC-based isolation
of cysteinyl-peptides, cysteine residues were modified
prior to protein digestion. This is routinely done in MS-
based protein analyses since it denatures proteins and
makes more sites accessible for proteolytic cleavage,
and thus leads to a higher protein sequence coverage
[18]. In the work presented here, following a reduction
step, cysteine residues are modified by DTNB (Ellman’s
reagent) [16]. This reaction renders cysteines highly hy-
drophobic, since a mixed disulfide between the side chain
of cysteine and a thionitrobenzoic acid (TNB) group is
generated (Fig. 1).
We use Ellman’s reagent for two important reasons: (i) this
reaction is known to be highly quantitative (e.g., [19], [20]),
and (ii) the TNB-group can be easily removed prior to the
secondary separation using a reducing agent. Following
this modification reaction, proteins are digested and
fractionated a first time by RP-HPLC. In what follows, we
refer to this separation as the primary run and typically,
48 primary fractions are collected (Fig. 2A). These frac-
tions contain two types of peptides; those containing at
least one TNB-altered cysteine and those that are free of
cysteine residues. Upon treatment of a primary fraction
with a reducing agent – here we use the strong reducing
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Figure 1. Chemical reactions employed for the CO-
FRADIC-based isolation of cysteine-peptides. All the
cysteine residues of proteins are modified with Ellman’s
reagent prior to digestion. Upon tryptic digestion, two
sorts of peptides are generated; peptides carrying (an)
altered cysteine residue(s) and cysteine-free peptides
(nonCys-peptides). This peptide mixture is fractionated
by RP-HPLC (primary run). The covalently attached group
is removed from the cysteine residues by a simple reduc-
tion step, which makes the cysteine-peptides more hy-
drophilic. Finally, upon a secondary separation, these
peptides will shift out of the primary collection interval
and can thus be isolated for further analysis.
agent and water-soluble TCEP [21] – the TNB-group is
removed from all peptides carrying cysteine(s). When
such a reduced fraction is re-run on the same column
and under identical chromatographic conditions (the sec-
ondary run(s)), a hydrophilic shift of the reduced, cyste-
ine-containing peptides is evoked, whereby these move
out of the primary collection interval and can be specifi-
cally collected (see Fig. 2B).
We have tested this reversible cysteinyl modification on a
number of synthetic peptides and under the conditions
used (see Section 2), cysteine-containing peptides typi-
cally elute in a time frame between 3 and 10 min prior
to their primary collection interval. This indicates that
multiple primary fractions can be pooled, reduced and
fractionated per secondary run. Hence, the number of
secondary runs and thus the total analysis time can be
significantly reduced. Here, we combine three primary
fractions that are separated by 16 min during the primary
run (Table 1) and collect the reduced cysteine-containing
peptides of three primary fractions during one secondary
run (Fig. 2B). We have noticed that when more than three
primary fractions are pooled, peptides shifting from one
primary fraction can elute in the time interval during which
nonshifting (cysteine-free) peptides from a previous pri-
mary fraction elute. For this reason, we pooled three pri-
mary fractions per secondary run. The cysteine-contain-
ing peptides that are shifted out of one primary fraction
are typically collected in six subfractions (see Fig. 2B)
and prior to LC-MS/MS analysis, secondary subfractions
bearing the same index are pooled and dried; e.g., for
the secondary RP-HPLC separation depicted in Fig. 2B,
secondary subfractions 91, 251 and 411 are pooled. This
implies that 96 LC-MS/MS runs will be performed per
proteome analysis using COFRADIC-isolated cysteinyl-
peptides.
3.2 Proteome analysis of human platelets using
isolated cysteine-containing peptides
The developed cysteine-COFRADIC protocol was ap-
plied to identify the proteins present in a proteome prep-
aration of human platelets. The isolated cysteine-contain-
ing peptides were analyzed by automated LC-MS/MS
and 2665 CID-spectra were obtained. Of these, 611
spectra (or 22.9%) were unambiguously linked to human
peptide sequences using the MASCOT database search
algorithm. Following database searching, we noticed that
99.2% of the identified spectra were linked to fully tryptic
peptides and the remainder (0.8%) were from partially
tryptic peptides. 522 of the identified peptides contained
at least one cysteine residue, indicating that our proce-
dure has an isolation efficiency of 85.4%. Some peptides
were analyzed and identified several times, reducing the
number of unique peptide sequences to 362. The list of
identified peptides and their corresponding proteins is
available as supplemental data (Supplementary Table 1).
Note that 63 peptides cannot be linked to a single protein
entry since at least one other protein (isoform) carrying
the same peptide (see supplementary Table 1) is identi-
fied. The obtained data allowed us to identify 163 different
proteins.
Proteins that are frequently underrepresented in 2-D gels
include proteins with low copy numbers and hydrophobic
proteins (e.g., [22]). To obtain a global view of our results,
the list of identified proteins was mapped onto the
human gene ontology annotation (GOA) database [23].
Patterns were detected using a software tool that allows
 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de
902 K. Gevaert et al. Proteomics 2004, 4, 897–908
Figure 2. Principle of COFRADIC for the isolation of cysteine-peptides. (A) A complex peptide
mixture – here, a tryptic digest of human plasma depleted of serum albumin and immunoglobulins –,
is first separated by RP-HPLC (the UV-absorbance profile at 214 nm is shown). During the primary
run, 48 different primary fractions are obtained. (B) Prior to the secondary run, three fractions that are
separated by 16 min (here, fractions numbered 9, 25, and 41) are pooled and treated with a reducing
agent, which removes the TNB group from the cysteine residues. When re-run on the same column
and under identical chromatographic conditions, cysteine-containing peptides have become more
hydrophilic and thus shift out of the primary collection interval and can be collected in an time interval
of 10 to 3 min prior to their original elution interval.
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visual analysis of the complex data structures used in the
GOA database. Based on the biological function and
localization of the identified proteins, 3 known protein
kinases (the tyrosine kinases Src and Yes and the integ-
rin-linked protein kinase) and 11 proteins that have at
least one helix passing through a biological membrane
were identified (Table 2). Since estimating the abun-
dances of proteins in gel-free proteome analysis without
adding internal standards [24] is difficult, we examined
the list of identified proteins in 2-D gel based studies to
see whether these selected proteins were previously
identified. Only two membrane-spanning proteins have
been previously identified in the platelet proteome using
2-D gels [25] (Table 2). Furthermore, none of the kinases
or the membrane spanning proteins are stored in the
Swiss-2DPAGE (http://ca.expasy.org/ch2d/). Taking to-
Table 2. List of human platelet proteins having at least
one membrane spanning-domain
Acc. No. Protein description
P27105 Erythrocyte band 7 integral membrane protein
P23229 Integrin alpha-6 precursor
P08514 Integrin alpha-IIb precursor (*)
P05556 Integrin beta-1 precursor
PO5106 Integrin beta-3 precursor
O00264 Membrane-associated progesterone receptor compo-
nent 1 (*)
P16284 Platelet endothelial cell adhesion molecule precursor
P07359 Platelet glycoprotein Ib alpha chain precursor
P16671 Platelet glycoprotem IV
P16109 P-selectin precursor
P16615 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Following searches in the gene ontology database, 11 dif-
ferent proteins were identified in our platelet proteome
that had at least one helix traversing through a biological
membrane. Their SWISS-PROT accession numbers and
descriptions are given in the first two columns. Proteins
that were identified in a previous, 2-D gel based study
[25] are indicated with an asterisk.
gether these observations indicate that these proteins are
not routinely identified on 2-D gels and may thus be low-
abundant (e.g., the protein kinases) or too hydrophobic
(e.g., the membrane passing proteins).
3.3 Proteome analysis of human plasma
depleted from serum albumin and
immunoglobulins using isolated cysteine-
containing peptides
For the proteome analysis of a human plasma sample we
decided to deplete serum albumin and antibodies from
the protein mixture as we expected to isolate too many
cysteine-containing peptides from these proteins, which
would mask peptides originating from minor proteins.
These depletion steps were visualized following SDS-
PAGE and, as specified by the manufacturer, most but
not all of the serum albumin and immunoglobulins were
removed; e.g., about one-third of the albumin could not
be extracted (data not shown). A total of 6253 MS/MS-
spectra was obtained using the cysteine-peptides iso-
lated out of a tryptic digest of 67 mL of the plasma sample.
Using MASCOTand restricting the search to human pro-
teins, 1523 spectra were identified (24.4%) of which 1094
(71.8%) contained at least one cysteine residue. In this
case, 96.1% of the identified peptides were correctly pro-
cessed, 3.7% were partially tryptic and only 0.2% (3 pep-
tides in total) were nontryptic. A total of 384 unique pep-
tides sequences were linked to the identified spectra,
thereby identifying 102 different proteins (see Table 3). As
expected some of the peptides could not be linked to an
unique protein sequence and thus identified multiple pro-
tein isoforms. This was especially prominent when tryptic
peptides from antibodies were isolated and identified. For
example, the isolated peptide Ac-SDDTAVYYCAR-COOH
could be linked to as many as 428 different protein
entries, all being the heavy chain variable region of anti-
bodies!
Table 3. List of proteins identified in a human plasma sample from which albumin and immunoglobulins were depleted
Description Acc. No. LC2-2D-
PAGE
LC2-
MS/MS
Concentration # of
cysteines
# of non-
Cys-peptides
1 Fibrinogen alpha/alpha-E chain precursor P02671 2–4 g/L [28] 12 6
2 Fibrinogen beta chain precursor P02675 2–4 g/L [28] 11 5
3 Fibrinogen betaB 1–118 223130 2–4 g/L [28] 3 1
4 Fibrinogen gamma chain precursor P02679 2–4 g/L [28] 10 2
5 Gamma-fibrinogen chain fragment 577055 2–4 g/L [28] 0 1
6 Fibrinogen alphaA 223918 2–4 g/L [28] 6 1
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Table 3. Continued
Description Acc. No. LC2-2D-
PAGE
LC2-
MS/MS
Concentration # of
cysteines
# of non-
Cys-peptides
7 Serotransferrin precursor P02787 3 3 1.8–2.7 g/L [28] 38 9
8 Haptoglobin-1 precursor P00737 3 3 0.27–2.47 g/L [29] 9 2
9 Haptoglobin-2 precursor P00738 3 3 0.27–2.47 g/L [29] 12 1
10 Complement C3 precursor P01024 3 3 1–2 g/L [28] 27 5
11 Apolipoprotein A-I precursor P02647 3 3 1.27–1.47 g/L [28] 0 8
12 Alpha-1-antitrypsin precursor P01009 3 3 1.3 g/l [28] 1 14
13 Alpha-1-acid glycoprotein 1 precursor P02763 3 0.45–1.28 g/L [29] 4 1
14 Alpha-2-macroglobulin precursor P01023 3 3 1.2 g/L [28] 25 15
15 Hemopexin precursor P02790 3 3 0.50–1 g/L [28] 12 1
16 Apolipoprotein A-II P02652 3 3 650–740 mg/L [28] 1 1
17 Alpha-1-acid glycoprotein 2 precursor P19652 3 ,700 mg/L [30] 5 1
18 Alpha-2-HS-glycoprotein precursor P02765 3 3 630 mg/L [28] 11 2
19 Ceruloplasmin precursor P00450 3 200–600 mg/L [29] 14 1
20 Alpha-1-antichymotrypsin precursor P01011 3 3 300–600 mg/L [29] 1 2
21 Complement C4 precursor P01028 3 3 200–600 mg/L [28] 28 0
22 Complement factor H precursor P08603 3 3 200–600 mg/L [28] 80 0
23 C4 complement C4d region 13936421 200–600 mg/L [28] 1 1
24 Vitamin D-binding protein precursor P02774 3 3 400 mg/L [28] 28 0
25 Vitronectin precursor P04004 3 3 350 mg/L [28] 14 0
26 Fibronectin 11119231 300 mg/L [28] 16 0
27 Transthyretin precursor P02766 3 250 mg/L [28] 1 2
28 Complement factor B precursor P00751 3 3 210 mg/L [28] 23 0
29 Coagulation factor XIII B chain precursor P05160 3 3 210 mg/L [31] 40 0
30 Plasminogen precursor P00747 3 3 70–200 mg/L [28] 48 0
31 Beta-2-glycoprotein I precursor P02749 3 150–170 mg/L [32] 22 0
32 Chain L, Antithrombin 1000039 3 115–160 mg/L [28] 6 0
33 Antithrombin-III precursor P01008 3 115–160 mg/L [28] 6 0
34 C4b-binding protein alpha chain precursor P04003 3 3 150 mg/L [28] 36 0
35 Prothrombin precursor P00734 3 3 110 mg/L [28] 24 0
36 Clusterin precursor P10909 3 35–105 mg/L [28] 10 0
37 AMBP protein precursor P02760 3 3 20–100 mg/L [28] 16 0
38 Apolipoprotein D P05090 3 3 ,100 mg/L [33] 5 0
39 Kininogen precursor P01042 3 3 ,75 mg/L [28] 18 0
40 Zinc-alpha-2-glycoprotein precursor P25311 3 40–75 mg/L [28] 4 0
41 Angiotensinogen precursor P01019 3 ,70 mg/L [34] 4 0
42 Alpha-2-antiplasmin precursor P08697 3 3 69 mg/L [28] 4 0
43 Heparin cofactor II precursor P05546 3 3 ,60 mg/L [28] 3 1
44 Plasma kallikrein precursor P03952 3 3 35–50 mg/L [28] 37 0
45 Plasma retinol-binding protein precursor P02753 3 46 mg/L [28] 6 0
46 Complement C1r component precursor P00736 3 3 34 mg/L [28] 27 0
47 Apolipoprotein C-IV precursor P55056 1–19 mg/L [35] 3 1
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Table 3. Continued
Description Acc. No. LC2-2D-
PAGE
LC2-
MS/MS
Concentration # of
cysteines
# of non-
Cys-peptides
48 Coagulation factor V precursor P12259 4–10 mg/L [28] 19 0
49 Sex hormone-binding globulin precursor P04278 3 ,4 mg/L [36] 4 0
50 Calgranulin A P05109 3 10–100 mg/L [37] 1 1
51 Complement receptor type 1 precursor P17927 13–81 mg/L [28] 120 0
52 55 kDa erythrocyte membrane protein Q00013 N.F. 4 0
53 N33 protein Q13454 N.F. 6 1
54 Alpha-1B-glycoprotein precursor P04217 3 3 N.F. 10 0
55 Vascular endothelial growth factor D precursor O43915 N.F. 9 1
56 Similar to katanin p60 12653659 N.F. 6 0
57 Complement-activating component of
Ra-reactive factor precursor
P48740 3 N.F. 28 0
58 Afamin precursor P43652 3 3 N.F. 34 0
59 Peptidoglycan recognition protein L precursor 15705411 N.F. 10 0
60 Microtubule-actin cross-linking factor 1 Q9UPN3 N.F. 63 1
61 Zinc finger transcription factor Trps1 Q9UHF7 N.F. 39 1
62 Cdc42 guanine nucleotide exchange factor
zizimin 1
Q9BZ29 N.F. 39 1
63 Hypothetical protein KIAA0008. Q15398 N.F. 12 1
64 COP9 signalosome complex subunit 1 Q13098 N.F. 10 1
65 Hepatocyte growth factor activator precursor Q04756 3 N.F. 39 0
66 Conserved oligomeric Golgi complex
component 7
P83436 N.F. 12 1
67 Monocarboxylate transporter 1 P53985 N.F. 12 1
68 Antigen KI-67 P46013 N.F. 40 1
69 G2/mitotic-specific cyclin B1 P14635 N.F. 5 1
70 Complement C1s component precursor P09871 3 3 N.F. 27 0
71 Leukocyte common antigen precursor P08575 3 N.F. 26 0
72 Apolipoprotein M O95445 N.F. 6 0
73 Guanine nucleotide exchange factor DBS O15068 N.F. 26 1
74 Hemoglobin beta chain P02023 3 N.F. 2 0
75 Serum albumin precursor P02768 3 3 N.A. 35 23
76 Ig kappa chain C region P01834 3 N.A. 3 3
77 Ig gamma-1 chain C region P01857 3 N.A. 9 3
78 Ig gamma-2 chain C region P01859 3 N.A. 11 1
79 Ig alpha-1 chain C region P01876 3 3 N.A. 15 2
80 Ig mu chain C region P01871 3 N.A. 12 0
81 Ig gamma-3 chain C region P01860 3 N.A. 16 0
82 Ig kappa chain C region 106529 3 N.A. 3 0
83 Ig alpha-2 chain C region P01877 3 N.A. 14 0
84 Ig lambda chain C regions P01842 3 N.A. 3 0
85 Ig heavy chain V-III region NIE P01770 N.A. 2 1
86 Ig delta chain C region P01880 3 N.A. 8 0
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Table 3. Continued
Description Acc. No. LC2-2D-
PAGE
LC2-
MS/MS
Concentration # of
cysteines
# of non-
Cys-peptides
87 Ig heavy chain V-II region NEWM P01825 N.A. 3 0
88 Ig heavy chain V-I region EU P01742 N.A. 2 1
89 Immunoglobulin J chain P01591 3 3 N.A. 8 0
90 Ig kappa chain precursor 1082538 N.A. 2 0
91 Ig gamma-4 chain C region P01861 N.A. 9 0
92 Ig heavy chain V-III region KOL P01772 N.A. 4 1
93 Immunoglobulin heavy chain VHDJ region 21670047 N.A. 2 0
94 Immunoglobulin kappa light chain variable
region
17483730 N.A. 2 0
95 Immunoglobulin heavy chain variable region 11875746 N.A. 2 0
96 Immunoglobulin heavy chain variable region 10636795 N.A. 2 0
97 Immunoglobulin heavy chain variable region 10636671 N.A. 3 0
98 Immunoglobulin gamma heavy chain variable
region
10636501 N.A. 3 0
99 Immunoglobulin heavy chain VH-I region 1294810 N.A. 2 0
100 Chain A, Immunoglobin Fc (Igg1) Complexed
With Protein G (C2 Fragment)
1065199 N.A. 4 1
101 Anti-herpes simplex virus glycoprotein D Ig
heavy chain variable region
1042148 N.A. 2 0
102 Ig Aalpha1 Bur 223099 3 N.A. 17 0
Plasma proteins that were identified by at least one unique peptide sequence are given by their description and database
accession number. The proteins were ranked according to their known concentration in plasma (N.F. indicates that the
protein concentration was not found in the literature, N.A. indicates that the protein concentration figures were not appli-
cable since those proteins were (partly) depleted from the plasma sample). The list of identified proteins was screened
against the list of proteins identified in a large scale LC/LC-2D-PAGE analysis [26] and in a gel-free LC-LC/MS/MS-analysis
[27]. Proteins that were identified in either one of those studies are indicated. The number of cysteine residues in the identi-
fied proteins was calculated by the ProtParam-tool which can be found at http://www.expasy.org/cgi-bin/protparam and
the number of identified non-cysteine containing peptides is indicated in the last column.
When the enriched plasma sample was digested with
trypsin and directly analyzed (i.e., without sorting for
cysteine-peptides) by LC-MS/MS only eight, abundant
plasma proteins were identified; alpha-1-antitrypsin
(P01009), alpha-2-HS-glycoprotein (P02765), alpha-2-
macroglobulin (P01023), apolipoprotein A-I (P02647),
apolipoprotein A-II (P02652), Ig alpha-1 chain C region
(P01876), serum albumin (P02768), and transthyretin
(P02766). These proteins were also identified following
the developed COFRADIC sorting procedure for cyste-
ine-peptides (shown in Table 3 as entries in italics). How-
ever, upon simplifying the peptide mixture, 94 other pro-
teins are additionally identified (Table 3), clearly illustrating
the power of the developed approach for gel-free prote-
omics using a 1-D chromatographic system.
4 Discussion
Reversible modification of cysteine residues using Ell-
man’s reagent is an elegant tool to isolate cysteine-con-
taining peptides using COFRADIC; the reaction is known
to be quantitative, the group remains fixed on the
cysteines during digestion and RP-HPLC separation and
can be easily and selectively removed by a reduction
step. Because of the hydrophobic nature of the TNB
group, its removal induces a hydrophilic shift which is suf-
ficiently large to enrich cysteine-containing peptides for
further gel-free proteome analysis. In silico calculations
indicate that among the proteomes of different model
organisms, about one fifth of all generated and detectable
tryptic peptides contain at least one cysteine residue
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(data not shown). This implies that isolation of cysteine-
containing peptides will lower the complexity of the sam-
ple by at least a factor five, which, however, can still be
insufficient to analyze every peptide present in the sample
and thus some proteins might escape analysis.
In a recently published comprehensive proteome study, a
combination of highly-resolving 2-D maps and mass
spectrometric analysis was used to identify the products
of 123 different open reading frames in a human platelet
proteome [25]. Following isolation of cysteine-containing
peptides using the COFRADIC-technology that we
developed, we were able to identify 163 different proteins,
demonstrating that our technology identifies more pro-
teins and is thus more sensitive than traditional studies.
However, during our experiments a weak point of this
type of gel-free proteome analysis became clear. Cyste-
ine residues appear to be randomly distributed within pro-
tein sequences. From one of our previous studies, we
noticed that most protein isoforms differ at their sequence
extremities, since by analyzing the COFRADIC-isolated
amino termini of proteins, a clear distinction between
many protein isoforms could be made [15]. However,
when cysteine-peptides are isolated, the chance is fairly
high that the isolatedpeptidesarenotspanning theextrem-
ities of proteins and therefore, multiple protein isoforms
are identified per isolated peptide (see supplementary
Table 1). Exactly knowing which protein isoform is present
in the analyzed proteome can be important since different
isoforms are sometimes organ-specific and may have dif-
ferent biochemical characteristics (e.g., the mammalian
sodium pumps, reviewed in [38]). From our experience
with traditional proteome studies involving 2-D PAGE, we
learned that, while protein isoforms may be separated in
2-D gels, mass spectrometric data generally do not cover
sufficiently sequences to specifically identify different iso-
forms. Indicating that unless monoclonal antibodies spe-
cific for protein isoforms are available, most traditional as
well as most non-gel proteome studies fail to distinguish
protein isoforms.
As can be judged from the list of identified plasma pro-
teins (Table 3), most of these are typical plasma proteins.
In order to estimate the dynamic range of our technology,
we searched the literature for known concentrations of
identified plasma proteins. Among the most abundant,
identified plasma proteins are the fibrinogens, serotrans-
ferrin and the haptoglobins, which are all present in g/L
concentrations. On the other hand, some of the less
abundant, known plasma proteins are the complement
receptor type 1 protein and calgranulin A which have con-
centrations in the mg/L range, and sex hormone-binding
globulin, coagulation factor V and apolipoprotein C-IV,
which have concentration in the low mg/L range (see
Table 3). From this data, we can conclude that the devel-
oped COFRADIC technology for the isolation and identi-
fication of cysteine-containing peptides using our Q-TOF
mass spectrometer has a dynamic range of 4–5 orders of
magnitude, which is consisted with earlier findings [39].
However, the dynamic range of proteins residing in
human plasma is much higher and is believed to span at
least 10 decades [40]. Therefore, if one would use the
developed technology to tackle the human plasma pro-
teome at least 105 to 106 times more material, i.e., 6.7–
67 L of plasma should have been used. Since it was never
our intention to identify all the proteins in plasma, such a
huge effort has not been made. Clearly, if one would like
to do this, LC-based separation techniques, e.g., such as
the ones described in [26], could be used prior to COFRA-
DIC.
Remarkably, more than 400 MS/MS spectra were linked
to peptides from human serum albumin (HSA), indicating
that the procedure used to deplete serum albumin from
plasma was not entirely successful. Other methods that
use HSA-specific antibodies for HSA depletion may be
more efficient for future analysis and may lead to a better
coverage (e.g., [41]). Notwithstanding the limitations of
our analysis, more than 100 different proteins have
already been identified in a very low volume of plasma
(less than 100 mL) (Table 3), a number which can only
increase when more starting material is used for these
analyses.
In two recent and more comprehensive plasma pro-
teome studies, considerably more material was used for
analysis; e.g., 20 mL of serum depleted from all major
proteins in the 2-D PAGE study [26] and 500 mL of anti-
body-depleted serum in the LC-LC/MS/MS study [27].
Hence, in those cases significantly more proteins (about
5 times more) were identified. However, our list contains
proteins that were not identified in these two analyses
(see Table 3). Among others, these proteins include the
known plasma protein apolipoprotein C-IV (P55056),
the cytoplasmic protein Cdc42 guanine nucleotide
exchange factor zizimin 1 (Q9BZ29), the conserved
oligomeric Golgi complex component 7 (P83436), the
nuclear antigen KI-67 (P46013) and the nuclear zinc fin-
ger transcription factor Trps1 (Q9UHF7). One possible
explanation is that the presence of these proteins is the
result of destruction of circulating blood cells or
endothelial cells. However, if this would happen, the
known most abundant household proteins (e.g., those
present in circulating platelets (supplementary Table 1))
should be massively present in the list of identified
plasma proteins, which is not the case, pointing to the
possibility that these proteins might be yet undiscovered
endogenous plasma proteins.
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As can be seen from Table 3, more than 50% of all identi-
fied proteins were identified solely by cysteine-containing
peptides, indicating the usefulness of enriching for cyste-
ine-peptides in gel-free proteome studies. Furthermore,
the contaminating non-cysteine containing peptides
seem to be mainly attributed to the major plasma proteins
in the sample (see the entries put in italics in Table 3),
which were also identified in a single LC-MS/MS run with-
out cysteine-peptide enrichment (see Section 3). Al-
though such peptides were present in the final mixture,
they did not seem to disturb the LC-MS/MS analysis to
such a degree that a lot of other peptides were obscured
by them. On the contrary, two proteins that do not carry
cysteines, a fragment of gamma-fibrinogen and apolipo-
protein A-I were actually identified using such peptides.
Finally, it is important to note that the whole COFRADIC
procedure for isolating cysteine-peptides is largely auto-
mated and thus quite fast. Furthermore, we are currently
setting up protocols for differential non-gel proteomics
using enzymatic incorporation of heavy oxygen atoms at
newly formed carboxy termini (e.g., [42]) that are compat-
ible with COFRADIC-based isolations of representative
peptides and have noticed that this type peptide labeling
strategy is compatible with all reaction conditions
employed during cysteine-COFRADIC.
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Global phosphoproteome analysis on human HepG2
hepatocytes using reversed-phase diagonal LC
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We present a phosphoproteomics approach using diagonal RP chromatography as the basic iso-
lation principle. Phosphopeptides present in a tryptic digest of total cellular lysates were first
enriched by Fe31-immobilized metal ion affinity chromatography. Further sorting of the phos-
phopeptides took place in three steps. First, the resulting peptide mixture was fractionated over
reversed-phase chromatography. Second, peptides present in each fraction were treated with
phosphatases. Third, the dephosphorylated peptides were then more hydrophobic and shifted
towards a later elution interval from the contaminating non-phosphopeptides eluting at the same
position as during the primary run. Since the phosphopeptides are isolated as their dephos-
phorylated form, additional proof for their original phosphorylation state was obtained by split-
differential 16O –18O labeling. The method was validated with alpha-casein phosphopeptides and
consecutively applied on HepG2 cells. We identified 190 phosphorylated peptides from 152 dif-
ferent proteins. This dataset includes 38 novel protein phosphorylation sites.
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1 Introduction
In order to obtain a better view on the global regulations of
the phosphorylation status of proteins and its biological
implications, several holistic attempts have been made to
generate qualitative and quantitative data on kinase and
phosphatase substrates and to correlate these with normal,
altered, or diseased cell stages. This is not an easy task, since
a large number of proteins are simultaneously phosphoryl-
ated in sub-stoichiometric concentrations and phosphoryla-
tion can occur on different residues such as serine, threo-
nine, and tyrosine next to histidine [1], lysine [2], and argi-
nine [3] – modifications that all have specific chemical
characteristics and stabilities.
As early as 1975, Kang and co-workers [4] used 2-D gel
analysis of 32P-labeled proteins for a global differential ana-
lysis. However, it took ten more years to develop a method
able to identify gel-separated proteins by micro-sequencing
[5] and later by fast PMF [6]. While it is routine to identify
phosphorylated proteins, locating the actual phosphorylation
sites still remains challenging [7]. In addition, 2-D gel-based
phosphoproteomics encompasses problems inherently
linked to limitations of the gel approach, such as limited
sensitivity, loss of proteins with extreme properties, etc.
Recently, alternative strategies were developed by different
groups. Central in many approaches is a highly resolving
chromatographic system, or combinations thereof, com-
bined with high-sensitivity MS for peptide identification [8–
12]. Other approaches rely on chemical modification of the
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phosphorylation sites creating derivatives such as phosphor-
amidates [13], biotinylated amino acids [14, 15], and thiols
[16], thereby generating sites that can be used in affinity-
adsorption strategies.
We recently developed a non-gel technology called com-
bined fractional diagonal chromatography (COFRADIC) to
isolate sets of representative peptides from digests of com-
plete proteomes. The basic principle of COFRADIC is to
induce a chromatographic shift by modifying a specific sub-
set of peptides. This alteration is done between two con-
secutive, identical separations. In the second run, altered
peptides elute differently from their original position and
segregate from the bulk of unaltered peptides that elute
unchanged.
So far, COFRADIC was applied for the isolation of
methionyl-peptides [17], cysteinyl-peptides [18], and peptides
covering the amino termini of proteins [19]. We have now
modified COFRADIC to isolate phosphorylated peptides in
trypsin digests of cell lysates. As for the previous systems, we
used a chromatographic shift, after phosphatase treatment of
peptide fractions collected during the primary run. In the
secondary run, ex-phosphopeptides shift towards later elu-
tion times and are identified by MS/MS analysis. Here we
provide details and an initial assessment of the procedure on
a total lysate of HepG2 cells.
2 Materials and methods
2.1 Sorting and identification of phosphorylated Æ-S1
casein peptides
In total, 1 nmol of bovine a-casein (70% pure; Sigma-
Aldrich, St. Louis, MO, USA) was digested for 4 h with 1 mg
of trypsin (sequencing grade, modified porcine trypsin from
Promega Corporation, Madison, WI, USA) in 100 mL freshly
prepared 50 mM ammonium bicarbonate. The generated
peptide mixture was separated by RP-HPLC onto a RP-HPLC
column (2.1 mm id6 150 mm 300SB-C18 column, Zor-
baxR; Agilent Technologies, Waldbronn, Germany) using an
Agilent 1100 Series HPLC system. The column was first
washed for 10 min with solvent A (10 mM ammonium ace-
tate at pH 5.5 in ACN/water (2/98, v/v), both Baker HPLC
analyzed; Mallinckrodt Baker, Deventer, The Netherlands),
and a linear gradient to 100% solvent B (10 mM ammonium
acetate at pH 5.5 in ACN/water (70/30, v/v)) was applied over
100 min. Using Agilent’s electronic flow controller box, a
constant flow of 80 mL/min was generated.
This separation is referred to as the primary run. From
40 min onwards until 80 min, fractions of 2 min each
(160 mL) were collected in a microtiter plate. From each pri-
mary fraction, 5 mLwas spotted on aMTP AnchorChip 600/
384 (Bruker Daltonics, Bremen, Germany) that was pre-
coated with a thin layer of MALDI-matrix (0.25 mg of CHCA
dissolved in 1 mL of acetone). The samples were auto-
matically analyzed in reflectron mode with a Bruker Ultra-
flex TOF/TOF mass spectrometer using the AutoXecute
module of Bruker’s flexControl 2.2. for each sample,
300 shots were acquired.
This fast mass screening allowed us to readily identify
fractions that might contain putative a-casein phosphopep-
tides. These fractions were retained, dried, and re-dissolved
in 50 mL of calf intestinal alkaline phosphatase (CIP) reaction
buffer as delivered by the manufacturer (New England Bio-
labs, Beverly, MA, USA) and a total of 10 U of CIP was used
per fraction to carry out the dephosphorylation. After 1 h at
377C, 50 mL of RP solvent A was added to the reaction mix-
ture and each of the fractions of interest was re-separated on
the same RP column. This is called the secondary run. Be-
cause we were expecting a hydrophobic shift associated with
dephosphorylation, we collected the peptides eluting in a 20
min interval, following the position of the non-altered pep-
tides of which the elution time was not affected due to iden-
tical separation conditions. Material eluting in each delayed
zone was collected in 8 mL droplets on a Bruker Anchor
Chip and analyzed as described.
2.2 Cell lysis and peptide pretreatments
HepG2 cells were grown at 377C in DMEM complemented
with 10% v/v heat-inactivated fetal calf serum, 25 U/mL of
penicillin, and 25 mg/mL of streptomycin as previously
described [20]. Cells were grown to sub-confluent levels and
stimulated with 10 mM forskolin (Sigma-Aldrich) for 30 min
at 377C. The cells were detached in enzyme-free PBS-based
cell dissociation buffer (Invitrogen, Carlsbad, CA, USA) for
15 min at 377C, briefly centrifuged, and extensively washed
in PBS. A pellet containing 25million HepG2 cells was dis-
solved in 5 mL of 4 M urea and 0.625% w/v CHAPS in
100 mM NaH2PO4 (pH 7.4). The cell disruption buffer fur-
ther contained protease inhibitors (Complete EDTA-free
protease inhibitor cocktail tablets; F. Hoffmann-La Roche,
Basel, Switzerland), phosphatase inhibitors (10 mM NaF,
200 mM sodium orthovanadate, 20 mM b-glycerophosphate,
5 mM phenylvalerate, and 2 mM levamisole hydrochloride) as
well as 10 mM Tris(2-carboxyethyl)phosphine (TCEP) and
100 mM iodoacetamide. Cell disruption started at room tem-
perature for 5 min and continued on ice for another 30 min.
During this procedure, the cells were kept in the dark. Dis-
rupted cells were briefly sonicated and centrifuged for
10 min at 13 0006 g at 47C and the pellets were discarded.
The protein solution was desalted onto two PD-10 col-
umns (Amersham Biosciences, Uppsala, Sweden) and col-
lected in a total of 7 mL of protein digestion buffer consisting
of 2 M of fresh urea in 100 mM Tris HCl (pH 8.7) and phos-
phatase inhibitors (see previous paragraph). The lysate was
incubated overnight at 377C with trypsin at an enzyme/sub-
strate ratio of 1/100w/w. A light precipitate that formed
during the digestion was removed by centrifugation at
13 0006 g after adjusting the pH to 3 with 1 M HCl. Phos-
phopeptides in this mixture were enriched on Fe31-loaded
IMAC beads (Sigma-Aldrich) at pH 3.0 according to the
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manufacturer’s protocol. Desorption from the IMAC resin
was done in a total volume of 2 mL of 0.4 M ammonium hy-
droxide. This mixture was divided into two equal parts and
dried in a centrifugal vacuum concentrator.
One part was re-dissolved in 50 mL of CIP reaction buffer
as delivered by the manufacturer (New England Biolabs) and
a total of 10 U of CIP, 200 U of lambda protein phosphatase
(Upstate, Milton Keynes, UK), and 0.66 U of alkaline Escher-
ichia coli phosphatase (Sigma-Aldrich) were added to
dephosphorylate all phosphopeptides. This reaction pro-
ceeded for 1 h at 377C after which the pH was lowered to
pH 5 by adding 80 mL of 0.5 M KH2PO4. Subsequently, 4 mg
of trypsin was added and the mixture was dried to complete
dryness. It was then re-dissolved in 150 mL H2
18O (93.7%
w/w pure; ARC Laboratories, Amsterdam, The Netherlands).
The trypsin-mediated oxygen exchange was continued over-
night at 377C. Finally the H2
18O-peptide solution was trans-
ferred to an Eppendorf tube in which 1.5 mmol of TCEP and
15 mmol of iodoacetamide were present as a dried pellet.
Trypsin inactivation by reductive alkylation proceeded at
pH 8.5 and resulted in the inhibition of the 18O/16O back-
exchange during further steps of the procedure [21].
The second part of the IMAC-enriched peptide mixture
was subjected to the same procedure except for addition of
phosphatases and replacement of H2
18O by natural water.
2.3 COFRADIC isolation of ex-phosphopeptides from
total lysate
Following trypsin inactivation, the two peptide mixtures
were mixed and loaded on an Agilent 1100 Series HPLC
system run under the conditions described in Section 2.1.
Peptides eluting between 22 and 70 min were collected in
48 fractions of 1 min each. Primary fractions that were sepa-
rated by 16 min (e.g., fractions 5, 21, and 37 or fractions 6, 22,
and 38 etc.) were pooled, dried, and reconstituted in 50 mL of
buffer containing the phosphatase cocktail (see Section 2.2).
The dephosphorylation reaction proceeded for 1 h at 377C
and was terminated by lowering the pH to 5.5 after adding
40 mL of solvent A and 10 mL of 50 mM acetic acid. The
pooled and dephosphorylated peptide fractions were re-
separated onto the same column system and under identical
chromatographic conditions.
Phosphopeptides which were dephosphorylated as the
result of the phosphatase treatment between the primary and
secondary rundisplayed a hydrophobic shift compared to their
original elution time. A second characteristic of the peptides
was the absence of the 18O-label such that they consisted of the
16O-isotopic envelope only. They were collected over 14 min.
This time interval started 1 min after each elution peak of the
non-modified peptides. For the examples given above, this
means that the ex-phosphopeptides of primary fraction 5
eluted between 6 and 20 min, fraction 21, between 22 and
36 min, and fraction 37, between 38 and 52 min. This proce-
dure yielded 48 secondary fractions of 1.12 mL each. These
were dried and re-dissolved in 20 mL of 0.05% formic acid in 2/
98 v/v ACN/water (solvent A). Half of this solution was loaded
on a trapping column (0.3 mm id6 5 mm, PepMap; LC
Packings, Amsterdam, The Netherlands) at a flow rate of
20 mL/min of solvent A for 5 min using a CapLC system
(Waters Corporation, Manchester, UK). The trapping column
was back-flushed, whereby the sample was loaded on a nano-
scale RP C18 column (75 mM id6 150 mm PepMap column;
LC Packings) and peptides were eluted from this column
using a gradient from 0 to 100% solvent B (0.05% formic acid
in 70/30 ACN/water) at 200 nL/min applied over 50 min. The
outlet of the nano-column was connected with a distal metal-
coated fused silica PicoTip needle (PicoTip FS360-20-10-D-
C7; New Objective, Woburn, MA, USA) and placed in front of
the inlet of a Q-TOF1 mass spectrometer (Micromass UK,
Cheshire, UK). Data-dependent acquisition began 20 min
after the solvent gradient was started andwas such that doubly
and triply charged ions were selected for fragmentation. Fol-
lowing each LC-MS/MS run, the obtained fragmentation
spectra were automatically converted to Micromass proprie-
tary pkl format using ProteinLynx from the Micromass Mass
Lynx software (version 3.4).
2.4 Identification of peptides by MASCOTand
evaluation of their in vivo phosphorylation status
All the obtained pkl files were merged in blocks of 299 per
MASCOT search (MASCOT version 1.9). MASCOT Daemon
(version 1.9) was used in the follow-up search setting, in such
a way that first the Swiss-Prot database (downloaded at ftp://
us.expasy.org/databases/swiss-prot) was searched (with
restriction to human proteins) and those pkl files that were
not identified were subsequently searched against all human
protein sequences present in NCBI’s non-redundant protein
database (downloaded at ftp://ftp.ncbi.nih.gov/genomes/
H_sapiens/protein). MASCOTsearch parameters were set as
follows: enzyme, trypsin; maximum number of missed
cleavages, 1; fixed modification, carbamidomethyl (C); vari-
able modifications, deamidation (NQ), oxidation (M), N-
acetyl (protein), and pyroglutamate formation (N-terminal
Q); peptide mass tolerance, 60.3 Da; MS/MS tolerance,
60.3 Da and instrument setting was set at ESI-QUAD-TOF.
Only MS/MS spectra that exceeded the MASCOT identity
threshold at the 95% significance level were withheld for fur-
ther analysis. Such spectra were examined for the presence of
typical peptide fragment ions (b- and y-type of fragment ions)
and only when the MASCOTscores were substantially higher
than the corresponding identity threshold score and suffi-
cient peptide sequence coverage was observed (typically over
50%) were these identifications considered positive.
Once identified by MASCOT, the mass spectrum (obtained
in MSmode) from the peptide was evaluated to check whether
18O-isotopes were incorporated into the peptide’s carboxyl end
group (false positive) or not (ex-phosphorylated peptide). Only
those peptides that did not contain the heavy oxygen isotopes
were withheld as peptides that were derived from in vivo phos-
phorylated and are listed in Supplementary Table 1.
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Table 1. List of identified phosphorylation sites in HepG2proteins. Phosphorylated peptides that were identified following targeted MS/
MS analysis of the primary COFRADIC fractions are given in bold. Sorted peptides containing only one possible phosphorylation
site (serine, threonine, or tyrosine) are given in normal type. The identified phosphorylation sites are underlined and indicated in
the penultimate column. Literature links to previous studies in which these phosphorylation sites were identified are given in the
last column
Acc. no. Start End Identified peptide Protein description Phosphorylation
site
Reference
Phosphoserine-containing peptides
1 P05386 98 113 KEESEESDDDMGFGLF 60S acidic ribosomal protein P1 S-104 [10, 12]
98 114 KEESEESDDDMGFGLFD S-104 [10, 12]
2 P12956 218 229 DIISIAEDEDLR ATP-dependent DNA helicase II,
70 kDa subunit
S-222
3 Q14019 111 117 EFVISDR Coactosin-like protein S-115
4 P17812 571 584 SGSSSPDSEITELK CTP synthase S-571, 573 & 574 [11]
5 P29692 144 169 KPATPAEDDEDDDIDLFGS
DNEEEDK
Elongation factor 1-delta S-162
6 Q99613 34 47 QPLLLSEDEEDTKR Eukaryotic translation initiation
factor 3 subunit 8
S-39
7 Q08379 7 14 QSKLAAAK Golgi autoantigen, golgin
subfamily A member 2
S-8
8 P04792 80 89 QLSSGVSEIR Heat shock 27 kDa protein S-82 [27]
9 13375676 137 151 IGELGAPEVWGLSPK Hypothetical protein FLJ22626 S-149
10 Q9Y4I1 1209 1217 QELESENKK Myosin Va S-1213
11 Q9H1E3 105 128 EMLMEDVGSEEEQEEE
DEAPFQEK
Nuclear ubiquitous casein and
cyclin-dependent kinases
substrate
S-113
12 Q15149 773 784 EEEEVGFDWSDR Plectin 1 S-782
13 P51531 1559 1575 AKPVVSDFDSDEEQDER Possible global transcription
activator SNF2L2
S-1564 & 1568
14 Q96B49 61 74 NLSDIDLMAPQPGV Similar to over-expressed breast
tumor protein
S-63
15 P26368 2 9 SDFDEFER Splicing factor U2AF 65-kDa
subunit
S-2
16 P35269 207 230 IHDLEDDLEMSSDASDAS
GEEGGR
Transcription initiation factor IIF,
alpha subunit
S-217, 218, 221 &
224
17 Q13595 2 12 SDVEENNFEGR Transformer-2 protein homolog S-2
18 Q13144 542 551 GGSPQMDDIK Translation initiation factor
eIF-2B epsilon subunit
S-544
19 O60841 131 145 VEMYSGSDDDDDFNK Translation initiation factor IF-2 S-135 & 137
131 148 VEMYSGSDDDDDFNKLPK S-135 & 137
Phosphothreonine-containing peptides
1 P12814 48 60 AGTQIENIEEDFR Alpha-actinin 1 T-50
2 Q9NY33 424 432 LTFLEEDDK Dipeptidyl-peptidase III T-425
3 P04075 60 68 QLLLTADDR Fructose-bisphosphate aldolase A T-65
4 P09651 130 139 IEVIEIMTDR Heterogeneous nuclear
ribonucleoprotein A1
T-138
5 Q15047 836 844 ILTDDFADK Histone-lysine N-methyltransferase,
H3 lysine-9 specific 4
T-838
6 Q01650 499 507 LMQVVPQET Large neutral amino acids
transporter small subunit 1
T-507
7 Q96PK2 5624 5635 LEMTAVADIFDR Microtubule-actin crosslinking
factor 1, isoform 4
T-5628
8 29743831 151 160 KITIADCGQL Similar to peptidyl-Pro cis trans
isomerase
T-153
9 P10599 96 104 LEATINELV Thioredoxin T-100
10 P18206 502 511 WIDNPTVDDR Vinculin T-507
11 P12955 188 196 TDMELEVLR Xaa-Pro dipeptidase T-188
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Table 1. Continued
Acc. no. Start End Identified peptide Protein description Phosphorylation
site
Reference
Phosphotyrosine-containing peptides
1 Q99460 45 55 IEVLYEDEGFR 26S proteasome non-ATPase
regulatory subunit 1
Y-49
2 O00571 342 350 YLVLDEADR DEAD-box protein 3 Y-342
3 P13639 265 272 YFDPANGK Elongation factor 2 Y-265
4 P00533 978 986 YLVIQGDER Epidermal growth factor receptor
precursor
Y-978
5 P30501 75 86 WVEQEGPEYWDR HLA class I histocompatibility
antigen, Cw-2 alpha chain
precursor
Y-83
3 Results
3.1 The phosphorylation sites of Æ-S1 casein:
A feasibility study
This experiment was undertaken to study the possibility of
using the diagonal chromatography approach to isolate and
identify phosphorylation sites in phoshoproteins. At this
stage it was important to learn about the extent and repro-
ducibility of the hydrophobic shift during RP chromatogra-
phy associated with the removal of one or more phosphate
groups from the phosphopeptides.
Therefore we used a tryptic digest of bovine a-casein that
was fractionated by RP-HPLC (Fig. 1A). The method is illus-
trated with the peptide mixture present in the fraction elut-
ing between 46 and 48 min (Fig. 1A), containing a peptide
with a mass of 1952.00 Da (M1H)1 indicative of an a-S1-
casein tryptic peptide with the expected phosphorylation site
at serine-130 (119YKVPQLEIVPNpSAEER134). The MALDI-
MS spectrum of the components of this fraction is shown in
Fig. 1B. After phosphatase treatment, the secondary run
(Fig. 1C) was analyzed in 8 mL aliquots (see Section 2) in an
elution interval between 48 and 68 min. Nearly all previously
identified peptides were observed in the non-shifted area
(Fig. 1D), while the only prominent peptide that was missing
was now found in its dephosphorylated form (1871.99 Da)
shifted by about 2 min (Fig. 1C and E). Its identity was con-
firmed by fragmentation analysis (Fig. 1F).
The UV profile in the 48 to 68 min interval shows two
additional peaks which could not be assigned to peptides.
Most likely these are contaminants introduced from the CIP
enzyme preparation. Peaks in front of the selected fraction
similarly represent UV-absorbing material mixed with a
small amount of CIP degradation products (Fig. 1C).
A repetition of this analysis on other fractions of interest
led to the assignment of phosphorylation sites at serines 61
and 63 (results not shown). Based on these results, we could
now set the parameters for a global phosphoproteome
study.
3.2 Parameters for a global phosphoproteome
analysis
Although the diagonal chromatography principle was
already successful, there were further additional steps nec-
essary in order to tackle a global analysis on total cellular
lysates. First, in contrast to the situation for a-casein, phos-
phopeptides from cell lysates seldom represent major com-
ponents. Therefore we decided to enrich for phosphopep-
tides using Fe31-IMAC beads. The retained peptide mixture
still contained a high number of non-phosphorylated
(mainly acidic) peptides. However, the latter could be easily
separated from the phosphopeptides by the phosphatase-
induced hydrophobic shift as shown in Section 3.1. Second,
the extent of the hydrophobic shift depends on the nature of
the peptide, the nature of the phosphorylated amino acid,
the number of phosphate groups removed, and the chro-
matographic system used. Shifts observed in the ammo-
nium acetate (pH 5.5)/ACN system were generally larger
than those in the 0.1% TFA/ACN system. The former was
therefore selected for further experiments. Here loss of one
phosphate group was typically associated with an average
delay of 3 min but was greater when phosphotyrosine was
present. Shifts of poly-phosphorylated peptides are gen-
erally much larger and more difficult to predict. Therefore,
we decided to use an interval of 14 min to collect the shifted,
dephosphorylated peptides. Third, in our approach phos-
phopeptides are recovered in their dephosphorylated form
(as ex-phosphopeptides). Thus, at this stage there is no trace
left over from the previous phosphorylation status (such as a
chemical tag or a heavy isotope). This creates a serious risk
of occasional capture of normal peptides shifting due to
slight variations in the chromatographic system and leading
to an incorrect recording as ex-phosphopeptides. In order to
solve this problem, we introduced a split-differential label-
ing approach. Prior to the sorting procedure, the tryptic
peptide mixture is divided into two equal parts. In one part
peptides are dephosphorylated and also stably tagged with
two 18O-atoms at the COOH-termini. The second part is
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Figure 1. Sorting of a phosphorylated tryptic peptide from bovine a-S1 casein. (A) UV absorption chromatogram
(214 nm) of 1 nmol of a tryptic digest of bovine a-casein. (B) MALDI mass spectrum of the primary fraction deli-
neated in (A); a phosphorylated peptide carrying phosphoserine-130 of a-S1 casein is indicated with an asterisk.
(C) Secondary RP-HPLC separation (UV absorption chromatogram at 214 nm is shown) of the selected primary
fraction that was treated with phosphatases. (D, E) MALDI mass spectra of the non-shifted (primary collection
interval) and shifted, ex-phosphorylated peptides (indicated with an asterisk in (C)). (F) MALDI-PSD spectrum of
the ex-phosphorylated peptide shown in (E); the sequence tag that could be derived using the y-type of fragment
ions is indicated and led to the validation of the peptide sequence 119YKVPQLEIVPNSAEER134 of a-S1 casein.
neither dephosphorylated nor labeled with 18O-isotopes.
Then both parts are mixed again for further sorting. At this
stage, the peptide mixture is composed of three types of
peptides: (a) peptides that were never phosphorylated in vivo,
present as 16O/18O-couples differing by 4 amu in a 1/1 ratio,
(b) peptides that were dephosphorylated by the phosphatase
treatment of the part that carries the 18O-isotopes, and
(c) their phosphorylated counterparts derived from the sec-
ond part and carrying only the natural oxygen isotopes.
During the primary run there is already a separation of the
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16O-labeled phosphopeptides from their dephosphorylated
counterparts that are 18O-labeled in as much that they elute
in different primary fractions. The consecutive phosphatase
treatment taking place between the primary and secondary
run now only affects the 16O-labeled phosphopeptides, be-
cause their 18O-labeled variants were dephosphorylated prior
to the first run. As a consequence of this split-differential
labeling, only the phosphorylated peptides labeled with the
16O-tag will show shifts. Other non-phosphorylated peptides
which might be caught accidentally in the shifted zone will
appear as 16O/18O-doublets and can be distinguished from the
real ex-phosphopeptides. Fourth, in order to reach a broad
specificity towards all types of phosphorylation sites, we now
used a cocktail of phosphatases including the phage lambda
phosphatase and the E. coli alkaline phosphatase in addition
to the CIP used in the a-casein experiment. A general layout
of the different steps used in the improved protocol is repre-
sented in Fig. 2. For technical details, refer to Section 2.3.
Figure 2. Scheme of the procedure leading to the isolation of
phosphorylated peptides and their localization in phosphorylat-
ed proteins.
3.3 The phosphoproteome of forskolin-stimulated
cultured HepG2 cells
A total of 25million HepG2 cells were used for phospho-
peptide isolation. Following COFRADIC MS/MS analysis of
the isolated peptides and data analysis, 294 spectra were
from ex-phosphorylated peptides and these were linked to
190 peptides (Supplementary Table 1). All together these
peptides identified 152 different phosphoproteins in HepG2
cells. Figure 3 shows a typical MS spectrum of a secondary
sub-fraction. Insets show the isotope envelopes of the 16O-
peptides assessed as ex-phosphorylated peptides. One 16O/
18O-doublet is shown (m/z = 670.78 Th) which is considered
to be a false positive.
An important aspect of our approach is the isolation of
peptides in their dephosphorylated state. In this respect, two
questions are eminent: are we really dealing with ex-phos-
phopeptides, and when there are multiple potential phos-
phorylation sites, which sites are phosphorylated in vivo? The
most direct answer is to isolate and sequence peptides in
their phosphorylated forms. Knowing that the phosphorylat-
ed derivatives of the peptides listed in Supplementary Table 1
should be searched for in the primary fractions as 16O-sin-
glets carrying additional masses of (multiples of) 80 Da, it is
possible to start a targeted analysis in each primary fraction.
Since these fractions are much more crowded than the sec-
ondary fractions containing the sorted peptides, and since
phosphopeptides are not easily ionized in acidic buffers in a
background of unphosphorylated peptides, we could only
directly assign a limited number of phosphorylation sites
(Table 1). The assignment of serine-39 as a previously unno-
ticed phosphorylation site in the eukaryotic translation
initiation factor 3, subunit 8 is documented in Fig. 4. Fol-
lowing COFRADIC, the peptide bearing this phosphoryla-
tion site was identified as 34QPLLLSEDEEDTKR47, starting
with a pyroglutamic acid and containing two possible phos-
phorylation sites: serine-39 and threonine-45 (Fig. 4A). A
mass inclusion list using the observed mass of the ex-phos-
phorylated peptide (1655.86 Da, (M1H)1) was generated,
including the possibility that either one (180 Da) or both
sites (1160 Da) were phosphorylated and that these peptides
are ionized to their doubly or triply charged form. When the
primary fraction from which this peptide was isolated was
analyzed in LC-MS/MS mode with this mass inclusion list, a
doubly charged peptide with an m/z value of 868.36 Th was
fragmented. A neutral loss of 98 Da is evident in the
obtained MS/MS spectrum, while a loss of 80 Da is not
observed (Fig. 4B). This already hints to a phosphorylated
serine or threonine residue present in the analyzed peptide
[22]. Upon comparison of the MS/MS spectra of the dephos-
phorylated and the phosphorylated peptide and closer
inspection of the b-type of peptide fragments (b5 to b’8), the
serine residue in the peptide was found to be converted to
dehydroalanine, which is consistent with beta-elimination of
phosphorylated serines observed in MS/MS spectra [23].
Furthermore, the y-type of fragment ions indicated that ser-
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Figure 3. Identification of phosphopeptides following MS/MS analysis of their ex-phosphorylated counterparts. A
typical mass spectrum obtained during LC-MS analysis of a secondary COFRADIC fraction is shown in the upper
panel. The insets show zoomed regions of this spectrum and the ions indicated with an asterisk were chosen for
MS/MS analysis. The isotope envelopes of the ions with m/z values of 429.25 Th (doubly charged), 580.26 Th (tri-
ply charged), and 742.29 Th (triply charged) do not contain any incorporated 18O-isotopes and thus belong to
sorted ex-phosphorylated peptides. Following MS/MS analysis of these ions, the following peptides were identi-
fied: 63KVVVSPTK70 (429.25 Th) from nucleolin (left spectrum of middle panel), 759REVLYDSEGLSGEER773 from the
FLJ00034protein (right spectrum of middle panel), and 250VISDSESDIGGSDVEFKPDTK270 from the DNA mismatch
repair protein MSH6 (right spectrum of lower panel). As can be seen in Supplementary Table 1, all these peptides
are predicted to contain kinase substrates. The ion with a m/z value of 670.78 Th (triply charged) contains 18O-iso-
topes (see inset). It could either be a false positive or a peptide which was not fully dephosphorylated before the
first run (see text). This peptide was also selected for MS/MS analysis (left spectrum of lower panel) and the
sequence 672SYLEGSSDNQLK683 from the DEAD-box protein 20 (G.I. number 12643886) was identified (in all MS/
MS spectra shown, only the y-type of fragment ions and thereby the visualized sequence tags are indicated).
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Figure 4. Characterization of
serine-39 as an in vivo phos-
phorylation site of the eukar-
yotic translation initiation fac-
tor 3, subunit 8. Following
COFRADIC isolation, a peptide
with the sequence 34QPLLLSE-
DEEDTKR47 (first residue is a
pyroglutamic acid) was identi-
fied; the observed b- and y-type
peptide fragments are indicat-
ed (A). Using a mass inclusion
list, the phosphorylated coun-
terpart of this peptide could be
analyzed in MS/MS mode in the
corresponding primary frac-
tion (B). Upon comparison of
the two fragmentation spectra
and closer inspection of the
observed fragment ions, the
serine residue was found to be
phosphorylated in vivo. In par-
ticular, a mass difference of
166.95 Da was found between
the y8 and y9 ion, corresponding
to the mass of the phosphoryl-
ated serine (S,P.). Upon CAD,
phosphoserine is frequently
converted to dehydroalanine as
evident from the massive loss of
98 Da of the precursor ion and
the difference of 18 Da between
the predicted b and y fragments
and the ones observed (indi-
cated by hyphens in panel B).
ine-39 was phosphorylated; a mass difference of 166.95 Da
was observed between the y8 and y9 ion. Taken together these
results allude to a possible control of the activity of this par-
ticular translation initiation factor by phosphorylation of
serine-39.
The list of identified peptides further contains 26 pep-
tides that carry only one potential phosphorylation site.
Given the experimental route that these peptides followed,
one can state that for these peptides the in vivo phosphoryl-
ated amino acid is hereby identified. Combining this sub-list
with the list obtained after targeted analysis of phosphoryl-
ated peptides present in the primary fractions leads to the
identification of 38 novel phosphorylation sites in 33 differ-
ent human proteins (see Table 1, without taking into account
the known phosphorylation sites of CTP synthase, hsp27,
and the 60S acidic ribosomal protein).
4 Discussion
Our approach is selective for phosphopeptides at two levels:
we enriched by Fe31-IMAC and we induced a shift by
dephosphorylation during diagonal chromatography.
The use of IMAC has been debated, since it was reported
to display different degrees of specificity depending on the
transition element used [9, 34]. In addition, IMAC appears
biased toward peptides carrying multiple carboxyl groups.
Here, we did not try other metal ions, neither did we make
methylesters to improve the specificity [8]. Rather, we relied
on the second step: selecting on the susceptibility of phos-
phopeptides for phosphatases. Our procedure partly resem-
bles that described by Bonenfant et al. [35]. In the latter, dif-
ferential protein phosphorylation is measured by a three-step
process including stable isotope labeling, IMAC enrichment,
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and alkaline phosphatase treatment to release IMAC-
retained peptides. While this procedure is suited for the
analysis of simple protein mixtures, our procedure is more
adapted for the analysis of complex mixtures, because of the
diagonal chromatography step which provides an additional
but necessary peptide selection.
The method described here will only reach its full
potential when IMAC enrichment, 18O-tagging, and
dephosphorylation are quantitative for all phosphopeptides.
Preliminary experiments using synthetic phosphopeptides
showed some variability in IMAC affinities, with often
higher retention yields for acidic than for basic phospho-
peptides (results not shown). In view of this variability, it is
possible that phosphorylation sites which are located within
basic sequences such as the c-AMP- and c-GMP-dependent
protein kinase consensus phosphorylation sites may have
been selectively lost in the IMAC enrichment procedure.
Similarly, small hydrophilic phosphopeptides could have
passed in the flow-through of the RP columns [36]. This
argues for the use of a multi-step approach in which the
first enrichment step could include an ion-exchange
adsorption [10, 11] or an immunoprecipitation step. Alter-
natively, the use of proteolytic enzymes with specificities
other than basic residues could be foreseen. Stable isotope
tagging is done by post-cleavage trypsin-catalyzed oxygen
exchange at the carboxyl groups of arginine and lysine. We
used this strategy because it can be carried out in conditions
optimized for oxygen exchange rather than for hydrolysis of
peptide bonds [21]. This tagging procedure adds a mass of
4 amu, which is sufficient to distinguish single (phospho-
rylated) from double (most likely contaminating peptides)
isotope envelopes. With different synthetic phosphopep-
tides, including phosphotyrosine peptides, we noticed com-
plete dephosphorylation by the cocktail of phosphatases.
Still, it remains possible that in the large set of cellular
phosphopeptides there are components with partial or
complete resistance to phosphatase activity. In the latter
case, no shifts will be produced at any level and such phos-
phopeptides will not be sorted in the COFRADIC proce-
dure. In cases where dephosphorylation does not proceed to
completion, 16O/18O-doublet envelopes are expected to
appear in which the 16O-variant is dominant. The peptide
ion with m/z value 670.78 Th shown in Fig. 3 could be such
an example as it has a 16O/18O-envelope and therefore
scored as a non-phosphorylated peptide. However, the cor-
responding sequence covered in the DEAD-box protein
20 contains a casein kinase II site predicted by PhosphoBase
[37]. This example illustrates the measures taken to avoid
assignment of false positives in our studies. As a con-
sequence, Supplementary Table 1 must be considered as a
minimal list.
Most identified ex-phosphorylated peptides belong to
proteins that are known to be phosphorylated; however, for
many of them the exact phosphorylation sites have not yet
been mapped. We noticed that the phosphorylation sites of
47 peptides (about 25% of all identified ex-phosphorylated
peptides) have been assigned in experiments conducted by
other research groups (most notably those described in [10,
11], Supplementary Table 1). This not only indicates that our
approach selects for in vivo phosphorylated peptides but also
points to the fact that our list contains many peptides of
which the exact phosphorylation sites can be determined in
further experiments.
Our list contains 18 COOH-terminal peptides of
17 different proteins. COOH-termini are often targets for
phosphorylation, regulating activities or protein interac-
tions (e.g., [38]). However, because these peptides do not
end on a basic residue, they cannot be tagged with 18O-
isotopes. Yet they appear as 16O-peptides like the sorted
dephosphorylated peptides. However, since they were
recovered in the shifted interval, they are likely to be true
ex-phosphopeptides. At least in two instances, we could
directly prove the presence of phosphorylated residues in
these C-terminal peptides. For the 60S acidic ribosomal
protein P1, we identified serine-104 as the target residue,
while for the CTP-synthase, we directly confirmed phos-
phoserine on sites 571, 573, and 574 (Table 1, entry 4 of
the phosphoserine-containing peptides). In other studies,
phosphorylation events occurring at the C-termini of the
60S ribosomal protein P0 and the tubulin a-1 chain have
been identified (Supplementary Table 1). Taken together
these findings suggest that the sorted C-terminal peptides
identified here may not be simply discarded but most
likely point to real phosphorylation events occurring in
HepG2 cells.
Table 1 sums up those ex-phosphorylated peptides that
contain only one possible phosphorylation site and/or of
which the phosphorylated counterpart was identified fol-
lowing direct MS/MS analysis of the primary fraction. In
total, 38 novel phosphorylation sites were discovered, the
majority of them serines. However, five peptides phospho-
rylated on tyrosine residues were also identified. One inter-
esting example is the EGF receptor. Although phosphoryla-
tion on tyrosines 1092, 1110, 1172, and 1197 has been il-
lustrated in the past, here we add a novel site to this
phosphorepertoire: phosphorylation on tyrosine-978, which
also resides in its cytoplasmic domain and could play a role
in docking known target molecules (e.g., the SH3 domain
containing CBL proteins) or attract other, yet undiscovered,
proteins to the receptor’s C-terminal domain. While infor-
mation in the literature on tyrosine phosphorylation of the
four other proteins is scarce, it was found that the chicken
embryo elongation factor 2 was phosphorylated on tyrosine
next to threonine phosphorylation [39]. Here, our findings
do indeed hint to phosphorylation on tyrosine-265 of the
elongation factor 2.
Most of the results obtained so far are novel. The biolog-
ical implications of these identified sites will need to be ana-
lyzed in more detailed studies. However, we have displayed a
powerful tool for detecting and also for measuring phos-
phorylations of proteins in a detailed manner in highly
complex mixtures such as complete cell lysates.
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2.3. Spectrum quality assignment: a priori and a posteriori filtering 
2.3.1. Introduction 
One of the simplest ways to optimize the efficiency of almost any analysis is to 
concentrate on the good data produced and to disregard the poor data. In proteomics, 
concentrating on good data can be achieved by differentiating between high quality and 
low quality spectra. Interestingly, one of the simplest ways to detect potentially erroneous 
peptide assignments is to differentiate between identifications from low quality spectra 
and those from high quality spectra. The only difference between the pre-identification 
filtering and the post-identification filtering lies in the stringency with which the spectra 
are classified. A pre-filter will be configured to operate at low stringency; we would 
rather have 15% of the poor spectra leaking through than suffer the erroneous removal of 
1% of the good spectra. Post-identification filtering can be stringent. Here we would not 
mind being presented with 10% of the really good identifications to reconsider, as long as 
more than 99% of the poor identifications are also labeled as suspect. 
In order to allow the filtering of spectra, an application was built in collaboration with 
Kristian Flikka and Professor Ingvar Eidhammer of the University of Bergen in Norway. 
The details of the approach and the corresponding results are outlined in the published 
paper below. 
It is of note that after this paper was accepted in Proteomics, two other papers on 
spectrum quality filtering were published by Nesvizhskii et al. [Nesvizhskii 2005] and 
Salmi et al. [Salmi 2006]. 
 
2.3.2. Publication 
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Improving the reliability and throughput of mass
spectrometry-based proteomics by spectrum quality
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In contemporary peptide-centric or non-gel proteome studies, vast amounts of peptide frag-
mentation data are generated of which only a small part leads to peptide or protein identification.
This motivates the development and use of a filtering algorithm that removes spectra that con-
tribute little to protein identification. Removal of unidentifiable spectra reduced both the amount
of computational and human time spent on analyzing spectra as well as the chances of obtaining
false identifications. Thorough testing on various proteome datasets from different instruments
showed that the best suggested machine-learning classifier is, on average, able to recognize half
of the unidentified spectra as bad spectra. Further analyses showed that several unidentified
spectra classified as good were derived from peptides carrying unanticipated amino acid mod-
ifications or contained sequence tags that allowed peptide identification using homology
searches. The implementation of the classifiers is available under the GNU General Public
License at http://www.bioinfo.no/software/spectrumquality.
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1 Introduction
When analyzing a complex peptide mixture by automated
one-or multidimensional LC MS/MS, a vast number of pep-
tide fragmentation spectra are typically obtained. These are
linked to peptides/proteins using popular search algorithms
such as MASCOT [1] and SEQUEST [2]. Nevertheless, a sig-
nificant number of MS/MS spectra remain unidentified, due
to different reasons; there may be too little fragment ion
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information in the spectrum, the fragmented precursor may
not be a peptide, the peptide may be modified in a way that is
unaccounted for by the search algorithm, or the peptide may
not be present in the searched database. Successful identifi-
cation further depends on good preprocessing of mass spec-
trometric data [3].
With the advent of several techniques for sensitive pro-
teome analysis [4, 5], the importance of automatic methods
for spectrum preprocessing has increased. Manual validation
of all resulting spectra in such studies is not feasible and
tools enabling an automatic quality control are therefore
important as an integrated part of a modern high-through-
put proteomics laboratory [3, 6].
Recently, a study was published [7] describing methods
for automatic spectrum quality assessment. In this paper,
two different classification schemes were evaluated: one
using handcrafted attributes and another using support
vector machines (SVM) based on observed m/z values. A
collection of spectra from a mixture of five known proteins
digested with four different proteases [8] was used to test
the classification algorithms. The spectra were initially
identified using SEQUEST [2], and identified spectra were
labeled “good”, whereas all other spectra were labeled “bad”.
When testing the SVM-based classifier, 90% of the identi-
fied spectra were labeled good and 75% of the unidentified
ones were labeled bad; thus, 75% of the unidentified spectra
could be removed, while removing 10% of the identified
ones.
Another study was recently published, presenting the
program SPEQUAL [9], in which spectra from 23 peptides
and 12 proteins were analyzed with respect to their quality,
based on three filter components. In particular, it was eval-
uated whether a spectrum’s charge was correctly assigned, a
score based on the sum of all peak intensities was applied
(TIC) and an S/N score was finally calculated. To test this
application, 10 000 spectra were manually given a quality
label, “low”, “intermediate”, or “high”. The labels were based
on the same three criteria as the algorithm itself was com-
posed of. The spectra were then run through the program,
and the output score was compared against the manually
assigned labels. A good correspondence between the pro-
gram score and the assigned labels was observed. The results
from the program were however not compared to the results
from database searches; thus, the number of identifications
that are lost using the SPEQUAL procedure, was not expli-
citly stated.
In our study, we adopted the notation of spectra, iden-
tified by MASCOT, as good, and unidentified as bad from
[7]. Furthermore, we employ a promising classifier based
on aggregation of one-dependence Bayesian classifiers [10]
testing this on data from different mass spectrometers
using different sets of samples that were all generated by
peptide-centric combined fractional diagonal chromatogra-
phy (COFRADIC) [11–13]. Various other Bayesian and
decision tree classifiers were tested and compared to the
aggregating one-dependence estimators (AODE) method.
We briefly address the issue of spectrum clustering, where
a dataset is reduced to containing only nonequivalent
spectra, and demonstrate the necessity of performing clus-
tering on the data in machine-learning studies of prote-
omic data. Removing redundant spectra decreases the
potential risk of overfitting the models to highly abundant
peptides and thus enables a reliable cross-validation of the
results. Results from the classification test using ESI IT
fragmentation data showed that 83% of the bad spectra
could be removed, while removing only 10% of the good
ones. The corresponding removal rate for clustered data
was 79%. The fact that the removal rate is lower for the
clustered data suggests that the original redundancy in the
data gives overoptimistic results; hence, a clustering is
crucial to get reliable test results.
By using the classifiers suggested in this article in con-
junction with a proteomics mass-spectrometry pipeline for
identification of proteins, we were able to reduce the number
of spectra needed for the analysis, detect false identifications,
and suggest a number of high-quality unidentified spectra
that were subsequently de novo sequenced.
2 Materials and methods
The data analysis was performed on peak lists generated by
the mass spectrometer vendor’s proprietary software using
the raw peptide fragmentation spectra. In order to devise a
powerful classifier, it was found important to use datasets for
training and testing that were realistic in terms of both size
and complexity.
Similar to Bern et al. [7], we denoted the spectra identi-
fied by the MASCOTalgorithm [1] as good, all others as bad.
2.1 Experimental data
We used four different proteome datasets that were
obtained following LC-MS/MS or MALDI-TOF-TOF analysis
of peptides isolated by two different strategies. Three differ-
ent mass spectrometers were used in these studies (see
below). Identification was done using MASCOT and all
identifications were manually verified. Spectra that scored
equal to or above the MASCOT identity threshold at the
95% confidence level were accepted. All spectra and identi-
fications are available at the PRIDE [14] server (http://
www.ebi.ac.uk/pride).
2.1.1 Q-TOF N-terminal dataset
These MS/MS spectra are from the extreme amino terminal
peptides of proteins which were isolated as described in [13].
A total of 10 054 spectra were available for this study. These
spectra were incrementally searched against the IPI database
containing only human proteins [15] and IPI-derived, N-
terminally truncated databases as described in [13] (PRIDE
accession number 1643).
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2.1.2 Q-TOF metOx dataset
This dataset consists of MS/MS spectra from tryptic methio-
nyl peptides as described in [13] and were searched against
the human IPI database. Here, 3565 spectra were studied
(PRIDE accession number 1644).
2.1.3 IT dataset
The data (7477 spectra) were obtained from an N-terminal
COFRADIC analysis of the human SH-SY5Ycell line. The IT
instrument used was a Bruker Esquire HCT (Bruker Dal-
tonics GmbH, Bremen, Germany). Sample preparation and
data processing were performed as described in [12]. These
spectra were incrementally searched against the human
subset of the Swiss-Prot (ftp://us.expasy.org/databases/
swiss-prot) and NCBI nr (ftp://ftp.ncbi.nih.gov/genomes/
H_sapiens/protein) databases and hereof derived, N-termin-
ally truncated databases as described in [13] (PRIDE acces-
sion number 1645).
2.1.4 MALDI-TOF-TOF dataset
PSD spectra were obtained using an Ultraflex MALDI-TOF/
TOFmass spectrometer (Bruker) operating in an automated
analysis mode. Peptides used for this analysis were methio-
nyl peptides isolated as their sulfoxide derivatives [11] from a
tryptic proteome digest of human Jurkat T-lymphocytes and
multipotent adult progenitor cells (MAPC). For this study, a
total of 8338 spectra were used, of which 3771 were made
available (corresponding to the Jurkat dataset). The PRLDE
accession number for the latter is 1646.
2.2 Extracting attributes
A variety of attributes may be considered relevant when
evaluating a spectrum’s quality, see [16]. Given a spectrum, it
should be possible to extract the value of any defined attrib-
ute and to represent it as a numerical value. Assume that if
we have k attributes, a spectrum is represented by a feature
vector x ¼ xi . . . xkh i, where xi is the value of the ith attrib-
ute. Furthermore, we seek to classify a spectrum into one of
two classes, denoted y, where y 2 fgood; badg.
A selection of attributes was used to capture the variety of
spectral features in the data material. Some of them are
classic; some are new. The attributes may be divided into two
categories; automatically specified and manually specified.
The automatic specification of attributes considers all possi-
ble between-peak mass differences (deltas) and all possible
m/z values. All the observedm/z values and deltas are scored
using the chi-square analysis for contingency tables, and
only the highest scoring ones are used as attributes. This is
done by counting the number of occurrences for each
m/z value, for both the good and the bad spectra. If an
m/z value is significantly over-represented in either the good
or bad spectra, the chi-square test will reveal this.
The manually specified attributes are listed in Table 1.
Some of these are commonly known, and can also be found
in the literature [7, 16], such as number of peaks, total peak
intensity, and total intensity of complement fragment ions.
Most of them are, however, other attributes, suggested by
experienced mass spectrometer operators. We defined the
relative intensity of each peak as the peak’s intensity divided
by the intensity of the highest peak. When specified, we only
considered peaks with a relative intensity above a certain
threshold; we used 0.1. This threshold was empirically found
to produce the overall best results. Using the rank-based
intensities suggested in [7] did not improve the results.
Combining the manually and automatically specified
attributes resulted in maximum 78 features, fewer if the
automatically specified features were not found significantly
different between the identified and unidentified spectra. To
avoid bias in the group of attributes, only the training spectra
were used as basis for feature selection.
2.3 Spectrum clustering
In several articles [17, 18] it has been shown that large col-
lections of tandem mass spectra often carry significant
redundancy. Different spectra that most likely represent the
same peptide will introduce overoptimistic results when
testing a classifier, and may also bias the classifier itself to-
ward the most frequently occurring spectra. For these rea-
sons we have trained and tested all methods on both full and
reduced datasets, where the reduced ones are the results of a
clustering based on the principles described in [18].
A possible drawback of collapsing several spectra into
one may be the loss of information about the relative impor-
tance of certain types of spectra, in particular for some con-
taminants. Typically, these consist of non-biopolymers (such
as PEG) that have quite similar fragmentation spectra
though different precursor masses. Since the precursor mass
needs to match up for spectra to be clustered, these contam-
inant spectra will not be collapsed and therefore the infor-
mation regarding abundance will not be lost.
2.4 Lining up an ensemble of machine-learning
methods
The recently developed Bayesian classifier AODE described
in [10] was put to the test against an assembly of methods,
some of which were also used in the article by Webb et al.
[10].
Generally, probability-based classifiers will estimate
PðyjxÞ for each value of y, i.e., the probabilities of a spectrum
belonging to class good or bad given the spectrum’s feature
vector x. Selecting the class y that maximizes an estimate
P^ðyjxÞ will then be the classification from the method. Using
Bayes theorem, the problem can be reduced to maximizing
P^ðxjyÞP^ðyÞ. This is not straightforward, as a direct estimate
for PðxjyÞ from training data requires a significant number
of observations for each possible x. For example, having
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Table 1. Overview of manually specified attribute variables
Feature id Description
num_peaks Number of peaks in spectrum
num_sign_peaks Number of peaks with relative intensity.0.1
rel_num_sign_peaks Number of significant peaks divided by precursor mass
avg_delta_mass The average delta mass in spectrum
std_dev_delta_mass SD of delta mass values
Precursor_charge Charge of precursor ion
precursor_mass Mass of uncharged precursor
precursor_mz m/z Value of precursor in parent spectrum
rel_intºf_prec_in_msms Relative intensity of precursor in fragment spectrum
delta_two_highest Intensity difference between top two peaks
avg_peak_density Number of peaks/(max_mz – min_mz)
num_dominant_peaks Number of peaks accounting for .5% of total intensity
avg_rel_peak_intens The average of relative peak intensities
std_dev_rel_peak_intens The SD of relative peak intensities
raw_total_intensity_threshed Total raw intensities for significant peaks
rel_total_intensity_threshed Total relative intensities for significant peaks
rel_int_by_compl_to_prec Total relative intensity of complement pairs
Significant peaks have relative intensity above 0.1.
50 attributes, each allowing ten different values, may pro-
duce up to 1050 different x-vectors. To circumvent this, the
nave Bayes (NB) [19] algorithm makes the assumption that
the attributes are independent of each other, only given the
class. Hereby follows that: PðxjyÞ ¼
Yk
i¼ 1
PðxijyÞ which is
what the classifier NB uses, and thus classifies an instance by
choosing the class that maximizes the probability estimates:
argmax
y
P
_ðyÞ
Yk
i¼1
P
_ðxijyÞ
 !
.
The NB algorithm is very fast, and delivers optimal clas-
sification when its constraint is satisfied. It performs quite
well, even when the underlying independence assumption is
clearly unrealistic. Significant work has been done to weaken
the attribute independence assumption; examples of this are:
Lazy Bayesian Rules (LBR) [20], Tree Augmented NB (TAN)
[21], Super parent TAN (SP-TAN) [22], and the recent algo-
rithm, AODE [10]. In the latter article it is suggested that the
AODE algorithm has performance comparable to that of
LBR and SP-TAN, but at a significantly lower computational
cost.
The idea of AODE is to aggregate the predictions made
by a collection of one-dependence classifiers. These classi-
fiers require each attribute to be depending on exactly one
other attribute in addition to the class. The difference in
computational cost between the NB and the AODE algo-
rithm can be illustrated as adding an extra dimension to the
table of probability estimates. For NB, this table is indexed by
the target attribute value and the class value. In AODE, there
is an extra dimension indexed by the value of the attribute
that the target is conditioned on.
To this end, we tested the Bayesian methods NB, AODE,
SP-TAN, LBR, TAN, and ODE, where SP-TAN and LBR both
have been shown to generate relatively small errors in their
predictions. Their drawback is the slow training/testing
execution, in particular for the LBRmethod. In this study, we
had to discard the LBR classifier, because of its prohibitively
long testing time. The ODE is equal to AODE, apart from the
aggregation of one-dependence estimators. Where AODE
aggregates one-dependence estimators, ODE only uses a
single one.
Decision trees, often represented by the C4.5 algorithm
[23], are used for a large variety of machine-learning tasks.
One of the advantages with decision trees is the fact that the
resulting trees can be examined to discover the features that
are most important. The alternating decision tree algorithm
[24] uses a data structure called ADTrees to represent deci-
sion tree classifiers. Both the ADTree and the C4.5 algorithm
were tested on all datasets and compared to the other meth-
ods.
2.5 Implementation
The classifiers have been thoroughly tested using five-fold
cross-validation. In addition, all the datasets have been
reduced to containing only spectra with little internal simi-
larity using a procedure similar to the one described in [18].
The implementation of the classification systems was done
in Java (http://java.sun.com) using the open source package
WEKA [25] (http://www.cs.waikato.ac.nz/ml/weka/). We
used the implementation by Webb et al. [10] for the SP-TAN
and ODE classifiers. For all methods, WEKA’s default pa-
rameter values were used. The reimplementation of C4.5 is
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denoted J48, and we applied boosting to enhance the perfor-
mance of the J48 algorithm. WEKA’s implementation of
AdaBoost M1 [26] was used for boosting.
For the Bayesian classifiers, the attribute values were
discretized by applying the MDL method [27]. In the perfor-
mance evaluations the spectra classified as good spectra are
denoted as the positives, the others as negatives.
3 Results
3.1 Spectrum quality classifier
An overview of the results can be found in Table 2 and Fig. 1.
As seen in Fig. 1, the classifier performance drops when
applied to the reduced versions of the datasets. This may be
caused by the fact that the presence of similar spectra in the
training- and test-sets corrupts the testing scheme and
emphasizes the importance of a stringent strategy when
testing machine-learning methods. The difference in perfor-
mance between the full and reduced datasets is small on the
MALDI-TOF-TOF instrument and on the IT instrument.
The nature of the MALDI-TOF-TOF experiments leads to
few fragmentations of the same peptide, which again reduce
the number of similar spectra. For the IT instrument the
explanation is most likely an improved dynamic mass-exclu-
sion strategy (as compared to the Q-TOF), which aims at re-
ducing the chance of a peptide being fragmented repeatedly
in a short time frame. From this point on we address perfor-
mance figures only on the reduced datasets, unless stated
otherwise.
The error rates in these experiments are heavily influ-
enced by the typical imbalanced nature of the data. In fact,
the number of unidentified (bad) spectra was typically six
times higher than the number of identified (good) spectra.
Thus, a simple classifier assigning all spectra as bad gives an
error rate of 1/7 = 0.143, which is relatively good. Using re-
Figure 1. ROC curves for all datasets, clustered and unclustered
using the AODE classifier. Difference in performance is illustrated
by the fact that all datasets have better ROC curves for the
unclustered versions of the data.
ceiver operator characteristics (ROC) curves and the area
under ROC curve (AUC) in this experiment is a more suit-
able measure of performance, because this also gives an
impression of how well a classifier can be adjusted to a cer-
tain target, if we for example only accept classifiers with a
true-positive rate of 0.98 or better.
Motivated by the high dimensionality of the data (many
attributes), various machine-learning methods often select
some attributes as more important than others. A useful
method for evaluating the importance of various attributes
is to calculate the information gain [28]. In Table 3, the ten
highest scoring attributes for each dataset are listed. The
manually specified attributes dominate the lists, in particu-
lar “tot_rel_int_by_compl_to_prec”, the total relative inten-
sity of pairs of peaks whose masses together correspond to
the precursor mass. Automatically specified attributes in the
list include among others “countDelta113.1” (leucine/iso-
Table 2. Overall results for all methods and datasets. The table shows the AUC and the true-negative (TN) rate for
each dataset on each method. AUC is the area under the ROC curve. TN rate is the rate of TNs, i.e., un-
identified spectra classified as bad, given a true-positive rate (rate of identified spectra labeled good) of
0.90. AODE simple is a version of the AODE classifier using only 10 attributes
Method Q-TOF N-terminal
(3265 spectra)
Q-TOF metOx
(2006 spectra)
IT (5948 spectra) MALDI–TOF-TOF
(7013 spectra)
AUC TN rate AUC TN rate AUC TN rate AUC TN rate
AODE 0.84 0.60 0.76 0.45 0.91 0.79 0.73 0.38
ODE 0.79 0.52 0.75 0.41 0.88 0.75 0.71 0.35
NB 0.79 0.52 0.75 0.40 0.88 0.74 0.71 0.35
TAN 0.83 0.61 0.77 0.48 0.90 0.78 0.73 0.36
SP-TAN 0.63 0.28 0.73 0.39 0.68 0.22 0.67 0.32
ADTree 0.82 0.54 0.75 0.41 0.89 0.76 0.70 0.32
J48 0.85 0.55 0.70 0.33 0.89 0.75 0.69 0.30
AODE simple 0.82 0.57 0.74 0.38 0.90 0.76 0.71 0.31
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Table 3. Importance of each attribute ranked using the information gain [28] measure. Each dataset has one column in the table, and the
top ten ranked attributes are shown sorted by importance. Datasets were reduced to containing only one instance of each spec-
trum
Q-TOF N-terminal Q-TOF metOx IT MALDI-TOF-TOF
tot_rel_int_by_compl_to_prec tot_rel_int_by_compl_to_prec tot_rel_int_by_compl_to_prec raw_total_intensity_threshed
precursor_mass precursor_mass Num_peaks std_dev_rel_peak_intens
raw_total_intensity_threshed precursor_mz avg_delta_mass avg_delta_mass
num_peaks countDelta1.0 std_dev_delta_mass num_peaks
countDelta113.1 num_peaks raw_total_intensity_threshed countDelta113.1
precursor_charge raw_total_intensity_threshed num_peaks_to_account_
forX_intensity
avg_rel_peak_intens
num_sign_peaks rawMass133.1 avg_rel_peak_intens precursor_mz
avg_delta_mass num_sign_peaks num_sign_peaks precursor_mass
std_dev_delta_mass rawMass89.1 CountDelta113.0 countDelta2.0
countDelta112.1 rawMass177.1 CountDelta170.1 countDelta112.8
leucine), “rawMass89.1”, “rawMass133.1”, and “raw-
Mass177.1” (fragment peaks of PEG that are most often seen
in the unidentified spectra). Attributes “countDelta112.1”
and “countDelta112.8” most likely also originate from leu-
cine or isoleucine. The mass difference of 112.1 can be
expected to occur together with the correct difference at 113.1
because the fragments are often represented with more than
one isotope, whereas the difference of 112.8 may stem from
inaccurate measurements. “countDelta170.1” may corre-
spond to a mass difference spanning two amino acids;
matching duplets include leucine/isoleucine plus glycine
and alanine plus valine.
The data from the IT instrument appear to give the most
beneficial results for most methods. By using the AODE
classifier, 62% of the unidentified IT MS/MS spectra can be
removed without removing more than 2% of the identified
spectra (Fig. 1). Among the tested methods, the AODE clas-
sifier gives the highest AUC (0.91), whereas the SP-TAN
method only has an AUC of 0.68.
It appears that the effectiveness of the classifiers varies
significantly between experiments as some datasets are more
difficult to classify for all tested methods. Comparing the
results for the two Q-TOF datasets reveals that spectra
derived from N-terminal peptides are possible to classify
quite well: 45% of the unidentified spectra can be removed
while removing only 2% of the identified ones, using the
AODE classifier. Q-TOF MS/MS spectra from methionyl
peptides are however less separable: only 25% of the un-
identified spectra can be removed when removing 2% of the
identified ones. The MALDI-TOF-TOF data results in very
few removable, unidentifiable spectra: 20% of the un-
identified spectra are recognized as bad, when removing only
2% of the identified ones.
We believe that these spectral differences might be due to
the fact that some experimental procedures and mass spec-
trometers generally generate fewer bad and unidentifiable
spectra as compared to other setups.
Difficulties in classifying MALDI-TOF-TOF data are
most likely caused by the overall high quality of the spectra
generated by this instrument. Indeed, when operating an
ESI-based mass spectrometer in an automated LC-MS/MS
mode, the instrument quite randomly and continuously
picks ions for subsequent fragmentation analysis, see [29].
As many contaminants (polymers, detergents) tend to ionize
quite easily, they are frequently picked up and analyzed fur-
ther by MS/MS, thereby inevitably resulting in easily recog-
nizable bad MS/MS spectra. MALDI-MS does not suffer
from this drawback as samples are archived and intelligent
peak picking algorithms are used that only mark ions that
are most likely derived from peptides and/or are intense
enough such that good-quality fragmentation spectra might
be generated. In particular, the instrument software is set to
only consider ions with an S/N of 60, rank them according to
the quality of their isotopic envelope, and submit only the
best of these to MS/MS analysis. Hence the general and
overall spectrum quality difference between MALDI and ESI
peptide fragmentation spectra.
More subtle differences as those indicated above for the
Q-TOF MS/MS spectra of amino terminal and methionyl
peptides might originate from the number of peptides that
were available for analysis. Clearly, isolated N-terminal
peptides offer the highest possible reduction in analytes to
be analyzed in peptide-centric proteome studies as every
protein is finally represented by only one peptide: its N-
terminal one. On the other hand, on average about one-
fifth of all peptides in a tryptic proteome digest contain
methionine. This implies that the filling of MS analysis
time with real peptides is less when analyzing N-terminal
peptides than with methionyl peptides, whereby in the
former case mass spectrometers are given an increased
opportunity for fragmenting “non-peptides” and thus start
filling data space with peak lists from bad spectra even-
tually making the distinction between good and bad spec-
tra easier (see also [13]).
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A version of the AODE classifier that only uses ten fea-
tures is also included for comparison. The ten features are
selected by using the information gain measure. This classi-
fier is a weaker performer than the full AODE classifier, al-
though the difference is relatively small. It may, however, be
beneficial to include more features to ensure that the classi-
fier is more robust to possible changes in the characteristics
of the datasets.
By examining background data for the ROC curves we
find the connection between the true-positive rate (fraction
of identified spectra, classified as good) and the false-positive
rate (fraction of unidentified spectra classified as good).
From Figs. 1, 2 we can see that by introducing a penalization
of the false negatives (good spectra classified as bad), we can
shape the classifier to suit different needs. Shaping Bayesian
classifiers is obtained by changing the prior class prob-
abilities. If originally there is a 9:1 relationship between the
bad and the good spectra, the prior class probabilities will be
0.9 and 0.1, respectively. Changing the prior probability of
the good ones to 0.2 will result in fewer misclassified good
spectra.
When retaining 90% of the identified spectra, it appears
that between 38 and 79% of the bad spectra can be removed,
depending on the dataset (see Table 2). Another scenario is to
fix the true-positive rate at ,0.98, i.e., only accept to falsely
remove 2% of the good spectra. Then, the fraction of bad
spectra that can be removed drops to between 20% and 62%
(not shown in table). It is worth having in mind that when
using a p-value cut-off on 0.05 using for example MASCOT
database search, we may expect up to 5% false positives.
Thus, we should not expect the classifier to be able to give a
true-positive rate of 1.0, as some of the identified (good)
spectra may be false identifications.
In order to choose the overall best classifier, we compared
the AUC values for all methods on all datasets, see Table 2.
The overall winner is the AODE classifier, as it is victorious
Figure 2. ROC curves for a selected dataset (QTOF metOx), to il-
lustrate the strength of different methods in different areas of the
ROC domain. Between TP rate 0.86 and TP rate 0.94 the ADTree
method goes from being fifth best to second best.
on two of the datasets, and close to best on the other two
datasets as well. The poor performance of the SP-TAN
method is somewhat surprising, but it appears that the high
number of attributes may be causing some of the problems.
When using few attributes (results not shown), SP-TAN was
more on par with the other methods.
On the Q-TOF metOx data, the performances of the
methods are somewhat similar. There is, however, a differ-
ence that can be seen in the ROC curves (Fig. 2). In the low
true-positive rate region the ADTree method is quite me-
diocre, but when true-positive rate rises between 0.86 and
0.94, it becomes almost on par with the best method. The
ROC curve of ADTree is, in other words, steeper in this
region. This illustrates the fact that before choosing a partic-
ular method, the desired strictness of the classifier should be
established.
Training times and testing times of the classifiers are
different for the various methods. An illustrative example of
execution times can be found in Table 4, using the Q-TOF N-
terminal dataset. For the Bayesian classifiers, the time used
for discretization is added to both training and testing times.
The AODE classifier was, for example, about five to ten times
faster than ADTree on training time, but ADTree classifies
instances extremely fast, so AODE could not compete in the
testing phase. The SP-TAN and the J48 classifiers are by far
the slowest on the training stage, but classify rapidly. All
other methods have execution times that should be recog-
nized as acceptable.
Table 4. Running time examples for all the methods on the Q-
TOF N-terminal dataset. Times are expressed in sec-
onds. Numbers should at most be used as a guide to the
relative relationship between the methods, as the actual
times depend on the implementation and runtime envi-
ronment
Classifier Training
time, s
Testing
time, s
Total
time, s
AODE 3 7 10
ODE 2.8 5 7.5
NB 2.5 2.5 5
TAN 12 11 23
SP-TAN 354 4 358
ADTree 23 1 24
J48 85 1 86
3.2 Applications of the classifier for proteomics
datasets
An important part of this work was to evaluate the potential
applications of the spectrum classifier in a high-throughput
proteomics workflow. Since the classifier described here was
designed to be versatile, we exploited its adaptability in
applying it to proteomics datasets both before and after the
identification process.
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When the classifier is configured to allow very few false-
negative spectra (identified spectra labeled bad), it can be
used as a spectrum prefilter, effectively removing “junk”
spectra (e.g., spectra from contaminants) prior to identifica-
tion. This reduces the chance of false identifications and
simultaneously boosts the identification efficiency. When we
applied this strategy to the clustered N-terminal COFRADIC
proteome of human blood platelets by allowing only 1.1%
false-negative spectra, approximately 30% of all spectra could
safely be removed prior to identification. Seven spectra were
labeled bad by the classifier, even though they had a MAS-
COT score above the identity threshold at 95% confidence.
We manually verified these seven identifications and found
four of them to be false identifications. The net result of
using this stringent classifier prior to identification would
therefore have been the loss of three good peptide identifica-
tions and the omission of four false-positive identifications
while the identification efficiency would have been boosted
by a factor of 1.43 through the retention of only 70% of the
spectra for effective database searching.
If the classifier is configured to be more sensitive to bad
spectra (by e.g., allowing for 10% false-negative spectra), it
can be used as a post-identification quality control, high-
lighting those spectra that, although successfully identified
by MASCOT at the 95% confidence interval, show signs of
potential “badness”. Since this subset will be of a more read-
ily manageable size, it can be manually validated, further re-
ducing the final false-positive count.
The classifier can also be applied post-identification to
reduce the number of unidentified spectra. These can occur
because of the absence of the corresponding peptide
sequence from the search database or because of unexpected
modifications on the peptide, resulting in aberrant frag-
mentation patterns as compared to in silico predicted pat-
terns. By applying the classifier to the unidentified spectra,
we can find those spectra that are classified as good. These
can then be submitted to a search against a larger, unre-
stricted database (e.g., without species restrictions). By
applying this strategy to the ion-trap spectra of the N-termi-
nal COFRADIC proteome of neuronal SH-SY5Y cells, we
could pick up the known cell culture contaminant BSA,
albeit by only two spectra. Human herpes virus and corona
virus surface proteins were also picked up.
Further compensation for the absence of matching
sequences can be obtained by using automated de novo
sequence analysis tools such as Lutefisk [30]. We applied
LutefiskXP to 467 spectra from theQ-TOFN-terminal dataset
that were unidentified yet marked good by the classifier, cor-
responding to 18% of the unidentified spectra. The resulting
sequence tags were submitted to BLASTand searched against
UniProt (www.uniprot.org). Lutefisk suggested 210 high
scoring (Pr(c) . 0.9) sequences and from these, 24 different
sequences gave perfect BLASTmatches. These matches iden-
tified 20 different human proteins, many of which were
abundant in blood platelets as assessed by our previous data
[13]. However, several of these proteins were not yet identified
in our platelet proteome study and can hence be added to the
list of platelet proteins. Examples include the pleckstrin
homology (PH) domain containing proteins ARHGEF18
(Q6DD92) and Pleckstrin (Q6FGM8) and the hypothetical
proteins FLJ45525 (Q6ZSH5) and Talin-1 (Q9UPX3).
The classifier also serves as a means to extract unexpected
modifications from the unidentified spectra. These modifica-
tions can stem either from in vivo processes or from in vitro
artifacts. We analyzed the unidentified, yet good spectra from
the N-terminal COFRADIC proteome of human blood plate-
lets for mass differences between fragment peaks that corre-
sponded with the modifications listed in UniMod [31], and
ranked them by number of occurrences. This crude list was
subsequently analyzed by hand to pick out thosemodifications
that seemed plausible based on the chemistry employed, or for
their biological significance. Cyclization of N-terminal S-carb-
amoylmethylcysteine (pyro-cmc) [32] and N-terminal carb-
amylation were selected as potential artifactual modifications
and N-terminal formylation along with mono-methylation of
lysines were considered as potential in vivomodifications. The
pyro-cmc modification resulted in 36 additional identified
spectra and N-terminal carbamylation was present in 15 spec-
tra, comprising 8 unique peptide sequences. Formylation
added 13 identified spectra containing 6 unique sequences,
and methylated lysines were picked up in 10 spectra that col-
lapsed into 6 unique peptide sequences. The classifier proved
very useful in this approach as it allows spectrumpreselection,
so only potentially meaningful fragmentation spectra are
searched for themass signatures of knownmodifications.
Additionally, because of the high prevalence of the pyro-
cmc modification, this has since been added as a variable
modification in searches for other datasets. In all of these
projects, more than 5% of the identified peptides carry this
modification, all of which would otherwise have resulted in
false negatives.
4 Discussion
Building a quality-based classifier for tandem mass spectro-
metric data has to take several aspects into consideration. We
have created a versatile classifier that can be adapted to dif-
ferent demands. Rebuilding of the model based on new
datasets is done within minutes. The thresholds deciding
when a spectrum is deemed bad can be altered to suit the
individual needs.
Results show that up to 62% of unidentified spectra can be
removedbefore the identification step, without removingmore
than 2% of the spectra that would have been identified. This
removal of bad spectra thus helps to boost the identification
efficiency aswell as a reduction in false-positive identifications.
Additional quality control of the obtained identifications can be
performed by selecting the borderline spectra from the identi-
fied set and manually validating these. Furthermore, selecting
the potentially identifiable spectra from the large group of un-
identified spectra after identification yields a reduced dataset
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that can be explored by alternative methods of identification
such as de novo sequence analysis and BLASTqueries. These
potential false-negative spectra can also be mined for unex-
pected modifications or biological contaminants resulting
from sample handling or cell culture artifacts.
The fact that our classifier can be fine-tuned to suit spe-
cific needs in stringency allows it to be easily adapted to dif-
ferent proteomics techniques, each yielding different levels
of protein coverage by the identified peptides. Higher
redundancy approaches (such as multidimensional protein
identification technology) can allow higher stringency as the
inadvertent loss of a few good spectra would have much less
impact on the total amount of proteins identified. Methods
with lower redundancy (for example N-terminal COFRA-
DIC) can choose to loose less good spectra and would thus
tolerate more bad spectra in the search set.
Direct comparison against the study described in [7] was
not possible because the data and software used in that study
was not available. The program SPEQUAL [9] is available
and has been tested on our datasets. There is however a dif-
ferent focus in their study; an example is that spectra without
correct charge state assigned are classified as low-quality
spectra. For our ITdata, 27% of the identified spectra have no
charge state assigned, and will thus be deemed low-quality by
SPEQUAL. This makes the SPEQUAL procedure somewhat
unsuited for the scope of this study.
The suggested versatile spectrum classifier can be an
important tool for high-throughput proteomics analyses with
applications in many key stages of the identification process.
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2.4. PRIDE: sharing data in a scientific community 
"Information, no matter how expensive to create, can be replicated and shared at 
little or no cost." 
 - Thomas Jefferson 
 
2.4.1. Introduction 
One of the basic premises of science since the Enlightenment is that it should be a 
collaborative effort, building on open communication of published results. After all it was 
Newton himself who asserted59: “If I have seen further it is by standing on the shoulders 
of Giants”. 
The PRoteomics IDEntifications (PRIDE) system was designed to alleviate the needs 
expressed in section 1.3.4 and the unofficial motto of PRIDE is therefore appropriately 
‘making publicly available data publicly accessible’. 
The need for the PRIDE system, its adherence to standards, data structure, interface and 
(potential) applications are fully discussed in two published papers, which are included 
below. 
Another discussion that was prompted during the involvement of the PRIDE system in 
disseminating the results of the HUPO Plasma Proteome Project (HPPP) pilot centered on 
what data types to make available. The issue of whether the proprietary binary data as 
recorded by the instrument should be made available in addition to the processed (text-
based) peak lists typically used for the identification process was discussed. This 
discussion has been explained and a choice has been motivated in the paper included in 
subsection 2.4.1.3. 
 
2.4.2. Publications 
2.4.2.1. Initial publication in Proteomics 
                                                 
59
 Paraphrasing twelfth-century French philosopher Bernard of Chartres. 
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The advent of high-throughput proteomics has enabled the identification of ever increasing
numbers of proteins. Correspondingly, the number of publications centered on these protein
identifications has increased dramatically. With the first results of the HUPO Plasma Proteome
Project being analyzed and many other large-scale proteomics projects about to disseminate their
data, this trend is not likely to flatten out any time soon. However, the publication mechanism of
these identified proteins has lagged behind in technical terms. Often very long lists of identifi-
cations are either published directly with the article, resulting in both a voluminous and rather
tedious read, or are included on the publisher’s website as supplementary information. In either
case, these lists are typically only provided as portable document format documents with a cus-
tom-made layout, making it practically impossible for computer programs to interpret them, let
alone efficiently query them. Here we propose the proteomics identifications (PRIDE) database
(http://www.ebi.ac.uk/pride) as a means to finally turn publicly available data into publicly
accessible data. PRIDE offers a web-based query interface, a user-friendly data upload facility, and
a documented application programming interface for direct computational access. The complete
PRIDE database, source code, data, and support tools are freely available for web access or
download and local installation.
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1 Introduction
The field of proteomics has rapidly grown into one of the
most active research areas in life sciences today. This
growth is largely attributable to the availability of ever
increasing amounts of gene and protein sequence infor-
mation and the many technical improvements in the elab-
orate machinery used to identify proteins in complex
mixtures, along with many novel techniques that reduce
the complexities of analyte mixtures, allowing protein
identification and characterization at an ever increasing
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try, Faculty of Medicine and Health Sciences, Ghent University,
A. Baertsoenkaai 3, B-9000 Ghent, Belgium
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ble document format; PPP, Plasma Proteome Project; PRIDE, pro-
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W3C, WWW Consortium; XML, extensible markup language;
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Figure 1. Illustration of the increase
in the number of protein identifica-
tions over time. Number of identifi-
cations in the local database of the
Department of Biochemistry at the
University of Ghent throughout 2004
is shown. Source data originate
from fragmentation spectra
obtained from three different mass
spectrometers: ESI-Q-TOF, ESI-IT,
and MALDI-TOF/TOF. Note that the
average increase since January 2004
amounts to 4000 identifications per
month, often punctuated by particu-
larly sharp increases when all three
machines are fully operational in
parallel. The vast majority of the
identifications stems from experi-
ments using the COFRADIC gel-free
technology [2–4].
pace, as reviewed in [1]. To illustrate this further, the actual
identification rate for a typical proteomics laboratory is given
in Fig. 1.
Correspondingly, publication of protein identification
data has been steadily on the rise over the past few years. The
number of hits returned per year since 2000 for a PubMed
query illustrates this in a simplistic, yet straightforward
manner (Fig. 2). Together with the growing number of pub-
lications, the lists of identifications have grown considerably
in size as well. Since these listings can easily contain thou-
sands of peptides or hundreds of proteins, they are often
published as supplementary information. In almost all cases
this supplementary information consists of one or more
portable document format (PDF) files detailing the identifi-
cations in a tabular format.
Yet even though PDF does an admirable job as a truly
portable format and is therefore a natural choice for publish-
ers, it is definitely not designed to convey structured informa-
tion. Tables in PDF are notoriously difficult to extract and this
problem is further exacerbated by the fact that nearly every
author uses a different formatting for these tables.
Since this relative inaccessibility of proteomics data pre-
sents a considerable stumbling block on the way to making
all these identifications really count for life sciences, the
construction of a centralized, freely accessible repository for
proteomics data is one of the primary requirements in pro-
teomics today [5, 6]. In a single sentence: publicly available
data needs to become publicly accessible data.
The pilot phase of the Plasma Proteome Project (PPP)
[7], the first of the HUPO proteomics projects [8] to reach an
important milestone, has been invaluable in achieving the
ambitious goal of designing and implementing such a repos-
itory [9].
Indeed, the need for a centralized data repository was
quickly realized during the initial planning phase for the
PPP and this resulted in both a short-term and a long-term
Figure 2. Illustration of the increase in protein
identification papers over the past few years.
Number of PubMed hits for each year since 2000
for the query “proteom* AND proteins AND
identified AND mass spectrometry” are shown.
Although this query is by no means exhaustive,
it provides a meaningful sampling of the avail-
able literature.
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approach to solving the data management problems. The
short-term solution dealt with the immediate need for data
storage and consisted of a relational database implemented
using Microsoft Structured Query Language Server (MS-
SQL). This database was constructed and continuously
updated by Marcin Adamski from the core bioinformatics
unit of David States at the University of Michigan (UM), Ann
Arbor. This database actually had a two-fold objective: first of
all, it served the vital purpose of centralizing the data pro-
duced in the PPP collaboration as it started to trickle (and
later pour) in from the different labs, and second, it served as
a test-bed for the construction of a centralized, project-inde-
pendent database for protein identifications at the European
Bioinformatics Institute (EBI). The aims of proteomics
identifications database project are three-fold: developing an
open source, publicly available set of tools to aid developers
in implementing ms are three-fold: (1) providing a central
repository for protein identification data, (2) building an
efficient web-based interface for queries and data submission,
and (3) developing an open source, publicity available set of
tools to aid developers in inplementing custom analysis tools.
The MS-SQL database constructed at UM proved to be an
excellent source of inspiration for the PRIDE data model as it
had been refined throughout the PPP in order to contain
detailed proteomics data from many different collaborating
laboratories across the globe. The design of PRIDE and the
functionality of its web interface will be discussed next, along
with future prospects for the data model as proteomics stand-
ards evolve.
2 Materials and methods
The PRIDE project was completely developed in the Java 2
programming language (Sun Microsystems) using the Java™
Development Kit (JDK) 1.4 from Sun Microsystems (http://
www.java.com/en/download/manual.jsp) as well as the
Java™ 2 Enterprise Edition (J2EE) extensions from Sun
Microsystems (http://java.sun.com/j2ee/index.jsp) for the
web development.
PRIDE makes use of many open source software tools,
components, and libraries. Object-relational bridge (OJB)
(http://db.apache.org/ojb) takes care of the declarative ob-
ject-relational mapping, Tomcat (http://jakarta.apache.org/
tomcat) functions as web server and servlet engine, Log4J
(http://logging.apache.org/log4j) as the logging framework,
and Maven (http://maven.apache.org) as the project man-
agement tool. All of the above were obtained from the
Apache Software Foundation (http://www.apache.org).
Extensible markup language (XML) parsing and writing
relies on the XML pull parser (XPP) libraries (http://
www.extreme.indiana.edu/xgws/xsoap/xpp). Unit testing
was performed using the JUnit framework (http://www.
junit.org). During development, the relational database man-
agement system (RDBMS) employed was MySQL (http://
www.mysql.com) and for the final prototyping and produc-
tion version PRIDE was ported to Oracle (http://www.or-
acle.com).
3 Results and discussion
3.1 PRIDE as a set of components
The PRIDE project consists of a number of distinct
parts, which are summarized in Fig. 3. The XML format
represents the basic data structure, whereas the relational
database implementation is just one of the possible ren-
derings of the hierarchical XML format in a relational
schema. The PRIDE core libraries contain an object
model of the PRIDE data structure and allow the pro-
grammer to interact seamlessly and effortlessly with the
PRIDE XML format and reference database implementa-
tion. The PRIDE web libraries provide a web-based view
on an underlying reference database and use the PRIDE
core libraries for data access. Query results from the web
can be sent in PRIDE XML format or in HTML after
XML stylesheet language (XSL) transformation of the
XML.
Figure 3. PRIDE components. PRIDE project consists of a
number of separate components which are outlined here.
PRIDE XML format is the basic data structure. RDBMS imple-
mentation is a possible rendering of the hierarchical XML for-
mat into a relational schema. PRIDE core libraries constitute
the basic object model representations of the PRIDE data
structure, as well as I/O objects that allow easy interaction
with both the reference database implementation and XML
format. PRIDE web libraries have been built to allow web-
based submission and access to PRIDE. Web libraries use the
PRIDE core libraries for data access and processing and can
report query results in PRIDE XML as well as in XSL-trans-
formed HTML.
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3.2 XML data structure
XML is a standard text format developed by the WWW Con-
sortium (W3C, http://www.w3c.org) that has quickly become
a very popular and widely applied means of storing data as
well as exchanging them. XML is a hierarchical (tree-like)
structure, which fits well with typical proteomics experi-
ments and can easily be validated. XML documents can also
readily be extended, which allows them to retain a rather
large degree of flexibility. For these reasons, XMLwas chosen
to form the basic data structure for the PRIDE project rather
than a relational database structure.
3.3 Relational database implementation
Relational databases provide highly efficient storage of
structured data and can readily be optimized for extremely
fast retrieval of data based on queries. These queries can be
fed to the database through the use of a standardized inter-
face: SQL.
Contrary to the traditional approach, which relies on a
relational schema as the basic data structure, PRIDE instead
builds upon the XML schema for reasons discussed above.
Since XML is hierarchical in nature, and a database is rela-
tional, the mapping of an XML schema to a database
schema is not straightforward. In fact, many different rela-
tional approaches can model exactly the same hierarchical
schema. Therefore, the reference implementation provided
by PRIDE is just one of the possible forms this database
might take. The strength of the XML schema-based struc-
ture is that, depending on specific needs, other relational
implementations can be created by third parties that
emphasize or optimize different aspects of the data stored.
As such, PRIDE can be molded to take many different
queryable forms, each with distinct strengths and weak-
nesses.
3.4 The PRIDE data format
In PRIDE, one or more experiments are contained in the
root tag “ExperimentCollection”. The ExperimentCollection
simply groups together one or more “Experiment” tags,
which are the top-level tags for individual results. As such, a
submitter is likely to submit a collection containing a single
experiment, unless the data are extensive or varied enough
to warrant the creation of multiple, distinct Experiment
elements within PRIDE. The downloadable flat file on the
other hand, will hold an ExperimentCollection root consist-
ing of all experiments that constitute the PRIDE database at
its release time. The ExperimentCollection structure will
enable easy splitting of the download into multiple files
when the PRIDE download file eventually becomes very
large.
The top-level structure of an experiment, schematically
represented and exemplified in Fig. 4, consists of seven con-
ceptually distinct parts, which will be summarized next.
The first of these is the experiment accession number.
This number is assigned after successful submission of an
experiment and provides a unique pointer to all the asso-
ciated data. The experiment accession number would be the
data element of choice for inclusion in papers as the PRIDE
reference because of its conciseness and since interested
readers can easily use it to quickly retrieve all relevant data
from the PRIDE web interface.
The second part contains meta-data about the experi-
ment: a descriptive title, contact person and/or address, a
short label, a description, and finally location information.
The contact person and location information are meant to be
complementary, i.e., to have geographic and laboratory
information in the location field, and contact person infor-
mation in the contact information. Typically, one would
expect the “contact person” field to contain the e-mail address
of the corresponding author of a publication.
The third element concerns the sample studied. It con-
sists of a description field and an attribute list. The structure
and usage of the latter is discussed in more detail below.
Protocol information constitutes the fourth part of an
experiment. Apart from a description and attribute list, it also
holds one or more sections about the mass spectrometer(s)
used. This latter section contains manufacturer, model,
source, and analyzer information which can be further sup-
plemented through an attribute list.
The fifth part details the information derived from the
mass spectrometer. This section holds the MS coefficient
(e.g., MS2, MS3), peak lists, optional raw data references,
comments, and an attribute list.
The most intricate subsection of an experiment is the
sixth part and deals with the identifications obtained from
the data specified in part five. Identifications have been split
in two different types: 2-D PAGE-based identifications and
nongel-based identifications. A schematic representation of
the shared and specific elements for both of these subtypes is
shown in Fig. 5. The shared elements are wrapped up in an
abstract ancestor element called “IdentificationType”. Note
that the additional information for 2-D PAGE-based identifi-
cations centers on protein-related data gathered during the
gel-separation phase, whereas the gel-free identifications
typically require more information about the effective iden-
tification score and threshold (if available). This has been
done to accommodate more stringent standards for identifi-
cations, as discussed in recent publications [10–12].
Finally, the seventh part is not restricted to the experi-
ment level but can be found in many of the smaller branches
as well. This is the “AttributeList” which represents a list of
attributes, to be keyed from controlled vocabularies, allowing
an extremely flexible way of integrating additional informa-
tion into the core schema without sacrificing the structure of
the whole. In fact, the PRIDE schema presents a minimum
minimorum of information about protein identifications in
present day proteomics. Many additional pieces of informa-
tion (e.g., from cone voltages and temperatures on ESI-type
ion sources to the specific search parameters used for
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Figure 4. Top-level view of the PRIDE XML data structure and example document. Boxed and numbered areas represent conceptually
distinct parts of the Experiment node top-level structure (see text for details). Optional elements are indicated by dashed boxes and mul-
tiplicity (if applicable) is shown below the box on the right. Note that an abbreviation has been introduced in the “PeakList” element due to
space constraints. Recursive “DaughterPeakList” element is symbolically filled out by “. . .”. An example of a simple AttributeList element
(number 7) is represented in the “Sample” element (number 3). Please also note that the presented document is meant to provide an
example only. As such, the occurrence of a “TwoDimensionalIdentification” in what is described as a “gel-free separation technique” has
only demonstrative purposes.
© 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de
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Figure 5. Detailed view of the identification data structures. Abstract ancestor element IdentificationType,
shown in (a) contains the shared data elements for the two implementing forms, “GelFreeIdentificationType”
(b) and “TwoDimensionalIdentificationType” (c). Both have specific properties which are displayed for each.
Note that the properties that were inherited from IdentificationType have been collapsed for clarity in (b) and
(c). Optional elements are indicated by dashed boxes and multiplicity (if applicable) is shown below the box on
the right.
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querying a sequence database with a fragmentation spec-
trum) that are gathered during the identification process are
extremely useful to other researchers, yet few people actively
gather and store this information in a structured way.
Therefore, the inclusion of this information cannot now be
mandatory, nor is it possible to mold it to a defined structure.
Indeed, the field of proteomics is still evolving quite rapidly,
and allowing for this kind of semistructured data makes
PRIDE flexible enough to accommodate future require-
ments without a major overhaul. In the long term, it is con-
ceivable that some of these attributes become standard ele-
ments, whereas others will become obsolete.
PRIDE will in fact be gradually extended to embrace the
proteomics standards initiative-general proteomics stand-
ards (PSI-GPS) [13] as they become available, thus shaping
the PRIDE format into an implementation of this broader
format. Most notably, the mzData format for storage of mass-
spectrometer derived information is quickly reaching
maturity, and as soon as the controlled vocabularies for this
format are released (expected by spring 2005), PRIDE will
incorporate this format. The mzIdent format, meant to cap-
ture the identifications that result from searches based on
MS data, is in a more primitive stage at this point, but PRIDE
will adopt this standard upon availability as well. The success
of previous PSI standard formats [14] has led us to commit-
ting ourselves to their GPS standards, yet other proposed
standards for data interchange formats which have been
published in peer-reviewed literature [15, 16] will also be
accommodated by automated conversion in the near future.
3.5 Comparison between the PRIDE data format and
the PPP database at UM
Even though the PRIDE database draws in part upon the
PPP structure devised at UM, both models do not overlap in
full. This is mainly due to the slightly different focus of the
respective databases. PRIDE, being developed as a generic
repository for proteomics data, necessarily lacks some of the
very detailed structures present in a single-purpose database
such as the PPP database at UM. Specifically, the PPP data-
base provides more structured detail both at the level of the
protocol description as well as the identification process
(including full details about the searches performed). This
additional level of detail in the PPP database enables the
collaboration to compare the findings across similar yet
slightly different plasma samples, across technologies and
platforms used, and across identification algorithms applied
to the data.
Although this information is not present in PRIDE as
structured data (i.e., there are no database columns or XML
tags with corresponding names), the ability to cope with this
data is inherently present through the use of attribute lists.
Coupled to controlled vocabularies, which can be both par-
ticular to as well as shared across experiments, these attrib-
ute lists enable storage of any desirable additional level of
detail at several crucial points in the PRIDE data structure.
3.6 The PRIDE web interface
PRIDE presents a default web interface that provides three
areas of functionality: the ability to search and query the
PRIDE database, the facility to register as a data submitter or
collaborator, and the ability to submit data to PRIDE.
Five types of queries are supported in the current release
(Fig. 6). Queries on experiment title and accession number
are particularly useful when the user wants to view the full
list of identifications for an (published) experiment. Addi-
tionally, queries can also be performed on a text fragment
from a reference, enabling users to obtain the identifications
associated with a certain publication or author. Querying the
database by protein accession number lists all known identi-
fications of the specified protein across experiments, togeth-
er with detailed identification information such as the pep-
tides identified and their modifications. Finally, PRIDE can
be searched by sample name. This allows the user to see all
proteins identified in a certain tissue, cell type, or organism,
again across all experiments and with full details.
The PRIDE web interface can be configured to return
HTML formatted results as well as XML formatted results.
As such, it caters for both human readers (HTML format)
and machine readers (XML format). The latter allows users
to write scripts that perform an off-line meta-analysis on the
results of PRIDE queries in an efficient way.
The ability to register as a data submitter or collaborator
has been implemented with several goals in mind. First,
restricting data submission to registered users coupled with
a simple level of data curation will help to avoid spurious data
being uploaded into PRIDE. The system allows the creation
of collaborations, such that submitted data can be kept pri-
vate and shared only amongst collaborators until such a time
as they wish to make their data public. This functionality
allows PRIDE to be used as a tool for collaboration and data
sharing within a consortium as well as serving as a final
repository for published data. The same applies to PRIDE as
a system for peer-reviewing data that has been submitted for
publication, since data can be privately shared between
author(s), the journal, and the reviewers. Obviously it is also
possible for a data submitter to declare their data publicly at
the point of submission, excluding it from any of the restric-
tions described above.
4 Concluding remarks
The PRIDE project has resulted in the construction of a
unique combination of tools, standards, and infrastructure
that for the first time enable the construction of a truly glob-
al, centralized proteomics data repository. The highly mod-
ular design makes PRIDE flexible enough to be adapted by
third parties to create more or less differing mirrors with
new or specialized views on the same data.
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Figure 6. PRIDE web interface for queries. Three types of query are supported (1) by experiment accession num-
ber, (2) by protein accession number, (3) by reference text fragment, (4) by sample, or (5) by experiment title.
Indeed, as PRIDE starts to gather data, we expect new
and unexpected uses of the publicly available data to come
up. Statisticians might seize the opportunity to con-
structively contribute to the way database search software
functions or could enhance the procedures used to distin-
guish between true identifications and false positives. Biolo-
gists can mine the data in search for new research targets
and software developers can come up with new ways to store,
visualize, and query the large amounts of data that will
accumulate over time.
It is our conviction that PRIDE will be an important
milestone in the evolution of the field of proteomics and it is
our hope that it will become the highly active hub of prote-
omics data that we designed it to be.
The PRIDE database can be accessed on-line at http://
www.ebi.ac.uk/pride.
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ABSTRACT
PRIDE, the ‘PRoteomics IDEntifications database’
(http://www.ebi.ac.uk/pride) is a database of protein
and peptide identifications that have been described
in the scientific literature. These identifications will
typically be from specific species, tissues and sub-
cellular locations, perhaps under specific disease
conditions. Any post-translational modifications
that have been identified on individual peptides can
be described. These identifications may be annotated
with supporting mass spectra. At the time of writing,
PRIDE includes the full set of identifications as sub-
mitted by individual laboratories participating in the
HUPO Plasma Proteome Project and a profile of the
human platelet proteome submitted by the University
of Ghent in Belgium. By late 2005 PRIDE is expected to
contain the identifications and spectra generated by
the HUPO Brain Proteome Project. Proteomics labor-
atories are encouraged to submit their identifications
and spectra to PRIDE to support their manuscript
submissions to proteomics journals. Data can be
submitted in PRIDE XML format if identifications are
included or mzData format if the submitter is depos-
iting mass spectra without identifications. PRIDE is a
web application, so submission, searching and data
retrieval can all be performed using an internet brow-
ser. PRIDE can be searched by experiment accession
number, protein accession number, literature refer-
ence and sample parameters including species,
tissue, sub-cellular location and disease state. Data
can be retrieved as machine-readable PRIDE or
mzData XML (the latter for mass spectra without
identifications), or as human-readable HTML.
INTRODUCTION
The vast quantity of data associated with a single proteomics
experiment can become problematic at the point of publishing
the results. Laboratories tend to publish their work in an appro-
priate journal with perhaps a PDF document listing the pro-
teins described. If space allows, the individual peptide
sequences may be included but there is little possibility of
including details of the mass spectra in this format. This
clearly creates difficulties while attempting to reproduce the
work of a laboratory to confirm their results.
Fortunately, the community has recognized and is tackling
this problem through the formation of groups concerned with
the development of standards for the capture and sharing of
proteomics data. One such group is the HUPO Proteomics
Standards Initiative (PSI) (1) who are in the process of devel-
oping standards tackling several aspects of proteomics, includ-
ing ontologies of proteomics related terms, XML schemata
and minimal reporting guidelines.
The Proteomics Identifications database (PRIDE), previ-
ously described by Martens et al. (2) is a PSI compliant public
repository for proteomics identifications to which any proteo-
mics laboratory is welcome to submit data. It is envisaged, but
not mandated, that any such submission would normally be in
the context of the corresponding submission of a manuscript to
a journal describing the identifications submitted to PRIDE.
As such, PRIDE aims to become the proteomics equivalent of
the ArrayExpress database (3) used to capture microarray
experiment data in support of journal publications.
PRIDE is not alone in this endeavor. Several other publicly
available databases exist for the purpose of capturing and
disseminating proteomics data from mass spectrometry.
Such databases include the Global Proteome Machine Data-
base (gpmDB) (4), The Institute for Systems Biology’s
PeptideAtlas (5) and the University of Texas’ Open Proteo-
mics Database (opd) (6). Currently in progress is the devel-
opment of a collaborative agreement to exchange data between
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these and other emerging proteomics data repositories,
including PRIDE.
DATABASE DESCRIPTION
What is the scope of PRIDE?
PRIDE can store
(i) The title and description of the experiment, together with
contact details of the submitter.
(ii) Literature references.
(iii) Protein identifications by accession number suppor-
ted by a corresponding list of one or more peptide
identifications.
(iv) For each peptide identified, the sequence and coordin-
ates of the peptide within the protein that it provides
evidence for. Optionally, a reference to any submitted
mass spectra that form the evidence for the peptide
identification.
(v) Any post-translational modifications (natural or artefac-
tual) coordinated in relation to the specific peptide that
they have been found upon.
(vi) A description of the sample under analysis, including but
not limited to the species of origin, tissue, sub-cellular
location (if appropriate), disease state and any other
relevant annotation.
(vii) A description of the instrumentation used to perform the
analysis, including mass spectrometer source, analysers
and detector, instrument settings and software settings
used in data processing to generate peak lists.
(viii) Processed peak lists supporting the identifications in
PRIDE in the versatile PSI mzData format.
PRIDE version 2.0, the release of PRIDE available at the
time of writing, makes use of HUPO PSI deliverables such as
the mzData XML schema (7) for capturing the settings and
output from mass spectrometry work flow, including items
vi–viii listed earlier. At present, the PRIDE XML schema
encompasses the mzData schema with additional elements
to allow protein and peptide identifications and post-
translational modifications to be captured. It is envisaged
that the analysisXML XML schema will be incorporated
into PRIDE following its first release as a finalized schema,
expected by early 2006, replacing large parts of the custom
schema currently present in PRIDE.
Datasets currently available in PRIDE
A significant dataset that is publicly available from PRIDE at
the time of writing is the set of protein and peptide identifica-
tions from the individual laboratories involved in the HUPO
Plasma Proteome Project (8). This project was in part respons-
ible for the requirements statement that initiated the PRIDE
project.
Another publicly available dataset in PRIDE is a profile of
the human platelet proteome (9) submitted by the Department
of Medical Protein Research, Ghent University. This depart-
ment is also scheduled to contribute a substantial dataset iden-
tifying proteolytic cleavage by caspases in apoptotic Jurkat
T-cells (10) as well as a large set of spectra used to evaluate
spectrum quality filtering software (11).
A dataset of protein and peptide identifications describing
the organelle proteome of the secretory pathway is currently
held as private data in PRIDE but is expected to be publicly
available following publication of the related manuscript. At
present this dataset can only be viewed by prior permission of
the submitters.
It is expected that by the end of 2005 PRIDE will also
contain the protein and peptide identifications and related
mass spectra from the HUPO Brain Proteome Project (12)
as a publicly available dataset.
Submission and retrieval of data
Data can be both submitted to and retrieved from PRIDE
through a web interface, using either the PRIDE XML schema,
which embeds mzData as a sub-element to allow inclusion of
details of the spectra, or using the mzData XML schema, in
which case all identifications will be omitted.
Data can also be viewed as a human-readable HTML table
illustrated in Figure 1.
Figure 2 illustrates the search page. Queries can include
experiment identifier, protein accession or identifier, literature
references and sample parameters, including species, tissue,
sub-cellular location and disease. The search results include all
the experiments that match the query, together with options of
how the data should be presented.
Data security in PRIDE: PRIDE as a tool for
journal review
Data submitted to PRIDE is marked as public or private. Pri-
vate data can be shared through a collaborative mechanism
that allows individuals to apply to join a collaboration, their
application then being confirmed or rejected by the creator of
the collaboration. As well as allowing collaborating laborat-
ories to share their data, this mechanism can also be used to
allow manuscript reviewers to access the corresponding
PRIDE entry in a confidential manner on a neutral site.
Use of controlled vocabularies and ontologies in PRIDE
By extending the mechanism designed for the mzData XML
schema, PRIDE makes extensive use of external controlled
vocabularies and ontologies (hereafter ‘CVs’) to annotate ent-
ries. The use of CVs ensures that queries for particular terms
will capture all of the relevant data without omission due to
differences in terminology. As a spin-off of the PRIDE devel-
opment program, a SOAP web service to allow external CVs
to be queried in an intelligent manner has been developed at
the EBI, initially for use by PRIDE (http://www.ebi.ac.uk/
ontology-lookup/). This service allows queries to take advant-
age of the hierarchical nature of ontologies. For example, if a
user requests all protein identifications found in pancreas, the
relevant Medical Subject Headings (MeSH) term will be
looked up in the ontology web service and PRIDE will be
queried for entries relating to the MeSH term ‘Pancreas’ as
well as all child terms, currently in this case including ‘Islets of
Langerhans’, ‘Pancreas, Exocrine’ and ‘Pancreatic Ducts’.
This mechanism assists the user by retrieving all the relevant
data without the need to have a detailed knowledge of the
terms involved.
CVs and ontologies suggested for use in PRIDE include
MeSH (13) for animal anatomy and disease states; Gene
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Ontology (GO) (14) for sub-cellular location; NEWT (15) for
taxonomy, which is a superset of the NCBI taxonomy (16); the
mass spectrometry ontology being developed by the HUPO
PSI; RESID for naturally occurring post-translational
modifications (17) and UNIMOD for protein modifications
encountered in mass spectrometry experiments (18).
A PRIDE CV has been created for cases where existing CVs
do not include a term required to annotate data in PRIDE.
The use of CVs and ontologies will allow the annotation of
certain specific experimental results such as peptide retention
times for LC-MS experiments or protein quantitation informa-
tion for quantitive or differential proteomics experiments.
Figure 1. An example of PRIDE data in tabulated HTML format.
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Where the required CV terms do not exist already, PRIDE can
accommodate these data elements through the use of user
parameters.
PRIDE is an open-source software development project
Care has been taken throughout the development of PRIDE to
ensure that all system components are open-source and freely
available. PRIDE is written in Java and made available under
the open-source Apache license. All the source code are freely
available from the CVS repository (http://sourceforge.net/cvs/
?group_id=122040). PRIDE uses the open-source Object-
Relational Bridge (OJB) (http://db.apache.org/ojb/) API for
database connectivity. As a consequence, PRIDE can easily be
adapted to run on any SQL-based relational database manage-
ment system. Configuration files exist for both Oracle (http://
www.oracle.com) and MySQL (http://www.mysql.com/).
DISCUSSION
Here we consider possible applications of PRIDE from the
perspective of the typical proteomics researcher. PRIDE offers
the user several useful query opportunities including:
 Retrieving all proteomics experiments in which a particular
protein of interest has been observed.
 Downloading proteome datasets of interest in a standard
format for further local analysis.
 Retrieving the complete list of protein identifications (and the
specific peptides found) for a given publication.
 Using the links provided via PRIDE to further explore the
proteins identified.
 Comparison of one’s own results with previous findings to
quickly determine overlap as well as potentially novel
findings.
 Planning of one’s experiments: finding experimental proto-
cols that have already been applied successfully to analyse
your sample or even protein of interest.
 Re-analysing previously published results using your own
techniques.
 Obtaining test sets for training or trying out novel algorithms
(e.g. algorithms for protein or peptide identification).
 Retrieving typical base line proteomes for specific tissues and
species.
 Allowing journal appointed reviewers to analyse the details of
the identifications and potentially the supporting spectra as
part of their review in a standardized manner.
FUTURE DEVELOPMENTS
The developers of PRIDE recognize that the system has room
to evolve in several important aspects.
It is important for the future of PRIDE to keep apace with
developments in the HUPO PSI. One important development
of this initiative is the analysisXML XML schema, designed
to hold details of protein and peptide identifications and
Figure 2. The PRIDE Advanced Search form.
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post-translational modifications, together with cross refer-
ences to the relevant mzData entries describing spectra. It
is intended that analysisXML will be fully supported by
PRIDE for import and export, without modification or data
loss, as soon as possible after the first stable release of the new
analysisXML XML schema.
Submitters of identifications to PRIDE will naturally make
use of their favored protein sequence database against which to
search their spectra. Consequently, PRIDE will quickly fill
with protein accessions and IDs from disparate protein
sequence databases. An important short-term goal of the
PRIDE project is to map all identifications to the UniProt
database (19), including cross references to as many other
protein databases as possible. This work will borrow heavily
from the IntAct project (20), both in terms of code base and
procedures for automatic and human curation.
A long-term goal of the PRIDE project is to provide an
automated program of regular re-analysis of mass spectra
deposited in PRIDE using the most up-to-date protein
sequence databases and available open-source search
algorithms such as X!Tandem (http://www.thegpm.org/
TANDEM/) (21). The submitter’s original identifications
would continue to be available as described in the correspond-
ing manuscript.
The EBI has developed a Distributed Annotation Server
(DAS) (22) service for PRIDE (http://www.ebi.ac.uk/das-
srv/pride/das/) using the BioJava Dazzle servlet (http://
www.biojava.org/dazzle/). This service is publicly available
and can be used to enable DAS clients such as Dasty (23),
designed for visualizing protein sequence and annotation, to
display identifying peptides for the protein specified in the
DAS request.
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SHORTCOMMUNICATION
Do we want our data raw? Including binary mass
spectrometry data in public proteomics data repositories
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With the human Plasma Proteome Project (PPP) pilot phase completed, the largest and most
ambitious proteomics experiment to date has reached its first milestone. The correspondingly
impressive amount of data that came from this pilot project emphasized the need for a cen-
tralized dissemination mechanism and led to the development of a detailed, PPP specific data
gathering infrastructure at the University of Michigan, Ann Arbor as well as the protein identi-
fications database project at the European Bioinformatics Institute as a general proteomics data
repository. One issue that crept up while discussing which data to store for the PPP concerns
whether the raw, binary data coming from the mass spectrometers should be stored, or rather the
more compact and already significantly processed peak lists. As this debate is not restricted to the
PPP but relates to the proteomics community in general, we will attempt to detail the relative
merits and caveats associated with centralized storage and dissemination of raw data and/or peak
lists, building on the extensive experience gained during the PPP pilot phase. Finally, some
suggestions are made for both immediate and future storage of MS data in public repositories.
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The completion of the human genome project, with the
corresponding rise of the field of proteomics, led to the crea-
tion of the HUPO projects as the next major collaborative
scientific enterprise in the life sciences [1]. In order to
achieve the high-aiming goals of these projects in a reason-
able time frame, collaborations between multiple labs
around the world have been set up, with each of these labs
analyzing standard samples using distinct protocols and
hardware. The Plasma Proteome Project (PPP), as the pio-
neering project in the larger HUPO consortium, is the first
of these to have amassed a large body of proteomics data
during its recently completed pilot phase [2]. Centralized
data storage and subsequent dissemination of these data to
the scientific community has been addressed through the
initial data collection and management work of Marcin
Adamski at the University of Michigan, Ann Arbor [3] and
the protein identification database (PRIDE) [4] project of the
European Bioinformatics Institute (EBI). During the con-
struction of these resources, a lot of discussion was attributed
to the storage of the MS data. In particular the storage of the
raw, binary data that the machines report has been discussed
thoroughly.
As the question of storing raw data has recently been
taken up by editors of proteomics journals as well [5], and
furthermore affects the proteomics community at large [6],
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we here present a series of advantages and limitations
inherent to the publication of raw data compared to pro-
cessed peak lists, building on the unique experiences
obtained through the PPP.
There seems to be a general consensus in the proteomics
community today to request submission of the source data
on which reported identifications are based [5]. This will
allow other researchers to verify and validate the published
conclusions independently. Publishing source data also has
the benefit of allowing additional (computational) analyses
by other researchers, which could lead to the uncovering of
new, biologically relevant information that was missed in the
original analysis.
These source data can take a number of forms, but by
far the most common representations are either the pro-
prietary, binary “raw” formats that the mass spectrometers
churn out during their analyses or the text-based, pro-
cessed peak lists that are typically submitted to search
engines for identification of the peptides that produced
those spectra. In the case of fragmentation spectra, the
peak lists contain the parent peptide m/z and charge (if the
charge is known) and a listing of measured m/z values and
their intensities for the fragment peaks. Search engines
then attempt to match these fragment peaks to in silico
generated fragmentation spectra of all peptides in a search
database. The peak lists are often called MS/MS spectra
and due to the extensive automation of acquisition soft-
ware, they are often the only format encountered by
researchers. These files can take a variety of formats, yet all
are essentially text-based, small (a few kilobytes per file),
readily readable by both humans and software programs
and easily compressible (two-fold to three-fold compression
ratios are routine using GNU ZIP (GZIP) (GNU – GNU’s
Not Unix)). Additionally, each of these peak list formats
can conveniently be transcribed in any other format. A few
common examples are SEQUEST files (dta), Micromass
peak lists (pkl), and MASCOT Generic Format files (mgf).
There is a slight variability in the amount of information
these different formats can accommodate, but in general
conversion between formats tends to be conservative. Fur-
thermore, the mzData format, a community standard
recently developed by the HUPO Proteomics Standards
Initiative (PSI) [7] that elicits broad support among both
instrument and software vendors, will ultimately eliminate
the need for these format conversions.
As noted above, peak lists present an already processed
view on the originally recorded data. Typically proprietary,
vendor-supplied software is used to extract these peak lists
from the raw data. Frequently applied processing techniques
during this extraction phase include noise-filtering, cen-
troiding, deconvolution, and deisotoping of the peaks. As
there is no standard protocol for these processing steps,
problems often arise because what one scientist regards as
standard processing might seem “lossy” conversion to
another, leading some to label these peak lists as an unfit
distribution medium for MS data.
The raw data formats in contrast are much larger in size
(typically well above 10 MB per file) and are usually stored in
a proprietary, binary format. This makes the files impractical
to read for both users and third-party software programs, all
the more so because the exact format description is typically
not disclosed by the vendors. Since the binary format can
already be a compressed representation of the data, standard
compression algorithms such as GZIP do not always reduce
the size of these files. A simple analysis was performed to il-
lustrate both size differences and the effects of data com-
pression (Fig. 1). The much larger size of the raw data does,
however, allow these files to contain much more information
than peak lists. Raw files contain all the individual peaks as
registered by the instrument detector and, for LC-MS
machines, can store elution profiles and times for the LC
part. Depending on the vendor and make of the machine,
other useful instrument-related information can be stored in
these files as well.
Recently, several interesting developments have been
described that can put this wealth of additional information
in raw files to good use [8, 9]. The key to interpreting these
raw data directly has been the development of specific soft-
ware to parse the binary content of these raw files into
intelligible data, a tedious and time-consuming task that
typically needs to be redone each time a new machine or a
new version of an existing machine or its operating software
appears. Furthermore, this reverse-engineering of a pro-
prietary format is typically frowned upon by vendors. Next
to the above-mentioned caveats associated with proprietary
raw data formats, there is also the very real problem of
“aging” that comes with any binary formatted data. As time
goes by, support for certain formats tends to evaporate and
within the space of several years, readers can no longer be
found for the format. A detailed review of the issues con-
cerning proprietary data formats and science can be found
in [10].
The mzXML format of the Institute of Systems Biology
[11], designed as an intermediate format between raw data
and peak lists, could bring some solace if it were supported
by vendors, but a more pervasive effort on behalf of the entire
community to standardize raw data formats is more likely to
succeed in eliciting such global support.
When it comes to storing mass spectrometric data in
proteomics data repositories, the discussion tends to focus
on an “either-or” decision. Most proponents for the storage of
raw data currently have (limited) facilities to parse this kind
of data, and are therefore able to exploit the richer informa-
tion therein. The other camp, which advocates the storage of
the processed peak lists, tends to lack this software, making
the raw data essentially inaccessible to them (unless they
happen to possess the particular, proprietary instrument
software that allows the transformation to peak lists). It is
our opinion that the choice should not be an exclusive one.
In fact, we are convinced that both formats have a distinct
and additive value at this time and as such fulfill com-
plementary roles.
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Figure 1. Comparing compressed and uncompressed file sizes for RAW data and the corresponding peak lists.
Figures for the data are based on the averages of multiple separate files for each measurement. Error bars
denote one SD on the averages. For the raw data, the sizes were averaged over ten individual files. Q-TOF I
(Micromass, Cheshire, UK) peak list data consist of 720 individual files, the Esquire HCT (Bruker Daltonik,
Bremen, Germany) IT peak list data count 1050distinct files. Both file sets were grouped into ten subgroups, with
each subgroup corresponding to the spectra extracted from a single parent raw file. File format chosen for the
peak lists was the intermediately verbose MASCOT Generic Format (http://www.matrixscience.com/help/
data_file_help.html). Peak lists have been tarred by GNU tar (http://www.gnu.org) to compensate for size-
bloating due to the minimal file size limit of the NTFS file system. Compression for both RAW files and peak lists
was done using GZIP with default compression settings. Note the extreme difference in file sizes between raw
data files and peak lists. Also notable is the difference in compression efficiency between Q-TOF I RAW files and
their Esquire HCT counterparts, especially since the compressed results are highly similar, indicative of a built-in
compression in the Esquire HCT files. Compressibility of the peak lists can be deduced from the data labels and
is always greater than 50%.
When a reevaluation of the peak lists using a different
search algorithm or using a newer sequence database as
search base is the scope of the research done with the origi-
nal data, peak lists typically are the most readily accessible
and efficient sources of MS data. For more advanced pur-
poses however, such as obtaining large training sets for
machine learning approaches for the prediction of peptide
elution times [12] or, in the case of quantitative proteomics
experiments based on stable isotope labeling [8], the raw for-
mats present the only data source rich enough for these
analyses.
Therefore, in the PPP, peak lists are part of the core data
structure, whereas submission of raw files is considered an
optional yet highly encouraged addition. The reason for this
optional inclusion of raw data is purely technical in origin, as
the sheer size of the files involved pushes infrastructure
requirements for both storage of the data and their sub-
sequent distribution to their limits.
Typically, funding for these infrastructure issues is
evaluated using a standard cost/benefit model, yet for raw
data files, the costs will surely outweigh the benefits in the
short term. Storing raw files will require large amounts of
disk space, which typically should be made redundant (e.g.,
using RAID systems), thus disk space requirements will be
at least twice the size of the data. Back-ups of this amount
of data also present a nontrivial challenge. Due to typical
low compression ratios, the amount of uncompressed tape
media space (which tends to be more expensive than hard
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drive space) required will be roughly equivalent to the total
data size. The distribution of the data after they have been
successfully stored, also accounts for a large part of the
cost involved since bandwidth does not come free, either.
As an illustration of the data storage requirements, we
consider the raw data for a single ICAT [13] or COFRADIC
[14] run through a complete proteome (30–40 separate LC-
MS/MS runs, with a 2 h gradient each) to have a com-
pressed size of roughly 1.5 GB for older or less sophisti-
cated machines, up to a massive 45 GB for newer, state-of-
the-art instruments! It can be expected that future
machines will generate even larger files as instrument
accuracy and resolution increases. Put in perspective, a
single proteome thus requires at least three times as much
storage space as the NCBI nonredundant protein database
(ftp://ftp.ncbi.nih.gov/blast/db/nr.tar.gz) in FASTA format,
or three times as much as the full Swiss-Prot database [15]
in the native text format! And although a 100 GB low end
hard disk can currently be purchased for about US $100, a
conservative cost estimate from the EBI averages to a total
cost of US $2000 per 100 GB stored for data on a public
high-availability FTP server, including distribution and
back-up costs!
Even though a truly distributed system (every lab hosting
its own raw data) maximizes cost-efficiency through dis-
tribution of both the storage and bandwidth cost, it is typi-
cally undesirable in the long run as the turn-over for avail-
ability of academic sites tends to be quite high. The installa-
tion of centralized repositories, located at dedicated institutes
such as the EBI or the National Center for Biotechnology
Information (NCBI), would be far more reliable in the long
run, yet these organizations typically suffer from a lack of
resources to host this amount of data. Compared to sequence
databases, for instance, the growth in data storage require-
ments (and hence the rise of the cost) will be far greater for
raw data, whereas the benefits (typically calculated in num-
ber of downloads or resulting publications) will most prob-
ably be less. The lack of open formats for the raw data adds to
the difficulty of establishing funding for centralized reposi-
tories, which brings us to a catch-22: for a true incentive to-
wards routine dissemination of raw data for published
papers, we need open standards for the data formats used,
but in order to push such open standards on the vendors, a
large user community is needed that can actively define
these standards as well as demand support for them from the
vendors.
As a conclusion, the following recommendations can
be made concerning the dissemination of MS data:
(1) peak lists should be made available by default. There is
no reason not to make these publicly available, and there
are no real storage or distribution issues to be considered.
(2) raw data have some clear benefits over peak lists, yet
currently lack both standardized formats as well as the
required infrastructure for centralized storage and dis-
tribution. Therefore, information on how to obtain raw
data should at the very least be referenced in the published
results for the time being. This can easily be done by pro-
viding links to individual lab websites from the journal
websites (note that this is a version of the “truly distributed
system” discussed above). (3) Efforts should be started at
centralized repositories to create the necessary infra-
structure so that in the mid- to long-term, source data will
preferentially be submitted in the raw format. Meanwhile,
(4) vendor support should be enlisted for open formats or
at least open access to software tools that allow users to
read and interpret the different formats of raw data. Since
these latter developments are mutually dependent, the
most important breakthrough to achieve seems to be the
establishment of centralized repositories. Perhaps some
lessons can be learned in this respect from the microarray
community, as they have faced (and largely overcome)
similar problems in the recent past [16].
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2.5. Application to human platelet proteomics 
2.5.1. An all-round showcase 
The meta-analysis of four distinct experiments comprising three different COFRADIC 
views of the human platelet proteome is an interesting showcase for the results discussed 
above. Two N-terminal COFRADIC experiments, one cysteine COFRADIC experiment 
and one methionine COFRADIC experiment were combined and re-searched to yield as 
complete a platelet proteome as was possible. It also allowed the study of potential 
complementarity or overlap in the different COFRADIC procedures. 
In order to manage the data from these projects and later re-search and integrate them 
ms_lims was instrumental. It also made analyses within and across COFRADIC 
techniques easy and fast. DBToolkit-derived databases for N-terminal COFRADIC 
increased the total number of identified proteins for the two corresponding projects by 
50%, with many of these additional identifications providing precise information about 
protein processing. The datasets (spectra and identifications) were also the first ones ever 
to be made publicly available via the PRIDE system and have correspondingly been 
stored as PRIDE accession numbers 1, 2 and 3. 
A later analysis of the complete N-terminal dataset with the spectrum classifier tool 
revealed a list of unidentified yet high quality spectra that were subjected to a detailed 
analysis for unexpected modifications. This resulted in the detection of the cyclization of 
N-terminal S-carbamoylmethylcysteine as an important yet unexpected artefactual 
modification. This discovery has since been taken into consideration within each N-
terminal COFRADIC project (see section 2.3 above). 
Taken together, the application of the tools discussed in the previous sections to this 
dataset allowed the identification and publication of the single largest set of identified 
proteins in human blood platelets to date. 
 
2.5.2. Publication 
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The human platelet proteomemapped by peptide-centric
proteomics: A functional protein profile
Lennart Martens, Petra Van Damme, Jozef Van Damme, An Staes, Evy Timmerman,
Bart Ghesquière, Grégoire R. Thomas, Joël Vandekerckhove, Kris Gevaert
Department of Medical Protein Research, Flanders Interuniversity Institute for Biotechnology,
Department of Biochemistry, Ghent University, Ghent, Belgium
Several studies have been published in which holistic approaches were used to characterise the
proteome and transcriptome of human platelets. The key intent being that a deeper under-
standing of the normal and aberrant physiological functions of platelets can only be achieved if
most biomolecular building blocks are mapped. Here we present the application of recently
developed novel technologies that overcome some of the shortcomings of gel-based proteomics.
Central in our approach is the so-called combined fractional diagonal chromatography (COFRA-
DIC)-technology in which sets of representative peptides are sorted in a diagonal RP chromato-
graphic system through a specific modification of their side chain. In this study we combined
three different COFRADIC sorting techniques to analyse the proteome of human platelets.
Methionyl, cysteinyl and amino terminal peptides were isolated and analysed byMS/MS.Merging
the peptide identifications obtained after database searching resulted in a core set of 641 platelet
proteins, which comprises the largest set identified today. In comparison to previously published
platelet proteomes, we identified 404 novel platelet proteins containing a high number of hydro-
phobic membrane proteins and hypothetical proteins. Furthermore we discuss the observed
characteristics and potential benefits of each of the different COFRADIC technologies for pro-
teome analysis and highlight important issues that need to be considered when searching
sequence databases using data obtained in peptide-centric, non-gel proteomics studies.
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1 Introduction
Blood platelets are vital for maintaining a closed blood flow
through the circulatory system. In normal physiological
conditions, platelets respond to a breach in this system by
adhering to the lesion site of a vessel wall and by forming a
fragile, primary thrombus. This primary thrombus becomes
firmer upon fibrin formation by thrombin cleavage of fi-
brinogen and thickens into a stiff, secondary thrombus.
Over the course of wound healing, a fraction of this hae-
mostatic thrombus is degraded by fibrinolysis [1]. Aberrant
platelet functions have been associated with various dis-
eases, both acquired and inherited. These diseases, char-
acterised by errors in platelet production (thrombocytopenia
and thrombocytosis) and errors in forming, storing and
releasing their molecules, cause platelets either to fail to
respond to injuries or to incorrectly stimulate clot formation
at uninjured sites. Some examples of inherited functional
platelet disorders include the Bernard–Soulier syndrome
(defects of the glycoprotein Ib-IX-V complex), the von Will-
Correspondence: Professor Kris Gevaert, Department of Medical
Protein Research, Flanders Interuniversity Institute for Biotech-
nology, Ghent University, A. Baertsoenkaai 3, B-9000 Ghent, Bel-
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enbrand disease (disorder of vWF) and the Wiskott–Aldrich
syndrome (decreased levels or absence of WASP) [2]. In
order to fully understand the ongoing biochemical pro-
cesses in platelets, large-scale proteomics [3–6] and tran-
scriptomics [7] studies have been performed. The general
idea being that a large catalogue of platelet proteins could
form the basis for further experiments, thus accentuating
the explorative role of these studies. While in one of the
largest ongoing 2-D gel based platelet proteome studies
today about 2300 distinct protein spots have been visualised
[4, 6], thus far only 411 different platelet proteins could be
identified after analysing the observed protein spots by LC-
MS/MS analysis.
Intrinsic shortcomings of 2-D PAGE, important instru-
mental improvements and the increasing availability of ge-
nome sequences have recently led to a new type of proteom-
ics; gel-free or non-gel proteomics. Here, isolated proteomes
are first digested (mostly using a highly specific protease)
after which either a specific class of peptides is affinity-iso-
lated for MS/MS analysis or the whole, extremely complex
peptide mixture is separated by a multidimensional
approach prior to analysis (for a recent review see [8]).
We have recently developed a technique for isolating
representative peptides out of a tryptic digest of a proteome.
It is based upon the principal of diagonal chromatography [9,
10]; between two identical, chromatographic separations a
chemical or enzymatic reaction is performed such that spe-
cific sets of peptides shift away from their original elution
position and are collected. From a proteomic point-of-view
such representative peptides preferably contain rare amino
acids that are uniformly distributed throughout a proteome.
Through this selective isolation technique, the complexity of
the final analyte mixture is reduced while the chance that
every original protein is represented by at least one peptide
remains high, thus achieving minimal complexity while
retaining maximal coverage.
Probably the simplest chemical reaction is used for the
isolation of methionyl peptides; after a primary separation,
the collected peptide fractions are treated with hydrogen
peroxide which oxidises methionine to its sulphoxide and
thus renders methionyl peptides more hydrophilic. During a
secondary, identical separation, methionyl peptides undergo
a hydrophilic shift and are collected for MS/MS analysis [11].
Cysteine residues in proteins are first modified using Ell-
man’s reagent, the proteins are subsequently trypsinised and
the peptide mixture is fractionated a first time. Prior to the
secondary fractionation, the hydrophobic thionitrobenzoic
acid group is removed from the cysteine backbone by a re-
ducing agent and cysteinyl peptides undergo a hydrophilic
shift, which allows easy isolation from the bulk of non-
cysteinyl peptides [12]. In both cases – isolation of methionyl
or cysteinyl peptides – the number of separations is reduced
by combining multiple primary fractions prior to the sec-
ondary separation. Hence, we have called this technology
‘combined fractional diagonal chromatography’ (COFRA-
DIC).
The highest complexity reduction, however, is obtained
by isolating only the amino terminal peptides out of the pro-
teome digest. In this case, the peptides of interest are not
shifted but all the internal ones are. After chemically mod-
ifying the proteins and subsequent trypsin digestion, only
the internal peptides will contain a free a-amino group,
which is modified by trinitrobenzenesulphonic acid prior to
the secondary separation. The modified internal peptides
thus become very hydrophobic (a trinitrophenyl moiety is
attached at their terminal amine) and shift out of the primary
collection interval. N-terminal peptides remain stationary
and are collected [13].
For the first time we have applied the three different
COFRADIC protocols for the characterisation of one pro-
teome: that of nonstimulated human platelets. After com-
bining the results, a core set of 641 platelet proteins was
identified. We here discuss notable differences observed after
identifying MS/MS spectra obtained from the three different
types of isolated peptides and difficulties encountered when
identifying proteins in large databases using only one or a
few peptides. A meta-analysis of the core platelet proteome
was performed and we noticed that although a large number
of proteins were classified as nuclear proteins, only a small
part did in fact have oligonucleotide binding properties.
Finally, as this proteome contains a high number of trans-
membrane proteins (87 different proteins or 13.5%) of which
the majority was never visualised/identified on a 2-D gel, we
here demonstrate that COFRADIC is significantly less
biased against identifying hydrophobic proteins compared to
2-D gel based analysis.
2 Materials and methods
2.1 Preparation of a human platelet proteome
A platelet-rich suspension isolated by thrombocytapheresis
was obtained from the Red Cross Blood Transfusion Centre
Oost-Vlaanderen, Ghent, Belgium. In each proteome
analysis 50 6 109 platelets were used. Residual white and
red blood cells were first removed by centrifugation of this
platelet-rich suspension at 300 6 g for 10 min. The iso-
lated supernatant containing the platelets was then cen-
trifuged at 1000 6 g for 10 min and the obtained pellet of
blood platelets was resuspended in 40 mL washing buffer
(0.2 g/L KCl, 0.2 g/L MgCl2, 8 g/L NaCl, 1 g/L D-glucose
and 70 mg/L EGTA in 25 mM sodium phosphate at a pH
of 7). The presence of EGTA in the buffer system pre-
vented artefactual activation of the platelets. This washing
procedure was repeated twice and the platelets were finally
resuspended in 10 mL of washing buffer and lysed by
adding 10 mL of 0.5% Triton X-100 in 25 mM of sodium
phosphate buffer (pH 7.5) containing a cocktail of protease
inhibitors (Roche Diagnostics, Mannheim, Germany).
Lysed platelets were put on ice for 30 min after which cel-
lular debris was removed by centrifugation (10 min at
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10 000 6 g). For each COFRADIC experiment, 500 mL of
this protein mixture (corresponding to 1.25 6 109 plate-
lets) was used.
2.2 COFRADIC isolation of methionyl, cysteinyl and
amino terminal peptides
COFRADIC-based isolation of representative peptides was
performed as described elsewhere [11–13].
2.3 Automated LC-MS/MS analysis and identification
of the generated MS/MS spectra by MASCOT
Secondary fractions containing sorted methionyl or cysteinyl
peptides were pooled prior to LC-MS/MS analysis in order to
reduce the number of analyses [11, 12], whereas fractions
containing sorted amino terminal peptides were not pooled
and each secondary fraction was analysed separately [13].
Dried peptides were redissolved in 20 mL of solvent A (0.1%
formic acid and 2% ACN in water; ACN and water were of
‘Baker HPLC analysed’ quality (Mallinckrodt Baker, Deven-
ter, The Netherlands). Ten microlitres of this peptide mixture
were injected on a 0.3 mm id 6 5 mm trapping column
(PepMap; LC Packings, Amsterdam, The Netherlands) at a
flow rate of 20 mL/min (total loading time of 5 min) using a
CapLC system (Micromass, Cheshire, UK). By switching the
stream valve, the trapping column is back-flushed with a
binary solvent gradient, which is started simultaneously with
the injection cycle. The sample is thereby loaded onto a
nanoscale RP C18 column (0.75 id 6 150 mm PepMap™
column; LC Packings). Peptides were eluted from the sta-
tionary phase using a linear gradient from 0 to 100% solvent
B (70% ACN in 0.1% formic acid) applied over a period of
25 min. The solvent delivery system was set at a constant
flow of 5 mL/min and using a 1/25 flow splitter, 200 nL/min
of solvent was directed through the nanocolumn.
The outlet of the nanocolumn was in-line connected with
a distal metal-coated fused silica PicoTip™ needle (PicoTip™
FS360-20-10-D-C7, New Objective, Woburn, MA, USA),
which was placed in front of the inlet of a Q-TOF1 mass
spectrometer (Micromass). Automated data-dependent
acquisition was initiated 15 min after the stream valve was
switched. The acquisition parameters were such that only
doubly and triply charged ions were selected for fragmenta-
tion and fragmentation spectra were merged over a period of
8 s. The stream valve was switched back 51 min after the start
of the injection cycle.
The acquired CID-spectra were automatically converted
to a MASCOT [14] acceptable format using the ProteinLynx
program of Micromass’ MassLynx software (version 3.4).
Different sequence databases were used in sequence to
identify the isolated peptides. In all three COFRADIC
experiments, MASCOT first searched in the regular IPI hu-
man protein database, version 2.31 (ftp://ftp.ebi.ac.uk/pub/
databases/IPI/current/ipi.HUMAN.dat.gz). For the methio-
nyl and cysteinyl peptides, the IPI human database was also
searched in MASCOT ‘No Enzyme’ mode. In this mode, all
residues are considered potential cleavage sites and thus all
possible peptide sequences can be considered for spectrum
matching. In the case of amino terminal COFRADIC two
additional in-house developed databases were searched: first
an amino terminal ‘ragged’ version of the truncated IPI hu-
man database where the truncation length for each IPI entry
was set to 100 amino terminal amino acids. This database
allowed the identification of post-translational protein pro-
cessing such as signal peptide cleavage. The second database
was also an amino terminal ragged version of the IPI human
database, yet this time the ragging occurred on the full pro-
tein sequences. The truncation and ragging was performed
using the DBToolkit software (http://www.proteomics.be/
bioinfo/lm/dbtoolkit) as described previously [13]. To avoid
the possibility that one MS/MS spectrum was linked to
identical sequences stored in different databases, the follow-
up search option that is available in the MASCOT daemon
tool was used in such a way that only the MS/MS spectra that
were not identified at the 95% confidence level in one data-
base, were used to search in the larger databases. The search
order employed for the methionyl and cysteinyl peptides was
first regular IPI human, then IPI human with the ‘No En-
zyme’ setting. For the amino terminal COFRADIC the
search order used was first the regular IPI human, then the
ragged IPI human database truncated to 100 amino terminal
residues and finally the ragged IPI human database without
truncation.
Depending upon the type of peptide analysed, the MAS-
COT search parameters were set differently as previously
described [11–13]. For all searches both the precursor mass
tolerance and the fragment mass tolerance were set to 0.3 Da.
Instrument setting was always ‘ESI Q-TOF’. For the regular
IPI database searches, as well as the ‘No Enzyme’ searches,
the number of allowed missed cleavages was set to 1. For the
truncated databases, no missed cleavages were allowed for
the searches, since one missed cleavage was already allowed
during construction of the truncated peptide databases. For
the N-terminal COFRADIC spectra, the fixed modifications
were set to acetylated lysines and carbamidomethyl
cysteines. The allowed variable modifications were acetylated
N-termini, deamidation for asparagines and glutamines,
oxidation of methionines and pyroglutamate for N-terminal
glutamines. For the methionine and cysteine COFRADIC
there were no fixed modifications and the following variable
modifications: deamidation for asparagines and glutamines,
oxidation of methionines and pyroglutamate for N-terminal
glutamines.
The DAT result files of MASCOT were automatically
queried using in-house developed software tools and only
MS/MS spectra that were identified by a score that exceeded
the identity threshold score of MASCOT at the 95% con-
fidence level were retained. The retained spectra were sub-
sequently manually validated and only spectra that held a
high number of typical fragment ions were considered as
positively identified (typically about 50% of b and y ions were
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present). The identified peptides were automatically stored
in a MySQL relational database in which links were made to
their MS/MS spectra and precursor proteins.
3 Results and discussion
3.1 MS/MS analysis of peptides sorted by different
COFRADIC techniques
Since we pursued a comprehensive analysis of the human
platelet proteome, we used three different COFRADIC tech-
nologies: sorting methionyl peptides [11], cysteinyl peptides
[12] and amino terminal peptides [13] respectively. These
peptides were analysed by automated LC-MS/MS on a Q-
TOF1 mass spectrometer and the obtained peak lists were
used as input for MASCOT [14]. Searches were done in ver-
sion 2.31 of the nonredundant International Protein Index
(IPI) database [15], with restriction to human proteins.
The spectra from the N-terminal COFRADIC analysis of
platelets as published previously [13], as well as those result-
ing from the cysteine COFRADIC analysis of platelets [12],
were re-searched in the IPI database along with the unpub-
lished methionine data. The reason for this re-searching was
two-fold: in this way a common search base is employed and,
at the same time, this search base is brought up-to-date. IPI
was chosen because it provides a minimally redundant view
on a number of popular sequence databases (e.g., Swiss-Prot
and NCBI nr). The identified peptides/proteins are stored in
the PRIDE database and accessible via http://www.ebi.ac.uk/
pride/. PRIDE experiment accession number 1 points to the
identified methionyl peptides, number 2 to the cysteinyl
peptides and numer 3 to the N-terminal peptides.
We noted a significant difference in the identification
efficiency of the obtained spectra (Table 1). Spectra from
methionyl peptides clearly have a higher identification effi-
ciency compared to those from sorted cysteinyl and amino
terminal peptides. In COFRADIC, methionyl peptides are
converted to their hydrophilic sulphoxide derivatives. When
analysed by mass spectrometers, such peptides are easily
recognised by the readily occurring neutral loss of methane-
sulphenic acid (CH3SOH) [16]. However, we also noted that
such peptides are impaired for fragmentation of their back-
bone and generally tend to give fewer and less intense frag-
ment ions. This phenomenon is especially prominent in
MALDI PSD [17] (results not shown). In this view, one would
expect that MS/MS spectra of such peptides are less infor-
mative and thus more difficult to link to peptides. Here, this
is clearly not the case. In fact the identification efficiency of
spectra from methionyl peptides is about twice as high as
that of cysteinyl and amino terminal peptides. Using the
same experimental setup, the average identification effi-
ciency of a typical human protein sample digested with
trypsin is 30%, which is comparable to the identification
efficiency observed for methionyl peptides.
Apparently this hints to the fact that MS/MS spectra
obtained from COFRADIC sorted cysteinyl and amino ter-
minal peptides aremore difficult to link to peptide sequences
by MASCOTcompared to those from methionyl peptides.
Possible causes for the apparent less efficient identifica-
tion of cysteinyl peptides might be due to the chemical reac-
tions employed for their isolation. For instance, the hydro-
phobic group could have reduced the solubility of the Cys-
modified peptides resulting in a loss of such peptides during
the primary separation. Between the primary and secondary
run, the hydrophobic thionitrobenzoic acid group is removed
from the cysteine backbone by a reduction reaction using
phosphines [12]. If such reaction mixtures are kept at room
temperature for a long time, the phosphines become oxi-
dised and do not protect the free thiol groups anymore.
Therefore, disulphide bridges might spontaneously occur
[18] leading to homo- or hetero-dimeric peptides that might
not get isolated for further LC-MS/MS analysis because of
their aberrant retention time or when analysed by MS/MS,
their sequence(s) will not be retrieved in databases since
their parent mass reflects the combined masses of the pep-
tides and as such is too high.
Sorted amino terminal peptides are not archetypal tryptic
peptides: they all end on an arginine residue, their amines
are acetylated and free thiol groups are alkylated [13]. We
performed a statistical study on the fragmentation behaviour
of these peptides compared to ‘normal’ tryptic peptides and
could not really find a dissimilarity indicating that the
chemical nature of these peptides does not modify CID
fragmentation such that peptide identification is hampered
(data not shown). A more likely cause for the reduced iden-
tification efficiency is due to the fact that the mass spec-
trometer encounters too much ‘dead time’ when analysing
amino terminal peptides. During COFRADIC, methionyl
and cysteinyl peptides are induced to shift out of their origi-
nal collection interval by making them more hydrophilic. An
interesting, secondary effect evoked here is the fact that sort-
Table 1. Comparison of the identification efficiencies and the number of identified platelet proteins using the three types of COFRADIC
sorting strategies
% of identified
spectra
Number of identified
proteins(2isoforms)
Number of identified
proteins(1isoforms)
Average number
of spectra/protein
Average number of
peptides/protein
Methionyl peptides 35.9 375 768 3.41 1.88
Cysteinyl peptides 20.3 157 349 3.45 1.99
N-terminal peptides 15.9 345 592 5.68 1.54
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ed peptides elute over a significantly larger interval than
during the primary run (typically about five times larger). In
order to reduce the number of LC-MS/MS runs, the second-
ary fractions containing sorted methionyl and cysteinyl pep-
tides are combined prior to the final LC-MS/MS analysis.
This has the additional effect of spreading the peptides in the
LC separation, effectively ‘filling’ the gradient such that pep-
tides are presented to the mass spectrometer during the
entire separation interval. Amino terminal COFRADIC can
be regarded as the reverse of the two other procedures; here
the peptides of interest remain stationary while the internal
ones are induced to shift out of the primary collection inter-
val. The secondary fractions are thus collected in exactly the
same time interval as the primary ones. When these frac-
tions are analysed by LC-MS/MS they elute in a significantly
smaller time window than the sorted methionyl and cystei-
nyl peptides. These almost discrete elution windows will be
surrounded by periods of dead time during which no pep-
tides elute, prompting the mass spectrometer to analyse
contaminating ions instead. Evidence for this comes from
the fact that the average TIC of MS/MS spectra from identi-
fied peptides is about three times higher than that of spectra
that were not linked to a peptide sequence. Although this
could indicate that the unidentified spectra are derived from
peptides with very low fragmentation efficiencies, most
probably these spectra are from contaminating ions (e.g., for
methioninyl peptides this difference in average TIC is only
about 1.5). Additionally, the higher sorting efficiency of
amino terminal COFRADIC results in a less diverse peptide
mixture in each elution window, which causes the mass
spectrometer to reanalyse the same peptide ions many times.
These effects lead to a larger fraction of unidentifiable spec-
tra, reducing the perceived identification efficiency, and
more redundant peptide identifications. Supporting evi-
dence for the latter comes from the fact that although the
smallest set of proteins identified by the methionine and the
amino terminal COFRADIC approach is highly similar (376
vs. 345, Table 1), the average number of spectra identified per
protein almost doubles in amino terminal COFRADIC
whereas the number of identified peptides is lower.
3.2 Different proteins are identified by different
COFRADIC sorting procedures
We used MASCOT to identify the peptides and set the iden-
tity threshold at the 95% significance level. We verified
MASCOT’s results and whenever a small number of frag-
ment ions or many rare fragments were identified (typically
a, c, x and z ions, nomenclature according to [19]) the identi-
fications were discarded. We finally combined the peptide
identifications obtained by following the three different
COFRADIC routes and linked them to 673 different protein
entries stored in the IPI database; however, inmany cases the
identified peptides could not be distinguished between dif-
ferent protein entries (mainly isoforms or splice variants).
About two-thirds of all proteins are identified in distinct
COFRADIC experiments and the overlap between the differ-
ent sets of identified proteins is small; for instance less than
6% of all proteins are identified in all three experiments (Fig.
1). We think that this is due to undersampling of ions bymass
spectrometers. In a typical COFRADIC experiment the flux of
peptides to the mass spectrometer is very high; on average
every second a few peptides elute from the RP column and
are ionised. In our instrumental setup a peptide typically
elutes in a time frame of 30 s and the duty cycle of the mass
spectrometer (MS scan followed by MS/MS analysis) is 8 s.
This indicates that of the high number of peptides eluting in
a 30 s window, only three to four will be fragmented and may
lead to peptide identification. Clearly a lot of information is
lost this way and one way to overcome this is to reanalyse the
sample using m/z exclusion lists or to separate the analytes to
a higher degree using multidimensional chromatographic
steps [20] either before or after the COFRADIC sorting step.
This should eventually lead to a higher number of peptides
(and proteins) identified and thus to a bigger overlap between
the results of the separate COFRADIC approaches.
Figure 1. Scheme showing the overlap between the proteins
identified by the three different COFRADIC approaches (the
number of proteins is indicated).
3.3 Meta-analysis of 641 platelet proteins identified
by COFRADIC
Peptides were identified in the IPI database, which is a non-
redundant amalgam of databases on the protein level and is
expected to become the most resourceful database for pro-
teome studies in the near future [15]. Most non-gel prote-
omics approaches are peptide-centric; i.e., only small pieces
of proteins (typically between 10 and 20 amino acids long)
are analysed and linked to the parent protein sequence.
Especially when analysing proteomes of higher eukaryotes,
such identified peptides can reside in multiple database
entries and it becomes very difficult to pick the protein form
that was actually present in the original sample. In some
cases meta-information can be used (e.g., the cell type or tis-
sue analysed) to narrow down the possibilities but it gen-
erally remains difficult to exactly identify a particular data-
base entry using only one or a few peptide sequences. Next to
this peptide redundancy issue we found that many proteins
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which were termed ‘hypothetical’ or ‘similar to’ in their
descriptions perfectly matched to well-characterised proteins
following homology searches (http://www.ebi.ac.uk/blast2/).
Most of these protein entries appeared to be shortened ver-
sions (more than 5% in total length) of other, well-char-
acterised proteins.
After cleaning up the original list of 673 protein entries,
we end up with a set of 641 different protein entries (Sup-
plementary Table 1). We call this set the core platelet pro-
teome as it might contain many more proteins. Indeed, only
in a minor number of cases can we use the identified pep-
tides to distinguish between different isoforms or splice var-
iants (mainly nonhighlighted entries in Supplementary
Table 1). Since protein isoforms tend to differ mainly at their
extremities we found that N-terminal peptides are more effi-
cient at distinguishing between isoforms than methionyl or
cysteinyl peptides.
A total of 3771 MS/MS spectra corresponding to 1625
different peptides identified the 641 proteins (Supplemen-
tary Table 1). In this study, 401 proteins (62.55%) were iden-
tified by a single peptide and of these 307 (47.89% of all pro-
teins) were identified by a single MS/MS spectrum. Recently,
there has been some debate in the literature concerning the
soundness of such ‘one-hit wonders’ [21] and in a recent
study, Western blots validated the peptide ratios originally
predicted by such unique peptides observed in the original
non-gel proteomics study [22]. This suggests that platelet
proteins that are here identified by a single spectrum or a
single peptide cannot simply be discarded and therefore
must be seen as part of the proteome. Certainly, if ‘interest-
ing proteins’ (e.g., potential drug targets or biomarkers) are
present as one-hit wonders, the protein’s identity can be fur-
ther verified by ‘reverse proteomics’. For instance, one or
more methionine-containing tryptic peptides predicted from
the protein sequence could be synthesised in their heavy (D,
13C, 15N, 18O) form and spiked in the peptide mixture (e.g.,
[23]). Since their chromatographic behaviour in the COFRA-
DIC sorting steps can be perfectly predicted, one can target
from the synthetic peptides the corresponding light peptides
in the complex mixture.
We have compared our non-gel platelet proteome with
five lists of platelet proteomes that have been published
before [3–6, 24] and together comprise the largest data set
obtained on the human platelet proteome thus far. About
62.5% (401 proteins) of the non-gel proteome has not yet
been identified in platelets before, which clearly illustrates
the discovery power of our non-gel technologies. Interest-
ingly, following comparison of the largest 2-D gel based pla-
telet proteome data set obtained thus far with our non-gel
proteome we noticed that only 164 of the proteins identified
on gel (out of a total of 411 [4, 6]) were identified in our study.
This apparent low overlap is probably due to the aforemen-
tioned undersampling of peptide ions by mass spectro-
meters; peptide ions of the missing proteins were probably
present in the analyte mixtures but were missed by the mass
spectrometer because of its rather long duty cycle.
One way of characterising a large set of proteins is to
classify it according to cellular location and molecular func-
tion using the data deposited in the Gene Ontology database
(http://www.geneontology.org) [25]. When classified by cel-
lular location, about 64% of the proteins are present in the
cytoskeleton, ER, mitochondrion, cytosol and Golgi appara-
tus while 16% are located in or at the plasma membrane (see
below) and 20% in the nucleus (Fig. 2A). The latter figure is
intriguing since platelets are devoid of nuclei while in our
analysis nuclear proteins appear to form the largest portion
of the platelet proteome (Fig. 2A). However, as they are frag-
ments of large progenitor cells (megakaryocytes), it could be
that platelets or a fraction of them still hold putative nuclear
proteins, particularly those that can shuttle between the
nucleus and the cytoplasm. Nevertheless, such nuclear pro-
teins might be the basis for future studies to find out their
role in anucleated platelets. Contamination of our platelet
preparation by nucleated blood cells is unlikely, as we have
not detected histones or histone fragments, known as ubi-
quitous major nuclear components. On the other hand, the
identification of a and b globin (11 and 3 spectra respectively)
and b-spectrin (1 spectrum) could point to contamination of
our platelet sample by red blood cells. However, the fact that
these abundant red blood cell proteins were identified using
a very small number of all obtained MS/MS spectra (0.4%)
indicates that these proteins were only very lowly abundant
in the analysed proteome [26, 27]. Furthermore, the clear
absence of other abundant erythrocyte proteins such as
alpha-spectrin, ankyrin, proteins bands 3, 4.1 and 4.2 [28]
suggests that this contamination is very limited; which
means that the very large majority of the proteins mentioned
in the core proteome are true platelet components.
After classifying the proteome according to the molecu-
lar function of its protein components, enzymes, enzyme
regulators, proteins involved in transport, cytoskeletal and
structural proteins, signal transducers and chaperones make
up the largest part of the proteome (see Fig. 2B). As expected,
regulation of gene expression such as transcription and
translation appears to be performed by a smaller set of pro-
teins.
3.4 Compositional comparison of the platelet
proteome to two proteomes of nucleated cells
analysed by COFRADIC
When the platelet proteome is compared to proteomes of
actively proliferating cells such as human Jurkat cells (829
proteins identified following COFRADIC analysis, unpub-
lished data) and human neuroblastoma SH-SY5Y cells (656
proteins identified following COFRADIC analysis, unpub-
lished data), we notice a significant difference in the pro-
tein localisation and protein function profiles for these
human cell types (Fig. 3). While the relative number of
proteins present in most subcellular structures (ER, mito-
chondria, cytosol, Golgi and plasma membrane) is highly
similar among the three proteomes, nuclear proteins
© 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de
Proteomics 2005, 5, 3193–3204 Clinical Proteomics 3199
Figure 2. Meta-analysis of the
identified platelet proteins.
Identified platelet proteins were
classified according to their cel-
lular location (pie chart A) and
according to their molecular
function (pie chart B) using the
data stored in the Gene Ontol-
ogy database (see text). Relative
quantity of proteins present in a
certain class is indicated.
Clearly, cytoplasmic proteins
make up the largest part of
identified proteins, although
20% of all proteins identified are
nuclear (A) while the major part
of the identified proteins are
enzymes and their regulators
(B).
in particular make up a bigger part of the proteomes of
nucleated cells compared to that of platelets (Fig. 3A). On
the other hand, the number of proteins involved in orga-
nising and modulating the cytoskeleton is almost doubled
in the proteome of human platelets compared to the two
other proteomes (Fig. 3A). This demonstrates an important
physiological role of platelets in thrombus formation and
consecutive contraction. Activated platelets change their
morphology promptly; a process evoked by signalling cas-
cades that eventually leads to a redistribution of cytoskele-
tal and cytoskeletal-associated proteins and a reconstruc-
tion of the actin cytoskeleton. Clearly, a high number of
structural and cytoskeletal proteins must be required for
this process.
Following a classification of the proteome building
blocks according to their known or predicted molecular
function it is clear that, as expected, apart from proteins
involved in regulating gene transcription, all functional clas-
ses are present in highly equivalent numbers in the three
proteomes (Fig. 3B).
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Figure 3. Radar plots comparing
the composition of the human
platelet proteome to proteomes
of nucleated human cells. In
both radar plots, the human
platelet proteome is indicated
by a blue line, whereas the pro-
teomes obtained following gel-
free analysis of human Jurkat T-
lymphocytes and human neuro-
blastoma SH-SY5Y cells are
indicated by green and red line
respectively (unpublished data).
Radar plot A shows the relative
distribution of the three different
proteomes according to the cel-
lular location of their compo-
nents as indicated in the Gene
Ontology database. Relative
distribution of the different mo-
lecular functions of the identi-
fied proteins is indicated in
radar plot B (for clarity reasons
enzymes (see Fig. 2B) are not
considered for this analysis).
Axis of both radar plots is nor-
malised to 1.
One of the weaker points of classical 2-D gel-based pro-
teome analysis is the fact that hydrophobic proteins tend to
be underrepresented in 2-D gels. This is because such pro-
teins are very hard to extract out of cellular membranes and
tend to precipitate near their pI during IEF. Suggested
remedies for this shortcoming include the use of chaotropic
agents such as thiourea [29] and/or nondetergents such as
sulphobetaines [30]. Non-gel proteome analytical techniques
tend to be not biased towards the identification of soluble
proteins as they first chop them up into peptides which are
generally more soluble and readily analysable by mass spec-
trometers. In this proteome study we identified 87 proteins
that contain at least one predicted transmembrane helix
(predictions were done with TMHMM Server v. 2.0 at http://
www.cbs.dtu.dk/services/TMHMM-2.0 [31]). Following
database searching, 69 of these were classified as trans-
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membrane proteins while only 12 of them have been char-
acterised before in platelet proteomes [3, 4, 6, 24] (Table 2).
After calculating the grand average of hydropathicity
(GRAVY) values of these membrane proteins, 24 are classi-
fied as hydrophobic proteins (positive GRAVY value [32]).
These results support the idea that the COFRADIC technol-
ogies are less biased towards hydrophobic membrane pro-
teins compared to gel-based technologies. Clearly this opens
up the possibility for discovering novel proteins at the sur-
face of platelets which may eventually be considered as novel
drug targets for treating or preventing cardiovascular dis-
eases [33].
Upon stimulation with various agents platelets alter their
shape, aggregate and release the content of their granules.
These processes are governed by signalling pathways that are
controlled by the action of kinases and phosphatases. A
thorough investigation of the phosphorylation flux in plate-
lets (e.g. [34]) characterises the affected proteins but one can
typically only ‘guess’ at the identity of the enzymes that are
responsible (e.g., by studying the motif surrounding the
phosphorylated amino acid). Knowing which kinases and
phosphatases are expressed in platelets may be of larger
interest since inhibitory drugs are currently being developed.
Our gel-free proteome contains 19 protein kinases and five
protein phosphatases (Table 3). Some of these kinases have
never been identified in a large-scale proteomics study in
platelets and when added to the repertoire of already known
platelet kinases [3–6], they may give deeper insight into the
kinome of platelets. Interestingly, other large-scale platelet
proteome studies identified a relatively higher number of
proteins involved in signalling (e.g., several adapter proteins,
small G proteins and their regulators) (e.g., [3, 4, 6]) and our
non-gel proteome analysis has clearly missed some of them.
A possible reasonmight be the fact that these proteins do not
provide methionyl, cysteinyl or amino terminal peptides that
fall into the analysis range of our COFRADIC technique (e.g.,
too hydrophobic or not easy to ionise or fragment). In this
view, combining gel-based and non-gel proteome analyses
might be valuable for augmenting the coverage of a given
proteome.
Finally, this core platelet proteome contains 51 hypothet-
ical proteins and for some of them minor homology to char-
acterised proteins was observed following BLAST analysis
(Supplementary Table 1). Such hypothetical proteins may
form the basis for future studies since no function (in plate-
lets) could be assigned to them as yet.
4 Concluding remarks
In this study, we have used three versions of the COFRADIC
technology to enrich three types of peptides during peptide-
centric proteome analysis. By doing this, we first illustrate
the versatility of COFRADIC, selecting à la carte, for either
methionyl, cysteinyl or amino terminal peptides, while sec-
ondly, by combining the data generated by these approaches,
we create the so far largest platelet proteome. It is interesting
to notice that the set of proteins identified by each selective
method is quite different with poor overlaps. As already
mentioned before, this is most likely due to an under-
sampling phenomenon. Indeed, peptide-centric approaches
are probably able to pick up most (even the minor) compo-
nents of a mixture. However, because of the high flux of
peptides on the one hand, and the large duty cycles of the
mass spectrometer on the other hand, the latter only picks up
a fraction of the passing peptide ions in a random manner
with some preference for the most abundant peptides (pro-
teins). Due to this random sampling process, it is necessary
to carry out repetitive analyses in order to obtain a satisfac-
tory level of protein coverage [26].
Comparison with the list of platelet proteins identified
from previous 2-D gel studies [3, 4, 6, 24] reveals about 40%
overlap with the proteins from our core list. Although this is
without doubt much better than the low levels of overlap
reported by similar comparative studies, it still reflects the
undersampling effect mentioned above, creating a false
image of complementarity between non-gel and 2-D gel
approaches. Combining the information content of pre-
viously reported proteomes with those of the platelet core
proteome generates a catalogue of over 1000 proteins which
may form the basis from which different types of platelet re-
search can initiate.
So far our core proteome contains 641 proteins. This is a
high number, but clearly does not represent the full pro-
teome of platelets. However, we have reasons to believe that a
great part of the major platelet proteins has been covered.
This is illustrated by the identification of all enzymes of the
glycolytic and pentose phosphate pathways, and by allocating
all eight subunits of the CCTchaperonin complex [35] and all
seven components of the Arp2/3 complex [36].
Eighty-seven proteins in the core list contain at least one
predicted transmembrane helix, 69 of these were previously
characterised as membrane proteins. Only 12 of them were
identified before in platelet proteomes. This illustrates the
superiority of peptide-centric over protein-centric proteome
approaches when it comes to identifying membrane pro-
teins. This can be explained by the fact that hydrophobic
proteins, which as a whole are hardly soluble, still may gen-
erate hydrophilic peptides which can be detected and serve as
signatures for their parent proteins [37]. Even proteins with
up to 7 and 12 predicted membrane-spanning helices and
high GRAVY values were identified based upon a combina-
tion of different peptides.
High-throughput gel-free proteome analyses provide
large sets of proteome data from different cell types. Al-
though containing a wealth of information, these rather long
lists of proteins at first appear to be but descriptive. However,
comparing different proteomes using meta-data stored in for
instance the Gene Ontology database indicates that COFRA-
DIC identifies a core set of protein functions expressed by
different human cell types (Fig. 3B). One may therefore
expect that this core set will pop up in each proteome of cul-
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Table 2. Identified platelet proteins that contain at least one helix spanning a biological membrane. Proteins are sorted according to the
number of their known transmembrane helices (column ‘KnownHel’) (N.K. indicates that this number is not known). Such helices
were predicted with the TMHMM Server v. 2.0 and these results are given in the column ‘PredHel’. GRAVY values of the proteins
were determined with the ProtParam tool at http://www.expasy.org/tools/protparam.html; positive GRAVYvalues indicate that the
identified proteins are hydrophobic, negative values indicate hydrophilic proteins. Entries highlighted in a greyish background
correspond to proteins that have previously been characterised in previous platelet proteome studies (see text)
IPI ID Description KnownHel PredHel GRAVY
value
1 IPI00337541.2 NAD(P) transhydrogenase, mitochondrial precursor 14 12 0.297
2 IPI00003909.1 Solute carrier family 2, facilitated glucose transporter, member 3 12 10 0.536
3 IPI00177817.4 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (splice isoform SERCA2A) 10 7 0.087
4 IPI00004092.2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (splice isoform SERCA3B) 10 7 0.077
5 IPI00302840.1 Sodium/potassium-transporting ATPase alpha-3 chain 10 10 20.016
6 IPI00151710.6 Similar to RIKEN cDNA F730003B03 8 8 20.147
7 IPI00027180.1 CAAX prenyl protease 1 homolog 7 7 0.119
8 IPI00028332.1 Taste receptor type 2 member 13 7 7 0.819
9 IPI00032150.1 Phosphatidate cytidylyltransferase 2 6 8 0.275
10 IPI00152536.2 Transmembrane cochlear-expressed protein 2 6 9 20.356
11 IPI00023639.1 CDP-diacylglycerol – inositol 3-phosphatidyltransferase 5 4 0.613
12 IPI00025292.1 Mannose-P-dolichol utilization defect 1 protein 5 5 0.679
13 IPI00215998.1 CD63 antigen 4 4 0.767
14 IPI00020446.1 CD82 antigen 4 4 0.378
15 IPI00375373.1 Chemokine-like factor super family member 5 (splice isoform 1) 4 4 0.448
16 IPI00218850.4 Secretory carrier-associated membrane protein 2 4 4 0.135
17 IPI00000612.1 Small membrane protein 1 4 4 0.580
18 IPI00218200.3 B-cell receptor-associated protein 31 3 3 20.157
19 IPI00032038.3 Carnitine O-palmitoyltransferase I, mitochondrial liver isoform 2 2 20.267
20 IPI00418495.1 CD36 antigen 2 2 0.015
21 IPI00017510.1 Cytochrome c oxidase polypeptide II 2 2 0.460
22 IPI00033075.1 Protein BAT5 2 2 20.243
23 IPI00021766.3 Reticulon 4 (splice isoform 1) 2 2 20.414
24 IPI00013897.1 ADAM 10 precursor 1 1 20.599
25 IPI00006608.1 Amyloid beta A4 protein precursor (splice isoform APP770) 1 1 20.584
26 IPI00019967.1 Apoptosis regulator BAX, membrane isoform alpha 1 1 20.055
27 IPI00020984.1 Calnexin precursor 1 1 20.874
28 IPI00008578.1 CD226 antigen precursor 1 1 20.225
29 IPI00301271.3 Dolichyl-diphosphooligosaccharide – protein glycosyltransferase 63 kDa subunit precursor 1 4 0.081
30 IPI00025874.1 Dolichyl-diphosphooligosaccharide – protein glycosyltransferase 67 kDa subunit precursor 1 1 20.208
31 IPI00032003.1 Emerin 1 1 20.716
32 IPI00216758.1 Endothelin-converting enzyme 1 (splice isoform A) 1 1 20.385
33 IPI00026530.2 ERGIC-53 protein precursor 1 1 20.542
34 IPI00144014.1 HLA class I histocompatibility antigen, Cw-7 alpha chain precursor 1 1 20.536
35 IPI00029046.1 Hypothetical protein KIAA0152 1 1 20.156
36 IPI00216221.1 Integrin alpha-6 precursor (splice isoform Alpha-6X1A) 1 1 20.381
37 IPI00295976.3 Integrin alpha-IIb precursor (splice isoform 1) 1 1 20.106
38 IPI00218629.1 Integrin alpha-IIb precursor (splice isoform 3) 1 1 20.150
39 IPI00009465.1 Integrin beta-1 precursor (splice isoform beta-1A) 1 1 20.407
40 IPI00303283.1 Integrin beta-3 precursor (splice isoform beta-3A) 1 1 20.334
41 IPI00001754.1 Junctional adhesion molecule 1 precursor 1 2 20.092
42 IPI00002334.1 Neuron specific protein family member 1 1 1 20.295
43 IPI00011255.1 Platelet glycoprotein Ib alpha chain precursor 1 1 20.152
44 IPI00007723.1 Platelet glycoprotein Ib beta chain precursor 1 1 0.311
45 IPI00027502.1 Platelet glycoprotein IX precursor 1 1 0.284
46 IPI00027410.1 Platelet glycoprotein V precursor 1 1 0.131
47 IPI00157687.1 Platelet/endothelial cell adhesion molecule 1 1 20.325
48 IPI00294472.3 Protein CGI-100 precursor 1 2 20.066
49 IPI00006072.1 Protein transport protein SEC61 gamma subunit 1 1 0.321
50 IPI00031421.3 Protein-tyrosine sulfotransferase 2 1 1 20.094
51 IPI00295339.2 P-selectin precursor 1 1 20.291
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Table 2. Continued
IPI ID Description KnownHel PredHel GRAVY
value
52 IPI00023807.1 Semaphorin 4D precursor 1 2 20.274
53 IPI00219682.2 Stomatin isoform a 1 1 0.043
54 IPI00329332.1 Syntaxin 12 1 1 20.580
55 IPI00289876.1 Syntaxin 7 1 1 20.631
56 IPI00028055.1 Transmembrane protein Tmp21 precursor 1 2 20.171
57 IPI00006865.1 Vesicle trafficking protein SEC22b 1 1 20.182
58 IPI00019982.5 Vesicle-associated membrane protein 3 1 1 20.079
59 IPI00006211.1 Vesicle-associated membrane protein-associated protein B/C (splice isoform 1) 1 1 20.380
60 IPI00009950.1 Vesicular integral-membrane protein VIP36 precursor 1 1 20.364
61 IPI00152377.1 Source of immunodominant MHC-associated peptides N.K. 10 0.038
62 IPI00220300.1 ATP synthase H1 transporting mitochondrial F0 complex, sununit F, isoform 2 N.K. 1 20.169
63 IPI00216583.1 G6B-A protein precursor N.K. 1 20.187
64 IPI00107540.1 Hypothetical protein (BLAST: similar to Integrin beta-1 precursor) N.K. 1 20.404
65 IPI00295313.1 JAW1-related protein MRVI1A long isoform N.K. 1 20.697
66 IPI00005202.1 Membrane associated progesterone receptor component 2 N.K. 1 20.493
67 IPI00009976.1 Putative T1/ST2 receptor binding protein precursor N.K. 1 20.005
68 IPI00060144.1 Similar to RIKEN cDNA 9430029K10 gene N.K. 4 0.282
69 IPI00386818.1 Vesicle-associated soluble NSF attachment protein receptor N.K. 1 20.678
Table 3. List of protein kinases and protein phosphatases identified in our non-gel human platelet proteome. IPI ID numbers of the proteins
are indicated in the second column and a brief protein description is given in the last column. Proteins that have already been
identified following large-scale platelet proteome studies are given in a grey background
Protein kinases
1 IPI00011891.2 5’-AMP-activated protein kinase, catalytic alpha-1 chain
2 IPI00016791.1 cGMP-dependent protein kinase 1, alpha isozyme
3 IPI00024403.1 Copine III
4 IPI00005689.2 Hypothetical protein KIAA1124 (BLAST: weakly similar to Rho-associated protein kinase 1)
5 IPI00002232.1 Hypothetical protein KIAA1361 (BLAST: protein is weakly similar to TRAF2 and NCK interacting kinase )
6 IPI00013219.1 Integrin-linked protein kinase 1
7 IPI00003479.1 Mitogen-activated protein kinase 1
8 IPI00010466.2 Protein kinase C, beta type (splice isoform beta-I)
9 IPI00329236.2 Protein kinase C, delta type
10 IPI00307155.4 Rho-associated protein kinase 2
11 IPI00099756.1 Serine/threonine protein kinase 13 (splice isoform 1)
12 IPI00329211.2 Serine/threonine protein kinase 3
13 IPI00021156.4 Serine/threonine-protein kinase Duet
14 IPI00219447.6 Serine/threonine-protein kinase PAK 2
15 IPI00328867.1 SRC protein
16 IPI00179357.1 Titin
17 IPI00145805.1 TRAF2 and NCK interacting kinase (splice isoform 1)
18 IPI00215778.1 Tyrosine-protein kinase LYN (splice isoform LYN B)
19 IPI00218278.1 Tyrosine-protein kinase SYK (splice isoform short)
Protein phosphatases
1 IPI00233255.3 Protein-tyrosine phosphatase, non-receptor type 11
2 IPI00289082.1 Protein-tyrosine phosphatase, non-receptor type 12
3 IPI00395552.1 Protein-tyrosine phosphatase, non-receptor type 6 (splice isoform 1)
4 IPI00179415.3 Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform
5 IPI00218236.3 Serine/threonine protein phosphatase PP1-beta catalytic subunit
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tivated human/mammalian cell lines and that the under-
lying proteins may differ between different cell types or tis-
sues and may thus be considered as future biomarkers.
Again, this highlights the value of peptide-centric proteom-
ics in unravelling systems biology.
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3. Conclusions 
3.1. Three goals for high-throughput proteomics 
The development of dramatically improved instrumentation and novel techniques that 
maximize the capabilities of these instruments has delivered the promise of high-
throughput proteomics in only a few years. The amounts of data produced rose in 
lockstep, with data yields rising several orders of magnitude over the same period. 
Interestingly, the most powerful new proteomics techniques are aimed primarily at 
maximizing the information content of the recorded data. This has the paradoxical effect 
of reducing the amount of redundancy in the generated data, thus prompting the need to 
make efficient use of the source information obtained. As the data finally obtained is 
often of high value to the scientific community it is often published as supplementary 
information but is renderred almost completely inaccessible through the use of PDF 
tables. 
There are therefore three goals to be defined for any such high-throughput proteomics 
laboratory: managing the information flood, maximizing the value of the generated 
information and allowing researchers to share their information with the community at 
large. Finally, it is important to note these three goals are interdependent as each builds 
upon the achievement of the previous one.  
There are also some issues to resolve for the field of proteomics as a whole. The first of 
these centers around its reluctance to take up an active role as a data producer with 
regards to sequence database providers. The second has to do with the software that is 
written for application in proteomics research laboratories and how it is made open 
source.  
 
3.2. Managing information 
In order to manage the thousands of fragmentation spectra produced daily by the different 
mass spectrometers in the proteomics laboratory at Ghent University, the ms_lims system 
was built. This system was designed to present a flexible, stable and user-friendly 
environment for the experimentalists and data analysts alike while building on low-cost, 
of-the-shelf components running open, freely available software components. The 
software has already gone through more than eighty released versions and continues to be 
updated today. The result is a highly mature, maintained software suite with a robust set 
of tools that support easy upgrading of both data stores and code base. Much of the code 
also operates in a frameworked design that allows third-party developers to add their own 
functionalities as required without having to rebuild the underlying software 
infrastructure from scratch. ms_lims has been freely available under the GNU GPL 
license since its inception and has been installed and tested in several locations. It has 
automated the complete identification pipeline, reducing processing time for a single 
proteome from weeks to one or two days. The time gained through the use of ms_lims 
can then be used to further analyse the final results, producing additional value from the 
data. As the stored data is maintained effortlessly over time, reanalysis of a given dataset 
is immediately possible at any point and cross-comparisons among disparate datasets are 
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suddenly possible. The ms_lims suite can thus be safely called the information backbone 
of the proteomics laboratory, with an analytical nervous system attached. 
In summary, the goal of the ms_lims system was to automate routine tasks in order to 
speed up data processing time and reduce the possibility of human error while aiding the 
experimentalists or biologists in obtaining structured overviews of the relevant data for 
their research, thus maximizing their analytic capabilities. 
 
3.3. Maximizing information 
The COFRADIC peptide-centric proteomics approach allows researchers to maximize 
the analytical capabilities of modern mass spectrometers by greatly limiting redundancy 
in the generated information. This enables the instruments to look deeper into the 
proteome while simultaneously broadening the analysed fraction of the proteome. 
In order to extract the most value from the recorded fragmentation spectra, it is necessary 
to distinguish between those spectra that are of high quality and those that are not. High 
quality spectra can then be subjected to exhaustive analysis in order to maximize the 
amount of identifications, while low quality spectra can be discarded. The spectrum 
quality assignment can also aid in identifying suspect identifications, thus increasing the 
reliability of the remaining identifications. In order to perform this task, a spectrum 
classification algorithm was developed through collaboration between the Proteomics 
Unit of the University of Bergen (PROBE) in Norway and the proteomics laboratory in 
Ghent. This software allows the separation of spectra to high quality and low quality bins 
according to a preset level of stringency. It is therefore possible to use it as a pre-filtering 
algorithm at low stringency (allowing some low quality spectra to pass through the filter 
in order to maximize the correct classification of high quality spectra) and as an 
erroneous identification detection tool at high stringency after the identification step. The 
algorithm builds on a learning algorithm called a Bayesian classifier that can be trained to 
respond correctly to different types of instruments and different types of analyzed 
spectra. The classifier software and code have been made publicly available under the 
GNU GPL license and have also been published. 
For exhaustive identification of good quality spectra, it is important to adapt existing 
identification software with proven reliability to peptide-centric principles. Additionally, 
popular protein sequence databases must simultaneously be transformed to a far richer 
and more efficient source of peptide information. Both effects are achieved by the 
processing of protein centric sequence databases into peptide sequence databases. The 
DBToolkit software was developed to fulfill this task in a user-friendly yet highly 
automatable way. DBToolkit was also built around several interconnected core 
frameworks to allow third-party developers to quickly expand the existing functionality. 
The application is open source under the GNU GPL license and has been published. 
 
3.4. Sharing information with the community 
Scientific research is never a solitary task. Although the path from the initial sample to a 
final list of annotated protein identifications may be a long and lonely one, all this hard 
work will typically culminate in a publication in a peer-reviewed journal. Since science is 
essentially a collaborative effort, most journals demand publication of the presented 
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results. In order to allow all interested parties to maximize the value of these datasets, the 
PRIDE system was developed in collaboration with the European Bioinformatics Institute 
in Hinxton, UK. PRIDE started out as a one-man project during a stay as a Marie-Curie 
fellow at the EBI and has grown in two years to a mature and stable project supported by 
many local installations and containing almost 200.000 protein identifications, supported 
by well over half a million identified peptides. PRIDE continues to grow every day and 
has attracted the interest of journals and funding agencies. Two full-time equivalents 
constitute the core of the PRIDE development team, with collaborators across the globe 
contributing internationalization, data submission pipelines and code fragments. PRIDE 
is a HUPO PSI standards compliant repository and has always been at the forefront to 
implement and support these standards as they emerge. Consisting of both structured and 
semi-structured data elements using ontologies, PRIDE presents a common core of 
required data while allowing virtually limitless annotation of a specific dataset. 
Being completely built out of open source components and in-house developed code 
released under the Apache license, there is no limitation to the use and incorporation of 
PRIDE components in new or existing software, regardless of any commercial interests. 
Preconfigured to work with both high-end professional database software as well as 
publicly available solutions, PRIDE can be downloaded and locally configured as an in-
house or institutional data repository. It can also be used on a larger scale for 
international collaborations, obviating the need for them to develop their own proprietary 
infrastructure. 
PRIDE has received attention from editorials in journals such as Nature and Expert 
Reviews in Proteomics and promises to grow as more and more authors and journals 
adopt the basic premise of scientific research: to share achievements with the scientific 
community at large. 
 
3.5. The need for expanding the unidirectional relation between 
proteomics labs and sequence database providers 
The relation between proteomics labs and database providers has so far been 
unidirectional in its strictest sense. The database providers make the fruits of their labour 
available over the internet, the proteomics lab downloads these databases and performs 
identifications. In the best case, the database provider is ultimately credited with a URL 
and/or reference in any publications resulting from the proteomics work.  
Of course, being primarily a sequence database consumer is not a crime. It is interesting 
however, that the proteomics community to date has not grasped the fact that they have 
become an important group of data producers. The community has also failed to 
appreciate that the data produced is not only useful from a biological point of view but 
also from the perspective of sequence database providers. 
It has been discussed in this dissertation that scientists working in proteomics have often 
commented on the disappearance of identifications when reconsidering certain 
identifications after sufficient time has passed (see section 1.2.2.4). Interestingly, these 
lamentations are only partially justified. Sequence database providers typically try to 
achieve two goals: provide sequence information (optionally adorned with additional 
annotations) of high quality and provide as much sequence information as possible. 
These goals are obviously somewhat incompatible. UniProt actually expressly hints at the 
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inherent conceptual differences by providing two subsets: UniProt/SWISS-PROT (biased 
towards quality of data) and UniProt/TrEMBL (biased towards quantity of data). It has 
been explained in section 1.2.2.2 that, in order to make the distinction between pure 
predictions and those that carry some experimental evidence, the NCBI - on a different 
level - similarly splits RefSeq into NP and XP entries. It should be noted that the 
evidence to move an entry from an XP accession to an NP accession is currently 
overwhelmingly derived from transcriptional studies. There are clear downsides to this 
approach in the generation of protein sequence entries, however (see [Claverie 2005] for 
an interesting discussion). Based on its prominent position as a data producer60, 
proteomics should by now have become an important source of evidence for the 
validation of protein sequence predictions, replacing the apparently inferior evidence line 
of transcriptional data61. The question then is why proteomics has not taken its rightful 
position as an important evidence provider. The answer is deceivingly simply: because 
the proteomics community today is overwhelmingly confined to being a data consumer. 
Since little or no data at all flows back to the sequence database providers, the 
information obtained by proteomics techniques can not be used as evidence here. 
The follow-up question then becomes: why is it that proteomics data does not flow back 
to the database providers? Most of the answers have been outlined in section 3.4, but 
apart from the practical considerations outlined there, a more subjective and controversial 
statement will be added here. This statement can be summarized by stating that the field 
of proteomics needs to mature. Achieving maturity as a scientific field requires more than 
good techniques, the acquisition of expensive instruments and long lists of protein 
identifications; it requires the practitioners to take responsibility for their produced data 
by expending the extra effort after the completion of a project to close the information 
sharing cycle all the way back to the initial database provider. 
 
3.6. The case for open source software in the life sciences 
All the software discussed in this dissertation has been made freely available as open 
source software. Licenses are either the non-restrictive Apache license or the ‘infective’ 
GNU GPL license. The software discussed has also been developed to be readily 
extensible and contains ample documentation for the aspiring contributor. 
These commitments to provide the source code are not without their price. Code opened 
to the community should be well documented, which is a common flaw of computer 
programmers. It should also be made available through an anonymous, open 
infrastructure such as the Concurrent Versioning System (CVS) or SubVersion and it 
should be able to accept code input from (trusted) third-party developers. Additionally, it 
should also be possible to use the software as a module in a third-party application, which 
in turn requires a certain amount of stability and a strict and traceable versioning of the 
individual source files and the whole project alike. Careful logging of each modification 
                                                 
60
 Also consider the wealth of additional information available through positional proteomics techniques 
such as N-terminal COFRADIC! 
61
 It should be stressed that the adjective ‘inferior’ is here applied for protein sequence predictions only. 
Transcriptional data is obviously pretty good evidence that certain genomic sequences are converted into 
RNA. 
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– especially where it concerns key algorithmic or API changes – is another major 
requirement for software upon which other people depend. 
All of the above are considered normal and are therefore very much standard practice in 
the software development industry. The lone hacker working in a mid-size proteomics lab 
or the mathematician providing a ready application to test her new algorithm might not 
feel up to the challenges involved in setting up all this infrastructure and code and project 
lifecycle management. However, when one looks at the above checklist from a purely 
objective point of view, it becomes clear that these (ultimately) simple and 
straightforward rules are essential to allowing others to productively benefit from one’s 
own development efforts. Open source requirements in proteomics should therefore be 
more than a request by journals to provide a zip file with some text documents (the code) 
on a website for a few months. Open source should instead become a way of working that 
is steeped in those practices that allow true collaborative efforts to emerge. 
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4. Nederlandstalige samenvatting 
Het veld van de proteoomanalyse is een snel groeiende discipline die toepassingen kent 
in fundamenteel en toegepast wetenschappelijk onderzoek. Voortbouwend op de 
indrukwekkende verwezenlijkingen van de genoomsequeneringsprojecten en een sterke 
technologische vooruitgang van de instrumenten, heeft de proteoomanalyse de laatste 
jaren inderdaad een enorme vooruitgang gekend. De traditionele methode van de twee-
dimensionele poly-acrylamide gelelectroforese voor eiwitscheiding gevolgd door 
eiwitidentificatie door middel van massaspectrometrische data, sequentiedatabanken en 
zoekalgoritmen is dan ook naar een zeer courant gebruikte techniek geëvolueerd. Deze 
techniek, hoewel erg succesvol, is echter onderhevig aan enkele belangrijke limitaties. De 
belangrijkste hiervan betreffen hydrofobe eiwitten en laag abundante eiwitten. De 
hydrofobe eiwitten zijn erg moeilijk in oplossing te houden en ontsnappen dan ook erg 
gemakkelijk aan identificatie omwille van precipitatie. De laag abundante eiwitten 
ontsnappen op hun beurt aan verdere analyse omdat zij niet gevisualiseerd kunnen 
worden na scheiding. 
Deze problemen worden echter aangepakt door verschillende nieuwe methoden voor 
proteoomanalyse. Deze nieuwe technieken onderscheiden zich van de klassieke gel-
gebaseerde methode door een verschuiving in de eenheid van analyse. Deze verschoof 
van het eiwit naar de peptiden die verkregen worden door middel van proteolytische 
digestie. Aangezien de peptiden een veel minder breed bereik van fysico-chemische 
parameters vertonen, zijn ze gemakkelijker te scheiden en in oplossing te houden. 
Bovendien levert een enkel eiwit gemiddeld een dertigtal verschillende peptiden wanneer 
het met het enzyme trypsine wordt behandeld. Deze redundantie zorgt ervoor dat voor 
sommige van deze peptide-gecentreerde technieken het missen van een bepaalde peptide 
gemakkelijk gecompenseerd kan worden door de vele andere peptiden die van hetzelfde 
eiwit afkomstig zijn. 
De toegenomen redundantie brengt echter ook een overeenkomstige toename in 
complexiteit met zich mee. In combinatie met het brede concentratiebereik van eiwitten 
in cellen zorgt deze complexiteit dikwijls voor problemen bij die peptide-centrische 
technieken die het volledige peptidenmengsel over één of meerdere dimensies (bv. 
ionenuitwisselingschromatografie en omgekeerde-fase hogedrukschromatografie) 
scheiden. De scheiding in de tijd van de peptiden is immers nooit perfect, waardoor er 
steeds verschillende peptiden in overlappende tijdsintervallen zullen elueren. Dit stelt een 
probleem voor de massaspectrometer aangezien deze een keuze moet maken in verband 
met het peptide dat geselecteerd zal worden voor gedetailleerde analyse door 
fragmentatie. Gedurende deze fragmentatiestap is de massaspectrometer blind voor 
andere peptiden die elueren. Wanneer nu verschillende peptiden tegelijkertijd 
aangeboden worden aan de massaspectrometer, zal er dus slechts een beperkt aantal in 
detail geanalyseerd kunnen worden. In de praktijk komt het er vaak op neer dat peptiden 
afkomstig van abundante eiwitten meer kans maken om geanalyseerd te worden. 
Om dit probleem te vermijden werden er andere peptide-gecentreerde technieken 
ontwikkeld die eerst de complexiteit van het mengsel na digestie trachten te reduceren. 
Het is belangrijk in te zien dat deze stap tegelijkertijd de representativiteit van het 
mengsel zo goed mogelijk dient te behouden. Een van deze selectiemethoden werd 
ontwikkeld in de proteoomanalytische groep van Prof. Dr. Joël Vandekerckhove en is 
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gebaseerd op de reeds lang gekende techniek van de diagonaalchromatografie. Deze 
techniek kreeg het acronym COFRADIC (voor COmbined FRActional DIagonal 
Chromatography) toebedeeld. Hierbij wordt een mengsel tweemaal onderworpen aan een 
identieke chromatografische stap, maar introduceert men tussen de eerste en de tweede 
stap een specifieke wijziging aan bepaalde peptiden waardoor hun elutietijd wijzigt. In de 
tweede chromatografische stap zullen deze peptiden dan herkenbaar zijn aan hun 
veranderde elutietijd. De wijzing aan de te selecteren peptiden kan bereikt worden door 
eender welke chemische of enzymatische reactie (met het voorbehoud dat deze reactie 
specifiek moet zijn), hetgeen een zeer brede waaier aan mogelijke selectiecriteria toelaat. 
Zo kan men selecteren op basis van peptidensequentie (bv. alle methionyl of cysteinyl 
peptiden), het dragen van post-translationele modificaties (bv. fosforylatie) of de 
lokalisatie van een peptide binnen een eiwit (bv. het aminoterminale peptide). 
Gezien de verschuiving van de analytische eenheid naar het peptide bij deze nieuwe 
proteoomanalytische methoden, is het nodig ook de gegevensanalyse aan te passen. Zeker 
in het geval van de selectiemethoden zoals COFRADIC is het belangrijk om rekening te 
houden met deze evolutie. Inderdaad, wanneer enkel bepaalde peptiden geselecteerd 
worden uit een complex mengsel, verdwijnt het voordeel van de redundantie tesamen met 
de complexiteit. Het wordt dan ook essentieel om elk peptide op te pikken aangezien het 
missen van een peptide kan gelijk staan aan het missen van een eiwit (bv. wanneer voor 
aminoterminale peptiden geselecteerd wordt; elk eiwit heeft immers slechts één 
aminoterminus). 
Een eerste stap die nodig is om de beschikbare zoekalgoritmen en sequentiedatabanken 
meer efficiënt aan te kunnen wenden, betreft het omzetten van de eiwitgebaseerde 
databanken naar peptide-gebaseerde versies. Hiertoe werd een software applicatie 
ontwikkeld (DBToolkit genaamd) die de meest courante databankformaten kan inlezen en 
op verschillende manieren kan omzetten naar peptide-databanken. Hierbij zijn twee 
processen van belang: het extraheren van additionele informatie uit de databanken en het 
elimineren van de redundantie op peptidenniveau in de databanken. Dit eerste process is 
opnieuw voornamelijk belangrijk in het geval van aminoterminale COFRADIC. Vele 
eiwitten worden immers verknipt aan hun aminoterminus tijdens hun maturatieproces en 
deze knipplaatsen komen doorgaans niet overeen met de knipplaatsen van standaard 
proteolytische enzymes, gebruikt in de proteoomanalyse. Het gevolg is dat de 
zoekalgoritmen de uiteindelijke aminoterminale peptiden niet in hun lijst van potentiële 
peptiden opnemen wanneer zij een in silico proteolytisch digest van een 
eiwitsequentiedatabank maken. DBToolkit lost dit probleem op door van elk correct 
proteolytisch peptide een collectie aminoterminaal ‘gerafelde’ peptiden te maken. Deze 
peptiden vormen samen een lijst van alle mogelijke aminoterminale peptiden van de 
eiwitten in de sequentiedatabank, ongeacht de locatie van de knipplaats. De tweede 
bewerking, het verwijderen van de redundantie op peptidenniveau, is een meer algemeen 
geldende maatregel. De meeste sequentiedatabanken zijn niet-redundant op 
eiwitsequentie niveau. Dit houdt in dat elke volledige sequentie slechts éénmaal 
voorkomt in de databank. Dit is echter geen garantie voor het niet-redundant zijn van de 
peptidensequenties. Deze hangt in de praktijk sterk of van de gebruikte databank, maar 
loopt al snel op tot 50% van de peptidensequenties voor een tryptisch digest! DBToolkit 
pakt dit probleem aan door elke peptidensequenties slechts éénmaal te vermelden in de 
uiteindelijke databank maar dan wel met expliciete vermelding van alle eiwitten die 
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aanleiding kunnen geven tot dit peptide. Op die manier gaat er geen informatie verloren 
bij deze conversie en kan men spreken van een verliesloze compressietechniek. Het 
belang van deze operatie wordt duidelijk wanneer we bekijken hoe bepaalde 
zoekalgoritmen onderscheid maken tussen correct positieve identificaties en vals 
positieve identificaties. Deze algoritmen, die  probabilistische algoritmen genoemd 
worden, berekenen een a priori drempelscore waarboven een identificatie moet scoren 
om – met een bepaalde betrouwbaarheid – als geïdentificeerd te worden geklasseerd. 
Deze drempelwaarde is afhankelijk van de grootte van de databank, zoals gemeten aan de 
hand van het aantal aminozuren in die databank. Het is duidelijk dat een databank met 
50% redundantie dus dubbel zo groot wordt ingeschat als ze eigenlijk is. Dit resulteert in 
een artificieel hoge drempelwaarde en dit heeft een negatieve invloed op de identificatie-
efficiëntie. 
Een tweede probleem waarmee de nieuwe peptide-gecentreerde technieken mee 
geconfronteerd worden, betreft de hoeveelheid informatie die routinematig gegenereerd 
wordt. De datastromen zijn dan ook met enkele grootte-ordes toegenomen over de laatste 
jaren. Daar waar het enkele jaren geleden nog gebruikelijk was om met een rekenblad 
zoals Excel de identificaties voor een bepaald staal te beheren, is dit nu eenvoudigweg 
onmogelijk geworden. Omdat deze technieken jong en vernieuwend zijn, bestaat er geen 
degelijke commerciële software om dit gegevensbeheer te verzorgen. Het is daarom 
noodzakelijk om zelf een databank en bijhorende software te ontwikkelen. In dit werk 
wordt dan ook de ms_lims software besproken, die ontwikkeld werd om de datastromen 
bij de peptide-gecentreerde proteoomanalyse te automatiseren. Centraal in het systeem 
staat een relationele databank waarin de gegevens opgeslaan worden, met daarrond een 
set van applicaties die een eenvoudige interactie met de data mogelijk maken. Deze 
modulair opgebouwde software voldoet aan enkele belangrijke eisen. Zo integreert ze op 
een volledig transparante manier de informatie afkomstig van diverse instrumenten, 
hierbij zorgvuldig tracerend welke data van welk instrument komt. Er is ook een 
koppeling met een van de meest gebruikte zoekalgoritmen (Mascot) waardoor de 
resultaten van de zoekopdrachten volautomatisch in de relationele databank worden 
opgeslaan. Verder zijn er verschillende programma’s voorhanden die een specifieke 
analyse van de gegevens toelaten. Een mooi voorbeeld hiervan is de applicatie die een 
differentiële analyse van één of meer projecten toelaat. Hierbij wordt er een, op robuuste 
statistiek gebaseerde, statistische analyse uitgevoerd op de verzamelde identificaties en 
kan de gebruiker eenvoudig de peptiden of eiwitten bestuderen die significant 
gereguleerd worden tussen verschillende stalen. 
De data die door de massaspectrometers aangeleverd wordt, kan echter ook nog op een 
andere manier geanalyseerd worden. Deze massaspectra zijn immers niet steeds 
afkomstig van peptiden. Dikwijls heeft de massaspectrometer een polymeer of 
contaminant gefragmenteerd en hiervan een spectrum opgesteld. Het is uiteraard zinloos 
om zulke spectra in de volledige identificatie-cyclus mee te nemen daar er nooit een 
peptidesequentie aan gekoppeld kan worden. Naast deze a priori filtering kan men echter 
ook een a posteriori filtering doorvoeren waarbij na identificatie een onafhankelijke 
kwaliteitsscore wordt toegekend aan een spectrum en deze tweede score in ogenschouw 
wordt genomen bij het aanvaarden of verwerpen van een identificatie. Op deze manier 
kan dan gezocht worden naar de vals positieve identificaties die resteren binnen het 
betrouwbaarheidsinterval dat in het zoekalgoritme ingesteld werd. Het is duidelijk dat een 
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andere stringentie gewenst is bij het a priori filteren dan bij het a posteriori filteren. 
Wanner er immers een te strenge selectie doorgevoerd wordt vooraleer tot identificatie 
over te gaan, is er een grote kans dat de filter, naast een heleboel slechte spectra, ook een 
aanzienlijk aantal goede spectra zal wegfilteren. Aangezien het nu zaak is zo efficiënt 
mogelijk met de opgenomen spectra om te gaan, is het belangrijk om tijdens deze stap te 
stringente selectie te vermijden. Omgekeerd dient de selectie erg streng te gebeuren 
tijdens het valideren van de bekomen identificaties. Hier is het immers wenselijk elk 
verdacht spectrum te signaleren. Om deze filtering te kunnen uitvoeren, werd in 
samenwerking met Kristian Flikka en Professor Ingvar Eidhammer van de Universiteit 
Bergen in Noorwegen een applicatie ontwikkeld om spectra te filteren met een vrij te 
kiezen stringentie. Deze aanpak laat ook toe om die spectra op te pikken die een erg hoge 
kwaliteitsscore krijgen, maar toch niet geïdentificeerd worden. Deze spectra kunnen 
onderworpen worden aan meer arbeidsintensieve analyses om ze vooralsnog te kunnen 
identificeren. 
Op een ander niveau worstelt de wereld van de proteoomanalyse met het probleem van 
het verspreiden en ter beschikking stellen van de bekomen identificaties. Tot voor kort 
werd dit soort data voornamelijk via onhandige en vaak incomplete PDF tabellen als 
supplementaire informatie verspreid door de wetenschappelijke vakbladen. Dit met 
enkele kwalijke gevolgen: spectra zijn niet inbegrepen in deze informatie zodat een 
herevaluatie en eventuele validatie van de bekomen identificaties onmogelijk wordt. 
Bovendien is de data in PDF formaat wel leesbaar voor mensen, maar niet voor 
computerprogramma’s. Gezien de enorme hoeveelheid identificaties die typisch 
gepubliceerd worden, is automatische verwerking in de praktijk echter noodzakelijk. Het 
uiteindelijke resultaat van deze omstandigheden is dat de informatie, eenmaal 
gepubliceerd, vergeten wordt en niet kan bijdragen aan verder wetenschappelijk werk. 
Om al deze problemen aan te pakken, werd in samenwerking met het European 
Bioinformatics Institute (EBI) het PRIDE (PRoteomics IDEntifications) project 
ontwikkeld. Dit systeem bestaat uit een open bestandsformaat in XML voor de 
verspreiding van data, een centrale database waarin deze data kan worden opgeslaan en 
een volledige set van software bibliotheken om met databank en XML formaat te 
interageren. De centrale databank is via het web te raadplegen en kan eveneens 
gedownload worden via FTP. Bovendien is het volledige pakket inclusief de broncode 
vrij beschikbaar. Dit laat geïnteresseerden toe om het systeem lokaal te installeren en 
zelfs om eigen veranderingen aan te brengen. PRIDE laat ook toe om online data in te 
dienen. Deze gegevens kunnen voor (on-)bepaalde tijd privaat gehouden worden en 
bijvoorbeeld alleen gedeeld worden binnen samenwerkingsverbanden of met een editor 
en peer-reviewers. 
Ten slotte wordt er een synthese-project voorgesteld: de toepassing van alle 
bovenvermelde applicaties en verschillende COFRADIC technieken om de meest 
complete dataset van het proteoom van humane bloedplaatjes samen te stellen. 
In conclusie kan gesteld worden dat het veld van de proteoomanalyse stilaan volwassen 
wordt en dat specifieke software-applicaties hiertoe sterk hebben bijgedragen. De 
doorgedreven automatisering van de gegevensstroom laat toe om aan een zeer hoog 
tempo analyses uit te voeren en de grote hoeveelheden informatie die hieruit voortkomen, 
kunnen op hun beurt op een efficiënte manier geraadpleegd worden aan de hand van 
analyse-software. De proteoomanalyse zal in de volgende jaren wel nog inspanningen 
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moeten doen om de rol van data producent op een georganiseerde en nuttige manier te 
dragen. Momenteel wordt nog teveel data achtergehouden om verschillende, weinig 
wetenschappelijke redenen. De infrastructuurproblemen die hiervoor vroeger als excuus 
werden aangehaald, zijn inmiddels grotendeels opgelost en met de komst van centrale 
identificatie-databanken zoals PRIDE ligt de weg open naar een meer constructieve en 
coöperatieve manier van onderzoek doen. 
Een laatste pleidooi betreft het overnemen van de methodes van de open source software-
ontwikkeling. Hierbij wordt niet alleen de broncode op de een of andere manier 
vrijgegeven, maar wordt er ontwikkeld volgens welbepaalde methoden die het delen van 
de code, het gebruik van de software alsook het wereldwijd samenwerken van 
ontwikkelaars ondersteund en stimuleert. 
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